
<html lang="en"     class="pb-page"  data-request-id="1f525d64-f3d4-420a-94f7-79d778d803ec"  
><head data-pb-dropzone="head"><meta name="pbContext" content=";requestedJournal:journal:jmcmar;journal:journal:jmcmar;page:string:Article/Chapter View;ctype:string:Journal Content;wgroup:string:ACHS website Group;issue:issue:10.1021/jmcmar.2019.62.issue-14;website:website:acspubs;pageGroup:string:Publication Pages;subPage:string:Full Text;article:article:10.1021/acs.jmedchem.9b00329"/></meta>




        <link rel="schema.DC" href="http://purl.org/DC/elements/1.0/" /></link><meta name="citation_journal_title" content="Journal of Medicinal Chemistry" /></meta><meta name="dc.Title" content="Discovery of 4-Aminoquinoline-3-carboxamide Derivatives as Potent Reversible Bruton’s Tyrosine Kinase Inhibitors for the Treatment of Rheumatoid Arthritis" /></meta><meta name="dc.Creator" content="Xia  Yao" /></meta><meta name="dc.Creator" content="Xiuyun  Sun" /></meta><meta name="dc.Creator" content="Shuyu  Jin" /></meta><meta name="dc.Creator" content="Ling  Yang" /></meta><meta name="dc.Creator" content="Hongjiang  Xu" /></meta><meta name="dc.Creator" content="Yu  Rao" /></meta><meta name="dc.Description" content="A structure-hopping strategy was applied to discover a series of novel 4-aminoquinoline-3-carboxamide derivatives as potent, reversible BTK inhibitors. Compared to the previously described cinnolin..." /></meta><meta name="Description" content="A structure-hopping strategy was applied to discover a series of novel 4-aminoquinoline-3-carboxamide derivatives as potent, reversible BTK inhibitors. Compared to the previously described cinnolin..." /></meta><meta name="dc.Publisher" content="American Chemical Society" /></meta><meta name="dc.Date" scheme="WTN8601" content="July 1, 2019" /></meta><meta name="dc.Type" content="research-article" /></meta><meta name="dc.Format" content="text/HTML" /></meta><meta name="dc.Identifier" scheme="doi" content="10.1021/acs.jmedchem.9b00329" /></meta><meta name="dc.Language" content="en" /></meta><meta name="dc.Coverage" content="world" /></meta><meta name="dc.Rights" content="Copyright © 2019 American Chemical Society" /></meta>
        
        

        
            <link rel="meta" type="application/atom+xml" href="https://doi.org/10.1021%2Facs.jmedchem.9b00329" /></link>
            <link rel="meta" type="application/rdf+json" href="https://doi.org/10.1021%2Facs.jmedchem.9b00329" /></link>
            <link rel="meta" type="application/unixref+xml" href="https://doi.org/10.1021%2Facs.jmedchem.9b00329" /></link>
        
    
    

<title>Discovery of 4-Aminoquinoline-3-carboxamide Derivatives as Potent Reversible Bruton’s Tyrosine Kinase Inhibitors for the Treatment of Rheumatoid Arthritis | Journal of Medicinal Chemistry</title>












<meta charset="UTF-8">




<meta name="robots" content="noarchive"/></meta>
<meta name="pb-robots-disabled">









        <meta property="og:url" content="https://pubs.acs.org/doi/full/10.1021/acs.jmedchem.9b00329" /></meta><meta property="og:title" content="Discovery of 4-Aminoquinoline-3-carboxamide Derivatives as Potent Reversible Bruton’s Tyrosine Kinase Inhibitors for the Treatment of Rheumatoid Arthritis" /></meta><meta property="og:image" content="https://pubs.acs.org/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-14/acs.jmedchem.9b00329/20190719/images/large/jm-2019-00329v_0016.jpeg" /></meta><meta property="og:description" content="A structure-hopping strategy was applied to discover a series of novel 4-aminoquinoline-3-carboxamide derivatives as potent, reversible BTK inhibitors. Compared to the previously described cinnoline scaffold compounds, the 4-aminoquinoline analogues showed significantly improved drug-like properties, especially in their aqueous solubility. The most potent compound, 25, displayed a stronger inhibitory effect on both BTKWT (IC50 = 5.3 nM) and BTKC481S (IC50 = 39 nM). In a rodent collagen-induced arthritis model, compound 25 efficiently reduced paw swelling without a loss in body weight. On the basis of potency, drug-like properties, stability, and noncovalent mode of inhibition, our representative inhibitors could have a promising profile to be treatments for a wide range of autoimmune diseases." /></meta><meta property="og:type" content="Article" /></meta><meta property="og:site_name" content="ACS Publications" /></meta><meta name="twitter:card" content="summary_large_image" /></meta><meta name="twitter:site" content="@ACSPublications" /></meta>
    


    <meta name="viewport" content="width=device-width,initial-scale=1,maximum-scale=10, user-scalable=0"/></meta>















    

    <meta name="dc.identifier" content="10.1021/acs.jmedchem.9b00329"/></meta>



<meta name="format-detection" content="telephone=no">













<link rel="stylesheet" type="text/css" href="/wro/kfa7~product.css">


    <link rel="stylesheet" href="/products/achs/releasedAssets/fonts/achs-fonts/font-roboto/font-roboto.css"/></link><link rel="stylesheet" href="/products/achs/releasedAssets/css/build-f32cfd249ff7cb4cf9c7.css"/></link><link rel="stylesheet" href="/products/achs/releasedAssets/fonts/achs-fonts/font-lato/font-lato.css"/></link>




<meta http-equiv="X-UA-Compatible" content="IE=edge">
<meta http-equiv="content-type" content="text/html; charset=UTF-8">
<link rel="stylesheet" type="text/css" href="/pb-assets/styles/achs-1625058702970.css">
<link rel="stylesheet" type="text/css" href="/pb-assets/styles/acs-1622125181777.css">
<script type="text/javascript" src="/templates/jsp/js/jquery-3.1.1.min.js"></script>
<script type="text/javascript" src="/pb-assets/javascript/eloqua-1619549134767.js"></script>
<script async="" type="text/javascript" src="https://www.googletagservices.com/tag/js/gpt.js" rel="preconnect"></script>

<script defer src="https://static.cloudflareinsights.com/beacon.min.js" data-cf-beacon='{"rayId":"5200035e6e4d5180","startTime":1570117212010}'></script>






    








    
        
            <script type="text/javascript">
                (function (i, s, o, g, r, a, m) {
                    i['GoogleAnalyticsObject'] = r;
                    i[r] = i[r] || function () {
                        (i[r].q = i[r].q || []).push(arguments)
                    }, i[r].l = 1 * new Date();
                    a = s.createElement(o), m = s.getElementsByTagName(o)[0];
                    a.async = 1;
                    a.src = g;
                    m.parentNode.insertBefore(a, m)
                })(window, document, 'script', '//www.google-analytics.com/analytics.js', 'ga');
                ga('create', 'UA-7663985-4'
                    
                    
                    , 'auto'
                    
                    );
                
                
                ga('send', 'pageview');
            </script>
            
        
    















    
    
            
                
                

                <link rel="canonical" href="https://pubs.acs.org/doi/10.1021/acs.jmedchem.9b00329">
            
        




























    
    

    
    
    
    
    <script src="//unpkg.com/@theidentityselector/thiss-ds"></script>

    <script type="text/javascript">

        var SeamlessAccessService = {
            spUrl: "/action/ssostart",
            returnURL: window.location.href,
            my_context: 'seamlessaccess.org',
            timeout: 5000,

            getWAYFLessUrl: function (entityId) {
                return this.spUrl + "?idp=" + encodeURIComponent(entityId)
                    + "&redirectUri=" + encodeURIComponent(this.returnURL);
            },
            retrieveEntity: function (ms) {
                var self = this;
                var persistService = new thiss.PersistenceService('https://service.seamlessaccess.org/ps/');

                if(ms == undefined || ms === ''){
                    ms = this.timeout;
                }

                return new Promise(function (resolve, reject) {
                    persistService.entities(self.my_context)
                        .then(function (res) {
                            // get the results
                            var results = res.data;
                            return resolve(results);
                        }, function (err) {
                            // failed
                            reject('retrieve entity error: ' + err);
                        });
                        // Set up the timeout
                        setTimeout(function() {
                            reject('Promise timed out ' + ms + ' ms');
                        }, ms);
                });
            },
            updateEntity: function (entitydata) {
                var self = this;
                var persistService =  new thiss.PersistenceService('https://service.seamlessaccess.org/ps/');

                var jsonObj = {};
                try {
                    //try to parse it, if it is a json string
                    jsonObj = JSON.parse(entitydata.val());
                } catch (e) {
                    jsonObj = entitydata;
                }
                return new Promise(function (resolve, reject) {
                    persistService.update(self.my_context, jsonObj)
                        .then(function (res) {
                            // Process the results
                            var ssoInstitutions = res.data;
                            return resolve(ssoInstitutions);
                        }, function (err) {
                            // failed
                            console.log('failed to update the local storage duo to: ' + err);
                            reject(err);
                        });
                })
            },
            removeEntity: function (entityId) {
                var self = this;
                var persistService =  new thiss.PersistenceService('https://service.seamlessaccess.org/ps/');

                return new Promise(function (resolve) {
                    persistService.remove(self.my_context, entityId)
                        .then(function (res) {
                            return resolve(res);
                        }, function (err) {
                            // failed
                            console.log('failed to remove from local storage duo to: ' + err);
                        });
                })
            },
            getAccessibleEntityStatus: function (doi, entityId) {
                return new Promise(function (resolve) {
                    $.ajax({
                        type: 'POST',
                        url: '/action/seamlessAccess',
                        accept: {
                            text: "application/json"
                        },
                        data: {doi: doi, entityid: entityId}

                    }).done(function (status) {
                        return resolve(status);
                    });
                });
            },
            getEntitiesWithAllInfo: function (doi) {
                let self = this,
                    arrayOfPromises = [];
                return new Promise(function (resolve, reject) {
                    self.retrieveEntity().then(function (res) {
                        let allSsoInstitutions = res;
                        for (i = 0; i < allSsoInstitutions.length; i++) {
                            let ssoInstitution = allSsoInstitutions[i];
                            arrayOfPromises.push(new Promise(function (resolve) {
                                self.getAccessibleEntityStatus(doi, ssoInstitution.entity.entityID)
                                    .then(function (entityStatus) {
                                        resolve({
                                            entityID: ssoInstitution.entity.entityID,
                                            entityTitle: ssoInstitution.entity.title,
                                            entityStatusObj: entityStatus,
                                            entitySsoUrl: self.getWAYFLessUrl(ssoInstitution.entity.entityID)
                                        });
                                    }, function (err) {
                                        console.log('failed to get the entity status: ' + err);
                                    });
                            }));
                        }
                        Promise.all(arrayOfPromises)
                            .then(function (finalResponse) {
                                resolve(finalResponse);
                            });

                    }).catch(function (err) {
                        reject(err);
                    })
                });
            }
        };

        window.addEventListener('load', function () {
            document.querySelectorAll(".sso-institution").forEach(function (institution) {
                var entityId = institution.getAttribute('data-entityid');
                var entityName = institution.getAttribute('data-name');
                var entitydata = {
                    entityID: entityId,
                    title: entityName
                };
                institution.addEventListener("click", function (e) {
                    e.preventDefault();
                    var self = this;
                    SeamlessAccessService.updateEntity(entitydata).then(function (res) {
                        console.log(res);
                        window.location.href = self.href;
                    }).catch(function (err){
                        window.location.href = self.href;
                    });
                });
            });
        });

    </script>




























    






    <meta name="google-site-verification" content="uBHpu2M2kL7VihPCSRXWyBSxooDf7L_BGgfHA3cjSfY" /></meta>


<link rel="prefetch" href="https://tpc.googlesyndication.com/safeframe/1-0-29/html/container.html"></head>
<body class="pb-ui">


























<script type="text/javascript">

    if(false) {
        document.getElementById("skipNavigationLink").onclick =function skipElement () {
            var element = document.getElementById('');
            if(element == null || element == undefined) {
                element = document.getElementsByClassName('').item(0);
            }
            element.setAttribute('tabindex','0');
            element.focus();

        }

    }

</script>











    <div id="pb-page-content" data-ng-non-bindable>
        <div data-pb-dropzone="main" data-pb-dropzone-name="Main">










        <div data-widget-def="UX3HTMLWidget" data-widget-id="ed6ae788-7707-48f4-b02c-3187c75e10db" class="hide">
        



        
        

        </div>
    




        
        




        
        



        <div class="pb-ad">
            <script type="text/javascript">
	var dartInstitutionType = 'none';
	var dartMember = 'false';
</script>
        </div>
    





        
        <script type="text/javascript">
$(document).ready(function() {
	setTimeout(function() {
		// var journalTitle = 'medicinal_chemistry';
		var taxonomyKeywords = $('.article_header-taxonomy');
		var articleKeyword = $('meta[name="keywords"]');
		var articleTitle = $('meta[name="dc.Title"]');
		var articleDescription = $('meta[name="dc.Description"]');
		var abstractKeyword = $('p.articleBody_abstractText:contains("Keywords: ")');
		var searchTerms = [];

		if (taxonomyKeywords.length > 0) {
			$(taxonomyKeywords).children(".rlist--inline").children("li").each(function() {
				searchTerms.push($(this).text());
			});
		}
		else if (articleKeyword.length > 0) { 
			searchTerms = searchTerms.concat(articleKeyword.prop('content').split(', '));
		}
		else if (abstractKeyword.length > 0) {
			searchTerms = searchTerms.concat(abstractKeyword.text().split("Keywords: ")[1].split('; '));
		}
		else if (articleDescription.length > 0) {
			$(articleDescription).each(function() {
				articleDescriptionKeywords = $(this).prop('content');
				articleDescriptionKeywords = articleDescriptionKeywords.replace(/.,/g,"");
				articleDescriptionKeywords = articleDescriptionKeywords.replace(/\s{2,}/g," ");
				searchTerms = searchTerms.concat(articleDescriptionKeywords.split(' '));
			});
		}

		if (articleTitle.length > 0) {
			searchTerms = searchTerms.concat(articleTitle.prop('content').split(' '));
		}

		googletag.cmd.push(function() {
			var mappingLeader = googletag.sizeMapping().
			addSize([320, 400], [320, 50]).
			addSize([320, 700], [320, 50]).
			addSize([750, 200], [728, 90]). 
			addSize([980, 690], [728, 90]).
			addSize([1024, 768], [728, 90]).
			build();
			//leaderboard
			googletag.defineSlot('/8868/journal/medicinal_chemistry/article', [728, 90], 'dfp-journal-article-leaderboard').defineSizeMapping(mappingLeader).setTargeting('location', 'leaderboard1').setTargeting('Keyword', searchTerms).addService(googletag.pubads());
			//recommend
			googletag.defineSlot("/8868/journal/medicinal_chemistry/article", [1, 1], "dfp-journal-article-recommend").setTargeting("ntvPlacement", ["1100167"]).setTargeting("location", "recommend").setTargeting('Keyword', searchTerms).addService(googletag.pubads());
			//googletag.pubads().enableSingleRequest();
			googletag.pubads().collapseEmptyDivs();
			googletag.pubads().setTargeting('inst',dartInstitutionType).setTargeting('memb',dartMember);
			googletag.pubads().addEventListener("slotRenderEnded", function(event) {
				if((event.isEmpty === false) && (event.slot.getSlotElementId() != "dfp-journal-article-recommend")) {
					$("#" + event.slot.getSlotElementId()).parents(".advertisement").slideDown();
				}
			});
			googletag.enableServices();
		});
	}, 1000);
});
</script>





        
        <script src="https://common.ccdc.cam.ac.uk/ccdc-widget/1.0.0.76/Widget.min.js"></script>




        
        <header class="header header_article_inactive">



        
        <div class="header_topbar hidden-sm hidden-xs">



        
        <div class="container"><div class="row"><div class="col-lg-3 col-md-4 col-sm-5 header_topbar_left">









        <div data-widget-def="UX3HTMLWidget" data-widget-id="0be92cec-36a8-4b4d-9a08-a28c790ce306" class="header_mainmenu">
        



        
        <ul>
	<li>
		<a href="http://www.acs.org">ACS</a>
	</li>
	<li class="header_mainmenu_current">
		<a href="/">ACS Publications</a>
	</li>
	<li>
		<a href="https://cen.acs.org">C&EN</a>
	</li>
	<li>
		<a href="https://www.cas.org">CAS</a>
	</li>
</ul>

        </div>
    
</div><div class="col-lg-9 col-md-8 col-sm-7 header_topbar_right">



        
        <div class="institution"><span class="institution-info-wrapper"><span class="institution__intro">Access provided by</span><span class="institution__name">Hong Kong University of Science and Technology Library</span></span></div>




        
        <div class="user-login-bar"><input type="hidden" name="statusEndpoint" value="https://sso.acs.org/idp/status" class="statusEndpoint"/></input><input type="hidden" name="clientID" value="atypon-lives" class="clientID"/></input><input type="hidden" name="heartBeatReloadInterval" value="1740000" class="heartBeatReloadInterval"/></input><input type="hidden" name="logoutUrl" value="https://pubs.acs.org/action/doLogout?logoutRedirectUrl=https%3A%2F%2Fsso.acs.org%2Fidp%2Fglogout%3Fappid%3Datypon-live%26returnURL%3Dhttps%253A%252F%252Fpubs.acs.org%252F" class="logoutUrl"/></input><img src="https://sso.acs.org/idp/heartbeat?appid=atypon-lives&amp;max_auth_age=2592000" alt="Blank image" class="ssoHeartBeatImg"/></img><span class="user-login-bar__value"><a href="https://pubs.acs.org/action/ssoRequestForLoginPage" class="user-login-bar__Login">Log In</a></span><input type="hidden" name="isUserLoggedIn" value="false" class="user-login-bar_is-loggedin"/></input><input type="hidden" name="isPaired" value="false" class="pair-device-is-paired"/></input><input type="hidden" name="isStronglyAuthenticated" value="false" class="isStronglyAuthenticated"/></input></div>
</div></div></div>
</div>




        
        <div class="header_content">



        
        <div class="container"><div class="row"><div class="header_content_main">



        
        <div class="header_content_row">



        
        <div class="header_content_left pull-left">



        
        <a href="/" title="ACS Publications. Most Trusted. Most Cited. Most Read"><img id="" alt="ACS Publications. Most Trusted. Most Cited. Most Read" src="/pb-assets/ux3/pubs-logo-481x82-1523435513963.png"/></img></a>




        
        <div class="pj-badge"></div><a href="/journal/jmcmar" title="journal logo" class="header_article-logo"><img src="/na101/home/literatum/publisher/achs/journals/covergifs/jmcmar/title.png" alt="Journal Logo"></a><div class="header_article-separator"></div>
</div><div class="header_content_center">



        
        <div class="header_contnav">
    <div class="header_contnav-row">
         <a href="#" title="Previous" class="header_contnav-pre">
                <i class="icon-angle-left"></i>
        </a>
       <div class="header_contnav-title">
            <span>
                <a href="#" title=""></a>
            </span>
        </div>
         <a href="#" title="Next" class="header_contnav-next">
                <i class="icon-angle-right"></i>
            </a>
    </div>
</div>
</div><div class="header_content_right pull-right">



        
        <div class="header_qv-link"><a href="#" title="Quick View" data-slide-target=".article_qv-xs-container" class="w-slide__btn slide-active icon-quickview">Quick View</a></div>




        
        <div class="header_article-share">



        
        <script type="text/javascript" async="async" src="//s7.addthis.com/js/300/addthis_widget.js#pubid=xa-4faab26f2cff13a7"></script><div class="share"><div class="share_button"><span class="share__label">Share</span><a href="#" data-db-target-for="527d28d6-3414-4cb2-9560-99e677e62c0d" data-db-switch="icon-close_thin" aria-label="share button" class="share__ctrl"><i aria-hidden="true" class="icon-Icon_Share"></i></a></div><div class="pb-dropzone" data-pb-dropzone="ShareDropzone1" title="ShareDropzone1"></div><div class="pb-dropzone" data-pb-dropzone="ShareDropzone2" title="ShareDropzone2"></div><div data-db-target-of="527d28d6-3414-4cb2-9560-99e677e62c0d" id="527d28d6-3414-4cb2-9560-99e677e62c0d_Pop" class="share__block dropBlock__holder fixed"><div class="pb-dropzone" data-pb-dropzone="shareBlock" title="shareBlock"></div><span class="sr-only">Share on</span><ul class="rlist w-slide--list addthis addthis_toolbox addthis_default_style addthis_32x32_style"><li><a role="link" class="addthis_button_facebook"><i aria-hidden="true" class="at-icon-wrapper icon-facebook"></i>Facebook</a></li><li><a role="link" class="addthis_button_twitter"><i aria-hidden="true" class="at-icon-wrapper icon-twitter"></i>Twitter</a></li><li><a role="link" class="addthis_button_wechat"><i aria-hidden="true" class="at-icon-wrapper icon-wechat"></i>WeChat</a></li><li><a role="link" class="addthis_button_linkedin"><i aria-hidden="true" class="at-icon-wrapper icon-linkedin"></i>Linked In</a></li><li><a role="link" class="addthis_button_reddit"><i aria-hidden="true" class="at-icon-wrapper icon-reddit"></i>Reddit</a></li><li><a role="link" class="addthis_button_email"><i aria-hidden="true" class="at-icon-wrapper icon-envelope-o"></i>Email</a></li></ul></div></div>
</div>




        
        <div class="header_article-separator"></div>




        
        <div class="quick-search"><a href="#" aria-label="quick search" class="quick-search_icon icon-search"></a><div class="quick-search_content"><form action="/action/checkIsValidDoi" name="defaultQuickSearch" method="get" title="Quick Search" autocomplete="off" class="quick-search_default"><input type="search" name="AllField" placeholder="Search text, DOI, authors, etc." aria-label="Search text, DOI, authors, etc." data-auto-complete-max-words="7" data-auto-complete-max-chars="32" data-contributors-conf="3" data-topics-conf="3" data-publication-titles-conf="3" data-history-items-conf="3" value="" required="true" class="quick-search_all-field autocomplete"/></input><button type="submit" title="Search" class="icon-search"></button><div role="radiogroup" aria-labelledby="journal filter" class="quick-search_journal-filter"><label for="thisJournalRadio" tabindex="0" aria-checked="true" role="radio" class="radio--primary"><input id="thisJournalRadio" type="radio" value="jmcmar" name="SeriesKey" checked="checked" class="all-content"/></input><span>J. Med. Chem.</span></label><label for="allPubRadio" tabindex="0" aria-checked="false" role="radio" class="radio--primary"><input id="allPubRadio" type="radio" value="" name="SeriesKey" class="all-content"/></input><span>All Publications/Website</span></label></div></form><p>OR SEARCH CITATIONS</p><form action="/action/quickLink" name="citationQuickSearch" method="get" title="Quick Search" class="quick-search_citation"><input type="hidden" name="quickLink" value="true"/></input><select name="quickLinkJournal" class="quick-search_journals-select"><option value="jmcmar">Journal of Medicinal Chemistry</option><option value="achre4">Accounts of Chemical Research</option><option value="amrcda">Accounts of Materials Research</option><option value="aastgj">ACS Agricultural Science & Technology</option><option value="aabmcb">ACS Applied Bio Materials</option><option value="aaembp">ACS Applied Electronic Materials</option><option value="aaemcq">ACS Applied Energy Materials</option><option value="aamick">ACS Applied Materials & Interfaces</option><option value="aanmf6">ACS Applied Nano Materials</option><option value="aapmcd">ACS Applied Polymer Materials</option><option value="abmcb8">ACS Bio & Med Chem Au</option><option value="abseba">ACS Biomaterials Science & Engineering</option><option value="accacs">ACS Catalysis</option><option value="acscii">ACS Central Science</option><option value="acbcct">ACS Chemical Biology</option><option value="achsc5">ACS Chemical Health & Safety</option><option value="acncdm">ACS Chemical Neuroscience</option><option value="acsccc">ACS Combinatorial Science</option><option value="aesccq">ACS Earth and Space Chemistry</option><option value="aelccp">ACS Energy Letters</option><option value="aeacb3">ACS Engineering Au</option><option value="aeacc4">ACS Environmental Au</option><option value="aeecco">ACS ES&T Engineering</option><option value="aewcaa">ACS ES&T Water</option><option value="afsthl">ACS Food Science & Technology</option><option value="aidcbc">ACS Infectious Diseases</option><option value="amlccd">ACS Macro Letters</option><option value="amacgu">ACS Materials Au</option><option value="amlcef">ACS Materials Letters</option><option value="amachv">ACS Measurement Science Au</option><option value="amclct">ACS Medicinal Chemistry Letters</option><option value="ancac3">ACS Nano</option><option value="anaccx">ACS Nanoscience Au</option><option value="acsodf">ACS Omega</option><option value="aoiab5">ACS Organic & Inorganic Au</option><option value="aptsfn">ACS Pharmacology & Translational Science</option><option value="apchd5">ACS Photonics</option><option value="apcach">ACS Physical Chemistry Au</option><option value="apaccd">ACS Polymers Au</option><option value="ascefj">ACS Sensors</option><option value="ascecg">ACS Sustainable Chemistry & Engineering</option><option value="asbcd6">ACS Synthetic Biology</option><option value="ancham">Analytical Chemistry</option><option value="bichaw">Biochemistry</option><option value="bcches">Bioconjugate Chemistry</option><option value="bomaf6">Biomacromolecules</option><option value="bipret">Biotechnology Progress</option><option value="cgeabj">C&EN Global Enterprise</option><option value="cenear">Chemical & Engineering News Archive</option><option value="chlseg">Chemical Health & Safety</option><option value="chlseg0">Chemical Health & Safety</option><option value="crtoec">Chemical Research in Toxicology</option><option value="chreay">Chemical Reviews</option><option value="cmatex">Chemistry of Materials</option><option value="cgdefu">Crystal Growth & Design</option><option value="enfuem">Energy & Fuels</option><option value="esthag">Environmental Science & Technology</option><option value="estlcu">Environmental Science & Technology Letters</option><option value="iepra6.2">I&EC Product Research and Development</option><option value="iechad">Industrial & Engineering Chemistry</option><option value="iecac0">Industrial & Engineering Chemistry Analytical Edition</option><option value="iecjc0">Industrial & Engineering Chemistry Chemical & Engineering Data Series</option><option value="iecfa7">Industrial & Engineering Chemistry Fundamentals</option><option value="iepdaw">Industrial & Engineering Chemistry Process Design and Development</option><option value="iepra6">Industrial & Engineering Chemistry Product Research and Development</option><option value="iecred">Industrial & Engineering Chemistry Research</option><option value="iecnav">Industrial and Engineering Chemistry, News Edition</option><option value="inocaj">Inorganic Chemistry</option><option value="jaaucr">JACS Au</option><option value="jacsat">Journal of the American Chemical Society</option><option value="jafcau">Journal of Agricultural and Food Chemistry</option><option value="jceaax">Journal of Chemical & Engineering Data</option><option value="jci001">Journal of Chemical Documentation</option><option value="jceda8">Journal of Chemical Education</option><option value="jchsc2">Journal of Chemical Health & Safety</option><option value="jchsc20">Journal of Chemical Health & Safety</option><option value="jcics1">Journal of Chemical Information and Computer Sciences</option><option value="jcisd8">Journal of Chemical Information and Modeling</option><option value="jctcce">Journal of Chemical Theory and Computation</option><option value="jcchff">Journal of Combinatorial Chemistry</option><option value="iechad.1">Journal of Industrial & Engineering Chemistry</option><option value="jmcmar.1">Journal of Medicinal and Pharmaceutical Chemistry</option><option value="jnprdf">Journal of Natural Products</option><option value="joceah">The Journal of Organic Chemistry</option><option value="jpchax">The Journal of Physical Chemistry</option><option value="jpchax.2">The Journal of Physical Chemistry</option><option value="jpcafh">The Journal of Physical Chemistry A</option><option value="jpcbfk">The Journal of Physical Chemistry B</option><option value="jpccck">The Journal of Physical Chemistry C</option><option value="jpclcd">The Journal of Physical Chemistry Letters</option><option value="jprobs">Journal of Proteome Research</option><option value="jamsef">Journal of the American Society for Mass Spectrometry</option><option value="jamsef1">Journal of the American Society for Mass Spectrometry</option><option value="jamsef0">Journal of the American Society for Mass Spectrometry</option><option value="langd5">Langmuir</option><option value="mamobx">Macromolecules</option><option value="mpohbp">Molecular Pharmaceutics</option><option value="nalefd">Nano Letters</option><option value="neaca9">News Edition, American Chemical Society</option><option value="orlef7">Organic Letters</option><option value="oprdfk">Organic Process Research & Development</option><option value="orgnd7">Organometallics</option><option value="iepra6.1">Product R&D</option><option value="scimts">SciMeetings</option><option value="jpchax.1">The Journal of Physical and Colloid Chemistry</option></select><input type="search" inputmode="numeric" pattern="[0-9]*" name="quickLinkVolume" autoComplete="false" placeholder="Vol" required="required" class="quick-search_volume-input"/></input><input type="search" inputmode="numeric" pattern="[0-9]*" name="quickLinkPage" autoComplete="false" placeholder="Page" required="required" class="quick-search_page-input"/></input><button type="submit" title="Search" class="icon-search"></button></form></div></div>




        
        <div class="header_my-activity">



        
        <a href="#"><i class="icon-id-badge" aria-hidden=”true”></i><span>My Activity</span></a>
<div class="header_my-activity-content">
    <div class="header_my-activity-single">
        <i aria-hidden="true" aria-label="close" class="icon-close"></i>
        <div class="" data-name="recentlyViewedDropzone">



        
        <div class="show-recently"><div class="show-recently-header">Recently Viewed</div><h6 class="show-recently-empty">You have not visited any articles yet, Please visit some articles to see contents here. </h6></div>
</div>
    </div>
</div>
</div>




        
        <div class="header_publications">



        
        <a href="#" class="pubModal_button"><i class="icon-book" aria-hidden=”true”></i><span>Publications</span></a>

</div>




        
        <div class="header_burger-menu">



        
        <a href="#?utm_source=Pubs_Solutions_Referer&amp;utm_medium=Pubs_MenuIcon&amp;utm_campaign=Pubs_Refere" class="header_burger-menu_button" title="menu button" aria-label="menu button"><i class="icon-navicon"></i><i
        class="icon-close"></i></a>
<div class="header_burger-menu_content">
    <ul class="hidden-lg">
        <li><a href="#" class="pubModal_button"><i class="icon-book" aria-hidden=”true”></i><span>publications</span></a></li>
        <li class="myActivityMobile"><a href="#" class="openTabletActivity"><i class="icon-id-badge" aria-hidden=”true”></i><span>my Activity</span></a>
            <ul>
                <li><a href="javascript:void(0)" class="recentlyViewed--open">Recently Viewed</a></li>
            </ul>
        </li>
    </ul>
    <ul>
        <li><a href="#">user resources</a>
            <ul>
                <li><a href="/page/remoteaccess"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Access Options');">Access Options</a></li>
                <li><a href="https://publish.acs.org/publish/"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Authors & Reviewers');">Authors &
                        Reviewers</a></li>
                <li><a href="http://www.acs.org/content/acs/en/membership-and-networks/acs/benefits/professional/publications-benefits.html"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'ACS Members');">ACS Members</a></li>
                <li><a href="https://preferences.acspubs.org/journals"
                        onclick="ga('send', 'event', 'Home_MainMenu', 'Click', 'eAlert');">eAlerts</a></li>
                <li><a href="/page/follow.html?widget=follow-pane-mobile"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'RSS & Mobile');">RSS & Mobile</a></li>
            </ul>
        </li>
		<li><a href="#">for organizations</a>
			<ul>
			    <li><a href="https://solutions.acs.org/?utm_source=Pubs_Solutions_Referer&amp;utm_medium=Pubs_MenuBotton&amp;utm_campaign=Pubs_Referer"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Products & Services');">Products & Services</a></li>
				<li><a href="https://solutions.acs.org/access-options/?utm_source=Pubs_Solutions_Referer&amp;utm_medium=Pubs_MenuBotton&amp;utm_campaign=Pubs_Referer"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Get Access');">Get Access</a></li>
				<li><a href="https://solutions.acs.org/resources/manage-my-account/?utm_source=Pubs_Solutions_Referer&amp;utm_medium=Pubs_MenuBotton&amp;utm_campaign=Pubs_Referer"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Manage My Account');">Manage My Account</a></li>
			</ul>
		</li>
        <li><a href="#">support</a>
            <ul>
                <li><a href="/page/demo/index.html">Website Demos & Tutorials</a></li>
                <li><a href="https://acs.service-now.com/acs"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Support FAQs');">Support FAQs </a></li>
                <li><a href="#"
                        onClick="SnapEngage.startLink();return false; ga('send', 'event', 'Top Nav', 'Menu', 'Live Chat with Agent');"
                        class="help help-chat">Live Chat with Agent</a></li>
                <li><a href="https://acsmediakit.org/digital/acs-pubs/?utm_source=Nav&amp;utm_medium=Pubs&amp;utm_campaign=CEN"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'For Advertisers');">For Advertisers</a></li>
                <li><a href="https://solutions.acs.org/help/?utm_source=Pubs_Solutions_Referer&amp;utm_medium=Pubs_MenuBotton&amp;utm_campaign=Pubs_Referer"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'For Librarians & Account Managers');">For
                        Librarians & Account Managers</a></li>
            </ul>
        </li>
        <li class="hidden-sm hidden-xs"><a href="#">pairing</a>
            <ul>
                <li><a class="header_burger-menu_pairadevice-link" href="/pairdevice">Pair a device</a></li>
                <li><a class="header_burger-menu_pairthisdevice-link" href="/action/devicePairingSubmitCode"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Pair this device');">Pair this device</a></li>
                <li><a class="header_burger-menu_pairedstatus" href="/action/devicePairingSubmitCode">Paired status</a>
                </li>
            </ul>
        </li>
        <li class="hidden-lg hidden-md">
            <a class="header_burger-menu_my-profile-link" href="/action/showPreferences">My Profile</a>
            <a class="header_burger-menu_login-link" href="/action/ssoRequestForLoginPage">Login</a>
            <a class="header_burger-menu_logout-link" href="#">Logout</a>
            <a class="header_burger-menu_pairadevice-link" href="/pairdevice">Pair a device</a>
            <a class="header_burger-menu_pairthisdevice-link" href="/action/devicePairingSubmitCode">Pair this
                device</a>
            <a class="header_burger-menu_pairedstatus" href="/action/devicePairingSubmitCode">Paired status</a>
        </li>
        <li><a href="#">about us</a>
            <ul>
                <li><a href="/page/about-us.html"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Overview');">Overview</a></li>
                <li><a href="http://acsopenscience.org"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'ACS & Open Access');">ACS & Open Access</a>
                </li>
                <li><a href="/#partners" onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Partners');">Partners</a></li>
                <li><a href="http://acsoncampus.acs.org"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Events');">Events</a></li>
            </ul>
        </li>
    </ul>
</div>
<div class="activity-container-tablet"><i aria-hidden="true" class="icon-close"></i></div>


<script type="text/javascript">
  (function() {
    var se = document.createElement('script'); se.type = 'text/javascript'; se.async = true;
    se.src = 'https://storage.googleapis.com/code.snapengage.com/js/921a4ec7-cecf-43a6-afa5-6cd1346520b1.js';
    var done = false;
    se.onload = se.onreadystatechange = function() {
      if (!done&&(!this.readyState||this.readyState==='loaded'||this.readyState==='complete')) {
        done = true;
        /* Place your SnapEngage JS API code below */
        /* SnapEngage.allowChatSound(true); Example JS API: Enable sounds for Visitors. */
      }
    };
    var s = document.getElementsByTagName('script')[0]; s.parentNode.insertBefore(se, s);
  })();
</script>

<style>
    #SnapABug_Button,
    #designstudio-button {
        display: none;
    }
</style>

</div>
</div>
</div>
</div></div></div>
</div>




        
        <div class="pub"><div aria-live="polite" aria-atomic="true" class="pub-modal"><div class="pub-modal_content loop-trap"><a href="#" aria-label="close" tabindex="0" class="pub-modal_close icon-close pull-right"></a><div class="pub-modal_row"><div class="pub-modal_left"><div class="pub-modal_left-content"><div class="pub-modal_control hidden-lg hidden-md"><span class="pub-modal_control-text">Publications</span><a href="#" title="Back button" class="pub-modal_back"><i class="icon-angle-left"></i></a></div><div class="pub-modal_types"><h6>CONTENT TYPES</h6><ul class="pub-modal_types-list"><li data-type="all" id="allID" class="pub-modal_types-active"><a href="#"><h4>All Types</h4></a></li></ul></div><div class="pub-modal_subjects hidden-sm hidden-xs"><h6>SUBJECTS</h6><ul class="pub-modal_subjects-list"></ul></div></div></div><div class="pub-modal_right"><div class="pub-modal_control hidden-lg hidden-md"><span class="pub-modal_control-text">Publications: All Types</span><a href="#" title="Back button" class="pub-modal_back"><i class="icon-angle-left"></i></a></div><div class="pub-modal_right--inner"><div class="pub-content"></div></div></div></div></div><input type="hidden" name="pubModalData" value="{&quot;types&quot;:[{&quot;code&quot;:&quot;journals&quot;,&quot;label&quot;:&quot;Journals&quot;},{&quot;code&quot;:&quot;books&quot;,&quot;label&quot;:&quot;Books and Reference&quot;},{&quot;code&quot;:&quot;news&quot;,&quot;label&quot;:&quot;News&quot;}],&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;,&quot;label&quot;:&quot;Analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;,&quot;label&quot;:&quot;Applied&quot;},{&quot;code&quot;:&quot;cat_biological&quot;,&quot;label&quot;:&quot;Biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;,&quot;label&quot;:&quot;Materials Science &amp; Engineering&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;,&quot;label&quot;:&quot;Organic-Inorganic&quot;},{&quot;code&quot;:&quot;cat_physical&quot;,&quot;label&quot;:&quot;Physical&quot;}],&quot;publications&quot;:[{&quot;char&quot;:&quot;A&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/achre4/2021/achre4.2021.54.issue-14/achre4.2021.54.issue-14/20210720/achre4.2021.54.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;achre4&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Accounts of Chemical Research&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/achre4&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/amrcda/2021/amrcda.2021.2.issue-7/amrcda.2021.2.issue-7/20210723/amrcda.2021.2.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;amrcda&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Accounts of Materials Research&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amrcda&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aastgj/2021/aastgj.2021.1.issue-3/aastgj.2021.1.issue-3/20210621/aastgj.2021.1.issue-3.largecover.jpg&quot;,&quot;code&quot;:&quot;aastgj&quot;,&quot;subjects&quot;:[],&quot;name&quot;:&quot;ACS Agricultural Science &amp; Technology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aastgj&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aabmcb/2021/aabmcb.2021.4.issue-7/aabmcb.2021.4.issue-7/20210719/aabmcb.2021.4.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aabmcb&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Bio Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aabmcb&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aaembp/2021/aaembp.2021.3.issue-7/aaembp.2021.3.issue-7/20210727/aaembp.2021.3.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aaembp&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Electronic Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aaembp&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aaemcq/2021/aaemcq.2021.4.issue-7/aaemcq.2021.4.issue-7/20210726/aaemcq.2021.4.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aaemcq&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Energy Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aaemcq&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aamick/2021/aamick.2021.13.issue-29/aamick.2021.13.issue-29/20210728/aamick.2021.13.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;aamick&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Materials &amp; Interfaces&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aamick&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aanmf6/2021/aanmf6.2021.4.issue-7/aanmf6.2021.4.issue-7/20210723/aanmf6.2021.4.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aanmf6&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Nano Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aanmf6&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aapmcd/2021/aapmcd.2021.3.issue-7/aapmcd.2021.3.issue-7/20210709/aapmcd.2021.3.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aapmcd&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Polymer Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aapmcd&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/abmcb8/largecover.png&quot;,&quot;code&quot;:&quot;abmcb8&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;}],&quot;name&quot;:&quot;ACS Bio &amp; Med Chem Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/abmcb8&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/abseba/2021/abseba.2021.7.issue-7/abseba.2021.7.issue-7/20210712/abseba.2021.7.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;abseba&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Biomaterials Science &amp; Engineering&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/abseba&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/accacs/2021/accacs.2021.11.issue-14/accacs.2021.11.issue-14/20210716/accacs.2021.11.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;accacs&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Catalysis&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/accacs&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/acscii/2021/acscii.2021.7.issue-7/acscii.2021.7.issue-7/20210728/acscii.2021.7.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;acscii&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Central Science&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/acscii&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/acbcct/2021/acbcct.2021.16.issue-7/acbcct.2021.16.issue-7/20210716/acbcct.2021.16.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;acbcct&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Chemical Biology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/acbcct&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/achsc5/2021/achsc5.2021.28.issue-4/achsc5.2021.28.issue-4/20210726/achsc5.2021.28.issue-4.largecover.jpg&quot;,&quot;code&quot;:&quot;achsc5&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Chemical Health &amp; Safety&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/achsc5&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/acncdm/2021/acncdm.2021.12.issue-14/acncdm.2021.12.issue-14/20210721/acncdm.2021.12.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;acncdm&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Chemical Neuroscience&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/acncdm&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/acsccc/2020/acsccc.2020.22.issue-12/acsccc.2020.22.issue-12/20201214/acsccc.2020.22.issue-12.largecover.jpg&quot;,&quot;code&quot;:&quot;acsccc&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Combinatorial Science&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/acsccc&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aesccq/2021/aesccq.2021.5.issue-7/aesccq.2021.5.issue-7/20210715/aesccq.2021.5.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aesccq&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Earth and Space Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aesccq&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aelccp/2021/aelccp.2021.6.issue-7/aelccp.2021.6.issue-7/20210709/aelccp.2021.6.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aelccp&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Energy Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aelccp&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/aeacb3/largecover.png&quot;,&quot;code&quot;:&quot;aeacb3&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;}],&quot;name&quot;:&quot;ACS Engineering Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aeacb3&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/aeacc4/largecover.png&quot;,&quot;code&quot;:&quot;aeacc4&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;}],&quot;name&quot;:&quot;ACS Environmental Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aeacc4&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aeecco/2021/aeecco.2021.1.issue-7/aeecco.2021.1.issue-7/20210709/aeecco.2021.1.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aeecco&quot;,&quot;subjects&quot;:[],&quot;name&quot;:&quot;ACS ES&amp;T Engineering&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aeecco&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aewcaa/2021/aewcaa.2021.1.issue-7/aewcaa.2021.1.issue-7/20210709/aewcaa.2021.1.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aewcaa&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS ES&amp;T Water&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aewcaa&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/afsthl/2021/afsthl.2021.1.issue-6/afsthl.2021.1.issue-6/20210716/afsthl.2021.1.issue-6.largecover.jpg&quot;,&quot;code&quot;:&quot;afsthl&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Food Science &amp; Technology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/afsthl&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;styleguide&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;category.books&quot;}],&quot;name&quot;:&quot;ACS Guide to Scholarly Communication&quot;,&quot;type&quot;:&quot;books&quot;,&quot;url&quot;:&quot;/series/styleguide&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;infocus&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;}],&quot;name&quot;:&quot;ACS In Focus&quot;,&quot;type&quot;:&quot;books&quot;,&quot;url&quot;:&quot;/series/infocus&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aidcbc/2021/aidcbc.2021.7.issue-7/aidcbc.2021.7.issue-7/20210709/aidcbc.2021.7.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aidcbc&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Infectious Diseases&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aidcbc&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/amlccd/2021/amlccd.2021.10.issue-7/amlccd.2021.10.issue-7/20210720/amlccd.2021.10.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;amlccd&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Macro Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amlccd&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/amacgu/largecover.png&quot;,&quot;code&quot;:&quot;amacgu&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;}],&quot;name&quot;:&quot;ACS Materials Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amacgu&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/amlcef/2021/amlcef.2021.3.issue-7/amlcef.2021.3.issue-7/20210705/amlcef.2021.3.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;amlcef&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Materials Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amlcef&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/amachv/largecover.png&quot;,&quot;code&quot;:&quot;amachv&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;}],&quot;name&quot;:&quot;ACS Measurement Science Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amachv&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/amclct/2021/amclct.2021.12.issue-7/amclct.2021.12.issue-7/20210708/amclct.2021.12.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;amclct&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Medicinal Chemistry Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amclct&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/ancac3/2021/ancac3.2021.15.issue-7/ancac3.2021.15.issue-7/20210727/ancac3.2021.15.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;ancac3&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Nano&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/ancac3&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/anaccx/largecover.png&quot;,&quot;code&quot;:&quot;anaccx&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;}],&quot;name&quot;:&quot;ACS Nanoscience Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/anaccx&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/acsodf/2021/acsodf.2021.6.issue-29/acsodf.2021.6.issue-29/20210727/acsodf.2021.6.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;acsodf&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Omega&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/acsodf&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/aoiab5/largecover.png&quot;,&quot;code&quot;:&quot;aoiab5&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;}],&quot;name&quot;:&quot;ACS Organic &amp; Inorganic Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aoiab5&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aptsfn/2021/aptsfn.2021.4.issue-3/aptsfn.2021.4.issue-3/20210611/aptsfn.2021.4.issue-3.largecover.jpg&quot;,&quot;code&quot;:&quot;aptsfn&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Pharmacology &amp; Translational Science&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aptsfn&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/apchd5/2021/apchd5.2021.8.issue-7/apchd5.2021.8.issue-7/20210721/apchd5.2021.8.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;apchd5&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Photonics&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/apchd5&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/apcach/largecover.png&quot;,&quot;code&quot;:&quot;apcach&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;}],&quot;name&quot;:&quot;ACS Physical Chemistry Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/apcach&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/apaccd/largecover.png&quot;,&quot;code&quot;:&quot;apaccd&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;}],&quot;name&quot;:&quot;ACS Polymers Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/apaccd&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/books/content/reagents/2017/acsreagents/acsreagents/20170228/acsreagents.largecover.png&quot;,&quot;code&quot;:&quot;reagents&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;}],&quot;name&quot;:&quot;ACS Reagent Chemicals&quot;,&quot;type&quot;:&quot;books&quot;,&quot;url&quot;:&quot;/series/reagents&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/ascefj/2021/ascefj.2021.6.issue-7/ascefj.2021.6.issue-7/20210723/ascefj.2021.6.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;ascefj&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Sensors&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/ascefj&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/ascecg/2021/ascecg.2021.9.issue-29/ascecg.2021.9.issue-29/20210726/ascecg.2021.9.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;ascecg&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Sustainable Chemistry &amp; Engineering&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/ascecg&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/books/content/symposium/2021/bk-2021-1379/bk-2021-1379/20210430-01/bk-2021-1379.largecover.jpg&quot;,&quot;code&quot;:&quot;symposium&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;category.books&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;383784032&quot;}],&quot;name&quot;:&quot;ACS Symposium Series&quot;,&quot;type&quot;:&quot;books&quot;,&quot;url&quot;:&quot;/series/symposium&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/asbcd6/2021/asbcd6.2021.10.issue-7/asbcd6.2021.10.issue-7/20210716/asbcd6.2021.10.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;asbcd6&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Synthetic Biology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/asbcd6&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;advances&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;category.books&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;383784032&quot;}],&quot;name&quot;:&quot;Advances in Chemistry&quot;,&quot;type&quot;:&quot;books&quot;,&quot;url&quot;:&quot;/series/advances&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/ancham/2021/ancham.2021.93.issue-29/ancham.2021.93.issue-29/20210727/ancham.2021.93.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;ancham&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Analytical Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/ancham&quot;}]},{&quot;char&quot;:&quot;B&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/bichaw/2021/bichaw.2021.60.issue-29/bichaw.2021.60.issue-29/20210727/bichaw.2021.60.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;bichaw&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Biochemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/bichaw&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/bcches/2021/bcches.2021.32.issue-7/bcches.2021.32.issue-7/20210721/bcches.2021.32.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;bcches&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Bioconjugate Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/bcches&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/bomaf6/2021/bomaf6.2021.22.issue-7/bomaf6.2021.22.issue-7/20210712/bomaf6.2021.22.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;bomaf6&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Biomacromolecules&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/bomaf6&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/bipret/largecover.jpg&quot;,&quot;code&quot;:&quot;bipret&quot;,&quot;subjects&quot;:[],&quot;name&quot;:&quot;Biotechnology Progress&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/bipret&quot;}]},{&quot;char&quot;:&quot;C&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/cgeabj/2021/cgeabj.2021.99.issue-27/cgeabj.2021.99.issue-27/20210726-01/cgeabj.2021.99.issue-27.largecover.jpg&quot;,&quot;code&quot;:&quot;cgeabj&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;}],&quot;name&quot;:&quot;C&amp;EN Global Enterprise&quot;,&quot;type&quot;:&quot;news&quot;,&quot;url&quot;:&quot;/journal/cgeabj&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/crtoec/2021/crtoec.2021.34.issue-7/crtoec.2021.34.issue-7/20210719/crtoec.2021.34.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;crtoec&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Chemical Research in Toxicology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/crtoec&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/chreay/2021/chreay.2021.121.issue-14/chreay.2021.121.issue-14/20210728/chreay.2021.121.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;chreay&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;articletoc&quot;},{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Chemical Reviews&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/chreay&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/cmatex/2021/cmatex.2021.33.issue-14/cmatex.2021.33.issue-14/20210727/cmatex.2021.33.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;cmatex&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Chemistry of Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/cmatex&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/cgdefu/2021/cgdefu.2021.21.issue-7/cgdefu.2021.21.issue-7/20210707/cgdefu.2021.21.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;cgdefu&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Crystal Growth &amp; Design&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/cgdefu&quot;}]},{&quot;char&quot;:&quot;E&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/enfuem/2021/enfuem.2021.35.issue-14/enfuem.2021.35.issue-14/20210715/enfuem.2021.35.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;enfuem&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Energy &amp; Fuels&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/enfuem&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/esthag/2021/esthag.2021.55.issue-14/esthag.2021.55.issue-14/20210720/esthag.2021.55.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;esthag&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Environmental Science &amp; Technology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/esthag&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/estlcu/2021/estlcu.2021.8.issue-7/estlcu.2021.8.issue-7/20210713/estlcu.2021.8.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;estlcu&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Environmental Science &amp; Technology Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/estlcu&quot;}]},{&quot;char&quot;:&quot;I&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iepra6.2&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;I&amp;EC Product Research and Development&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iepra6.2&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iechad&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iechad&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iecac0&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Analytical Edition&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iecac0&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iecjc0&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Chemical &amp; Engineering Data Series&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iecjc0&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iecfa7&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Fundamentals&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iecfa7&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iepdaw&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Process Design and Development&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iepdaw&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iepra6&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Product Research and Development&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iepra6&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/iecred/2021/iecred.2021.60.issue-29/iecred.2021.60.issue-29/20210728/iecred.2021.60.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;iecred&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Research&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iecred&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/inocaj/2021/inocaj.2021.60.issue-14/inocaj.2021.60.issue-14/20210719/inocaj.2021.60.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;inocaj&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Inorganic Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/inocaj&quot;}]},{&quot;char&quot;:&quot;J&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jaaucr/2021/jaaucr.2021.1.issue-7/jaaucr.2021.1.issue-7/20210726/jaaucr.2021.1.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jaaucr&quot;,&quot;subjects&quot;:[],&quot;name&quot;:&quot;JACS Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jaaucr&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jafcau/2021/jafcau.2021.69.issue-29/jafcau.2021.69.issue-29/20210728/jafcau.2021.69.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;jafcau&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Agricultural and Food Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jafcau&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jceaax/2021/jceaax.2021.66.issue-7/jceaax.2021.66.issue-7/20210708/jceaax.2021.66.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jceaax&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Chemical &amp; Engineering Data&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jceaax&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;jci001&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Chemical Documentation&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jci001&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jceda8/2021/jceda8.2021.98.issue-7/jceda8.2021.98.issue-7/20210713/jceda8.2021.98.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jceda8&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;divched&quot;}],&quot;name&quot;:&quot;Journal of Chemical Education&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jceda8&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;jcics1&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Chemical Information and Computer Sciences&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jcics1&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jcisd8/2021/jcisd8.2021.61.issue-7/jcisd8.2021.61.issue-7/20210726/jcisd8.2021.61.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jcisd8&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Chemical Information and Modeling&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jcisd8&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jctcce/2021/jctcce.2021.17.issue-7/jctcce.2021.17.issue-7/20210713/jctcce.2021.17.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jctcce&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Chemical Theory and Computation&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jctcce&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iechad.1&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Industrial &amp; Engineering Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iechad.1&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;jmcmar.1&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Medicinal and Pharmaceutical Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jmcmar.1&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-14/jmcmar.2021.64.issue-14/20210722/jmcmar.2021.64.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;jmcmar&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Medicinal Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jmcmar&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jnprdf/2021/jnprdf.2021.84.issue-7/jnprdf.2021.84.issue-7/20210723/jnprdf.2021.84.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jnprdf&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Natural Products&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jnprdf&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/joceah/2021/joceah.2021.86.issue-14/joceah.2021.86.issue-14/20210716/joceah.2021.86.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;joceah&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Organic Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/joceah&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;jpchax&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Physical Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jpchax&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jpcafh/2021/jpcafh.2021.125.issue-29/jpcafh.2021.125.issue-29/20210729/jpcafh.2021.125.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;jpcafh&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Physical Chemistry A&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jpcafh&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jpcbfk/2021/jpcbfk.2021.125.issue-29/jpcbfk.2021.125.issue-29/20210729/jpcbfk.2021.125.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;jpcbfk&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Physical Chemistry B&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jpcbfk&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jpccck/2021/jpccck.2021.125.issue-29/jpccck.2021.125.issue-29/20210729/jpccck.2021.125.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;jpccck&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Physical Chemistry C&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jpccck&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jpclcd/2021/jpclcd.2021.12.issue-29/jpclcd.2021.12.issue-29/20210729/jpclcd.2021.12.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;jpclcd&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Physical Chemistry Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jpclcd&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jprobs/2021/jprobs.2021.20.issue-7/jprobs.2021.20.issue-7/20210702/jprobs.2021.20.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jprobs&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Proteome Research&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jprobs&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jacsat/2021/jacsat.2021.143.issue-29/jacsat.2021.143.issue-29/20210728/jacsat.2021.143.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;jacsat&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of the American Chemical Society&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jacsat&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jamsef/2021/jamsef.2021.32.issue-7/jamsef.2021.32.issue-7/20210707/jamsef.2021.32.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jamsef&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of the American Society for Mass Spectrometry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jamsef&quot;}]},{&quot;char&quot;:&quot;L&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/langd5/2021/langd5.2021.37.issue-29/langd5.2021.37.issue-29/20210727/langd5.2021.37.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;langd5&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Langmuir&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/langd5&quot;}]},{&quot;char&quot;:&quot;M&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/mamobx/2021/mamobx.2021.54.issue-14/mamobx.2021.54.issue-14/20210727/mamobx.2021.54.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;mamobx&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Macromolecules&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/mamobx&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/mpohbp/2021/mpohbp.2021.18.issue-7/mpohbp.2021.18.issue-7/20210705/mpohbp.2021.18.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;mpohbp&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Molecular Pharmaceutics&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/mpohbp&quot;}]},{&quot;char&quot;:&quot;N&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/nalefd/2021/nalefd.2021.21.issue-14/nalefd.2021.21.issue-14/20210728/nalefd.2021.21.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;nalefd&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Nano Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/nalefd&quot;}]},{&quot;char&quot;:&quot;O&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/orlef7/2021/orlef7.2021.23.issue-14/orlef7.2021.23.issue-14/20210716/orlef7.2021.23.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;orlef7&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Organic Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/orlef7&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/oprdfk/2021/oprdfk.2021.25.issue-7/oprdfk.2021.25.issue-7/20210716/oprdfk.2021.25.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;oprdfk&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Organic Process Research &amp; Development&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/oprdfk&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/orgnd7/2021/orgnd7.2021.40.issue-14/orgnd7.2021.40.issue-14/20210726/orgnd7.2021.40.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;orgnd7&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Organometallics&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/orgnd7&quot;}]},{&quot;char&quot;:&quot;P&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iepra6.1&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Product R&amp;D&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iepra6.1&quot;}]}]}"/></input></div></div>
</header>




        
        <main data-widget-id="28284a6d-730d-4a56-93ad-909787c5ac1b" id="" class="content article"><article data-figures="https://pubs.acs.org/action/ajaxShowFigures?doi=10.1021%2Facs.jmedchem.9b00329&amp;ajax=true" data-references="https://pubs.acs.org/action/ajaxShowEnhancedAbstract?doi=10.1021%2Facs.jmedchem.9b00329&amp;ajax=true" data-enable-mathjax="true"><div class="figure-viewer"><div class="figure-viewer_row"><div class="figure-viewer_col loop-trap"><div aria-live="polite" aria-atomic="true" class="figure-viewer_modal"><a href="#" title="Close" aria-label="close" tabindex="0" class="figure-viewer_close icon-close"></a><h2 class="figure-viewer_label"><span class="figure-viewer_current"></span></h2><div class="figure-viewer_image"><a href="#" title="Next" class="figure-viewer_next icon-angle-right"></a><a href="#" title="Previous" class="figure-viewer_prev icon-angle-left"></a><div class="figure-viewer_image-content"><img src="" alt="Figure 1" class="fv-img"/></img><img src="/pb-assets/ux3/loading-1525090748317.gif" alt="Loading Img" class="loading-img"/></img></div></div><div class="figure-viewer_links"><a href="#" title="Download Hi-Res Image" target="_blank" class="figure-viewer_hi-res-link"><i class="icon-file-image-o"></i><span>Download Hi-Res Image</span></a><span class="fv-separator"></span><a href="#" title="Download to MS-PowerPoint" class="figure-viewer_ms-p-link"><i class="icon-file-powerpoint-o"></i><span>Download to MS-PowerPoint</span></a><span class="cit-this-container"><a href="/action/showCitFormats?doi=10.1021/acs.jmedchem.9b00329&amp;href=/doi/10.1021/acs.jmedchem.9b00329" title="Cite This" class="figure-viewer-cite-this-link"><i class="icon-check-circle"></i><span><strong>Cite This:</strong></span></a><span class="article_header-cite-this figure-viewer-cite-this"><span class="cit-fg-title"><i>J. Med. Chem.</i></span><span class="cit-fg-year"> 2019</span><span class="cit-fg-volume">, 62</span><span class="cit-fg-issue">, 14</span><span class="cit-fg-pageRange">, 6561-6574</span></span></span></div></div></div></div></div><div class="article_fullPage"><div class="article_header"><div class="articleHeaderDropzone5" data-pb-dropzone="articleHeaderDropzone5"><div class="advertisement">
	<div class="advertisement-link">
		<a href="http://acsmediakit.org">ADVERTISEMENT</a>
	</div>
	<div id="dfp-journal-article-leaderboard">
		<script type="text/javascript">
			$(document).ready(function() {
				setTimeout(function() {
					googletag.cmd.push(function() { googletag.display("dfp-journal-article-leaderboard"); });
				}, 1400);
			});
		</script>
	</div>
</div></div><div class="container container_scaled-down"><div class="row"><div class="col-xs-12.clearfix"><div class="article_header-left pull-left"><div class="article_header-dropzone-1"><div class="articleHeaderDropzone1" data-pb-dropzone="articleHeaderDropzone1"><div class="content-navigation clearfix"><a href="/toc/jmcmar/62/14" title="Return to Issue" id="returnToIssues" class="content-navigation__btn--return"><span>RETURN TO ISSUE</span></a><a href="/doi/10.1021/acs.jmedchem.9b00260" title="Previous" id="prevID" class="content-navigation__btn--pre"><i class="icon-angle-left"></i><span>PREV</span></a><span class="content-navigation__contentType">Article</span><a href="/doi/10.1021/acs.jmedchem.9b00362" title="Next" id="nextID" class="content-navigation__btn--next"><span>NEXT</span><i class="icon-angle-right"></i></a></div></div></div><div class="headerLogo_e-alertsMobile_container"><div class="article_header-logo hidden-lg"><div class="pj-badge"></div><a href="/journal/jmcmar" title="Journal Logo"><img src="/specs/ux3/releasedAssets/images/loader.gif" data-src="/na101/home/literatum/publisher/achs/journals/covergifs/jmcmar/title.png" alt="Journal Logo" /></img></a></div><div class="e-alertsMobile_container hidden-md hidden-lg"></div></div><h1 class="article_header-title"><span class="hlFld-Title">Discovery of 4-Aminoquinoline-3-carboxamide Derivatives as Potent Reversible Bruton’s Tyrosine Kinase Inhibitors for the Treatment of Rheumatoid Arthritis</span></h1><ul class="loa"><li><span><span class="hlFld-ContribAuthor">Xia Yao</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Xia Yao</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Ministry of Education (MOE) Key Laboratory of Protein Sciences, School of Pharmaceutical Sciences, MOE Key Laboratory of Bioorganic Phosphorus Chemistry & Chemical Biology, Tsinghua University, Beijing 100084, P. R. China</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Xia++Yao">Xia Yao</a></span></div><div class="loa-info-orcid"><img src="/products/achs/releasedAssets/images/orchid.png" alt="Orcid" /></img><a href="http://orcid.org/0000-0003-2406-268X" title="Orcid link">http://orcid.org/0000-0003-2406-268X</a></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Xiuyun Sun</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Xiuyun Sun</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Ministry of Education (MOE) Key Laboratory of Protein Sciences, School of Pharmaceutical Sciences, MOE Key Laboratory of Bioorganic Phosphorus Chemistry & Chemical Biology, Tsinghua University, Beijing 100084, P. R. China</div><div class="loa-info-affiliations-info">Tsinghua-Peking Center for Life Sciences, Beijing 100084, P. R. China</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Xiuyun++Sun">Xiuyun Sun</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Shuyu Jin</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Shuyu Jin</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Key Laboratory of Structure-Based Drugs Design & Discovery of Ministry of Education, Shenyang Pharmaceutical University, Shenyang 110016, P. R. China</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Shuyu++Jin">Shuyu Jin</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Ling Yang</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Ling Yang</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">R&D Institute, Chia Tai Tianqing Pharmaceutical Group Co., LTD, Nanjing 210023, P. R. China</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Ling++Yang">Ling Yang</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Hongjiang Xu</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Hongjiang Xu</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">R&D Institute, Chia Tai Tianqing Pharmaceutical Group Co., LTD, Nanjing 210023, P. R. China</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Hongjiang++Xu">Hongjiang Xu</a></span></div></div></span></li><span class="comma-separator">, and </span><li><span><span class="hlFld-ContribAuthor">Yu Rao</span><strong>*</strong><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Yu Rao</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Ministry of Education (MOE) Key Laboratory of Protein Sciences, School of Pharmaceutical Sciences, MOE Key Laboratory of Bioorganic Phosphorus Chemistry & Chemical Biology, Tsinghua University, Beijing 100084, P. R. China</div></div><span class="conrtib-corresp"><strong>*</strong>E-mail: <a href="/cdn-cgi/l/email-protection#d7aea5b6b897a3a4beb9b0bfa2b6f9b2b3a2f9b4b9"><span class="__cf_email__" data-cfemail="dda4afbcb29da9aeb4b3bab5a8bcf3b8b9a8f3beb3">[email protected]</span></a></span><span class="conrtib-corresp"></span><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Yu++Rao">Yu Rao</a></span></div><div class="loa-info-orcid"><img src="/products/achs/releasedAssets/images/orchid.png" alt="Orcid" /></img><a href="http://orcid.org/0000-0002-4356-8531" title="Orcid link">http://orcid.org/0000-0002-4356-8531</a></div></div></span></li><span class="comma-separator"></span></ul><div class="article_header-meta clearfix"><div class="article_header-meta-left pull-left"><input type="hidden" name="journalCodeForjhpLink" value="jmcmar" /></input><input type="hidden" name="journalNameForjhpLink" value="Journal of Medicinal Chemistry" /></input><div class="article_header-cite-this"><a href="/action/showCitFormats?doi=10.1021%2Facs.jmedchem.9b00329&amp;href=/doi/10.1021%2Facs.jmedchem.9b00329" title="Cite This"><i class="icon-check-circle"></i><strong>Cite this: </strong></a><span class="cit-title"><i>J. Med. Chem.</i></span> <span class="cit-year-info"><span>2019</span></span><span class="cit-volume">, 62</span><span class="cit-issue">, 14</span><span class="cit-pageRange">, 6561–6574</span></div><div class="article_header-epubdate"><span class="pub-date epub-date">Publication Date</span><span class="web-text"> (Web)</span><span class="date-separator">:</span><span class="pub-date-value">July 1, 2019</span><div class="article_header-history base dropBlock"><a href="#" data-db-target-for="article_header-history" title="History" target="_self" class="" aria-expanded="false"><i class="icon-angle-down"></i><i class="icon-angle-up"></i></a><div data-db-target-of="article_header-history" class="dropBlock__holder" aria-hidden="true"><div class="articleHeaderHistoryDropzone" data-pb-dropzone="articleHeaderHistoryDropzone"><h4>Publication History</h4>




        
        <ul class="rlist article-chapter-history-list"><li><span class="item_label"><b>Received</b></span>21 February 2019</li><li><span class="item_label"><b>Published</b> online</span>1 July 2019</li><li><span class="item_label"><b>Published</b> in</span><span class="item_label-issue">issue</span> 25 July 2019</li></ul></div></div></div></div><div class="article_header-doiurl"><a href="https://doi.org/10.1021/acs.jmedchem.9b00329" title="DOI URL">https://doi.org/10.1021/acs.jmedchem.9b00329</a></div><div class="article_header-article-copyright"><strong>Copyright © 2019 American Chemical Society</strong></div><div class="article_rightPermissionsLink"><div class="articleHeaderDropzone4" data-pb-dropzone="articleHeaderDropzone4"><div class="articleRightsPermissionsLink"><a href="/servlet/linkout?type=rightslink&amp;url=startPage%3D6561%26pageCount%3D14%26copyright%3DAmerican%2BChemical%2BSociety%26author%3DXia%2BYao%252C%2BXiuyun%2BSun%252C%2BShuyu%2BJin%252C%2Bet%2Bal%26orderBeanReset%3Dtrue%26imprint%3DAmerican%2BChemical%2BSociety%26volumeNum%3D62%26issueNum%3D14%26contentID%3Dacs.jmedchem.9b00329%26title%3DDiscovery%2Bof%2B4-Aminoquinoline-3-carboxamide%2BDerivatives%2Bas%2BPotent%2BReversible%2BBruton%25E2%2580%2599s%2BTyrosine%2BKinase%2BInhibitors%2Bfor%2Bthe%2BTreatment%2Bof%2BRheumatoid%2BArthritis%26numPages%3D14%26pa%3D%26issn%3D0022-2623%26publisherName%3Dacs%26publication%3Djmcmar%26rpt%3Dn%26endPage%3D6574%26publicationDate%3DJuly%2B2019">RIGHTS & PERMISSIONS</a></div></div></div><div class="article_header-access-block"><div class="article_header-open-access"></div><div class="article_header-access-icon"><img src="/products/achs/releasedAssets/images/subscribed.svg" alt="Subscribed Access" /></img></div></div></div><div class="article_header-meta-center pull-left"><div class="articleHeaderDropzone3" data-pb-dropzone="articleHeaderDropzone3"><div class="articleMetrics"><div class="articleMetrics_table"><div class="articleMetrics_row"><input type="hidden" name="articleMetricsDoi" value="10.1021/acs.jmedchem.9b00329"/></input><div class="articleMetrics_metric"><h6>Article Views</h6><div class="articleMetrics-val">2300</div></div><div class="articleMetrics_altmetric"><h6>Altmetric</h6><div class="articleMetrics-val articleMetrics_score">-</div><div class="altmetric-donut hidden"><div data-badge-details="right" data-badge-type="donut" data-hide-no-mentions="false" data-condensed="true" class="altmetric-embed"></div></div></div><div class="articleMetrics_count"><h6>Citations</h6><div class="articleMetrics-val"><a href="#citeThis" class="internalNav">6</a></div></div></div></div><div class="articleMetrics_about"><div class="base dropBlock"><a href="#" data-db-target-for="aboutArticleMetrics" class="article_aboutLink">LEARN ABOUT THESE METRICS</a><div data-db-target-of="aboutArticleMetrics" aria-live="polite" aria-atomic="true" role="alert" class="dropBlock__holder"><i aria-hidden="true" class="icon-close_thin"></i><p>Article Views are the COUNTER-compliant sum of full text article downloads since November 2008 (both PDF and HTML) across all institutions and individuals. These metrics are regularly updated to reflect usage leading up to the last few days.</p><p>Citations are the number of other articles citing this article, calculated by Crossref and updated daily.<a href="https://www.crossref.org/services/cited-by/" title="Find more information about Crossref citation counts"> Find more information about Crossref citation counts.</a></p><p>The Altmetric Attention Score is a quantitative measure of the attention that a research article has received online. Clicking on the donut icon will load a page at altmetric.com with additional details about the score and the social media presence for the given article. Find more information on<a href="https://help.altmetric.com/support/solutions/articles/6000233311-how-is-the-altmetric-attention-score-calculated" title="The Altmetric Attention Score and how the score is calculated"> the Altmetric Attention Score and how the score is calculated.</a></p></div></div></div></div></div></div><div class="article_header-meta-right"><div class="articleHeaderDropzone6" data-pb-dropzone="articleHeaderDropzone6"><div data-widget-def="UX3share" data-widget-id="787b5b92-0445-40f4-bdd2-9591d56f4a67" class="article_header-share share_label_visible">
        



        
        <script data-cfasync="false" src="/cdn-cgi/scripts/5c5dd728/cloudflare-static/email-decode.min.js"></script><script type="text/javascript" async="async" src="//s7.addthis.com/js/300/addthis_widget.js#pubid=xa-4faab26f2cff13a7"></script><div class="share"><div class="share_button"><span class="share__label">Share</span><a href="#" data-db-target-for="787b5b92-0445-40f4-bdd2-9591d56f4a67" data-db-switch="icon-close_thin" aria-label="share button" class="share__ctrl"><i aria-hidden="true" class="icon-Icon_Share"></i></a></div>



        
        <div class="achs-addto-mendeley"><input type="hidden" name="statusEndpoint" value="https://sso.acs.org/idp/status" class="statusEndpoint"/></input><input type="hidden" name="clientID" value="atypon-lives" class="clientID"/></input><input type="hidden" class="doi" value="10.1021/acs.jmedchem.9b00329" /></input><span class="achs-addto-mendeley_label achs-addto-mendeley_addToLabel">Add to</span><span class="achs-addto-mendeley_label achs-addto-mendeley_viewInLabel">View In</span><a title="Add to mendeley button" class="achs-addto-mendeley_button" tabindex="0"><i class="achs-addto-mendeley_icon icon-mendeley"></i><i class="achs-addto-mendeley_close icon-close"></i></a><div data-db-target-of="5423a74c-bbd8-47b1-9f43-99423ee72e5c" class="achs-addto-mendeley_list dropBlock__holder"><ul><li><a href="#" title="Add Full Text with Reference" class="achs-addto-mendeley_disabled-button add-full-document"><i class="icon-bookmark-o"></i><span>Add Full Text with Reference</span></a></li><li><a href="#" title="Add Description" class="achs-mendeley_button add-metadata-description"><i class="icon-mendeley"></i><span>Add Description</span></a></li></ul></div><a href="#" title="View in mendeley button" class="achs-addto-mendeley_viewin-button"><i class="icon-mendeley"></i></a><div class="achs_loader"><div class="achs_loader_dot"></div><div class="achs_loader_dot"></div><div class="achs_loader_dot"></div></div><input type="hidden" name="meta-data" value="{&quot;title&quot;:&quot;Discovery of 4-Aminoquinoline-3-carboxamide Derivatives as Potent Reversible Bruton’s Tyrosine Kinase Inhibitors for the Treatment of Rheumatoid Arthritis&quot;,&quot;type&quot;:&quot;journal&quot;,&quot;authors&quot;:[{&quot;first_name&quot;:&quot;Xia&quot;,&quot;last_name&quot;:&quot;Yao&quot;},{&quot;first_name&quot;:&quot;Xiuyun&quot;,&quot;last_name&quot;:&quot;Sun&quot;},{&quot;first_name&quot;:&quot;Shuyu&quot;,&quot;last_name&quot;:&quot;Jin&quot;},{&quot;first_name&quot;:&quot;Ling&quot;,&quot;last_name&quot;:&quot;Yang&quot;},{&quot;first_name&quot;:&quot;Hongjiang&quot;,&quot;last_name&quot;:&quot;Xu&quot;},{&quot;first_name&quot;:&quot;Yu&quot;,&quot;last_name&quot;:&quot;Rao&quot;}],&quot;source&quot;:&quot;Journal of Medicinal Chemistry&quot;,&quot;year&quot;:&quot;2019&quot;,&quot;month&quot;:&quot;07&quot;,&quot;day&quot;:&quot;01&quot;,&quot;issue&quot;:&quot;14&quot;,&quot;volume&quot;:&quot;62&quot;,&quot;pages&quot;:&quot;6561-6574&quot;,&quot;identifiers&quot;:{&quot;doi&quot;:&quot;10.1021/acs.jmedchem.9b00329&quot;},&quot;abstract&quot;:&quot;A structure-hopping strategy was applied to discover a series of novel 4-aminoquinoline-3-carboxamide derivatives as potent, reversible BTK inhibitors. Compared to the previously described cinnoline scaffold compounds, the 4-aminoquinoline analogues showed significantly improved drug-like properties, especially in their aqueous solubility. The most potent compound, 25, displayed a stronger inhibitory effect on both BTKWT (IC50 = 5.3 nM) and BTKC481S (IC50 = 39 nM). In a rodent collagen-induced arthritis model, compound 25 efficiently reduced paw swelling without a loss in body weight. On the basis of potency, drug-like properties, stability, and noncovalent mode of inhibition, our representative inhibitors could have a promising profile to be treatments for a wide range of autoimmune diseases.&quot;}" class="meta-data"/></input><input type="hidden" name="mendeley-api-endpoint" value="https://api.mendeley.com/documents" class="mendeley-api-endpoint"/></input><input type="hidden" name="pub-access" value="full" class="pub-access"/></input><input type="hidden" name="library-url" value="https://www.mendeley.com/library/" class="library-url"/></input><input type="hidden" name="selected-share-option" class="selected-share-option"/></input></div>




        
        <div class="cit-download-dropdown"><span class="cit-download-dropdown_label">Export</span><a href="#" data-db-target-for="cit-download-dropdown_content" title="Download citation button" class="cit-download-dropdown_button"><span>RIS</span><i aria-hidden="true" aria-label="close" class="icon-close"></i></a><div data-db-target-of="cit-download-dropdown_content" class="cit-download-dropdown_content"><ul><li><a href="/action/downloadCitation?doi=10.1021%2Facs.jmedchem.9b00329&amp;include=cit&amp;format=ris&amp;direct=true&amp;downloadFileName=acs.jmedchem.9b00329" title="Citation"><span>Citation</span></a></li><li><a href="/action/downloadCitation?doi=10.1021%2Facs.jmedchem.9b00329&amp;include=abs&amp;format=ris&amp;direct=true&amp;downloadFileName=acs.jmedchem.9b00329" title="Citation and abstract"><span>Citation and abstract</span></a></li><li><a href="/action/downloadCitation?doi=10.1021%2Facs.jmedchem.9b00329&amp;include=ref&amp;format=ris&amp;direct=true&amp;downloadFileName=acs.jmedchem.9b00329" title="Citation and references"><span>Citation and references</span></a></li><li><a href="/action/showCitFormats?doi=10.1021%2Facs.jmedchem.9b00329&amp;include=cit&amp;format=ris&amp;direct=true&amp;downloadFileName=acs.jmedchem.9b00329&amp;href=/doi/10.1021/acs.jmedchem.9b00329" title="Cite This"><i class="icon-plus-square"></i><span>More Options</span></a></li></ul></div></div>
<div data-db-target-of="787b5b92-0445-40f4-bdd2-9591d56f4a67" id="787b5b92-0445-40f4-bdd2-9591d56f4a67_Pop" class="share__block dropBlock__holder fixed"><span class="sr-only">Share on</span><ul class="rlist w-slide--list addthis addthis_toolbox addthis_default_style addthis_32x32_style"><li><a role="link" class="addthis_button_facebook"><i aria-hidden="true" class="at-icon-wrapper icon-facebook"></i>Facebook</a></li><li><a role="link" class="addthis_button_twitter"><i aria-hidden="true" class="at-icon-wrapper icon-twitter"></i>Twitter</a></li><li><a role="link" class="addthis_button_wechat"><i aria-hidden="true" class="at-icon-wrapper icon-wechat"></i>Wechat</a></li><li><a role="link" class="addthis_button_linkedin"><i aria-hidden="true" class="at-icon-wrapper icon-linkedin"></i>Linked In</a></li><li><a role="link" class="addthis_button_reddit"><i aria-hidden="true" class="at-icon-wrapper icon-reddit"></i>Reddit</a></li></ul></div></div>

        </div></div></div></div><div class="article_header-footer"><div class="article_header-footer-left pull-left clearfix"><div class="article_header-links pull-left"><input class="pub-doi" type="hidden" name="pub-doi" value="10.1021/acs.jmedchem.9b00329" /></input><a href="/doi/pdf/10.1021/acs.jmedchem.9b00329" title="PDF" target="_blank" class="button_primary pdf-button"><i class="icon-file-pdf-o"></i><span>PDF (3 MB)
                            </span></a><a href="/servlet/linkout?suffix=s0&amp;dbid=16384&amp;doi=10.1021/acs.jmedchem.9b00329&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fid%3Ddoi%3A10.1021%252Facs.jmedchem.9b00329%26sid%3Dliteratum%253Aachs%26pmid%3D31260299%26genre%3Darticle%26aulast%3DYao%26date%3D2019%26atitle%3DDiscovery%2Bof%2B4-Aminoquinoline-3-carboxamide%2BDerivatives%2Bas%2BPotent%2BReversible%2BBruton%25E2%2580%2599s%2BTyrosine%2BKinase%2BInhibitors%2Bfor%2Bthe%2BTreatment%2Bof%2BRheumatoid%2BArthritis%26jtitle%3DJournal%2Bof%2BMedicinal%2BChemistry%26title%3DJournal%2Bof%2BMedicinal%2BChemistry%26volume%3D62%26issue%3D14%26spage%3D6561%26epage%3D6574%26issn%3D0022-2623" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a><div class="articleHeaderDropzone8" data-pb-dropzone="articleHeaderDropzone8"><div class="external-alerts-management"><input type="hidden" name="pub-type" value="article" class="pub-type"/></input><input type="hidden" name="is-enabled" value="true" class="is-enabled"/></input><input type="hidden" name="is-authenticated" value="false" class="is-authenticated"/></input><input type="hidden" name="pub-code" value="jmcmar" class="pub-code"/></input><input type="hidden" name="linkout-url" value="https://preferences.acspubs.org/journals" class="linkout-url"/></input><button data-toggle="modal" data-target="#ealertsModal" class="ealerts-toggle-btn hidden"></button><a class="button_primary_2 niHeader_getEAlerts jhHeader_sub_info"><i class="icon-send"></i><i class="icon-envelope"></i><i class="icon-check"></i><span class="ealerts-btn-text">Get e-Alerts</span><i aria-hidden="true" aria-label="close" class="icon-close"></i></a><div class="ux-modal-container"><div id="ealertsModal" style="display: none;" aria-live="polite" aria-atomic="true" class="modal"><div class="modal__dialog"><div class="modal__body"><iframe src="" class="ealerts-frame"></iframe></div></div></div></div><input type="hidden" id="ealertsModalSrc" value="https://preferences.acspubs.org/jmcmar?ifr=1"/></input></div></div></div><div class="article_header-suppInfo pull-left"><i class="icon-supporting-info"></i><span class="article_header-suppInfo-text">Supporting Info (4)</span><span class="article_header-suppInfo-arrow">»</span><a href="#" data-slide-target=".tab__pane-suppInfo" title="Supporting Information" class="article_header-suppInfo-link-mobile hidden-sm hidden-md hidden-lg w-slide__btn">Supporting Information
                </a><a href="#article_content-right" title="Supporting Information" data-scrollDuration="1000" class="article_header-suppInfo-link internalNav hidden-xs">Supporting Information
                </a></div></div><div class="article_header-footer-right"><div class="articleHeaderDropzone7" data-pb-dropzone="articleHeaderDropzone7"><div class="article_header-footer-right"><div class="article_header-taxonomy"><span>SUBJECTS:</span><ul class="rlist--inline loa"><li><a href="/action/doSearch?ConceptID=292464" title="Rodent models">Rodent models</a>,</li><li><a href="/action/doSearch?ConceptID=292528" title="Inhibitors">Inhibitors</a>,</li><li><a href="/action/doSearch?ConceptID=291793" title="Inhibition">Inhibition</a>,</li><li><a href="/action/doSearch?ConceptID=292524" title="Peptides and proteins">Peptides and proteins</a>,</li><li><a href="/action/doSearch?ConceptID=291454" title="Solubility">Solubility</a></li></ul></div></div></div></div></div></div><div class="article_header-right pull-left hidden-md hidden-sm hidden-xs"><div class="articleHeaderDropzone2" data-pb-dropzone="articleHeaderDropzone2"><div class="cover-image"><div class="cover-image__image"><a href="/toc/jmcmar/62/14" title="Go to Journal of Medicinal Chemistry "><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-14/jmcmar.2019.62.issue-14/20190725/jmcmar.2019.62.issue-14.largecover.jpg" alt="Go to Journal of Medicinal Chemistry "/></img></a></div></div>




        
        
<script>
 $(document).ready(function() {
   $('.article_header .external-alerts-management .niHeader_getEAlerts').each(function(){
	 var Tab = $(this).attr("href");
	   if(typeof Tab != undefined && Tab != false){
		 console.log("Testing Tab");
		 $(this).attr('href','#');
	   }
   });
 });
 $(document).on('click', '.article_header .external-alerts-management .niHeader_getEAlerts', function (e) {
	 //do something
	 if($(this).hasClass('registered')){
	  //send data to analytics for registered users
	      ga('send','event','Registered e-Alert','Article Page Click','jmcmar');
	  }else{
	     //send data to analytics for non-registered users
	      ga('send','event','Get e-Alert','Article Page Click','jmcmar');
	  }
  });
</script>





        
        <div class="pj-badge"></div>




        
        <div class="aJhp_link"></div>
<a href="/action/doUpdateAlertSettings?action=addJournal&amp;journalCode=jmcmar" class="button_primary_2"><i class="icon-send"></i><span>Get e-Alerts</span></a></div></div></div></div></div></div></div><div class="article_abstract"><div class="container container_scaled-down"><div class="row"><div class="col-xs-12"><h2 class="article_abstract-title" id="Abstract">Abstract</h2><div class="article_abstract-content hlFld-Abstract" id="abstractBox"><figure id="_i1" data-index="0" class="article__inlineFigure article_abstract-img"><img class="inline-fig internalNav" src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-14/acs.jmedchem.9b00329/20190719/images/medium/jm-2019-00329v_0016.gif" alt="" id="tgr1" /></img><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-14/acs.jmedchem.9b00329/20190719/images/large/jm-2019-00329v_0016.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.9b00329&amp;id=_i1"><span>Download MS PowerPoint Slide</span></a></div></div></figure><p class="articleBody_abstractText">A structure-hopping strategy was applied to discover a series of novel 4-aminoquinoline-3-carboxamide derivatives as potent, reversible BTK inhibitors. Compared to the previously described cinnoline scaffold compounds, the 4-aminoquinoline analogues showed significantly improved drug-like properties, especially in their aqueous solubility. The most potent compound, <b>25</b>, displayed a stronger inhibitory effect on both BTK<sup><i>WT</i></sup> (IC<sub>50</sub> = 5.3 nM) and BTK<sup><i>C481S</i></sup> (IC<sub>50</sub> = 39 nM). In a rodent collagen-induced arthritis model, compound <b>25</b> efficiently reduced paw swelling without a loss in body weight. On the basis of potency, drug-like properties, stability, and noncovalent mode of inhibition, our representative inhibitors could have a promising profile to be treatments for a wide range of autoimmune diseases.</p></div></div></div></div></div><div class="article_content"><ul class="tab-nav-shortcut"><li><i class="icon-image"></i></li><li><i class="icon-link"></i></li><li><i class="icon-supporting-info"></i></li></ul><div class="container container_scaled-down"><div class="row"><div class="col-xs-12"><div class="article_content-table hlFld-FullText"><div class="article_content-row"><div class="article_content-left"><div id="sec1" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i2">Introduction</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_75517" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_75517" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div class="NLM_p">Rheumatoid arthritis (RA) is a multifactorial autoimmune disease that can cause serious cartilage destruction and bone erosion.<a onclick="showRef(event, 'ref1'); return false;" href="javascript:void(0);" class="ref ref1">(1)</a> Therapeutic medications for RA include nonsteroidal anti-inflammatory drugs (NSAIDs), disease-modifying antirheumatic drugs (DMARDs), TNF alpha inhibitors, IL-6 inhibitors, T-cell activation inhibitors, B-cell depleters, immunosuppressants, and so forth.<a onclick="showRef(event, 'ref2'); return false;" href="javascript:void(0);" class="ref ref2">(2)</a> Tofacitinib, a JAK1/3 inhibitor, was approved by the FDA in 2012 and served as the first kinase inhibitor for the treatment of autoimmune diseases. It has been reported that tofacitinib has an efficacy similar to adalimumab in RA patients who show a poor response to methotrexate (MTX) administration.<a onclick="showRef(event, 'ref3'); return false;" href="javascript:void(0);" class="ref ref3">(3)</a> The success of tofacitinib motivated us to search for other kinase targets that are implicated in RA.<a onclick="showRef(event, 'ref4'); return false;" href="javascript:void(0);" class="ref ref4">(4)</a> Recently, several findings suggested that inhibiting the activity of Bruton’s tyrosine kinase (BTK) could provide a promising treatment profile for autoimmune diseases such as RA and systemic lupus erythematosus (SLE).<a onclick="showRef(event, 'ref5 ref6'); return false;" href="javascript:void(0);" class="ref ref5 ref6">(5,6)</a> BTK belongs to the Tec non-receptor tyrosine kinase family and participates in various signal pathways, including B cell receptor (BCR) pathway. It is well known that BTK plays an important role in the differentiation, activation, proliferation, and survival of B lymphocytes.<a onclick="showRef(event, 'ref7 ref8 ref9'); return false;" href="javascript:void(0);" class="ref ref7 ref8 ref9">(7−9)</a> Studies in rodent arthritis models have provided evidence for a dual mechanism of action: (i) inhibition of BCR-dependent B lymphocyte activation and autoantibody secretion and (ii) suppression of myeloid cell-dependent inflammatory cytokine production.<a onclick="showRef(event, 'ref10 ref11'); return false;" href="javascript:void(0);" class="ref ref10 ref11">(10,11)</a></div><div class="NLM_p">For over a decade, several BTK inhibitors have been discovered for clinical therapy in hematologic malignancies and chronic inflammatory diseases.<a onclick="showRef(event, 'ref12 ref13 ref14 ref15'); return false;" href="javascript:void(0);" class="ref ref12 ref13 ref14 ref15">(12−15)</a> Among these molecules, Ibrutinib (<a data-tab="pane-pcw-Figures" href="#fig1" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig1" id="" class=" internalNav">1</a></a>, <b>1</b>),<a onclick="showRef(event, 'ref16 ref17'); return false;" href="javascript:void(0);" class="ref ref16 ref17">(16,17)</a> the most advanced BTK inhibitor, has been approved for B cell malignancies and chronic lymphocytic leukemia.<a onclick="showRef(event, 'ref18 ref19 ref20 ref21 ref22'); return false;" href="javascript:void(0);" class="ref ref18 ref19 ref20 ref21 ref22">(18−22)</a> Ibrutinib is an irreversible inhibitor of BTK that covalently binds to Cys481 in the kinase domain. Though covalent BTK inhibitors, such as spebrutinib (CC-292. <a data-tab="pane-pcw-Figures" href="#fig1" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig1" id="" class=" internalNav">1</a></a>, <b>2</b>)<a onclick="showRef(event, 'ref23'); return false;" href="javascript:void(0);" class="ref ref23">(23)</a> and acalabrutinib (ACP-196. <a data-tab="pane-pcw-Figures" href="#fig1" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig1" id="" class=" internalNav">1</a></a>, <b>3</b>),<a onclick="showRef(event, 'ref24 ref25'); return false;" href="javascript:void(0);" class="ref ref24 ref25">(24,25)</a> are currently involved in clinical development for RA, these molecules actually possess many safety risks. For instance, the Michael receptor portions of covalent inhibitors raise the concern of unwanted off-target inhibition.<a onclick="showRef(event, 'ref26'); return false;" href="javascript:void(0);" class="ref ref26">(26)</a> In addition, haptenization of serum proteins by reactive groups potentially leads to allergic reactions in patients, such as fever, lymphadenopathy, edema, and albuminuria. It is widely acknowledged that reversible inhibitors are more likely to provide a lower risk of toxicity in RA patients compared to an irreversible inhibitor. However, compared to covalent inhibitors, the development of reversible BTK inhibitors has been slow.<a onclick="showRef(event, 'ref27 ref28 ref29 ref30 ref31 ref32 ref33 ref34 ref35 ref36 ref37 ref38 ref39 ref40 ref41 ref42 ref43 ref44 ref45 ref46'); return false;" href="javascript:void(0);" class="ref ref27 ref28 ref29 ref30 ref31 ref32 ref33 ref34 ref35 ref36 ref37 ref38 ref39 ref40 ref41 ref42 ref43 ref44 ref45 ref46">(27−46)</a> To date, no reversible inhibitors have been approved for clinical applications. The well-known noncovalent BTK inhibitors, RN-486 (<a data-tab="pane-pcw-Figures" href="#fig1" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig1" id="" class=" internalNav">1</a></a>, <b>4</b>) and GDC-0834 (<a data-tab="pane-pcw-Figures" href="#fig1" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig1" id="" class=" internalNav">1</a></a>, <b>5</b>), both suffer from poor stability and pharmacokinetic (PK) profiles.<a onclick="showRef(event, 'ref42'); return false;" href="javascript:void(0);" class="ref ref42">(42)</a> Considering the prospects of BTK for the treatment of autoimmune disorders, the development of novel reversible inhibitors with favorable drug-like properties is urgently needed. In this work, a structure-hopping strategy was applied to discover 4-aminoquinoline-3-carboxamide derivatives as potent BTK inhibitors. Removal of the insignificant nitrogen and incorporation of methoxy and fluorine group substitutions significantly improved the aqueous solubility without compromising the activity against BTK. The most potent inhibitor exhibited strong inhibition of BTK and cellular Tyr223 autophosphorylation. In addition, the modeling of compound <b>25</b> in the active site of BTK suggested that the binding pose of our reversible inhibitor was orthogonal to that of Ibrutinib. As a result, <b>25</b> exhibited an IC<sub>50</sub> value of 39 nM against the BTK<sup><i>C481S</i></sup> protein and provided improved kinase selectivity when compared to Ibrutinib, particularly against EGFR, TEC, and ITK.<a onclick="showRef(event, 'ref17 ref47 ref48 ref49'); return false;" href="javascript:void(0);" class="ref ref17 ref47 ref48 ref49">(17,47−49)</a> In a rodent collagen-induced arthritis (CIA) model, compound <b>25</b> efficiently reduced paw swelling without a loss in body weight, implying that our inhibitor is efficacious and well tolerated in this study.</div><figure id="fig1" data-index="1" class="article__inlineFigure"><h2 class="fig-label">Figure 1</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-14/acs.jmedchem.9b00329/20190719/images/medium/jm-2019-00329v_0001.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-14/acs.jmedchem.9b00329/20190719/images/large/jm-2019-00329v_0001.jpeg" id="gr1" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 1. Well-known BTK inhibitors.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-14/acs.jmedchem.9b00329/20190719/images/large/jm-2019-00329v_0001.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.9b00329&amp;id=fig1"><span>Download MS PowerPoint Slide</span></a></div></div></figure></div><div id="sec2" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i3">Results and Discussion</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_77735" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_77735" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div id="sec2_1" class="NLM_sec NLM_sec_level_2"><div id="ac_i4" class="anchor-spacer"></div><h3 class="article-section__title" id="_i4"> Design and in Vitro Study</h3><div class="NLM_p">Previously, compound <b>6</b> was reported as a potent reversible BTK inhibitor.<a onclick="showRef(event, 'ref35'); return false;" href="javascript:void(0);" class="ref ref35">(35)</a> While it demonstrated good in vitro activity against BTK, compound <b>6</b> exhibited poor aqueous solubility (at pH 7.4 < 0.05 μg/mL), which limited its in vivo study. Given the stability and inhibitory activity of compound <b>6</b>, we envisioned that optimization might yield a promising lead candidate with improved physiochemical properties with a retention in potency. It is well acknowledged that compounds with suitable aqueous solubility and Clog <i>P</i> values are more likely to provide acceptable PK properties for oral administration.<a onclick="showRef(event, 'ref50'); return false;" href="javascript:void(0);" class="ref ref50">(50)</a></div><div class="NLM_p">Our preliminary studies suggested that the cinnoline moiety might be the source of the poor solubility observed for compound <b>6</b>. By analyzing the binding mode of <b>6</b> (PDB code: <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=4Z3V">4Z3V</a>), we found that the cinnoline-N2 atoms did not make direct H-bond interactions with the kinase domain. Based on this observation, the initial design was to remove the insignificant nitrogen and introduce various substitutions, which aimed to disrupt the molecular planarity and lead to additional interactions with the protein.</div><div class="NLM_p">To our delight, compared to compound <b>6</b>, compound <b>7</b> bearing a 4-aminoquinoline-3-carboxamide core improved the aqueous solubility by more than 200-fold but with a significant decrease in inhibitory activity. Additionally, compound <b>7</b> exhibited a suitable Clog <i>P</i> value, consistent with our drug-like physicochemical criteria. However, replacement of the cinnoline moiety with 4-hydroxyquinoline-3-carboxamide (<b>8</b>) resulted in a dramatic loss in BTK inhibition, indicating that the 4-NH<sub>2</sub> group is important for ligand binding (<a class="ref showTableEvent internalNav" data-ID="tbl1" href="#tbl1">Table <a class="ref showTableEvent internalNav" data-ID="tbl1" href="#tbl1">1</a></a>).</div><div class="NLM_table-wrap" id="tbl1"><div class="hlFld-FigureCaption"><div class="NLM_caption" id=""><div class="title2">Table 1. In Vitro BTK Inhibition, Aqueous Solubility, and Clog <i>P</i> Value</div></div></div><img class="imgWithoutFigViewer " src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-14/acs.jmedchem.9b00329/20190719/images/medium/jm-2019-00329v_0011.gif" alt="" id="gr11" /></img><div class="NLM_table-wrap-foot" id="IDtable-wrap-foot-t1fn1"><div class="footnote" id="t1fn1"><sup><sup>a</sup></sup><p class="last">BTK inhibition (%) by the compound at 100 nM, data represented as mean ± SD of triplicates.</p></div><div class="footnote" id="t1fn2"><sup><sup>b</sup></sup><p class="last">Kinetic solubility (μg/mL) in PBS (pH 7.4) at 25 °C, determined by HPLC, <i>n</i> = 3.</p></div><div class="footnote" id="t1fn3"><sup><sup>c</sup></sup><p class="last">Values are predicted by ChemBioDraw software Ultra 14.0.</p></div></div><div></div></div><div class="NLM_p">The docking pose of compound <b>7</b> bound to the ATP site of BTK suggested that the 4-aminoquinoline-3-carboxamide moiety would form three direct and one water-mediated H-bond interaction with the hinge region of BTK. The indazole moiety stabilized the conformation of the P-loop by forming crucial hydrogen bonds with Phe413 and Gly414 (<a data-tab="pane-pcw-Figures" href="#fig2" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig2" id="" class=" internalNav">2</a></a>A). Compared to RN-486, compound <b>7</b> lacked the hydrophobic interaction with the H3 pocket of BTK, which induced a significant conformational change in BTK such that the key activating tyrosine, Tyr551, was unphosphorylated and sequestered from solvent (<a data-tab="pane-pcw-Figures" href="#fig2" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig2" id="" class=" internalNav">2</a></a>B). It has been reported that the H3 pocket is responsible for the exquisite selectivity of the well-known reversible BTK inhibitor CGI-1746.<a onclick="showRef(event, 'ref28'); return false;" href="javascript:void(0);" class="ref ref28">(28)</a> Based on these observations, the first design was to compensate for the hydrophobic interaction with the H3 pocket of the quinoline compounds.</div><figure id="fig2" data-index="2" class="article__inlineFigure"><h2 class="fig-label">Figure 2</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-14/acs.jmedchem.9b00329/20190719/images/medium/jm-2019-00329v_0002.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-14/acs.jmedchem.9b00329/20190719/images/large/jm-2019-00329v_0002.jpeg" id="gr2" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 2. (A) Putative binding mode of compound <b>7</b>. The red arrow points out the extended orientation for the hydrophobic groups to grow toward the H3 pocket. Selected residues are displayed in stick representation. Orange dashes represent hydrogen bonds. (B) Docking structure of BTK bound to compound <b>7</b> (green and blue) superimposed on the X-ray cocrystal structure of BTK bound to RN-486 (PDB code: <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=4OTR">4OTR</a>, gray and yellow). RN-486 had a hydrophobic interaction with the H3 pocket which induced a significant position change of key activating tyrosine Tyr551 such that it was in the unphosphorylated state and sequestered from solvent.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-14/acs.jmedchem.9b00329/20190719/images/large/jm-2019-00329v_0002.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.9b00329&amp;id=fig2"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p">Because the methyl substituent of compound <b>7</b> was proposed to have hydrophobic interactions with Leu528, the quinoline and indazole rings were locked at a dihedral angle of 104°. To increase the possibility that the extended groups could approach the H3 pocket, the methyl group should be removed. As shown in <a class="ref showTableEvent internalNav" data-ID="tbl2" href="#tbl2">Table <a class="ref showTableEvent internalNav" data-ID="tbl2" href="#tbl2">2</a></a>, compound <b>9</b> without the methyl substituent inhibited BTK 41.6% at 100 nM, which was less potent than compound <b>7</b>. The hydrophobic phenoxyl, phenylamino, benzyloxyl, and benzyl(methyl)amino groups provided obvious changes in the overall lipophilicity and significantly decreased the inhibitory activity (<b>10–13</b>). Similarly, the 1,1′-biphenyl-4-yloxyl, 1,1′-biphenyl-3-yloxyl, and 4-(4-phenoxyphenoxyl) substituted compounds showed very weak inhibition of BTK kinase (<b>14–16</b>). We suspected that our designed compounds failed to induce the formation of the H3 pocket; instead, the substituted groups increased the steric bulk and prohibited the inhibitors from accessing to the ATP binding site of BTK.</div><div class="NLM_table-wrap" id="tbl2"><div class="hlFld-FigureCaption"><div class="NLM_caption" id=""><div class="title2">Table 2. Enzymatic BTK Potency of Compounds Bearing Lipophilic Groups on the Indazole Ring</div></div></div><img class="imgWithoutFigViewer " src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-14/acs.jmedchem.9b00329/20190719/images/medium/jm-2019-00329v_0012.gif" alt="" id="GRAPHIC-d7e542-autogenerated" /></img><img class="imgWithoutFigViewer " src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-14/acs.jmedchem.9b00329/20190719/images/medium/jm-2019-00329v_0013.gif" alt="" id="gr12" /></img><div class="NLM_table-wrap-foot" id="IDtable-wrap-foot-t2fn1"><div class="footnote" id="t2fn1"><sup><sup>a</sup></sup><p class="last">BTK inhibition (%) by the compound at 100 nM, data represented as mean ± SD of triplicates. n.a. means no activity.</p></div><div class="footnote" id="t2fn2"><sup><sup>b</sup></sup><p class="last">Values are predicted by ChemBioDraw software Ultra 14.0.</p></div></div><div></div></div><div class="NLM_p">Our second optimization focused on introducing additional interactions with the protein, seeking highly potent inhibitors with a minimal change to the lipophilicity. Quite often, fluorine is used to modulate physicochemical properties, improve metabolic stability, and enhance binding affinity to the target protein.<a onclick="showRef(event, 'ref51'); return false;" href="javascript:void(0);" class="ref ref51">(51)</a> As shown in <a class="ref showTableEvent internalNav" data-ID="tbl3" href="#tbl3">Table <a class="ref showTableEvent internalNav" data-ID="tbl3" href="#tbl3">3</a></a>, compound <b>17</b>, with a 5-F substitution, exhibited a significantly improved effect on BTK, which maintained a substantial amount of the BTK inhibition but potentially increased the aqueous solubility profile relative to <b>6</b>. Furthermore, we explored the potency of the compounds with 6-F, 6-NO<sub>2</sub> and 6-NH<sub>2</sub> substitutions (<b>18–20</b>), but only compound <b>20</b> displayed an acceptable inhibition rate of 36.5% inhibition at a concentration of 20 nM. In addition, replacement of the indazole by a benzimidazolone ring resulted in a loss of affinity for BTK (<b>21–24</b>), which might be attributed to the missing π-stacking interaction with the P-loop. Finally, we kept the 5-F substitution and replaced the methyl group with a methoxy group on the indazole ring. The resulting compound <b>25</b> exhibited 68.7% inhibition at a concentration of 20 nM, which might possess higher potency and more favorable drug-like properties than the lead compound.</div><div class="NLM_table-wrap" id="tbl3"><div class="hlFld-FigureCaption"><div class="NLM_caption" id=""><div class="title2">Table 3. In Vitro Potency of 4-Aminoquinoline-3-carboxamide Derivatives<a class="ref internalNav" href="#t3fn1" aria-label="a">a</a></div></div></div><img class="imgWithoutFigViewer " src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-14/acs.jmedchem.9b00329/20190719/images/medium/jm-2019-00329v_0014.gif" alt="" id="GRAPHIC-d7e595-autogenerated" /></img><img class="imgWithoutFigViewer " src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-14/acs.jmedchem.9b00329/20190719/images/medium/jm-2019-00329v_0015.gif" alt="" id="gr13" /></img><div class="NLM_table-wrap-foot" id="IDtable-wrap-foot-t3fn1"><div class="footnote" id="t3fn1"><sup><sup>a</sup></sup><p class="last">BTK inhibition (%) by the compound at 20 nM, data represented as mean ± SD of triplicates. n.a. means no activity.</p></div><div class="footnote" id="t3fn2"><sup><sup>b</sup></sup><p class="last">Values are predicted by ChemBioDraw software Ultra 14.0.</p></div></div><div></div></div><div class="NLM_p">Inspired by the improved activity of the 4-aminoquinoline-3-carboxamide derivatives, the selected compounds were further assessed by their IC<sub>50</sub> values against BTK and kinetic aqueous solubility profiles. As shown in <a class="ref showTableEvent internalNav" data-ID="tbl4" href="#tbl4">Table <a class="ref showTableEvent internalNav" data-ID="tbl4" href="#tbl4">4</a></a>, the compounds bearing a quinoline core showed over a 100-fold improvement in aqueous solubility, supporting our initial strategy. The 5-F substitution on the quinoline ring exhibited a 6-fold increase in potency (<b>17</b>, IC<sub>50</sub> of 11.6 nM; <b>7</b>, IC<sub>50</sub> of 72.8 nM). Compound <b>25</b> was found to be equipotent to compound <b>6</b> but with significantly improved aqueous solubility (at pH 7.4 = 7.3 μg/mL), which was more advantageous for further in vivo tests.</div><div class="NLM_table-wrap" id="tbl4"><div class="hlFld-FigureCaption"><div class="NLM_caption" id=""><div class="title2">Table 4. IC<sub>50</sub> Values and Aqueous Solubility Profiles</div></div></div><div class="scrollable-table-wrap"><table class="table "><colgroup><col align="left" /></col><col align="char" char="±" /></col><col align="left" /></col></colgroup><thead><tr valign="top" class="colsep0"><th class="colsep0 rowsep0" align="center">compd.</th><th class="colsep0 rowsep0" align="center" char="±">BTK IC<sub>50</sub> (nM)<a class="ref internalNav" href="#t4fn1" aria-label="a">a</a></th><th class="colsep0 rowsep0" align="center">aq solubility (μg/mL)<a class="ref internalNav" href="#t4fn2" aria-label="b">b</a></th></tr></thead><tbody><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>7</b></td><td class="colsep0 rowsep0" align="char" char="±">72.8 ± 0.9</td><td class="colsep0 rowsep0" align="left">10.5</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>17</b></td><td class="colsep0 rowsep0" align="char" char="±">11.6 ± 0.7</td><td class="colsep0 rowsep0" align="left">5.2</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>25</b></td><td class="colsep0 rowsep0" align="char" char="±">5.3 ± 1.3</td><td class="colsep0 rowsep0" align="left">7.3</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>6</b></td><td class="colsep0 rowsep0" align="char" char="±">5.6 ± 1.0</td><td class="colsep0 rowsep0" align="left"><0.05</td></tr></tbody></table></div><div class="NLM_table-wrap-foot" id="IDtable-wrap-foot-t4fn1"><div class="footnote" id="t4fn1"><sup><sup>a</sup></sup><p class="last">Data are mean ± SD of three independent experiments.</p></div><div class="footnote" id="t4fn2"><sup><sup>b</sup></sup><p class="last">Kinetic solubility (μg/mL) in PBS (pH 7.4) at 25 °C, determined by HPLC, <i>n</i> = 3.</p></div></div></div><div class="NLM_p">In the BCR signaling pathway, BTK Tyr551 transphosphorylation is followed by the autophosphorylation of Tyr223 in the SH3 domain. In this way, BTK is activated and transphosphorylates the downstream substrate PLCγ2. Given their good kinase activity, selected compounds were further evaluated for their inhibition of cellular autophosphorylation in Ramos cells. Herein, the phosphorylation levels of BTK (Tyr223) and total BTK protein levels were analyzed by western blotting with anti-pY223 or anti-total BTK antibodies. As shown in <a data-tab="pane-pcw-Figures" href="#fig3" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig3" id="" class=" internalNav">3</a></a>A, compounds <b>6</b>, <b>17</b>, and <b>25</b> all exhibited dose-dependent inhibition and efficiently blocked Tyr223 autophosphorylation at a concentration of 1 μM. As expected, inhibitor <b>25</b> (EC<sub>50</sub> of 42.7 nM) was 2.4-fold more potent than <b>6</b> (EC<sub>50</sub> of 100.9 nM) in cell-based assays (<a data-tab="pane-pcw-Figures" href="#fig3" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig3" id="" class=" internalNav">3</a></a>B), which may be derived from the better aqueous solubility and cell permeability of the quinoline core.</div><figure id="fig3" data-index="3" class="article__inlineFigure"><h2 class="fig-label">Figure 3</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-14/acs.jmedchem.9b00329/20190719/images/medium/jm-2019-00329v_0003.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-14/acs.jmedchem.9b00329/20190719/images/large/jm-2019-00329v_0003.jpeg" id="gr3" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 3. BTK inhibitors blocked autophosphorylation of Tyr223. (A) Concentration-dependent inhibition by compound <b>6</b>, <b>17</b>, and <b>25</b> in Ramos cells of pervanadate-mediated phosphorylation of BTK Tyr223. The phosphorylation levels of BTK (Tyr223) and total BTK protein levels were analyzed by western blotting. (B) EC<sub>50</sub> curves of compound <b>25</b> and <b>6</b>. Data are mean ± SD of three independent experiments.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-14/acs.jmedchem.9b00329/20190719/images/large/jm-2019-00329v_0003.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.9b00329&amp;id=fig3"><span>Download MS PowerPoint Slide</span></a></div></div></figure></div><div id="sec2_2" class="NLM_sec NLM_sec_level_2"><div id="ac_i9" class="anchor-spacer"></div><h3 class="article-section__title" id="_i9"> Docking Study and Selectivity Profile</h3><div class="NLM_p">To better understand why the substitution of fluorine and methoxy groups resulted in more than a 10-fold improvement in potency compared to compound <b>7</b> (<b>7</b>, IC<sub>50</sub> = 72.8 nM; <b>25</b>, IC<sub>50</sub> = 5.3 nM), we performed molecular docking studies on compounds <b>7</b> and <b>25</b>. As shown in <a data-tab="pane-pcw-Figures" href="#fig4" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig4" id="" class=" internalNav">4</a></a>A, when properly aligned, compound <b>25</b> appeared to situate into a space that was slightly different from that of <b>7</b>. The incorporation of the fluorine and methoxy substitutions likely tuned the conformation, altering the dihedral angle between the quinoline and indazole rings from 104° in compound <b>7</b>–100° in compound <b>25</b>. In addition, the fluorine atom was proposed to add a hydrophobic interaction with Leu528. The movement of the indazole ring allowed <b>25</b> to form stable π–cation interactions with Lys430 (<a data-tab="pane-pcw-Figures" href="#fig4" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig4" id="" class=" internalNav">4</a></a>B). The modeling of our inhibitors in the active site of BTK also suggested that the binding pose of compound <b>25</b> was orthogonal to that of Ibrutinib (<a data-tab="pane-pcw-Figures" href="#fig5" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig5" id="" class=" internalNav">5</a></a>A). Compound <b>25</b> did not interact with Cys481 that was responsible for the covalent interaction of Ibrutinib. Given that the BTK<sup><i>C481S</i></sup> mutation is prevalent in patients who relapse after Ibrutinib treatment, we hypothesized that our inhibitor could retain activity against the C481S mutant form of BTK. Herein, ACP-196 was selected as a control compound, which is a second-generation covalent inhibitor of BTK, with higher potency and less off-target effects than Ibrutinib. As expected, <b>25</b> efficiently inhibited BTK<sup><i>C481S</i></sup> with an IC<sub>50</sub> value of 39 nM. In contrast, ACP-196 only showed equivalent potency to <b>25</b> against BTK<sup><i>WT</i></sup> but failed to block the phosphorylation effect of BTK<sup><i>C481S</i></sup>. In addition, we tested the effects of <b>25</b> and ACP-196 against EGFR and TEC, two well-known off-targets of Ibrutinib. To our delight, <b>25</b> and ACP-196 had no effect on EGFR, and their IC<sub>50</sub> values were above 2 μM. For TEC kinase, <b>25</b> was less potent than ACP-196. The selectivity of <b>25</b> for BTK<sup><i>WT</i></sup> over TEC was more than 40-fold (<a data-tab="pane-pcw-Figures" href="#fig5" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig5" id="" class=" internalNav">5</a></a>B). Inspired by the preliminary selectivity data, a kinase selectivity profile for compound <b>25</b> was further assessed for the closely related kinases from the TEC and SRC families (<a class="ref showTableEvent internalNav" data-ID="tbl5" href="#tbl5">Table <a class="ref showTableEvent internalNav" data-ID="tbl5" href="#tbl5">5</a></a>). Based on the determined IC<sub>50</sub> values, compound <b>25</b> was more selective for BTK than other members of the TEC and SRC kinase families. The selectivity ratios were all greater than 30-fold, except for BLK (28-fold). It is of note that compound <b>25</b> was 58-fold less potent against ITK, which is highly homologous to BTK but positively regulates the T cell receptor signaling pathway and acts as a crucial regulator in multiple physiological processes of T lymphocytes.<a onclick="showRef(event, 'ref52'); return false;" href="javascript:void(0);" class="ref ref52">(52)</a> The selectivity data indicated that <b>25</b> might have a slight effect on the physiological process of T cells. Above all, it was envisioned that our reversible inhibitor would have fewer side effects than the covalent BTK inhibitors. Because <b>25</b> could have a profile to provide potential treatment for patients with B cell malignancies harboring the BTK<sup><i>C481S</i></sup> mutation with less off-target effects, this compound is currently being evaluated in Ibrutinib-resistant NHL and CLL studies.</div><figure id="fig4" data-index="4" class="article__inlineFigure"><h2 class="fig-label">Figure 4</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-14/acs.jmedchem.9b00329/20190719/images/medium/jm-2019-00329v_0004.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-14/acs.jmedchem.9b00329/20190719/images/large/jm-2019-00329v_0004.jpeg" id="gr4" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 4. Docking study of 4-aminoquinoline-3-carboxamide derivatives. (A) Putative binding modes of compound <b>7</b> (orange) and <b>25</b> (green) in the BTK kinase domain (yellow cartoon). Selected residues are shown in stick representation. (B) Summary of receptor interactions with compound <b>25</b>. Dark blue ball (positive charged interaction); cyan and red ball (polar interaction); green ball (hydrophobic interaction); purple arrow (H-bond); red line (π–cation interaction).</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-14/acs.jmedchem.9b00329/20190719/images/large/jm-2019-00329v_0004.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.9b00329&amp;id=fig4"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure id="fig5" data-index="5" class="article__inlineFigure"><h2 class="fig-label">Figure 5</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-14/acs.jmedchem.9b00329/20190719/images/medium/jm-2019-00329v_0005.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-14/acs.jmedchem.9b00329/20190719/images/large/jm-2019-00329v_0005.jpeg" id="gr5" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 5. Compound <b>25</b> binds to the kinase domain of BTK with a different manner of the existing ATP-mimetic covalent inhibitors. (A) Superposition of the cocrystal structure of Ibrutinib (orange, PDB code: <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=5P9J">5P9J</a>) and docking pose of <b>25</b> (blue). Ibrutinib forms a covalent bond with residue Cys481 and occupies the hydrophobic pocket behind the gatekeeper residue Thr474; <b>25</b> does neither. Residue Cys481 is shown in stick representation. (B) IC<sub>50</sub> values of <b>25</b> and ACP-196 against BTK, BTK<sup><i>C481S</i></sup>, EGFR, and TEC kinases.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-14/acs.jmedchem.9b00329/20190719/images/large/jm-2019-00329v_0005.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.9b00329&amp;id=fig5"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_table-wrap" id="tbl5"><div class="hlFld-FigureCaption"><div class="NLM_caption" id=""><div class="title2">Table 5. Kinase Selectivity Profile of Compound <b>25</b></div></div></div><div class="scrollable-table-wrap"><table class="table "><colgroup><col align="left" /></col><col align="left" /></col><col align="left" /></col><col align="left" /></col></colgroup><thead><tr valign="top" class="colsep0"><th class="colsep0 rowsep0" align="center">kinase</th><th class="colsep0 rowsep0" align="center">kinase family</th><th class="colsep0 rowsep0" align="center">IC<sub>50</sub> (nM)<a class="ref internalNav" href="#t5fn1" aria-label="a">a</a></th><th class="colsep0 rowsep0" align="center">selectivity ratio<a class="ref internalNav" href="#t5fn2" aria-label="b">b</a></th></tr></thead><tbody><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">BTK</td><td class="colsep0 rowsep0" align="left">TEC</td><td class="colsep0 rowsep0" align="left">5.3</td><td class="colsep0 rowsep0" align="left"> </td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">ITK</td><td class="colsep0 rowsep0" align="left">TEC</td><td class="colsep0 rowsep0" align="left">306.9</td><td class="colsep0 rowsep0" align="left">58</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">TEC</td><td class="colsep0 rowsep0" align="left">TEC</td><td class="colsep0 rowsep0" align="left">227.0</td><td class="colsep0 rowsep0" align="left">43</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">BLK</td><td class="colsep0 rowsep0" align="left">SRC</td><td class="colsep0 rowsep0" align="left">150.2</td><td class="colsep0 rowsep0" align="left">28</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">SRC</td><td class="colsep0 rowsep0" align="left">SRC</td><td class="colsep0 rowsep0" align="left">902.5</td><td class="colsep0 rowsep0" align="left">170</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">FYN</td><td class="colsep0 rowsep0" align="left">SRC</td><td class="colsep0 rowsep0" align="left">165.2</td><td class="colsep0 rowsep0" align="left">31</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">YES</td><td class="colsep0 rowsep0" align="left">SRC</td><td class="colsep0 rowsep0" align="left">>10 000</td><td class="colsep0 rowsep0" align="left">>1000</td></tr></tbody></table></div><div class="NLM_table-wrap-foot" id="IDtable-wrap-foot-t5fn1"><div class="footnote" id="t5fn1"><sup><sup>a</sup></sup><p class="last">Run in triplicates.</p></div><div class="footnote" id="t5fn2"><sup><sup>b</sup></sup><p class="last">Kinase of interest IC<sub>50</sub>/BTK IC<sub>50</sub>.</p></div></div></div></div><div id="sec2_3" class="NLM_sec NLM_sec_level_2"><div id="ac_i11" class="anchor-spacer"></div><h3 class="article-section__title" id="_i11"> Plasma Stability and in Vivo PK Profile</h3><div class="NLM_p">Inspired by the high potency and selectivity profile, we further evaluated the drug-like properties of compound <b>25</b> with a plasma incubation assay and a rat PK study. Determination of the plasma recovery rate revealed the remarkable stability of our BTK inhibitor. The percent of the remaining parent compound was above 88% after incubation in plasma samples from humans, dogs, rats, mice, and monkeys at 37 °C for up to 2 h. In addition, no significant interspecies differences were observed (<a class="ref showTableEvent internalNav" data-ID="tbl6" href="#tbl6">Table <a class="ref showTableEvent internalNav" data-ID="tbl6" href="#tbl6">6</a></a>). Compound <b>25</b> also exhibited a favorable PK profile in rats. After a single 2 mg/kg iv dose, the mean clearance rate (CL) and half-life (<i>t</i><sub>1/2</sub>) of compound <b>25</b> were 20.8 mL/min/kg and 1.2 h, respectively. Meanwhile, acceptable absorption properties were demonstrated after oral administration at a dose of 5 mg/kg. Compound <b>25</b> showed a moderate oral bioavailability (<i>F</i>) of 25% (<a class="ref showTableEvent internalNav" data-ID="tbl7" href="#tbl7">Table <a class="ref showTableEvent internalNav" data-ID="tbl7" href="#tbl7">7</a></a>).</div><div class="NLM_table-wrap" id="tbl6"><div class="hlFld-FigureCaption"><div class="NLM_caption" id=""><div class="title2">Table 6. In Vitro Plasma Stability of Compound <b>25</b><a class="ref internalNav" href="#t6fn1" aria-label="a">a</a></div></div></div><div class="scrollable-table-wrap"><table class="table "><colgroup><col align="left" /></col><col align="left" /></col><col align="left" /></col><col align="left" /></col><col align="left" /></col><col align="left" /></col></colgroup><thead><tr valign="top" class="colsep0"><th class="colsep0 rowsep0" align="center">compd.</th><th class="colsep0 rowsep0" align="center">human (%)</th><th class="colsep0 rowsep0" align="center">dog (%)</th><th class="colsep0 rowsep0" align="center">rat (%)</th><th class="colsep0 rowsep0" align="center">mouse (%)</th><th class="colsep0 rowsep0" align="center">monkey (%)</th></tr></thead><tbody><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>25</b></td><td class="colsep0 rowsep0" align="left">93</td><td class="colsep0 rowsep0" align="left">88</td><td class="colsep0 rowsep0" align="left">96</td><td class="colsep0 rowsep0" align="left">98</td><td class="colsep0 rowsep0" align="left">88</td></tr></tbody></table></div><div class="NLM_table-wrap-foot" id="IDtable-wrap-foot-t6fn1"><div class="footnote" id="t6fn1"><sup><sup>a</sup></sup><p class="last">% of remaining parent compound after 2 h incubation in plasma at 37 °C with initial concentration of 1 μM.</p></div></div></div><div class="NLM_table-wrap" id="tbl7"><div class="hlFld-FigureCaption"><div class="NLM_caption" id=""><div class="title2">Table 7. PK Profile of Compound <b>25</b> in Rats<a class="ref internalNav" href="#t7fn1" aria-label="a">a</a></div></div></div><div class="scrollable-table-wrap"><table class="table "><colgroup><col align="left" /></col><col align="left" /></col><col align="left" /></col><col align="left" /></col><col align="left" /></col></colgroup><thead><tr valign="top" class="colsep0"><th class="colsep0 rowsep0" align="center">compd.</th><th class="colsep0 rowsep0" align="center">CL (mL/min/kg), iv</th><th class="colsep0 rowsep0" align="center"><i>V</i><sub>d</sub> (L/kg)</th><th class="colsep0 rowsep0" align="center"><i>T</i><sub>1/2</sub> (h), iv</th><th class="colsep0 rowsep0" align="center"><i>F</i> (%)</th></tr></thead><tbody><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>25</b></td><td class="colsep0 rowsep0" align="left">20.8</td><td class="colsep0 rowsep0" align="left">2.1</td><td class="colsep0 rowsep0" align="left">1.2</td><td class="colsep0 rowsep0" align="left">25</td></tr></tbody></table></div><div class="NLM_table-wrap-foot" id="IDtable-wrap-foot-t7fn1"><div class="footnote" id="t7fn1"><sup><sup>a</sup></sup><p class="last">Male Sprague-Dawley rats iv at 2 mg/kg (10% DMSO, 90% PEG400) and po at 5 mg/kg (0.5% methylcellulose suspension), <i>n</i> = 6.</p></div></div></div></div><div id="sec2_4" class="NLM_sec NLM_sec_level_2"><div id="ac_i14" class="anchor-spacer"></div><h3 class="article-section__title" id="_i14"> In Vivo CIA Study</h3><div class="NLM_p">Given the high in vitro potency and favorable PK profile of compound <b>25</b>, we further evaluated the potential of our reversible inhibitor to treat RA using a rodent CIA model. Arthritis was established in male DBA/1 mice by injecting type II collagen twice separately on day 0 and day 20 of the study. On day 29, the CIA model mice were randomized and treated orally with 0.2 mg/kg dexamethasone (DXMS), 10 mg/kg compound <b>25</b>, or vehicle control QD. The paw volumes were then measured on days 29, 33, 36, 40, and 43. From day 29 to day 36, in vehicle-treated mice, there was a dramatic increase in the paw volume, indicating that the arthritis model was successfully established. Compared to the vehicle group, the mice that were administered <b>25</b> or DXMS did not show disease progression. Furthermore, the paw volumes of the drug-treated groups significantly decreased over the duration of treatment. The QD 10 mg/kg dosage of <b>25</b> showed comparable efficacy relative to DXMS (<a data-tab="pane-pcw-Figures" href="#fig6" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig6" id="" class=" internalNav">6</a></a>A). During the study period, the body weights of the mice in these four groups were recorded to evaluate the toxicity of the test compounds. As shown in <a data-tab="pane-pcw-Figures" href="#fig6" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig6" id="" class=" internalNav">6</a></a>B, the mice in the <b>25</b>-treated group had a better appetite than those treated with DXMS, which implied that our inhibitor may have lower side effects in vivo.</div><figure id="fig6" data-index="6" class="article__inlineFigure"><h2 class="fig-label">Figure 6</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-14/acs.jmedchem.9b00329/20190719/images/medium/jm-2019-00329v_0006.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-14/acs.jmedchem.9b00329/20190719/images/large/jm-2019-00329v_0006.jpeg" id="gr6" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 6. Efficacy of compound <b>25</b> in the rodent CIA model. (A) Paw swelling rate of four groups, including vehicle, <b>25</b> (10 mg/kg, QD), DXMS (0.2 mg/kg, QD) and naive, male DBA/1 mice, <i>n</i> = 6. Data are represented as mean ± SEM in the graphs. ***<i>P</i> < 0.001, ****<i>P</i> < 0.0001 vs vehicle control by Dunnett’s test. (B) Average body weights of the mice over study days.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-14/acs.jmedchem.9b00329/20190719/images/large/jm-2019-00329v_0006.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.9b00329&amp;id=fig6"><span>Download MS PowerPoint Slide</span></a></div></div></figure></div><div id="sec2_5" class="NLM_sec NLM_sec_level_2"><div id="ac_i15" class="anchor-spacer"></div><h3 class="article-section__title" id="_i15"> Chemistry</h3><div class="NLM_p">All of the title molecules <b>7–25</b> were prepared with a convergent route as depicted in <a class="ref internalNav" href="#sch1" aria-label="Schemes 1">Schemes 1</a>–<named-content content-type="anchor" rid="sch2" type="simple"></named-content><named-content content-type="anchor" rid="sch3" type="simple"></named-content><a class="ref internalNav" href="#sch4" aria-label="4">4</a>. <a class="ref internalNav" href="#sch1" aria-label="Scheme 1">Scheme 1</a> shows the preparation of the quinoline moieties, intermediates <b>30a–d</b>. The corresponding anilines and diethyl ethoxymethylenemalonate were heated at 100 °C for 2 h. After completion of the reaction, the mixtures were added into boiling Dowtherm A. Cyclization was accomplished under high temperatures to give quinolones <b>27a–d</b>. After hydrolysis, one-pot reactions by the addition of SOCl<sub>2</sub> followed by ammonium solution furnished compounds <b>29a–d</b>. Then, intermediates <b>30a–d</b> were finally accomplished by treating <b>29a–d</b> with 7 M NH<sub>3</sub> in MeOH. Notably, the products that resulted from these four steps were purified by filtration without column chromatography, simplifying and expediting the synthesis.</div><figure id="sch1" data-index="7" class="article__inlineFigure"><h2 class="fig-label">Scheme 1</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-14/acs.jmedchem.9b00329/20190719/images/medium/jm-2019-00329v_0007.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-14/acs.jmedchem.9b00329/20190719/images/large/jm-2019-00329v_0007.jpeg" id="gr7" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 1. Synthesis of Quinoline Intermediates<sup>a</sup></div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-14/acs.jmedchem.9b00329/20190719/images/large/jm-2019-00329v_0007.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.9b00329&amp;id=sch1"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label"><sup>a</sup></span>Reagents and conditions: (a) (i) diethyl ethoxymethylenemalonate, 100 °C, 2 h, (ii) Dowtherm A, 250 °C, 4–12 h, 40–60% (b) LiOH, THF/EtOH/H<sub>2</sub>O = 4:4:2, 55 °C, 4–8 h, 75–82%; (c) (i) SOCl<sub>2</sub>, DMF, 70 °C, 3–6 h, (ii) NH<sub>3</sub>·H<sub>2</sub>O, DCM, 0 °C—rt, 1 h, 40–60%; (d) 7 M NH<sub>3</sub> in MeOH, 80 °C, overnight, 50–55%.</p></p></figure><figure id="sch2" data-index="8" class="article__inlineFigure"><h2 class="fig-label">Scheme 2</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-14/acs.jmedchem.9b00329/20190719/images/medium/jm-2019-00329v_0008.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-14/acs.jmedchem.9b00329/20190719/images/large/jm-2019-00329v_0008.jpeg" id="gr8" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 2. Synthetic Route of Title Compounds <b>9–16</b><sup>a</sup></div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-14/acs.jmedchem.9b00329/20190719/images/large/jm-2019-00329v_0008.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.9b00329&amp;id=sch2"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label"><sup>a</sup></span>Reagents and conditions: (a) diisopropylamine, <i>n</i>-butyllithium, DMF, anhydrous THF, −78 °C—rt, 3 h, 50%; (b) R<sub>1</sub>YH, K<sub>2</sub>CO<sub>3</sub>, DMA, 100 °C, 3–8 h, 35–61%; (c) N<sub>2</sub>H<sub>4</sub>·H<sub>2</sub>O/DME 1:1, 170–200 °C, 24–48 h, 20–62%; (d) <i>t</i>-buLi, tributyl borate, anhydrous THF, −78 °C—rt, overnight, 21–62%; (e) Pd(dppf)Cl<sub>2</sub>, 2 M Na<sub>2</sub>CO<sub>3</sub>, 1,4-dioxane, microwave, 140 °C, 1–2 h, 23–84%</p></p></figure><figure id="sch3" data-index="9" class="article__inlineFigure"><h2 class="fig-label">Scheme 3</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-14/acs.jmedchem.9b00329/20190719/images/medium/jm-2019-00329v_0009.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-14/acs.jmedchem.9b00329/20190719/images/large/jm-2019-00329v_0009.jpeg" id="gr9" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 3. Synthetic Route of Title Compounds <b>7</b>, <b>25</b>, and <b>17–20</b><sup>a</sup></div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-14/acs.jmedchem.9b00329/20190719/images/large/jm-2019-00329v_0009.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.9b00329&amp;id=sch3"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label"><sup>a</sup></span>Reagents and conditions: (a) Fe, NH<sub>4</sub>Cl, EtOH/H<sub>2</sub>O 3:1, 80 °C, 1 h, 80–90%; (b) (i) 50% HBF<sub>4</sub>, NaNO<sub>2</sub>, H<sub>2</sub>O, 0 °C, 3 h; (ii) AcOK, 18-crown-6, CHCl<sub>3</sub>, rt, 3 h; (iii) Boc<sub>2</sub>O, DMAP, Et<sub>3</sub>N, MeCN, rt, 1 h, 25–35%; (c) (i) Pd(dppf)Cl<sub>2</sub>, B<sub>2</sub>pin<sub>2</sub>, KOAc, 1,4-dioxane, 90 °C, overnight; (ii) TFA/DCM 1:1, rt, 2 h, 55–60%; (d) Pd(dppf)Cl<sub>2</sub>, 2 M Na<sub>2</sub>CO<sub>3</sub>, 1,4-dioxane, 140 °C, microwave, 1–2 h, 44–65%.</p></p></figure><figure id="sch4" data-index="10" class="article__inlineFigure"><h2 class="fig-label">Scheme 4</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-14/acs.jmedchem.9b00329/20190719/images/medium/jm-2019-00329v_0010.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-14/acs.jmedchem.9b00329/20190719/images/large/jm-2019-00329v_0010.jpeg" id="gr10" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 4. Synthetic Route of Title Compounds <b>21–24</b><sup>a</sup></div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-14/acs.jmedchem.9b00329/20190719/images/large/jm-2019-00329v_0010.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.9b00329&amp;id=sch4"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label"><sup>a</sup></span>Reagents and conditions: (a) <i>N</i>,<i>N</i>′-carbonyldiimidazole, rt, overnight, 75–78%; (b) Pd(dppf)Cl<sub>2</sub>, B<sub>2</sub>pin<sub>2</sub>, KOAc, 1,4-dioxane, 90 °C, 6 h, 80–83%; (c) Pd(dppf)Cl<sub>2</sub>, 2 M Na<sub>2</sub>CO<sub>3</sub>, 1,4-dioxane, microwave, 140 °C, 2 h, 43–51%.</p></p></figure><div class="NLM_p">The synthesis of title compounds <b>9–16</b> is shown in <a class="ref internalNav" href="#sch2" aria-label="Scheme 2">Scheme 2</a>. Starting from 1-bromo-3,5-difluorobenzene <b>31</b>, after treatment with LDA and DMF, the aldehyde intermediate <b>32</b> was obtained. Then, the intermediates <b>33b–h</b> were furnished by an SN<sub>AR</sub> reaction and converted into indazoles via the addition of hydrazinehydrate. Specifically, the synthesis of compound <b>9</b> was started from the commercially available 4-bromo-2-fluorobenzaldehyde <b>33a</b>. Under strongly basic conditions, the brominated indazoles were transformed into their corresponding borate intermediates <b>35a–h</b>. The final step was a Suzuki couplings, which worked well under microwave conditions.</div><div class="NLM_p">As shown in <a class="ref internalNav" href="#sch3" aria-label="Scheme 3">Scheme 3</a>, the compounds bearing methyl- or methoxyl-substituted indazoles were prepared according to the described synthetic methods. First, the reduction of <b>36</b> gave the substituted aniline intermediates <b>37a–b</b>. In this synthetic route, milder conditions devoid of high temperatures and strong bases were used to prepare the indazole intermediates. Initially, the anilines were transformed into diazonium salts by the addition of fluoroboric acid and NaNO<sub>2</sub>. Then, under KOAc conditions, the cyclization occurred to afford the 5-membered indazole rings. The NH groups were protected with a Boc group with DMAP and Et<sub>3</sub>N. After Miyaura borylation, Boc deprotection was accomplished in the presence of TFA. Finally, a Suzuki coupling reaction was used to furnish the desired compounds <b>7</b>, <b>25</b>, and <b>17–20</b>.</div><div class="NLM_p last">Title compounds <b>21–24</b> were synthesized as shown in <a class="ref internalNav" href="#sch4" aria-label="Scheme 4">Scheme 4</a>. Cyclization of <b>40</b> with CDI in DMF at room temperature produced the benzimidazolones in of 75 and 78% yield. Miyaura borylation was performed as mentioned above. Additionally, Suzuki coupling reactions were conducted to obtain the desired compounds.</div></div></div><div id="sec3" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i20">Conclusions</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_32830" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_32830" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div class="NLM_p last">In summary, we have disclosed a series of novel 4-aminoquinoline-3-carboxamide derivatives as potent reversible BTK inhibitors with significantly improved drug-like properties, especially the aqueous solubility profile. Compound <b>25</b> exhibited high potency with an enzymatic IC<sub>50</sub> value of 5.3 nM against BTK and a cellular autophosphorylation inhibition EC<sub>50</sub> of 42.7 nM. As supported by docking studies, the incorporation of fluorine and methoxy substitutions resulted in a more than 10-fold increase in potency through the introduction of additional interactions (a hydrophobic interaction with Leu528 and π–cation interaction with Lys430) and likely tuned the bound conformation. In addition, our inhibitors are predicted to bind to the kinase domain of BTK in an orthogonal orientation to that of Ibrutinib, providing improved selectivity over the closely related TEC and SRC family kinases. In the rodent CIA model, representative compound <b>25</b> efficiently reduced paw swelling without affecting the appetite of the mice, which implied that our inhibitor was both efficacious and well tolerated in this study. Furthermore, a plasma recovery assay and a rat PK study demonstrated the favorable PK profile of our compound. Above all, compound <b>25</b> has been identified as a novel and highly potent reversible inhibitor that has the potential to behave as an orally available therapy for the treatment of RAs.</div></div><div id="sec4" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i21">Experimental Section</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_80430" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_80430" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div id="sec4_1" class="NLM_sec NLM_sec_level_2"><div id="ac_i22" class="anchor-spacer"></div><h3 class="article-section__title" id="_i22"> Materials</h3><div class="NLM_p last">All commercial materials purchased from Bidepharm, Aladdin, and J&K Chemical LTD were used without further purification. All solvents we used for reaction and purification were of analytical grade. Analytical TLC was performed on Yantai Chemical Industry Research Institute silica gel 60 F254 plates, and flash column chromatography was performed on Qingdao Haiyang Chemical Co. Ltd silica gel 60 (200–250 mesh). The rotavapor was BUCHI’s Rotavapor R-3. MicroCal iTC200 system (GE Healthcare). The <sup>1</sup>H, <sup>13</sup>C, and <sup>19</sup>F NMR spectra were recorded on a Bruker 400 MHz spectrometer. Low-resolution mass spectral analyses were performed with a Waters AQUITY UPLCTM/MS. Purity of all title compounds was ≥95%. HPLC purity determination was performed on a SHIMADZU system using a Vydac 218TP C18 column (5 μm, 4.6 × 250 mm) with a gradient of 9–80% acetonitrile (containing 0.1% TFA) in water (containing 0.1% TFA) over 20 min. UV detection (λ = 254 nm). ACP-196 was purchased from MedChemExpress (HY-17600-32534), and the purity was above 99%. DXMS was purchased from MedChemExpress (HY-14648-11202), and the purity was above 98%.</div></div><div id="sec4_2" class="NLM_sec NLM_sec_level_2"><div id="ac_i23" class="anchor-spacer"></div><h3 class="article-section__title" id="_i23"> General Procedure for the Synthesis of Title Compounds <b>7–25</b></h3><div class="NLM_p">To a mixture of 4-amino-8-bromoquinoline-3-carboxamide <b>30a–d</b> (0.1 mmol), 2 M aqueous NaHCO<sub>3</sub> (0.1 mL), and Pd(dppf)Cl<sub>2</sub> (7 mg, 0.01 mmol) in 1, 4-dioxane (2 mL) was added boronic acid intermediates <b>35a–h</b> (0.15 mmol) or borates <b>39a–b</b> (0.15 mmol) or <b>42a–b</b> (0.15 mmol) and heated in microwave at 140 °C for 1–2 h. The catalyst was removed by filtration and the filtrate was evaporated to dryness. Purification by column chromatography on silica gel (eluting with DCM–MeOH, 10:1) afforded the title compounds <b>7–25</b>.</div><div id="sec4_2_1" class="NLM_sec NLM_sec_level_3"><div id="ac_i24" class="anchor-spacer"></div><h4 class="article-section__title" id="_i24"> 4-Amino-8-(5-methyl-1<i>H</i>-indazol-6-yl)quinoline-3-carboxamide (<b>7</b>)</h4><div class="NLM_p last">It is obtained as a white solid. Yield: 44%. <sup>1</sup>H NMR (400 MHz, CD<sub>3</sub>OD, ppm): δ 8.60 (s, 1H), 8.36 (d, <i>J</i> = 7.3 Hz, 1H), 8.05 (s, 1H), 7.73–7.67 (m, 3H), 7.43 (s, 1H), 2.02 (s, 3H). LRMS (ESI): calcd for C<sub>18</sub>H<sub>15</sub>N<sub>5</sub>O [M + H]<sup>+</sup>, 318.36; found, 318.70. HPLC purity: 95%. <i>t</i><sub>R</sub> = 12.12 min.</div></div><div id="sec4_2_2" class="NLM_sec NLM_sec_level_3"><div id="ac_i25" class="anchor-spacer"></div><h4 class="article-section__title" id="_i25"> 4-Hydroxy-8-(5-methyl-1<i>H</i>-indazol-6-yl)quinoline-3-carboxamide (<b>8</b>)</h4><div class="NLM_p last">It is obtained as a white solid. Yield: 56%. <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>, ppm): δ 13.14 (s, 1H), 9.30 (s, 1H), 8.47 (s, 1H), 8.34 (d, <i>J</i> = 7.6 Hz, 1H), 8.11 (s, 1H), 7.79 (s, 1H), 7.63–7.46 (m, 4H), 2.02 (s, 3H). LRMS (ESI): calcd for C<sub>18</sub>H<sub>14</sub>N<sub>4</sub>O<sub>2</sub> [M + H]<sup>+</sup>, 319.34; found, 319.58.</div></div><div id="sec4_2_3" class="NLM_sec NLM_sec_level_3"><div id="ac_i26" class="anchor-spacer"></div><h4 class="article-section__title" id="_i26"> 4-Amino-8-(1<i>H</i>-indazol-6-yl)quinoline-3-carboxamide (<b>9</b>)</h4><div class="NLM_p last">It is obtained as a white solid. Yield: 40%. <sup>1</sup>H NMR (400 MHz, CD<sub>3</sub>OD, ppm): δ 8.67 (s, 1H), 8.35 (d, <i>J</i> = 8.5 Hz, 1H), 8.14 (s, 1H), 7.91 (d, <i>J</i> = 8.3 Hz, 1H), 7.84 (d, <i>J</i> = 7.1 Hz, 1H), 7.72–7.68 (m, 2H), 7.29 (d, <i>J</i> = 8.3 Hz, 1H). LRMS (ESI): calcd for C<sub>17</sub>H<sub>13</sub>N<sub>5</sub>O [M + H]<sup>+</sup>, 304.33; found, 304.54.</div></div><div id="sec4_2_4" class="NLM_sec NLM_sec_level_3"><div id="ac_i27" class="anchor-spacer"></div><h4 class="article-section__title" id="_i27"> 4-Amino-8-(4-phenoxy-1<i>H</i>-indazol-6-yl)quinoline-3-carboxamide (<b>10</b>)</h4><div class="NLM_p last">It is obtained as a white solid. Yield: 84%. <sup>1</sup>H NMR (400 MHz, CD<sub>3</sub>OD, ppm): δ 8.67 (s, 1H), 8.21 (d, <i>J</i> = 8.3 Hz, 1H), 7.79 (s, 1H), 7.72 (d, <i>J</i> = 7.1 Hz, 1H), 7.55 (t, <i>J</i> = 7.7 Hz, 1H), 7.41–7.36 (m, 3H), 7.20–7.13 (m, 3H), 6.75 (s, 1H). LRMS (ESI): calcd for C<sub>23</sub>H<sub>17</sub>N<sub>5</sub>O<sub>2</sub> [M + H]<sup>+</sup>, 396.43; found, 396.51.</div></div><div id="sec4_2_5" class="NLM_sec NLM_sec_level_3"><div id="ac_i28" class="anchor-spacer"></div><h4 class="article-section__title" id="_i28"> 4-Amino-8-(4-(phenylamino)-1<i>H</i>-indazol-6-yl)quinoline-3-carboxamide (<b>11</b>)</h4><div class="NLM_p last">It is obtained as a yellow solid. Yield: 61%. <sup>1</sup>H NMR (400 MHz, CD<sub>3</sub>OD, ppm): δ 8.68 (s, 1H), 8.20 (d, <i>J</i> = 8.2 Hz, 1H), 8.13 (s, 1H), 7.73 (d, <i>J</i> = 7.0 Hz, 1H), 7.55 (t, <i>J</i> = 7.8 Hz, 1H), 7.25–7.22 (m, 4H), 7.12 (s, 1H), 7.02 (s, 1H), 6.89 (t, <i>J</i> = 7.0 Hz, 1H). LRMS (ESI): calcd for C<sub>23</sub>H<sub>18</sub>N<sub>6</sub>O [M + H]<sup>+</sup>, 395.45; found, 395.56.</div></div><div id="sec4_2_6" class="NLM_sec NLM_sec_level_3"><div id="ac_i29" class="anchor-spacer"></div><h4 class="article-section__title" id="_i29"> 4-Amino-8-(4-(benzyloxy)-1<i>H</i>-indazol-6-yl)quinoline-3-carboxamide (<b>12</b>)</h4><div class="NLM_p last">It is obtained as a white solid. Yield: 23%. <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>, ppm): δ 13.22 (s, 1H), 8.73 (s, 1H), 8.47 (s, 1H), 8.15 (s, 1H), 7.84 (s, 1H), 7.67 (s, 1H), 7.52 (d, <i>J</i> = 7.1 Hz, 2H), 7.42 (t, <i>J</i> = 7.1 Hz, 2H), 7.35 (t, <i>J</i> = 7.3 Hz, 1H), 7.28 (s, 1H), 6.83 (s, 1H), 5.29 (s, 2H). LRMS (ESI): calcd for C<sub>24</sub>H<sub>19</sub>N<sub>5</sub>O<sub>2</sub> [M + H]<sup>+</sup>, 410.46; found, 410.76.</div></div><div id="sec4_2_7" class="NLM_sec NLM_sec_level_3"><div id="ac_i30" class="anchor-spacer"></div><h4 class="article-section__title" id="_i30"> 4-Amino-8-(4-(benzyl(methyl)amino)-1<i>H</i>-indazol-6-yl)quinoline-3-carboxamide (<b>13</b>)</h4><div class="NLM_p last">It is obtained as a yellow solid. Yield: 50%. <sup>1</sup>H NMR (400 MHz, CD<sub>3</sub>OD, ppm): δ 8.63 (s, 1H), 8.32 (d, <i>J</i> = 7.6 Hz, 1H), 8.00 (s, 1H), 7.83 (d, <i>J</i> = 7.6 Hz, 1H), 7.67 (t, <i>J</i> = 8.3 Hz, 1H), 7.35–7.26 (m, 5H), 7.01 (s, 1H), 6.41 (s, 1H), 4.79 (s, 2H), 3.13 (s, 3H). LRMS (ESI): calcd for C<sub>25</sub>H<sub>22</sub>N<sub>6</sub>O [M + H]<sup>+</sup>, 423.50; found, 423.77.</div></div><div id="sec4_2_8" class="NLM_sec NLM_sec_level_3"><div id="ac_i31" class="anchor-spacer"></div><h4 class="article-section__title" id="_i31"> 8-(4-([1,1′-Biphenyl]-4-yloxy)-1<i>H</i>-indazol-6-yl)-4-aminoquinoline-3-carboxamide (<b>14</b>)</h4><div class="NLM_p last">It is obtained as a white solid. Yield: 38%. <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>, ppm): δ 13.31 (s, 1H), 8.82 (s, 1H), 8.58 (s, 1H), 8.32 (d, <i>J</i> = 8.5 Hz, 1H), 8.02 (s, 1H), 7.87 (s, 1H), 7.77–7.64 (m, 5H), 7.55–7.25 (m, 8H), 6.91 (s, 1H). LRMS (ESI): calcd for C<sub>29</sub>H<sub>21</sub>N<sub>5</sub>O<sub>2</sub> [M + H]<sup>+</sup>, 472.53; found, 472.60.</div></div><div id="sec4_2_9" class="NLM_sec NLM_sec_level_3"><div id="ac_i32" class="anchor-spacer"></div><h4 class="article-section__title" id="_i32"> 8-(4-([1,1′-Biphenyl]-3-yloxy)-1<i>H</i>-indazol-6-yl)-4-aminoquinoline-3-carboxamide (<b>15</b>)</h4><div class="NLM_p last">It is obtained as a white solid. Yield: 38%. <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>, ppm): δ 13.25 (s, 1H), 8.77 (s, 1H), 8.62 (s, 1H), 8.33 (s, 1H), 7.95–7.87 (m, 2H), 7.67–7.65 (m, 3H), 7.51–7.37 (m, 10H), 7.19 (s, 1H), 6.89 (s, 1H). LRMS (ESI): calcd for C<sub>29</sub>H<sub>21</sub>N<sub>5</sub>O<sub>2</sub> [M + H]<sup>+</sup>, 472.53; found, 472.61.</div></div><div id="sec4_2_10" class="NLM_sec NLM_sec_level_3"><div id="ac_i33" class="anchor-spacer"></div><h4 class="article-section__title" id="_i33"> 4-Amino-8-(4-(4-phenoxyphenoxy)-1<i>H</i>-indazol-6-yl)quinoline-3-carboxamide (<b>16</b>)</h4><div class="NLM_p last">It is obtained as a white solid. Yield: 23%. <sup>1</sup>H NMR (400 MHz, CD<sub>3</sub>OD, ppm): δ 8.65 (s, 1<i>H</i>), 8.34 (d, <i>J</i> = 8.3 Hz, 1H), 7.91 (s, 1H), 7.82 (d, <i>J</i> = 7.1 Hz, 1H), 7.68 (t, <i>J</i> = 8.0 Hz, 1H), 7.39 (s, 1H), 7.32 (d, <i>J</i> = 7.7 Hz, 2H), 7.20 (d, <i>J</i> = 8.8 Hz, 2H), 7.09 (t, <i>J</i> = 7.4 Hz, 1H), 7.02 (d, <i>J</i> = 8.9 Hz, 2H), 6.97 (d, <i>J</i> = 8.2 Hz, 2H), 6.65 (s, 1H). LRMS (ESI): calcd for C<sub>29</sub>H<sub>21</sub>N<sub>5</sub>O<sub>3</sub> [M + H]<sup>+</sup>, 488.53; found, 488.85.</div></div><div id="sec4_2_11" class="NLM_sec NLM_sec_level_3"><div id="ac_i34" class="anchor-spacer"></div><h4 class="article-section__title" id="_i34"> 4-Amino-5-fluoro-8-(5-methyl-1<i>H</i>-indazol-6-yl)quinoline-3-carboxamide (<b>17</b>)</h4><div class="NLM_p last">It is obtained as a white solid. Yield: 65%. <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>, ppm): δ 12.90 (s, 1H), 8.66 (s, 1H), 8.00 (s, 2H), 7.58–7.53 (m, 2H), 7.34–7.29 (m, 2H), 7.23 (s, 1H), 1.96 (s, 3H). <sup>13</sup>C NMR (100 MHz, DMSO-<i>d</i><sub>6</sub>, ppm): δ 170.5, 159.5 (d, <i>J</i> = 252 Hz), 152.5, 150.3, 148.6, 139.1, 138.7, 137.3 (d, <i>J</i> = 4 Hz), 132.7, 131.3 (d, <i>J</i> = 10 Hz), 129.2, 122.5, 119.4, 110.8, 109.6 (d, <i>J</i> = 22 Hz), 108.5 (d, <i>J</i> = 7 Hz), 103.3, 20.3. <sup>19</sup>F NMR (376 MHz, DMSO-<i>d</i><sub>6</sub>, ppm): δ −112.8. LRMS (ESI): calcd for C<sub>18</sub>H<sub>14</sub>FN<sub>5</sub>O [M + H]<sup>+</sup>, 336.35; found, 336.18. HPLC purity: 99%. <i>t</i><sub>R</sub> = 11.57 min.</div></div><div id="sec4_2_12" class="NLM_sec NLM_sec_level_3"><div id="ac_i35" class="anchor-spacer"></div><h4 class="article-section__title" id="_i35"> 4-Amino-6-fluoro-8-(5-methyl-1<i>H</i>-indazol-6-yl)quinoline-3-carboxamide (<b>18</b>)</h4><div class="NLM_p last">It is obtained as a white solid. Yield: 53%. <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>, ppm): δ 12.94 (s, 1H), 8.65 (s, 1H), 8.47 (s, 2H), 8.20 (dd, <i>J</i> = 10.6, 2.6 Hz, 1H), 8.02 (s, 1H), 7.97 (s. 1H), 7.59 (s. 1H), 7.51 (dd, <i>J</i> = 8.6, 2.5 Hz, 1H), 7.34 (s, 1H), 7.29 (s, 1H), 1.98 (s, 1H). LRMS (ESI): calcd for C<sub>18</sub>H<sub>14</sub>FN<sub>5</sub>O [M + H]<sup>+</sup>, 336.35; found, 336.56.</div></div><div id="sec4_2_13" class="NLM_sec NLM_sec_level_3"><div id="ac_i36" class="anchor-spacer"></div><h4 class="article-section__title" id="_i36"> 4-Amino-8-(5-methyl-1<i>H</i>-indazol-6-yl)-6-nitroquinoline-3-carboxamide (<b>19</b>)</h4><div class="NLM_p last">It is obtained as a white solid. Yield: 55%. <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>, ppm): δ 13.00 (s, 1H), 9.49 (d, <i>J</i> = 2.4 Hz, 1H), 9.06 (s, 2H), 8.80 (s, 1H), 8.22 (d, <i>J</i> = 2.4 Hz, 1H), 8.09 (s, 1H), 8.04 (s, 1H), 7.62 (s, 1H), 7.50 (s, 1H), 7.34 (s, 1H), 2.00 (s, 3H). LRMS (ESI): calcd for C<sub>18</sub>H<sub>14</sub>N<sub>6</sub>O<sub>3</sub> [M + H]<sup>+</sup>, 363.36; found, 363.54.</div></div><div id="sec4_2_14" class="NLM_sec NLM_sec_level_3"><div id="ac_i37" class="anchor-spacer"></div><h4 class="article-section__title" id="_i37"> 4,6-Diamino-8-(5-methyl-1<i>H</i>-indazol-6-yl)quinoline-3-carboxamide (<b>20</b>)</h4><div class="NLM_p last">To a suspension of 4-amino-8-(5-methyl-1<i>H</i>-indazol-6-yl)-6-nitroquinoline-3-carboxamide <b>19</b> (26 mg, 0.07 mmol) and NH<sub>4</sub>Cl (2.6 mg, 0.05 mmol) in ethanol (0.9 mL) and water (0.3 mL) was added iron powder (23.5 mg, 0.42 mmol). The reaction mixture was heated at 80 °C for 2 h. The iron was removed by filtration, and the filtrate was concentrated to dryness. Purification by column chromatography on silica gel (10% methanol in DCM) afforded <b>20</b> (12 mg, 50% yield). <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>, ppm): δ 12.88 (s, 1H), 8.37 (s, 1H), 8.02–8.00 (m, 3H), 7.81 (s, 1H), 7.55 (s, 1H), 7.22–7.15 (m, 3H), 6.98 (d, <i>J</i> = 2.3 Hz, 1H), 5.38 (s, 2H), 1.99 (s, 3H). LRMS (ESI): calcd for C<sub>18</sub>H<sub>16</sub>N<sub>6</sub>O [M + H]<sup>+</sup>, 333.37; found, 333.37.</div></div><div id="sec4_2_15" class="NLM_sec NLM_sec_level_3"><div id="ac_i38" class="anchor-spacer"></div><h4 class="article-section__title" id="_i38"> 4-Amino-5-fluoro-8-(2-oxo-2,3-dihydro-1<i>H</i>-benzo[<i>d</i>]imidazole-5-yl)quinoline-3-carboxamide (<b>21</b>)</h4><div class="NLM_p last">It is obtained as a white solid. Yield: 46%. <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>, ppm): δ 10.63 (s, 1H), 10.61 (s, 1H), 8.77 (s, 1H), 8.05 (s, 2H), 7.61 (dd, <i>J</i> = 7.8, 6.6 Hz, 1H), 7.40 (s, 2H), 7.28 (dd, <i>J</i> = 13.3, 8.0 Hz, 1H), 7.12 (s, 1H), 7.06 (d, <i>J</i> = 7.9 Hz, 1H), 6.97 (d, <i>J</i> = 8.0 Hz, 1H). LRMS (ESI): calcd for C<sub>17</sub>H<sub>12</sub>FN<sub>5</sub>O<sub>2</sub> [M + H]<sup>+</sup>, 338.32; found, 338.37.</div></div><div id="sec4_2_16" class="NLM_sec NLM_sec_level_3"><div id="ac_i39" class="anchor-spacer"></div><h4 class="article-section__title" id="_i39"> 4-Amino-6-fluoro-8-(2-oxo-2,3-dihydro-1<i>H</i>-benzo[<i>d</i>]imidazole-5-yl)quinoline-3-carboxamide (<b>22</b>)</h4><div class="NLM_p last">It is obtained as a white solid. Yield: 43%. <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>, ppm): δ 10.69 (s, 1H), 10.66 (s, 1H), 8.78 (s, 1H), 8.46 (s, 2H), 8.10 (dd, <i>J</i> = 10.6, 2.6 Hz, 1H), 8.04 (s, 1H), 7.55 (dd, <i>J</i> = 9.2, 2.6 Hz, 1H), 7.47 (s, 1H), 7.24 (s, 1H), 7.17 (d, <i>J</i> = 8.0 Hz, 1H), 7.00 (d, <i>J</i> = 8.0 Hz, 1H). LRMS (ESI): calcd for C<sub>17</sub>H<sub>12</sub>FN<sub>5</sub>O<sub>2</sub> [M + H]<sup>+</sup>, 338.32; found, 338.46.</div></div><div id="sec4_2_17" class="NLM_sec NLM_sec_level_3"><div id="ac_i40" class="anchor-spacer"></div><h4 class="article-section__title" id="_i40"> 4-Amino-5-fluoro-8-(6-methyl-2-oxo-2,3-dihydro-1<i>H</i>-benzo[<i>d</i>]imidazole-5-yl)quinoline-3-carboxamide (<b>23</b>)</h4><div class="NLM_p last">It is obtained as a white solid. Yield: 51%. <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>, ppm): δ 10.51 (s, 1H), 9.81 (s, 1H), 8.73 (s, 1H), 8.07 (s, 1H), 7.58 (t, <i>J</i> = 6.8 Hz, 1H), 7.39 (s, 1H), 7.27 (dd, <i>J</i> = 13.2, 8.0 Hz, 1H), 6.75 (s, 1H), 6.69 (s, 1H), 2.32 (s, 3H). LRMS (ESI): calcd for C<sub>18</sub>H<sub>14</sub>FN<sub>5</sub>O<sub>2</sub> [M + H]<sup>+</sup>, 352.35; found, 352.33.</div></div><div id="sec4_2_18" class="NLM_sec NLM_sec_level_3"><div id="ac_i41" class="anchor-spacer"></div><h4 class="article-section__title" id="_i41"> 4-Amino-6-fluoro-8-(6-methyl-2-oxo-2,3-dihydro-1<i>H</i>-benzo[<i>d</i>]imidazole-5-yl)quinoline-3-carboxamide (<b>24</b>)</h4><div class="NLM_p last">It is obtained as a white solid. Yield: 50%. <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>, ppm): δ 10.54 (s, 1H), 9.91 (s, 1H), 8.73 (s, 1H), 8.49 (s, 2H), 8.16 (d, <i>J</i> = 10.5 Hz, 1H), 8.03 (s, 1H), 7.53 (d, <i>J</i> = 7.8 Hz, 1H), 7.34 (s, 1H), 6.77 (s, 2H), 2.33 (s, 3H). LRMS (ESI): calcd for C<sub>18</sub>H<sub>14</sub>FN<sub>5</sub>O<sub>2</sub> [M + H]<sup>+</sup>, 352.35; found, 352.43.</div></div><div id="sec4_2_19" class="NLM_sec NLM_sec_level_3"><div id="ac_i42" class="anchor-spacer"></div><h4 class="article-section__title" id="_i42"> 4-Amino-5-fluoro-8-(5-methoxy-1<i>H</i>-indazol-6-yl)quinoline-3-carboxamide (<b>25</b>)</h4><div class="NLM_p last">It is obtained as a white solid. Yield: 60%. <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>, ppm): δ 12.87 (s, 1H), 8.65 (s, 1H), 7.99 (s, 2H), 7.55 (dd, <i>J</i> = 8.0, 6.2 Hz, 1H), 7.36 (s, 1H), 7.25–7.24 (m, 3H), 3.61 (s, 3H). <sup>13</sup>C NMR (100 MHz, DMSO-<i>d</i><sub>6</sub>, ppm): δ 170.5, 159.4 (d, <i>J</i> = 252 Hz), 152.5, 152.4, 150.1, 149.0, 135.2, 134.6 (d, <i>J</i> = 3 Hz), 132.8, 131.7 (d, <i>J</i> = 10 Hz), 125.3, 122.5, 112.4, 109.3 (d, <i>J</i> = 23 Hz), 108.4 (d, <i>J</i> = 7 Hz), 103.2, 99.1, 55.6. <sup>19</sup>F NMR (376 MHz, DMSO-<i>d</i><sub>6</sub>, ppm): δ −113.0. LRMS (ESI): calcd for C<sub>18</sub>H<sub>14</sub>FN<sub>5</sub>O<sub>2</sub> [M + H]<sup>+</sup>, 352.35; found, 352.42. HPLC purity: 98%. <i>t</i><sub>R</sub> = 11.55 min.</div></div></div><div id="sec4_3" class="NLM_sec NLM_sec_level_2"><div id="ac_i43" class="anchor-spacer"></div><h3 class="article-section__title" id="_i43"> General Procedure for the Synthesis of Intermediates <b>30a–d</b></h3><div class="NLM_p">Step 1: A solution of aniline <b>26a–d</b> (10 mmol) and ethyl ethoxymethylenemalonate (4 mL, 10 mmol) was heated at 100 °C for 2 h. Then, the molten mass was added slowly onto the boiling Dowtherm A (10 mL), and the mixture was heated at reflux for 4–12 h. After the mixture cooled to rt, the precipitated solid was collected by filtration and dried to afford the product.</div><div class="NLM_p">Step 2: Ethyl quinoline-3-carboxylate <b>27a–d</b> (6.4 mmol) were dissolved in THF/EtOH/H<sub>2</sub>O (4:4:2, 50 mL) and added lithium hydroxide (3 equiv). The resulting mixture was heated at 55 °C for 4–8 h, after which the volatile solvent was evaporated to give an aqueous phase which was acidified to pH = 3 with 1.5 N HCl aqueous solution. The resulting precipitate was filtered and dried to yield quinoline-3-carboxylic acid <b>28a–d</b>, which was used without further purification. A solution of quinoline-3-carboxylic acid <b>28a–d</b> (3.5 mmol) in SOCl<sub>2</sub> (5 mL) and cat. DMF (two drops) was heated to 70 °C for 3–6 h. The reaction mixture was then concentrated under reduced pressure to obtain a residue which was then dissolved in DCM (50 mL) and 25% aq ammonia (50 mL) was added at 0 °C. The resulting precipitate was filtered to obtain the desired amide <b>29a–d</b>.</div><div class="NLM_p">Step 3: The amide <b>29a–d</b> was placed in the sealed tube and dissolved in 7 M ammonium methanol solution. The reaction mixture was heated at 80 °C overnight. The precipitated solid was collected by filtration and dried to afford the product <b>30a–d</b>.</div><div id="sec4_3_1" class="NLM_sec NLM_sec_level_3"><div id="ac_i44" class="anchor-spacer"></div><h4 class="article-section__title" id="_i44"> 4-Amino-8-bromoquinoline-3-carboxamide (<b>30a</b>)</h4><div class="NLM_p last">It is obtained as a white solid. Total yield: 10%. <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>, ppm): δ 8.89 (s, 1H), 8.60 (s, 1H), 8.33 (d, <i>J</i> = 8.4 Hz, 1H), 8.07–8.05 (m, 2H), 7.40 (s, 1H), 7.37 (t, <i>J</i> = 8.0 Hz, 1H).</div></div><div id="sec4_3_2" class="NLM_sec NLM_sec_level_3"><div id="ac_i45" class="anchor-spacer"></div><h4 class="article-section__title" id="_i45"> 4-Amino-8-bromo-5-fluoroquinoline-3-carboxamide (<b>30b</b>)</h4><div class="NLM_p last">It is obtained as a white solid. Total yield: 16%. <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>, ppm): δ 8.88 (s, 1H), 8.15 (s, 1H), 8.06 (dd, <i>J</i> = 8.4, 5.2 Hz, 1H), 7.51 (s, 1H), 7.22 (d, <i>J</i> = 13.2, 8.4 Hz, 1H).</div></div><div id="sec4_3_3" class="NLM_sec NLM_sec_level_3"><div id="ac_i46" class="anchor-spacer"></div><h4 class="article-section__title" id="_i46"> 4-Amino-8-bromo-6-fluoroquinoline-3-carboxamide (<b>30c</b>)</h4><div class="NLM_p last">It is obtained as a white solid. Total yield: 14%. <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>, ppm): δ 8.87 (s, 1H), 8.56 (s, 1H), 8.24 (m, 1H), 8.10 (dd, <i>J</i> = 7.8, 2.4 Hz, 1H), 7.45 (s, 1H).</div></div><div id="sec4_3_4" class="NLM_sec NLM_sec_level_3"><div id="ac_i47" class="anchor-spacer"></div><h4 class="article-section__title" id="_i47"> 4-Amino-8-bromo-6-nitroquinoline-3-carboxamide (<b>30d</b>)</h4><div class="NLM_p last">It is obtained as a white solid. Total yield: 6%. <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>, ppm): δ 9.21 (s, 1H), 9.07 (d, <i>J</i> = 2.3 Hz, 1H), 8.93 (d, <i>J</i> = 2.3 Hz, 1H), 8.33 (s, 1H), 8.17 (s, 1H).</div></div><div id="sec4_3_5" class="NLM_sec NLM_sec_level_3"><div id="ac_i48" class="anchor-spacer"></div><h4 class="article-section__title" id="_i48"> 4-Bromo-2,6-difluorobenzaldehyde (<b>32</b>)</h4><div class="NLM_p last">In a round-bottom flask, <i>n</i>-butyl lithium (8.8 mL, 22 mmol) was added dropwise to a solution of diisopropyl amine (3.2 mL, 22 mmol) in dry THF at −78 °C under a nitrogen atmosphere over a period of 5 min. Then, the mixture was warmed to −20 °C and stirred for another 25 min. 1-Bromo-3,5-difluorobenzene <b>31</b> (2.4 mL, 20 mmol) in dry THF (10 mL) was added at −78 °C, and stirring was continued for a further 25 min, followed by the addition of DMF (1.7 mL, 22 mmol) in dry THF at −78 °C. The resulting mixture was stirred at room temperature for 2 h. The reaction was quenched by ammonium chloride solution. Then, the organic solvent was removed under the reduced pressure. The residue was dissolved in DCM and extracted by water for three times. Purification by column chromatography on silica gel (2% ethyl acetate in hexane) afforded 2.3 g of the product (50% yield). <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>, ppm): δ 10.29 (s, 1H), 7.26–7.21 (m, 2H).</div></div></div><div id="sec4_4" class="NLM_sec NLM_sec_level_2"><div id="ac_i49" class="anchor-spacer"></div><h3 class="article-section__title" id="_i49"> General Procedure for the Synthesis of Intermediates <b>35a–h</b></h3><div class="NLM_p">Step 1: To a suspension of <b>32</b> (1.1 g, 5 mmol) and K<sub>2</sub>CO<sub>3</sub> (1.0 g, 7.5 mmol) in <i>N</i>,<i>N</i>-dimethylacetamide (5 mL) was added corresponding substituted phenol or aniline (1 equiv). The resulting mixture was stirred at 100 °C for 4 h. After cooling to rt, the suspension was extracted with EtOAc and water. The organic layer was collected and concentrated under vacuum. Purification by column chromatography on silica gel (1% ethyl acetate in hexane) afforded corresponding products <b>33b–h</b> (35–61% yield).</div><div class="NLM_p">Step 2: Hydrazinehydrate (10 mL) was added over 5 min to a solution of the prepared aldehyde <b>33b–h</b> or readily available 4-bromo-2-fluorobenzaldehyde <b>33a</b> (10 mmol) in DME (10 mL). The reaction mixture was refluxed for 15 h and concentrated in vacuo to approximately 10 mL. Water (10–20 mL) was added to the mixture. The resulting product precipitate was filtered off and dried in vacuo to provide the 1<i>H</i>-indazole <b>34a–h</b> as a solid.</div><div class="NLM_p">Step 3: A solution of <b>34a–h</b> (200 mg, 1.02 mmol) in anhydrous THF (4 mL) was treated dropwise with <i>tert</i>-butyllithium (1.3 M solution in pentane, 2.6 mL, 3.4 mmol). After stirring for 25 min, the mixture was treated dropwise with tributyl borate (0.83 mL, 3.06 mmol) and allowed to warm up to room temperature. After stirring overnight, the reaction mixture was quenched by saturated ammonium chloride solution and concentrated under vacuum. The resulting residue was dissolved in sodium hydroxide solution (20 mL, 1 M) and washed by DCM. Then, the aqueous layer was acidified with conc. HCl solution to pH = 2, extracted with ether. The combined ether extracts were dried over sodium sulfate and concentrated to obtain (1<i>H</i>-indazol-6-yl)boronic acid <b>35a–h</b> as a solid, which was used for the next step without further purification.</div><div id="sec4_4_1" class="NLM_sec NLM_sec_level_3"><div id="ac_i50" class="anchor-spacer"></div><h4 class="article-section__title" id="_i50"> 5-Bromo-2,4-dimethylaniline (<b>37a</b>)</h4><div class="NLM_p last">To a suspension of 1-bromo-2,4-dimethyl-5-nitrobenzene <b>36a</b> (9.2 g, 40 mmol) and NH<sub>4</sub>Cl (1.5 g, 28 mmol) in ethanol (25 mL) and water (10 mL) was added iron powder (13.4 g, 240 mmol). The reaction mixture was heated at 80 °C for 1 h. The iron was removed by filtration and the filtrate was concentrated to dryness. The resulting residue was dissolved in DCM and washed by brine for three times. The organic phase was dried over sodium sulfate and concentrated to obtain 5-bromo-2,4-dimethylaniline <b>37a</b> (6.4 g, 80% yield) as a yellow solid, which was used for the next step without further purification.</div></div><div id="sec4_4_2" class="NLM_sec NLM_sec_level_3"><div id="ac_i51" class="anchor-spacer"></div><h4 class="article-section__title" id="_i51"> 5-Bromo-4-methoxy-2-methylaniline (<b>37b</b>)</h4><div class="NLM_p last">To a suspension of 1-bromo-2-methoxy-4-methyl-5-nitrobenzene <b>36b</b> (9.9 g, 40 mmol) and NH<sub>4</sub>Cl (1.5 g, 28 mmol) in ethanol (25 mL) and water (10 mL) was added iron powder (13.4 g, 240 mmol). The reaction mixture was heated at 80 °C for 1 h. The iron was removed by filtration, and the filtrate was concentrated to dryness. The resulting residue was dissolved in DCM and washed by brine for three times. The organic phase was dried over sodium sulfate and concentrated to obtain 5-bromo-4-methoxy-2-methylaniline <b>37b</b> (7.8 g, 90% yield) as a yellow solid, which was used for the next step without further purification.</div></div><div id="sec4_4_3" class="NLM_sec NLM_sec_level_3"><div id="ac_i52" class="anchor-spacer"></div><h4 class="article-section__title" id="_i52"> <i>tert</i>-Butyl 6-Bromo-5-methyl-1<i>H</i>-indazole-1-carboxylate (<b>38a</b>)</h4><div class="NLM_p">Step 1: Aniline <b>37a</b> (4.0 g, 20 mmol) was added to a 50% aqueous solution of fluroboric acid (20 mL) at rt and stirred for 5 min. The mixture was cooled to 0 °C and an aqueous solution of NaNO<sub>2</sub> (1.7 g, 24 mmol) was added. The reaction mixture was stirred at 10 °C for 3 h, during which the product precipitated. The cooled suspension was filtrated and the solid product washed with a small amount of water, methanol, and ether. The resulting solid was dried under high vacuum.</div><div class="NLM_p">Step 2: The solution of 18-crown-6 (185 mg, 0.7 mmol) and potassium acetate (2.7 g, 28 mmol) in dry CHCl<sub>3</sub> was stirred at rt for 10 min. Then, the solid resulted from step 1 (4.2 g, 14 mmol) was added to the solution in small portions under a N<sub>2</sub> atmosphere. The reaction mixture was stirred at rt for 3 h. The suspension was filtrated and the residue was washed with CHCl<sub>3</sub>. The organic layer was washed with water and concentrated in vacuo to give the crude product.</div><div class="NLM_p last">Step 3: The product from step 2 (2.1 g, 10 mmol) and DMAP (244 mg, 2 mmol) was dissolved in acetonitrile (20 mL). Et<sub>3</sub>N (2.4 mL, 17 mmol) and di-<i>tert</i>-butyl carbonate (3.0 mL, 13 mmol) were added to the solution. Then, the reaction mixture was stirred at rt for 1 h. The brown solution was evaporated to dryness. The residue was dissolved in DCM and washed with brine. The organic phase was collected and concentrated under the vacuum. Purification by column chromatography on silica gel (eluting with petroleum ether-ethyl acetate, 4:1) afforded the desired compound <b>38a</b> (2.2 g, 35% yield).</div></div><div id="sec4_4_4" class="NLM_sec NLM_sec_level_3"><div id="ac_i53" class="anchor-spacer"></div><h4 class="article-section__title" id="_i53"> <i>tert</i>-Butyl 6-Bromo-5-methoxy-1<i>H</i>-indazole-1-carboxylate (<b>38b</b>)</h4><div class="NLM_p last">The synthesis of <b>38b</b> was the same as described as <b>38a</b>. Purification by column chromatography on silica gel (eluting with petroleum ether-ethyl acetate, 4:1) afforded the desired compound <b>38b</b> (1.6 g, 25% yield).</div></div><div id="sec4_4_5" class="NLM_sec NLM_sec_level_3"><div id="ac_i54" class="anchor-spacer"></div><h4 class="article-section__title" id="_i54"> 5-Methyl-6-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-1<i>H</i>-indazole (<b>39a</b>)</h4><div class="NLM_p last"><i>tert</i>-Butyl 6-bromo-5-methyl-1<i>H</i>-indazole-1-carboxylate <b>38a</b> (1.6 g, 5 mmol) is dissolved in argon-purged anhydrous 1,4-dioxane (10 mL). To this solution are added bis(pinacolato)diboron (1.5 g, 6 mmol), KOAc (0.98 g, 10 mmol), and Pd(dppf)Cl<sub>2</sub> (0.36 g, 0.5 mmol). The reaction is heated to 95 °C overnight under an argon atmosphere and then cooled to rt and diluted with brine and EtOAc. The organic layer was evaporated to dryness and then purified by column chromatography on silica gel (eluting with petroleum ether-ethyl acetate, 4:1). The resulting product in DCM (2 mL) was treated with TFA (2 mL). The reaction mixture was stirred at rt for 1 h and then concentrated to obtain <b>39a</b> (0.77 g, 60% yield) as a dark solid, which could be used for the next step without further purification. <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>, ppm): δ 10.84 (s, 1H), 8.01 (s, 2H), 7.52 (s, 1H), 2.64 (s, 3H), 1.39 (s, 12H).</div></div><div id="sec4_4_6" class="NLM_sec NLM_sec_level_3"><div id="ac_i55" class="anchor-spacer"></div><h4 class="article-section__title" id="_i55"> 5-Methoxy-6-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-1<i>H</i>-indazole (<b>39b</b>)</h4><div class="NLM_p last"><i>tert</i>-Butyl 6-bromo-5-methyl-1<i>H</i>-indazole-1-carboxylate <b>38b</b> (1.5 g, 4.6 mmol) is dissolved in argon-purged anhydrous 1,4-dioxane (10 mL). To this solution are added bis(pinacolato)diboron (1.4 g, 5.5 mmol), KOAc (0.9 g, 9.2 mmol), and Pd(dppf)Cl<sub>2</sub> (0.34 g, 0.46 mmol). The reaction is heated to 95 °C overnight under argon atmosphere and then cooled to rt and diluted with brine and EtOAc. The organic layer was evaporated to dryness and then purified by column chromatography on silica gel (eluting with petroleum ether-ethyl acetate, 4:1). The resulting product in DCM (2 mL) was treated with TFA (2 mL). The reaction mixture was stirred at rt for 1 h and then concentrated to obtain <b>39b</b> (0.7 g, 55% yield) as a dark solid, which could be used for the next step without further purification. <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>, ppm): δ 7.96 (s, 1H), 7.83 (s, 1H), 7.06 (s, 1H), 3.84 (s, 3H), 1.37 (s, 12H).</div></div></div><div id="sec4_5" class="NLM_sec NLM_sec_level_2"><div id="ac_i56" class="anchor-spacer"></div><h3 class="article-section__title" id="_i56"> General Procedure for the Synthesis of Intermediate <b>42</b></h3><div class="NLM_p">Step 1: A solution of 1,2-diaminobenzene <b>40</b> (10 mmol) in DMF (10 mL) was treated with <i>N</i>,<i>N</i>′-carbonyldiimidazole (2 equiv) and stirred at room temperature for 18 h. After removal of the DMF in vacuo, the resulting white solid was washed with H<sub>2</sub>O and dried on high vacuum to give <b>41</b> (75–78%) as a white solid.</div><div class="NLM_p last">Step 2: 5-Bromo-1,3-dihydro-benzoimidazol-2-one <b>41</b> (5 mmol) is dissolved in argon-purged anhydrous DMF (5 mL). To this solution are added bis(pinacolato)diboron (1.2 equiv), KOAc (3 equiv), and PdCl<sub>2</sub>(dppf), 1:1 complex with CH<sub>2</sub>Cl<sub>2</sub> (0.1 equiv). The reaction is heated to 95 °C overnight with mechanical stirring and then cooled to room temperature and diluted with brine (50 mL) and EtOAc (75 mL). The mixture is filtered to remove a dark brown solid, which is washed thoroughly with EtOAc. The layers are separated and the organics washed with water, then dried with anhydrous MgSO<sub>4</sub>, filtered, and evaporated under reduced pressure. Trituration with 1:1 CH<sub>2</sub>Cl<sub>2</sub>/hexanes affords the products <b>42</b> (80–83%)</div></div><div id="sec4_6" class="NLM_sec NLM_sec_level_2"><div id="ac_i57" class="anchor-spacer"></div><h3 class="article-section__title" id="_i57"> Cell Culture</h3><div class="NLM_p last">Ramos cells were cultured complete growth medium RPMI 1640 supplemented with 10% FBS and 1% penicillin–streptomycin and grown at 37 °C with 5% CO<sub>2</sub>.</div></div><div id="sec4_7" class="NLM_sec NLM_sec_level_2"><div id="ac_i58" class="anchor-spacer"></div><h3 class="article-section__title" id="_i58"> Antibodies</h3><div class="NLM_p last">Anti-BTK antibody was purchased from Absin (abs135992, 1:1000 dilution). Anti-BTK (phospho Y223) antibody was purchased from Abcam (ab68217, 1:1000 dilution). Anti-GAPDH antibodies were purchased from CWBIO (CW0100M, 1:2000 dilution). Anti-mouse IgG-HRP and anti-rabbit IgG-HRP were purchased from Cell Signaling Technology and used at 1:5000 dilution.</div></div><div id="sec4_8" class="NLM_sec NLM_sec_level_2"><div id="ac_i59" class="anchor-spacer"></div><h3 class="article-section__title" id="_i59"> BTK Enzymatic Assay</h3><div class="NLM_p">BTK enzymatic activity was determined with the off-chip mobility shift assay. The compound was diluted to 50× of the final concentration with DMSO. The compound (10 μL) was added into 90 μL of 1× kinase buffer (50 mM HEPES, pH 7.5, 0.01% Brij-35) and the solution was mixed for 10 min on a shaker. The diluted solution (5 μL) was transferred into a 384-well plate in triplicates. 1× kinase base buffer (10 μL) containing BTK<sup><i>WT</i></sup> (Carna, Cat. no. 08-180) or BTK<sup><i>C481S</i></sup> (Carna, Cat. no. 08-547) was added into the 384-well plate and incubated with the compound for 10 min. Then, 10 μL of 1× kinase buffer containing FAM-labeled peptide (GL Biochem, Cat. no. 112394, Lot. no. P131014-XP112394) and ATP (Sigma, Cat. no. A7699-1G, CAS no. 987-65-5) was added. It was incubated at 28 °C for a specified period of time. Stop buffer (25 μL, 100 mM HEPES, pH 7.5, 0.015% Brij-35, 0.2% Coating Reagent #3, 50 mM EDTA) was added to stop reaction. Data were collected on Caliper.<span class="NLM_disp-formula" id="ueq1"><img class="imgWithoutFigViewer " src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-14/acs.jmedchem.9b00329/20190719/images/medium/jm-2019-00329v_m001.gif" alt="" id="_i60" /></img></span>“max” stands for DMSO control and “min” stands for low control.</div><div class="NLM_p">The data were fitted in XLfit excel add-in version 4.3.1 to obtain IC<sub>50</sub> values.</div><div class="NLM_p">The equation used is<span class="NLM_disp-formula" id="ueq2"><img class="imgWithoutFigViewer " src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-14/acs.jmedchem.9b00329/20190719/images/medium/jm-2019-00329v_m002.gif" alt="" id="_i61" /></img></span></div><div class="NLM_p last">The results are represented as mean ± SD from at least three separate assays performed in triplicates.</div></div><div id="sec4_9" class="NLM_sec NLM_sec_level_2"><div id="ac_i62" class="anchor-spacer"></div><h3 class="article-section__title" id="_i62"> EGFR Inhibition Assay</h3><div class="NLM_p last">EGFR assay was detected by a <i>Z</i>′-LYTETM kinase assay kit (Invitrogen, PV3193). The test compounds were diluted to 3-fold serial dilutions in aqueous solution (containing 4% DMSO). The fluorescence signals were detected at 400 nm (excitation) and 445/520 nm (emission) using an EnVision multilabel plate reader (PerkinElmer Life Sciences, Boston, MA, USA). The IC<sub>50</sub> values represented as mean from at least three separate assays performed in triplicates.</div></div><div id="sec4_10" class="NLM_sec NLM_sec_level_2"><div id="ac_i63" class="anchor-spacer"></div><h3 class="article-section__title" id="_i63"> TEC Inhibition Assay</h3><div class="NLM_p last">Tec kinase (Carna, Cat. no. 08-182) enzymology assays were performed according to the protocols specified in HTRF KinEase assays sold by Cisbio Bioassays. Basically, kinase and substrate were mixed with various concentrations of compounds at rt, followed by addition of ATP to start enzymatic reactions. After 1 h, the reactions were stopped by EDTA detection solution, and then europilated antiphosphotyrosine antibodies and streptavidin XL665 conjugates were added. The mixtures were incubated at rt for another 1 h and read by EnVision multilabel plate reader. Data analysis was performed with GraphPad Prism 7. The results represented as mean from at least three separate assays performed in triplicates.</div></div><div id="sec4_11" class="NLM_sec NLM_sec_level_2"><div id="ac_i64" class="anchor-spacer"></div><h3 class="article-section__title" id="_i64"> YES Inhibition Assay</h3><div class="NLM_p last">YES (Eurofins, Cat. no. 14-178) is incubated with 8 mM MOPS pH 7.0, 0.2 mM EDTA, 0.1 mg/mL poly(Glu, Tyr) 4:1, 10 mM magnesium acetate and [gamma-<sup>33</sup>P]-ATP (specific activity and concentration as required). The reaction is initiated by the addition of the Mg/ATP mixture at room temperature. After incubation for 40 min, the reaction is stopped by the addition of phosphoric acid to a final concentration of 0.5%. The reaction mixture (10 μL) is then transferred onto a Filtermat A and washed four times by 0.425% phosphoric acid and once by methanol before drying and scintillation counting. The results are represented as mean from at least three separate assays performed in triplicates.</div></div><div id="sec4_12" class="NLM_sec NLM_sec_level_2"><div id="ac_i65" class="anchor-spacer"></div><h3 class="article-section__title" id="_i65"> ITK Inhibition Assay</h3><div class="NLM_p last">ITK (Eurofins, Cat. 14-660) is incubated with 8 mM MOPS pH 7.0, 0.2 mM EDTA, 0.33 mg/mL myelin basic protein, 10 mM magnesium acetate, and [gamma-<sup>33</sup>P]-ATP (specific activity and concentration as required). The reaction is initiated by the addition of the Mg/ATP mix. After incubation for 40 min at room temperature, the reaction is stopped by the addition of phosphoric acid to a concentration of 0.5%. The reaction mixture (10 μL) is then transferred onto a P30 filtermat and washed four times for 4 min in 0.425% phosphoric acid and once in methanol prior to drying and scintillation counting. The results represented as mean from at least three separate assays performed in triplicates.</div></div><div id="sec4_13" class="NLM_sec NLM_sec_level_2"><div id="ac_i66" class="anchor-spacer"></div><h3 class="article-section__title" id="_i66"> SRC Inhibition Assay</h3><div class="NLM_p last">SRC (Eurofins, Cat. 23-042) is incubated with 8 mM MOPS pH 7.0, 0.2 mM EDTA, 250 μM KVEKIGEGTYGVVYK (Cdc2 peptide), 10 mM magnesium acetate, and [gamma-<sup>33</sup>P]-ATP (specific activity and concentration as required). The reaction is initiated by the addition of the Mg/ATP mixture at room temperature. After incubation for 40 min, the reaction is stopped by the addition of phosphoric acid to a final concentration of 0.5%. The reaction mixture (10 μL) is then transferred onto a Filtermat A and washed four times by 0.425% phosphoric acid and once by methanol before drying and scintillation counting. The results are represented as mean from at least three separate assays performed in triplicates.</div></div><div id="sec4_14" class="NLM_sec NLM_sec_level_2"><div id="ac_i67" class="anchor-spacer"></div><h3 class="article-section__title" id="_i67"> FYN Inhibition Assay</h3><div class="NLM_p last">FYN (Eurofins, Cat. 14-441) is incubated with 50 mM Tris pH 7.5, 0.1 mM EGTA, 0.1 mM Na<sub>3</sub>VO<sub>4</sub>, 250 μM KVEKIGEGTYGVVYK (Cdc2 peptide), 10 mM magnesium acetate, and [gamma-<sup>33</sup>P]-ATP (specific activity and concentration as required). The reaction is initiated by the addition of the Mg/ATP mix. After incubation for 40 min at room temperature, the reaction is stopped by the addition of phosphoric acid to a concentration of 0.5%. The reaction mixture (10 μL) is then transferred onto a P30 filtermat and washed four times for 4 min in 0.425% phosphoric acid and once in methanol prior to drying and scintillation counting. The results are represented as mean from at least three separate assays performed in triplicates.</div></div><div id="sec4_15" class="NLM_sec NLM_sec_level_2"><div id="ac_i68" class="anchor-spacer"></div><h3 class="article-section__title" id="_i68"> BLK Inhibition Assay</h3><div class="NLM_p last">BLK (Eurofins, Cat. 14-316) is incubated with 50 mM Tris pH 7.5, 0.1 mM EGTA, 0.1 mM Na<sub>3</sub>VO<sub>4</sub>, 0.1% 6-mercaptoethanol, 0.1 mg/mL poly(Glu, Tyr) 4:1, 10 mM magnesium acetate, and [gamma-<sup>33</sup>P]-ATP (specific activity and concentration as required). The reaction is initiated by the addition of the Mg/ATP mixture at room temperature. After incubation for 40 min, the reaction is stopped by the addition of phosphoric acid to a final concentration of 0.5%. The reaction mixture (10 μL) is then transferred onto a Filtermat A and washed four times by 0.425% phosphoric acid and once by methanol before drying and scintillation counting. The results are represented as mean from at least three separate assays performed in triplicates.</div></div><div id="sec4_16" class="NLM_sec NLM_sec_level_2"><div id="ac_i69" class="anchor-spacer"></div><h3 class="article-section__title" id="_i69"> Cellular BTK Phosphorylation</h3><div class="NLM_p last">Ramos cells were plated in a 12-well volume plate at 1.6 × 10<sup>6</sup> cells per well, and compounds diluted in RPMI 1640 media were added to the cells. After 2 h incubation, the cells were treated with activator solution (1.9 mM H<sub>2</sub>O<sub>2</sub> and 5 mM Na<sub>3</sub>VO<sub>4</sub>) for 15 min. Cells were lysed with RIPA lysis buffer, and the phosphorylation levels of BTK (Tyr223) were analyzed by western blotting. The results are represented as mean ± SD from at least three separate assays performed in triplicates.</div></div><div id="sec4_17" class="NLM_sec NLM_sec_level_2"><div id="ac_i70" class="anchor-spacer"></div><h3 class="article-section__title" id="_i70"> In Vitro Plasma Stability</h3><div class="NLM_p last">The compound with an initial concentration of 1 μM was incubated in human, beagle dog, SD rat, mouse, and monkey plasma samples for 2 h at 37 °C. Then, the samples were quenched by adding 10 volumes of 100% methanol supplemented with internal standard and centrifuged at 12 000 rpm for 5 min. Following that, the supernatants were transferred to a new plate containing an equal volume of water for analysis by liquid chromatography coupled to triple quadrupole mass spectrometry (LC–MS/MS). The results are represented as mean from three separate assays performed in triplicates.</div></div><div id="sec4_18" class="NLM_sec NLM_sec_level_2"><div id="ac_i71" class="anchor-spacer"></div><h3 class="article-section__title" id="_i71"> Animals</h3><div class="NLM_p last">All animal care and experimental protocols were performed in accordance with the “Guide for the Care and Use of Laboratory Animals”(National Institutes of Health Publication, revised 1996, no. 86-23, Bethesda, MD) and approved by the Institutional Animal Care and Use Committee (IACUC) of Tsinghua University. Male Sprague–Dawley rats with a body weight of 187–205 g at 5–7 weeks old and male DBA/1 mice of 18–20 g at 4–6 weeks old were purchased from Shanghai Slac Laboratory Animal Ltd., Shanghai, China.</div></div><div id="sec4_19" class="NLM_sec NLM_sec_level_2"><div id="ac_i72" class="anchor-spacer"></div><h3 class="article-section__title" id="_i72"> In Vivo PKs Study</h3><div class="NLM_p last">A single dose of compound <b>25</b> (2 mg/kg in 10% DMSO and 90% PEG400) was administered by tail vein injection to feed male Sprague-Dawley rats (<i>n</i> = 6). Compound <b>25</b> was also dosed orally (5 mg kg<sup>–1</sup>) as a suspension in 0.5% methylcellulose to fasted male Sprague–Dawley rats (<i>n</i> = 6). Blood samples (∼0.2 mL) were obtained via a jugular cannula at pre-dose, 0.033 (IV only), 0.25, 0.5, 1, 2, 4, 6, 8, 10, and 24 h post dose. Blood was centrifuged at 4000 rpm for 15 min at 4 °C, and plasma was collected and stored at −20 °C until analysis by LC–MS/MS. Serial PK profiles were generated for each dosing group.</div></div><div id="sec4_20" class="NLM_sec NLM_sec_level_2"><div id="ac_i73" class="anchor-spacer"></div><h3 class="article-section__title" id="_i73"> Mice CIA Study</h3><div class="NLM_p last">Male DBA/1 mice were immunized intradermally at the base of the tail with bovine collagen type II emulsified in Complete Freund’s Adjuvant (CFA) on day 0; on day 20, mice were challenged with collagen type II in Incomplete Freund’s Adjuvant (IFA). On day 29, the CIA model mice were randomized and treated orally with 0.2 mg/kg DXMS (<i>n</i> = 6), 10 mg/kg compound <b>25</b> (<i>n</i> = 6) and vehicle control (<i>n</i> = 6) QD. Paw thickness measurements by a caliper were performed throughout the day.</div></div><div id="sec4_21" class="NLM_sec NLM_sec_level_2"><div id="ac_i74" class="anchor-spacer"></div><h3 class="article-section__title" id="_i74"> Docking Simulations of BTK Inhibitors</h3><div class="NLM_p last">Prediction of ligand binding to BTK was done with Schrodinger Suite 2017-1. Processing of the protein structure was performed with the Protein Preparation Wizard. Converting of ligands from 2D to 3D structures was performed using LigPrep. Molecular docking was performed with Glide.</div></div><div id="sec4_22" class="NLM_sec NLM_sec_level_2"><div id="ac_i75" class="anchor-spacer"></div><h3 class="article-section__title" id="_i75"> Solubility Determinations</h3><div class="NLM_p last">The dry powder was equilibrated with 0.1 M phosphate buffer (pH 7.4) in a glass vial at 25 °C (water bath), and it was shaken for 24 h. After filtration using a 0.45 μm PVDF membrane filter, the concentration of corresponding compound was determined by HPLC, comparing the peak area obtained with that from a standard solution of the compound in DMSO. The results are represented as mean from three separate assays performed in triplicates.</div></div></div><div class="NLM_back"><div class="article_supporting-info" id="notes1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i76"><a href="/doi/suppl/10.1021/acs.jmedchem.9b00329" class="ext-link">Supporting Information</a></h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_34812" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_34812" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><p class="last">The Supporting Information is available free of charge on the <a href="/" class="ext-link">ACS Publications website</a> at DOI: <a href="/doi/abs/10.1021/acs.jmedchem.9b00329" class="ext-link">10.1021/acs.jmedchem.9b00329</a>.<ul class="NLM_list-list_type-label" id="silist"><li><p class="inline">Western blotting data for evaluation EC<sub>50</sub> values of compounds <b>6</b> and <b>25</b>, analytical RP-HPLC trace(s) for compound <b>6</b>, <b>7</b>, <b>17</b>, and <b>25</b>, and NMR spectra of all new compounds (<a href="/doi/suppl/10.1021/acs.jmedchem.9b00329/suppl_file/jm9b00329_si_001.pdf" class="ext-link">PDF</a>)</p></li><li><p class="inline">Docking model of compound <b>7</b> (<a href="/doi/suppl/10.1021/acs.jmedchem.9b00329/suppl_file/jm9b00329_si_002.pdb" class="ext-link">PDB</a>)</p></li><li><p class="inline">Docking model of compound <b>25</b> (<a href="/doi/suppl/10.1021/acs.jmedchem.9b00329/suppl_file/jm9b00329_si_003.pdb" class="ext-link">PDB</a>)</p></li><li><p class="inline">Molecular formula strings (<a href="/doi/suppl/10.1021/acs.jmedchem.9b00329/suppl_file/jm9b00329_si_004.csv" class="ext-link">CSV</a>)</p></li></ul></p><div class="supInfoBoxOnFTP "><div class="sup-info-attachments"><ul><li><a class="suppl-anchor" href="/doi/suppl/10.1021/acs.jmedchem.9b00329/suppl_file/jm9b00329_si_001.pdf">jm9b00329_si_001.pdf (1.1 MB)</a></li><li><a class="suppl-anchor" href="/doi/suppl/10.1021/acs.jmedchem.9b00329/suppl_file/jm9b00329_si_002.pdb">jm9b00329_si_002.pdb (533.2 kb)</a></li><li><a class="suppl-anchor" href="/doi/suppl/10.1021/acs.jmedchem.9b00329/suppl_file/jm9b00329_si_003.pdb">jm9b00329_si_003.pdb (533.3 kb)</a></li><li><a class="suppl-anchor" href="/doi/suppl/10.1021/acs.jmedchem.9b00329/suppl_file/jm9b00329_si_004.csv">jm9b00329_si_004.csv (1.29 kb)</a></li></ul></div></div></div><div class="testing" data-doi="10.1021/acs.jmedchem.9b00329" data-url="https://widgets.figshare.com/static/figshare.js" id="figshare-widget"></div><div class="TermsAndConditionsDropzone3" data-pb-dropzone="TermsAndConditionsDropzone3"><div data-widget-def="UX3HTMLWidget" data-widget-id="85b54935-30e9-4058-a6d2-0b40fb754a85" class="mb-4">
        



        
            <h2 class="">
                Terms & Conditions
            </h2>
        
        <p>Most electronic Supporting Information files are available without a subscription to ACS Web Editions. Such files may be downloaded by article for research use (if there is a public use license linked to the relevant article, that license may permit other uses). Permission may be obtained from ACS for other uses through requests via the RightsLink permission system: <a href="/page/copyright/permissions.html" title="RightsLink">http://pubs.acs.org/page/copyright/permissions.html</a>.</p>

        </div></div><div class="authorInformationSection"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="authorInformationSection">Author Information</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_82875" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_82875" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><ul><li><span class="author-information-subsection-header">Corresponding Author</span><ul><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Yu Rao</span> - <span class="hlFld-Affiliation affiliation">Ministry
of Education (MOE) Key Laboratory of Protein Sciences, School of Pharmaceutical
Sciences, MOE Key Laboratory of Bioorganic Phosphorus Chemistry &
Chemical Biology, Tsinghua University, Beijing 100084, P. R. China</span>; 
    <span class="author-orcid"><img src="/products/achs/releasedAssets/images/orchid.png" alt="Orcid" /></img><a href="http://orcid.org/0000-0002-4356-8531" title="Orcid link">http://orcid.org/0000-0002-4356-8531</a>; 
    </span><span class="author-email">
                Email: <a href="/cdn-cgi/l/email-protection#afd6ddcec0efdbdcc6c1c8c7dace81cacbda81ccc1"><span class="__cf_email__" data-cfemail="d1a8a3b0be91a5a2b8bfb6b9a4b0ffb4b5a4ffb2bf">[email protected]</span></a></span></div></li></ul></li><li><span class="author-information-subsection-header">Authors</span><ul><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Xia Yao</span> - <span class="hlFld-Affiliation affiliation">Ministry
of Education (MOE) Key Laboratory of Protein Sciences, School of Pharmaceutical
Sciences, MOE Key Laboratory of Bioorganic Phosphorus Chemistry &
Chemical Biology, Tsinghua University, Beijing 100084, P. R. China</span>; 
    <span class="author-orcid"><img src="/products/achs/releasedAssets/images/orchid.png" alt="Orcid" /></img><a href="http://orcid.org/0000-0003-2406-268X" title="Orcid link">http://orcid.org/0000-0003-2406-268X</a></span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Xiuyun Sun</span> - <span class="hlFld-Affiliation affiliation">Ministry
of Education (MOE) Key Laboratory of Protein Sciences, School of Pharmaceutical
Sciences, MOE Key Laboratory of Bioorganic Phosphorus Chemistry &
Chemical Biology, Tsinghua University, Beijing 100084, P. R. China</span>; 
    <span class="hlFld-Affiliation affiliation">Tsinghua-Peking
Center for Life Sciences, Beijing 100084, P. R. China</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Shuyu Jin</span> - <span class="hlFld-Affiliation affiliation">Key
Laboratory of Structure-Based Drugs Design & Discovery of Ministry
of Education, Shenyang Pharmaceutical University, Shenyang 110016, P. R. China</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Ling Yang</span> - <span class="hlFld-Affiliation affiliation">R&D
Institute, Chia Tai Tianqing Pharmaceutical
Group Co., LTD, Nanjing 210023, P. R. China</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Hongjiang Xu</span> - <span class="hlFld-Affiliation affiliation">R&D
Institute, Chia Tai Tianqing Pharmaceutical
Group Co., LTD, Nanjing 210023, P. R. China</span></div></li></ul></li><li><span class="author-information-subsection-header">Author Contributions</span><p>X.Y. and X.S. authors contributed equally. The manuscript was written through contributions of all authors. All authors have given approval to the final version of the manuscript.</p></li><li><span class="author-information-subsection-header">Funding</span><p>This work was supported by the National Natural Science Foundation of China (#81573277, 81622042, 81773567), National Major Scientific and Technological Special Project for “Significant New Drugs Development” (#SQ2017ZX095003, 2018ZX09711001) and Tsinghua University Initiative Scientific Research Program. This work was also financially supported by the NSFC (no. 81670187) and Beijing Natural Science Foundation (no. 7172047).</p></li><li><span class="author-information-subsection-header">Notes</span><div class="authorInformation_notesSection">The authors declare no competing financial interest.<br /></br></div></li></ul></div><div class="ack" id="ack1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i78">Acknowledgments</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_47430" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_47430" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><p class="last">We would like to thank Prof. Qinghua, Tao for providing cell culture room. This work was supported by the National Natural Science Foundation of China (#81573277, 81622042, 81773567), National Major Scientific and Technological Special Project for “Significant New Drugs Development” (#SQ2017ZX095003, 2018ZX09711001), and Tsinghua University Initiative Scientific Research Program. This work was also financially supported by the NSFC (no. 81670187) and Beijing Natural Science Foundation (no. 7172047).</p></div><table summary="" class="NLM_def-list" id="dl1"><tr><td colspan="2" class="NLM_title">Abbreviations</td></tr><tr><td class="NLM_term">BTK</td><td class="NLM_def"><p class="first last">Bruton’s tyrosine kinase</p></td></tr><tr><td class="NLM_term">RA</td><td class="NLM_def"><p class="first last">rheumatoid arthritis</p></td></tr><tr><td class="NLM_term">CIA</td><td class="NLM_def"><p class="first last">collagen-induced arthritis</p></td></tr><tr><td class="NLM_term">NSAIDs</td><td class="NLM_def"><p class="first last">non-steroidal anti-inflammatory drugs</p></td></tr><tr><td class="NLM_term">DMARDs</td><td class="NLM_def"><p class="first last">disease-modifying anti-rheumatic drugs</p></td></tr><tr><td class="NLM_term">MTX</td><td class="NLM_def"><p class="first last">methotrexate</p></td></tr><tr><td class="NLM_term">SLE</td><td class="NLM_def"><p class="first last">systemic lupus erythematosus</p></td></tr><tr><td class="NLM_term">BCR</td><td class="NLM_def"><p class="first last">B cell receptor</p></td></tr><tr><td class="NLM_term">MCL</td><td class="NLM_def"><p class="first last">mantle-cell lymphoma</p></td></tr><tr><td class="NLM_term">CLL</td><td class="NLM_def"><p class="first last">chronic lymphocytic leukemia</p></td></tr><tr><td class="NLM_term">WM</td><td class="NLM_def"><p class="first last">Waldenström’s macroglobulinemia</p></td></tr><tr><td class="NLM_term">aq sol</td><td class="NLM_def"><p class="first last">aqueous solubility</p></td></tr><tr><td class="NLM_term">PK</td><td class="NLM_def"><p class="first last">pharmacokinetic</p></td></tr><tr><td class="NLM_term">EGFR</td><td class="NLM_def"><p class="first last">epidermal growth factor receptor</p></td></tr><tr><td class="NLM_term">DXMS</td><td class="NLM_def"><p class="first last">dexamethasone</p></td></tr><tr><td class="NLM_term">LDA</td><td class="NLM_def"><p class="first last">lithium diisopropylamide</p></td></tr><tr><td class="NLM_term">DMF</td><td class="NLM_def"><p class="first last"><i>N</i>,<i>N</i>-dimethylformamide</p></td></tr><tr><td class="NLM_term">THF</td><td class="NLM_def"><p class="first last">tetrahydrofuran</p></td></tr><tr><td class="NLM_term">DMA</td><td class="NLM_def"><p class="first last"><i>N</i>,<i>N</i>-dimethylacetamide</p></td></tr><tr><td class="NLM_term">DME</td><td class="NLM_def"><p class="first last">1,2-dimethoxyethane</p></td></tr><tr><td class="NLM_term">RT</td><td class="NLM_def"><p class="first last">room temperature</p></td></tr><tr><td class="NLM_term">DMAP</td><td class="NLM_def"><p class="first last">4-dimethylaminopyridine</p></td></tr><tr><td class="NLM_term">TFA</td><td class="NLM_def"><p class="first last">trifluoroacetic acid</p></td></tr><tr><td class="NLM_term">DCM</td><td class="NLM_def"><p class="first last">dichloromethane</p></td></tr><tr><td class="NLM_term">TLC</td><td class="NLM_def"><p class="first last">thin layer chromatography</p></td></tr></table><div class="refs-header-label"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i80">References</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_63224" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_63224" class="dropBlock__holder"></div></div></div></div></div><hr /></hr></div><p class="references-count">
            This article references 52 other publications.
        </p><ol id="references" class="useLabel"><li id="ref1"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref1'); return false;" data-citation="" class="refNumLink">1</a></strong><div class="NLM_citation" id="cit1"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Mcinnes, I. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schett, G.</span></span> <span> </span><span class="NLM_article-title">The pathogenesis of rheumatoid arthritis</span>. <i>N. Engl. J. Med.</i> <span class="NLM_year" style="font-weight: bold;">2011</span>,  <span class="NLM_volume"><i>365</i></span>,  <span class="NLM_fpage">2205</span>– <span class="NLM_lpage">2219</span>, <span class="refDoi"> DOI: 10.1056/nejmra1004965</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref1/cit1&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00329&amp;key=10.1056%2Fnejmra1004965" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref1/cit1&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00329&amp;key=22150039" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref1/cit1&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00329&amp;key=1%3ACAS%3A528%3ADC%252BC3MXhs1ajsrrM" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=365&publication_year=2011&pages=2205-2219&author=I.+B.+Mcinnesauthor=G.+Schett&title=The+pathogenesis+of+rheumatoid+arthritis&doi=10.1056%2Fnejmra1004965"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit1R"><div class="casContent"><span class="casTitleNuber">1</span><div class="casTitle"><span class="NLM_cas:atitle">The pathogenesis of rheumatoid arthritis</span></div><div class="casAuthors">McInnes, Lain B.; Schett, Georg</div><div class="citationInfo"><span class="NLM_cas:title">New England Journal of Medicine</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">365</span>
        (<span class="NLM_cas:issue">23</span>),
    <span class="NLM_cas:pages">2205-2219</span>CODEN:
                <span class="NLM_cas:coden">NEJMAG</span>;
        ISSN:<span class="NLM_cas:issn">0028-4793</span>.
    
            (<span class="NLM_cas:orgname">Massachusetts Medical Society</span>)
        </div><div class="casAbstract">A review discusses key pathogenic advances in rheumatoid arthritis, genetics, environmental factors, immunol. processes, inflammation, and structural damage.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrJslDVaG7MxbVg90H21EOLACvtfcHk0lj-DQCzFNwliQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXhs1ajsrrM&md5=31a79ccb05bca03f207b15f934b2d52d</span></div><a href="/servlet/linkout?suffix=cit1&amp;dbid=16384&amp;doi=10.1056%2Fnejmra1004965&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1056%252Fnejmra1004965%26sid%3Dliteratum%253Aachs%26aulast%3DMcinnes%26aufirst%3DI.%2BB.%26aulast%3DSchett%26aufirst%3DG.%26atitle%3DThe%2520pathogenesis%2520of%2520rheumatoid%2520arthritis%26jtitle%3DN.%2520Engl.%2520J.%2520Med.%26date%3D2011%26volume%3D365%26spage%3D2205%26epage%3D2219%26doi%3D10.1056%2Fnejmra1004965" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref2"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref2'); return false;" data-citation="" class="refNumLink">2</a></strong><div class="NLM_citation" id="cit2"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Smolen, J. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Aletaha, D.</span></span> <span> </span><span class="NLM_article-title">Rheumatoid arthritis therapy reappraisal: strategies, opportunities and challenges</span>. <i>Nat. Rev. Rheumatol.</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>11</i></span>,  <span class="NLM_fpage">256</span>– <span class="NLM_lpage">289</span>, <span class="refDoi"> DOI: 10.1038/nrrheum.2015.8</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref2/cit2&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00329&amp;key=10.1038%2Fnrrheum.2015.8" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=11&publication_year=2015&pages=256-289&author=J.+S.+Smolenauthor=D.+Aletaha&title=Rheumatoid+arthritis+therapy+reappraisal%3A+strategies%2C+opportunities+and+challenges&doi=10.1038%2Fnrrheum.2015.8"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit2&amp;dbid=16384&amp;doi=10.1038%2Fnrrheum.2015.8&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnrrheum.2015.8%26sid%3Dliteratum%253Aachs%26aulast%3DSmolen%26aufirst%3DJ.%2BS.%26aulast%3DAletaha%26aufirst%3DD.%26atitle%3DRheumatoid%2520arthritis%2520therapy%2520reappraisal%253A%2520strategies%252C%2520opportunities%2520and%2520challenges%26jtitle%3DNat.%2520Rev.%2520Rheumatol.%26date%3D2015%26volume%3D11%26spage%3D256%26epage%3D289%26doi%3D10.1038%2Fnrrheum.2015.8" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref3"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref3'); return false;" data-citation="" class="refNumLink">3</a></strong><div class="NLM_citation" id="cit3"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Kremer, J. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bloom, B. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Breedveld, F. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Coombs, J. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fletcher, M. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gruben, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Krishnaswami, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Burgos-Vargas, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wilkinson, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zerbini, C. A. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zwillich, S. H.</span></span> <span> </span><span class="NLM_article-title">The safety and efficacy of a JAK inhibitor in patients with active rheumatoid arthritis: Results of a double-blind, placebo-controlled phase IIa trial of three dosage levels of CP-690,550 versus placebo</span>. <i>Arthritis Rheum.</i> <span class="NLM_year" style="font-weight: bold;">2009</span>,  <span class="NLM_volume"><i>60</i></span>,  <span class="NLM_fpage">1895</span>– <span class="NLM_lpage">1905</span>, <span class="refDoi"> DOI: 10.1002/art.24567</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref3/cit3&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00329&amp;key=10.1002%2Fart.24567" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref3/cit3&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00329&amp;key=19565475" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref3/cit3&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00329&amp;key=1%3ACAS%3A528%3ADC%252BD1MXptlKktLg%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=60&publication_year=2009&pages=1895-1905&author=J.+M.+Kremerauthor=B.+J.+Bloomauthor=F.+C.+Breedveldauthor=J.+H.+Coombsauthor=M.+P.+Fletcherauthor=D.+Grubenauthor=S.+Krishnaswamiauthor=R.+Burgos-Vargasauthor=B.+Wilkinsonauthor=C.+A.+F.+Zerbiniauthor=S.+H.+Zwillich&title=The+safety+and+efficacy+of+a+JAK+inhibitor+in+patients+with+active+rheumatoid+arthritis%3A+Results+of+a+double-blind%2C+placebo-controlled+phase+IIa+trial+of+three+dosage+levels+of+CP-690%2C550+versus+placebo&doi=10.1002%2Fart.24567"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit3R"><div class="casContent"><span class="casTitleNuber">3</span><div class="casTitle"><span class="NLM_cas:atitle">The safety and efficacy of a JAK inhibitor in patients with active rheumatoid arthritis: results of a double-blind, placebo-controlled phase IIa trial of three dosage levels of CP-690,550 versus placebo</span></div><div class="casAuthors">Kremer, Joel M.; Bloom, Bradley J.; Breedveld, Ferdinand C.; Coombs, John H.; Fletcher, Mark P.; Gruben, David; Krishnaswami, Sriram; Burgos-Vargas, Ruben; Wilkinson, Bethanie; Zerbini, Cristiano A. F.; Zwillich, Samuel H.</div><div class="citationInfo"><span class="NLM_cas:title">Arthritis & Rheumatism</span>
        (<span class="NLM_cas:date">2009</span>),
    <span class="NLM_cas:volume">60</span>
        (<span class="NLM_cas:issue">7</span>),
    <span class="NLM_cas:pages">1895-1905</span>CODEN:
                <span class="NLM_cas:coden">ARHEAW</span>;
        ISSN:<span class="NLM_cas:issn">0004-3591</span>.
    
            (<span class="NLM_cas:orgname">John Wiley & Sons, Inc.</span>)
        </div><div class="casAbstract">To det. the efficacy, safety, and tolerability of 3 different dosages of CP-690,550, a potent, orally active JAK inhibitor, in patients with active rheumatoid arthritis (RA) in whom methotrexate, etanercept, infliximab, or adalimumab caused an inadequate or toxic response.  Patients (n = 264) were randomized equally to receive placebo, 5 mg of CP-690,550,15 mg of CP-690,550, or 30 mg of CP-690,550 twice daily for 6 wk, and were followed up for an addnl. 6 wk after treatment.  The primary efficacy end point was the American College of Rheumatol. 20% improvement criteria (ACR20) response rate at 6 wk.  By week 6, the ACR20 response rates were 70.5%, 81.2%, and 76.8% in the 5 mg, 15 mg, and 30 mg twice daily groups, resp., compared with 29.2% in the placebo group (P < 0.001).  Improvements in disease activity in CP-690,550-treated patients compared with placebo were seen in all treatment groups as early as week 1.  ACR50 and ACR70 response rates significantly improved in all treatment groups by week 4.  The most common adverse events reported were headache and nausea.  The infection rate in both the 15 mg twice daily group and the 30 mg twice daily group was 30.4% (vs. 26.2% in the placebo group).  No opportunistic infections or deaths occurred.  Increases in mean low-d. lipoprotein cholesterol and high-d. lipoprotein cholesterol levels, and increases in mean serum creatinine level (0.04-0.06 mg/dL) were seen in all CP-690,550 treatment arms.  Our findings indicate that CP-690,550 is efficacious in the treatment of RA, resulting in rapid, statistically significant, and clin. meaningful redns. in the signs and symptoms of RA.  Further studies of CP-690,550 in RA are warranted.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoBhxBhh_mG7rVg90H21EOLACvtfcHk0lhMAiK1dS-Swg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1MXptlKktLg%253D&md5=ab5fb34e43d8643871560c67bbbca07d</span></div><a href="/servlet/linkout?suffix=cit3&amp;dbid=16384&amp;doi=10.1002%2Fart.24567&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fart.24567%26sid%3Dliteratum%253Aachs%26aulast%3DKremer%26aufirst%3DJ.%2BM.%26aulast%3DBloom%26aufirst%3DB.%2BJ.%26aulast%3DBreedveld%26aufirst%3DF.%2BC.%26aulast%3DCoombs%26aufirst%3DJ.%2BH.%26aulast%3DFletcher%26aufirst%3DM.%2BP.%26aulast%3DGruben%26aufirst%3DD.%26aulast%3DKrishnaswami%26aufirst%3DS.%26aulast%3DBurgos-Vargas%26aufirst%3DR.%26aulast%3DWilkinson%26aufirst%3DB.%26aulast%3DZerbini%26aufirst%3DC.%2BA.%2BF.%26aulast%3DZwillich%26aufirst%3DS.%2BH.%26atitle%3DThe%2520safety%2520and%2520efficacy%2520of%2520a%2520JAK%2520inhibitor%2520in%2520patients%2520with%2520active%2520rheumatoid%2520arthritis%253A%2520Results%2520of%2520a%2520double-blind%252C%2520placebo-controlled%2520phase%2520IIa%2520trial%2520of%2520three%2520dosage%2520levels%2520of%2520CP-690%252C550%2520versus%2520placebo%26jtitle%3DArthritis%2520Rheum.%26date%3D2009%26volume%3D60%26spage%3D1895%26epage%3D1905%26doi%3D10.1002%2Fart.24567" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref4"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref4'); return false;" data-citation="" class="refNumLink">4</a></strong><div class="NLM_citation" id="cit4"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Gadina, M.</span></span> <span> </span><span class="NLM_article-title">Advances in kinase inhibition</span>. <i>Curr. Opin. Rheumatol.</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>26</i></span>,  <span class="NLM_fpage">237</span>– <span class="NLM_lpage">243</span>, <span class="refDoi"> DOI: 10.1097/bor.0000000000000023</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref4/cit4&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00329&amp;key=10.1097%2Fbor.0000000000000023" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref4/cit4&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00329&amp;key=24419749" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref4/cit4&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00329&amp;key=1%3ACAS%3A528%3ADC%252BC2cXitFWmtbs%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=26&publication_year=2014&pages=237-243&author=M.+Gadina&title=Advances+in+kinase+inhibition&doi=10.1097%2Fbor.0000000000000023"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit4R"><div class="casContent"><span class="casTitleNuber">4</span><div class="casTitle"><span class="NLM_cas:atitle">Advances in kinase inhibition: treating rheumatic diseases and beyond</span></div><div class="casAuthors">Gadina, Massimo</div><div class="citationInfo"><span class="NLM_cas:title">Current Opinion in Rheumatology</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">26</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">237-243</span>CODEN:
                <span class="NLM_cas:coden">CORHES</span>;
        ISSN:<span class="NLM_cas:issn">1040-8711</span>.
    
            (<span class="NLM_cas:orgname">Lippincott Williams & Wilkins</span>)
        </div><div class="casAbstract">Purpose of review: Kinases inhibitors are now used for the treatment of autoimmune diseases.  Here, the most recent findings related to their mechanism of action and some of the newest mols. and targets which are being investigated for autoimmune and inflammatory disorders are reviewed.  Recent findings: Similarly to p38 inhibitors, current spleen tyrosine kinase inhibitors have not fulfilled the expectations of researchers and clinicians, and will likely not be used therapeutically in autoimmunity.  Bruton's tyrosine kinase inhibitors remain in the preclin. phase.  Studies on the mechanism of action of successful Janus kinase (Jak) inhibitors have revealed that, apart from T and B cells, bone cells such as osteoclasts and innate immunity cells such as dendritic cells are pos. affected.  More specific, novel Jak inhibitors are now in clin. trials and newer Jak inhibitors are being developed.  Other kinases are emerging from basic studies as potentially druggable and will surely be investigated.  Summary: First-generation pan-Jak inhibitors can be useful for a wide variety of diseases.  They act on adaptive as well as innate immune cells and can promote tolerance.  More specific inhibitors will soon be available and these may be used in a disease-specific manner.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGr4w_eWCaCWi7Vg90H21EOLACvtfcHk0lhMAiK1dS-Swg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXitFWmtbs%253D&md5=1e84017807d214979d8fce85e796157d</span></div><a href="/servlet/linkout?suffix=cit4&amp;dbid=16384&amp;doi=10.1097%2Fbor.0000000000000023&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1097%252Fbor.0000000000000023%26sid%3Dliteratum%253Aachs%26aulast%3DGadina%26aufirst%3DM.%26atitle%3DAdvances%2520in%2520kinase%2520inhibition%26jtitle%3DCurr.%2520Opin.%2520Rheumatol.%26date%3D2014%26volume%3D26%26spage%3D237%26epage%3D243%26doi%3D10.1097%2Fbor.0000000000000023" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref5"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref5'); return false;" data-citation="" class="refNumLink">5</a></strong><div class="NLM_citation" id="cit5"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Whyburn, L. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Halcomb, K. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Contreras, C. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lowell, C. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Witte, O. N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Satterthwaite, A. B.</span></span> <span> </span><span class="NLM_article-title">Reduced Dosage of Bruton’s Tyrosine Kinase Uncouples B Cell Hyperresponsiveness from Autoimmunity in lyn–/– Mice</span>. <i>J. Immunol.</i> <span class="NLM_year" style="font-weight: bold;">2003</span>,  <span class="NLM_volume"><i>171</i></span>,  <span class="NLM_fpage">1850</span>– <span class="NLM_lpage">1858</span>, <span class="refDoi"> DOI: 10.4049/jimmunol.171.4.1850</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref5/cit5&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00329&amp;key=10.4049%2Fjimmunol.171.4.1850" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref5/cit5&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00329&amp;key=12902486" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref5/cit5&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00329&amp;key=1%3ACAS%3A528%3ADC%252BD3sXmtVWntbc%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=171&publication_year=2003&pages=1850-1858&author=L.+R.+Whyburnauthor=K.+E.+Halcombauthor=C.+M.+Contrerasauthor=C.+A.+Lowellauthor=O.+N.+Witteauthor=A.+B.+Satterthwaite&title=Reduced+Dosage+of+Bruton%E2%80%99s+Tyrosine+Kinase+Uncouples+B+Cell+Hyperresponsiveness+from+Autoimmunity+in+lyn%E2%80%93%2F%E2%80%93+Mice&doi=10.4049%2Fjimmunol.171.4.1850"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit5R"><div class="casContent"><span class="casTitleNuber">5</span><div class="casTitle"><span class="NLM_cas:atitle">Reduced Dosage of Bruton's Tyrosine Kinase Uncouples B Cell Hyperresponsiveness from Autoimmunity in lyn-/- Mice</span></div><div class="casAuthors">Whyburn, Lindsey R.; Halcomb, Kristina E.; Contreras, Cristina M.; Lowell, Clifford A.; Witte, Owen N.; Satterthwaite, Anne B.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Immunology</span>
        (<span class="NLM_cas:date">2003</span>),
    <span class="NLM_cas:volume">171</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">1850-1858</span>CODEN:
                <span class="NLM_cas:coden">JOIMA3</span>;
        ISSN:<span class="NLM_cas:issn">0022-1767</span>.
    
            (<span class="NLM_cas:orgname">American Association of Immunologists</span>)
        </div><div class="casAbstract">The development of autoimmunity is correlated with heightened sensitivity of B cells to B cell Ag receptor (BCR) crosslinking.  BCR signals are down-regulated by Lyn, which phosphorylates inhibitory receptors.  Lyn-/- mice have reduced BCR signaling thresholds and develop autoantibodies, glomerulonephritis, splenomegaly due to myeloid hyperplasia, and increased B-1 cell nos.  Bruton's tyrosine kinase (Btk), a crit. component of BCR signaling pathways, is required for autoantibody prodn. in lyn-/- mice.  It is unclear whether Btk mediates autoimmunity at the level of BCR signal transduction or B cell development, given that lyn-/-Btk-/- mice have a severe redn. in conventional B and B-1 cell nos.  To address this issue, we crossed a transgene expressing a low dosage of Btk (Btklow) in B cells to lyn-/-Btk-/- mice.  Conventional B cell populations were restored to levels similar to those in lyn-/- mice.  These cells were as hypersensitive to BCR crosslinking as lyn-/- B cells as measured by proliferation, Ca2+ flux, and activation of extracellular signal-regulated kinase and Akt.  However, lyn-/-Btklow mice did not produce anti-ssDNA, anti-dsDNA, anti-histone, or anti-histone/DNA IgM or IgG.  They also lacked B-1 cells and did not exhibit splenomegaly.  Thus, B cell hyperresponsiveness is insufficient for autoimmunity in lyn-/- mice.  These studies implicate B-1 and/or myeloid cells as key contributors to the lyn-/- autoimmune phenotype.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqfv6aQDPmpNbVg90H21EOLACvtfcHk0lhMAiK1dS-Swg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3sXmtVWntbc%253D&md5=4a83a9bb23bec2c63db3447c519da533</span></div><a href="/servlet/linkout?suffix=cit5&amp;dbid=16384&amp;doi=10.4049%2Fjimmunol.171.4.1850&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.4049%252Fjimmunol.171.4.1850%26sid%3Dliteratum%253Aachs%26aulast%3DWhyburn%26aufirst%3DL.%2BR.%26aulast%3DHalcomb%26aufirst%3DK.%2BE.%26aulast%3DContreras%26aufirst%3DC.%2BM.%26aulast%3DLowell%26aufirst%3DC.%2BA.%26aulast%3DWitte%26aufirst%3DO.%2BN.%26aulast%3DSatterthwaite%26aufirst%3DA.%2BB.%26atitle%3DReduced%2520Dosage%2520of%2520Bruton%25E2%2580%2599s%2520Tyrosine%2520Kinase%2520Uncouples%2520B%2520Cell%2520Hyperresponsiveness%2520from%2520Autoimmunity%2520in%2520lyn%25E2%2580%2593%252F%25E2%2580%2593%2520Mice%26jtitle%3DJ.%2520Immunol.%26date%3D2003%26volume%3D171%26spage%3D1850%26epage%3D1858%26doi%3D10.4049%2Fjimmunol.171.4.1850" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref6"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref6'); return false;" data-citation="" class="refNumLink">6</a></strong><div class="NLM_citation" id="cit6"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Brunner, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Müller, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wirth, T.</span></span> <span> </span><span class="NLM_article-title">Bruton’s Tyrosine Kinase is involved in innate and adaptive immunity</span>. <i>Histol. Histopathol.</i> <span class="NLM_year" style="font-weight: bold;">2005</span>,  <span class="NLM_volume"><i>20</i></span>,  <span class="NLM_fpage">945</span>, <span class="refDoi"> DOI: 10.14670/HH-20.945</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref6/cit6&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00329&amp;key=10.14670%2FHH-20.945" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref6/cit6&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00329&amp;key=15944945" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref6/cit6&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00329&amp;key=1%3ACAS%3A528%3ADC%252BD2MXpsFKjtL4%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=20&publication_year=2005&pages=945&author=C.+Brunnerauthor=B.+M%C3%BCllerauthor=T.+Wirth&title=Bruton%E2%80%99s+Tyrosine+Kinase+is+involved+in+innate+and+adaptive+immunity&doi=10.14670%2FHH-20.945"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit6R"><div class="casContent"><span class="casTitleNuber">6</span><div class="casTitle"><span class="NLM_cas:atitle">Bruton's Tyrosine Kinase is involved in innate and adaptive immunity</span></div><div class="casAuthors">Brunner, C.; Mueller, B.; Wirth, T.</div><div class="citationInfo"><span class="NLM_cas:title">Histology and Histopathology</span>
        (<span class="NLM_cas:date">2005</span>),
    <span class="NLM_cas:volume">20</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">945-955</span>CODEN:
                <span class="NLM_cas:coden">HIHIES</span>;
        ISSN:<span class="NLM_cas:issn">0213-3911</span>.
    
            (<span class="NLM_cas:orgname">Jimenez Godoy, S.A.</span>)
        </div><div class="casAbstract">A review.  Btk is a cytoplasmic tyrosine kinase, which is mainly involved in B cell receptor signaling.  Gene targeting expts. revealed that Btk is important for B cell development and function.  However, Btk is not only expressed in B cells, but also in most other hematopoietic lineages except for T cells and plasma cells.  Recently we found that Btk is involved in Toll-like receptor signaling.  Toll-like receptors play an important role in innate immunity.  They are highly expressed on mast cells, macrophages and dendritic cells, which are essential for the recognition and consequently for the elimination of microbial pathogens.  Therefore Btk might play an important role for the function of immunocompetent cells of innate as well as adaptive immunity.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqQA-9NFdeNr7Vg90H21EOLACvtfcHk0lhq9FW90oFhYg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2MXpsFKjtL4%253D&md5=97cbcc5df2704d4b58933085ab8ff929</span></div><a href="/servlet/linkout?suffix=cit6&amp;dbid=16384&amp;doi=10.14670%2FHH-20.945&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.14670%252FHH-20.945%26sid%3Dliteratum%253Aachs%26aulast%3DBrunner%26aufirst%3DC.%26aulast%3DM%25C3%25BCller%26aufirst%3DB.%26aulast%3DWirth%26aufirst%3DT.%26atitle%3DBruton%25E2%2580%2599s%2520Tyrosine%2520Kinase%2520is%2520involved%2520in%2520innate%2520and%2520adaptive%2520immunity%26jtitle%3DHistol.%2520Histopathol.%26date%3D2005%26volume%3D20%26spage%3D945%26doi%3D10.14670%2FHH-20.945" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref7"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref7'); return false;" data-citation="" class="refNumLink">7</a></strong><div class="NLM_citation" id="cit7"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Satterthwaite, A. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Witte, O. N.</span></span> <span> </span><span class="NLM_article-title">Btk function in B cell development and response</span>. <i>Semin. Immunol.</i> <span class="NLM_year" style="font-weight: bold;">1998</span>,  <span class="NLM_volume"><i>10</i></span>,  <span class="NLM_fpage">309</span>– <span class="NLM_lpage">316</span>, <span class="refDoi"> DOI: 10.1006/smim.1998.0123</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref7/cit7&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00329&amp;key=10.1006%2Fsmim.1998.0123" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref7/cit7&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00329&amp;key=9695187" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref7/cit7&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00329&amp;key=1%3ACAS%3A528%3ADyaK1cXltlCiuro%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=10&publication_year=1998&pages=309-316&author=A.+B.+Satterthwaiteauthor=Z.+Liauthor=O.+N.+Witte&title=Btk+function+in+B+cell+development+and+response&doi=10.1006%2Fsmim.1998.0123"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit7R"><div class="casContent"><span class="casTitleNuber">7</span><div class="casTitle"><span class="NLM_cas:atitle">Btk function in B cell development and response</span></div><div class="casAuthors">Satterthwaite, Anne B.; Li, Zuomei; Witte, Owen N.</div><div class="citationInfo"><span class="NLM_cas:title">Seminars in Immunology</span>
        (<span class="NLM_cas:date">1998</span>),
    <span class="NLM_cas:volume">10</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">309-316</span>CODEN:
                <span class="NLM_cas:coden">SEIME2</span>;
        ISSN:<span class="NLM_cas:issn">1044-5323</span>.
    
            (<span class="NLM_cas:orgname">Academic Press</span>)
        </div><div class="casAbstract">A review with 85 refs.  Mutations in Bruton's tyrosine kinase (Btk) result in the B cell immunodeficiencies XLA (X-linked agammaglobulinemia) in humans and Xid (X-linked immunodeficiency) in mice.  Both the maintenance of peripheral B cell nos. and their response to B cell antigen receptor (BCR) crosslinking depend on Btk.  Btk integrates signals from multiple cell surface receptors, including BCR and G-protein coupled receptors.  These Btk dependent signals control B cell proliferation and survival by mediating Ca2+ flux, activating JNK and p38 and inducing cell cycle regulatory genes.  (c) 1998 Academic Press.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqVrVOyUeT25bVg90H21EOLACvtfcHk0lhq9FW90oFhYg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK1cXltlCiuro%253D&md5=f03605bc9f39d663d28794c7b7e40138</span></div><a href="/servlet/linkout?suffix=cit7&amp;dbid=16384&amp;doi=10.1006%2Fsmim.1998.0123&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1006%252Fsmim.1998.0123%26sid%3Dliteratum%253Aachs%26aulast%3DSatterthwaite%26aufirst%3DA.%2BB.%26aulast%3DLi%26aufirst%3DZ.%26aulast%3DWitte%26aufirst%3DO.%2BN.%26atitle%3DBtk%2520function%2520in%2520B%2520cell%2520development%2520and%2520response%26jtitle%3DSemin.%2520Immunol.%26date%3D1998%26volume%3D10%26spage%3D309%26epage%3D316%26doi%3D10.1006%2Fsmim.1998.0123" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref8"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref8'); return false;" data-citation="" class="refNumLink">8</a></strong><div class="NLM_citation" id="cit8"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Khan, W. N.</span></span> <span> </span><span class="NLM_article-title">Regulation of B lymphocyte development and activation by Bruton’s tyrosine kinase</span>. <i>Immunol. Res.</i> <span class="NLM_year" style="font-weight: bold;">2001</span>,  <span class="NLM_volume"><i>23</i></span>,  <span class="NLM_fpage">147</span>– <span class="NLM_lpage">156</span>, <span class="refDoi"> DOI: 10.1385/ir:23:2-3:147</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref8/cit8&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00329&amp;key=10.1385%2Fir%3A23%3A2-3%3A147" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref8/cit8&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00329&amp;key=11444380" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref8/cit8&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00329&amp;key=1%3ACAS%3A528%3ADC%252BD3MXltFWqsb0%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=23&publication_year=2001&pages=147-156&author=W.+N.+Khan&title=Regulation+of+B+lymphocyte+development+and+activation+by+Bruton%E2%80%99s+tyrosine+kinase&doi=10.1385%2Fir%3A23%3A2-3%3A147"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit8R"><div class="casContent"><span class="casTitleNuber">8</span><div class="casTitle"><span class="NLM_cas:atitle">Regulation of B lymphocyte development and activation by Bruton's tyrosine kinase</span></div><div class="casAuthors">Khan, Wasif N.</div><div class="citationInfo"><span class="NLM_cas:title">Immunologic Research</span>
        (<span class="NLM_cas:date">2001</span>),
    <span class="NLM_cas:volume">23</span>
        (<span class="NLM_cas:issue">2 & 3</span>),
    <span class="NLM_cas:pages">147-156</span>CODEN:
                <span class="NLM_cas:coden">IMRSEB</span>;
        ISSN:<span class="NLM_cas:issn">0257-277X</span>.
    
            (<span class="NLM_cas:orgname">Humana Press Inc.</span>)
        </div><div class="casAbstract">A review discussed the role of Bruton's tyrosine kinase in B lymphocyte development and activation.  The generation and maintenance of B lymphocytes is controlled by biochem. signals transmitted by the B cell antigen receptor (BCR) complex.  These signals are transduced by multiple cytoplasmic protein tyrosine kinases (PTKs) including Lyn, Syk, and Bruton's tyrosine kinase (BTK).  Upon BCR engagement, these PTKs activate downstream effectors, including transcription factors that modulate gene expression.  In turn, activation of downstream effectors is crit. for B cell survival, cell cycle progression, and antibody prodn.  Our studies focus on the role of BTK in these biol. responses.  We have discovered that BTK is required for activation of the BCR-responsive transcription factor, NF-κB.  Furthermore, BTK-dependent activation of NF-κB is essential for reprogramming the expression of genes that control B cell survival and proliferation.  The biochem. mechanisms by which BTK regulates signaling components that activate NF-κB, and the identification of BTK-responsive genes are under investigation.  Elucidation of these regulatory mechanisms is expected to reveal new therapeutic targets for B cell pathologies involving defects in BTK, including X-linked agammaglobulinemia (XLA).</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrx0btKIFSX9LVg90H21EOLACvtfcHk0lhq9FW90oFhYg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3MXltFWqsb0%253D&md5=564d950f06ab14daff2b45f5a3d863f4</span></div><a href="/servlet/linkout?suffix=cit8&amp;dbid=16384&amp;doi=10.1385%2Fir%3A23%3A2-3%3A147&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1385%252Fir%253A23%253A2-3%253A147%26sid%3Dliteratum%253Aachs%26aulast%3DKhan%26aufirst%3DW.%2BN.%26atitle%3DRegulation%2520of%2520B%2520lymphocyte%2520development%2520and%2520activation%2520by%2520Bruton%25E2%2580%2599s%2520tyrosine%2520kinase%26jtitle%3DImmunol.%2520Res.%26date%3D2001%26volume%3D23%26spage%3D147%26epage%3D156%26doi%3D10.1385%2Fir%3A23%3A2-3%3A147" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref9"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref9'); return false;" data-citation="" class="refNumLink">9</a></strong><div class="NLM_citation" id="cit9"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Kil, L. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">de Bruijn, M. J. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">van Nimwegen, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Corneth, O. B. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">van
Hamburg, J. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dingjan, G. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Thaiss, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rimmelzwaan, G. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Elewaut, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Delsing, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">van Loo, P. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hendriks, R. W.</span></span> <span> </span><span class="NLM_article-title">Btk levels set the threshold for B-cell activation and negative selection of autoreactive B cells in mice</span>. <i>Blood</i> <span class="NLM_year" style="font-weight: bold;">2012</span>,  <span class="NLM_volume"><i>119</i></span>,  <span class="NLM_fpage">3744</span>– <span class="NLM_lpage">3756</span>, <span class="refDoi"> DOI: 10.1182/blood-2011-12-397919</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref9/cit9&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00329&amp;key=10.1182%2Fblood-2011-12-397919" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref9/cit9&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00329&amp;key=22383797" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref9/cit9&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00329&amp;key=1%3ACAS%3A528%3ADC%252BC38XmslWms7k%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=119&publication_year=2012&pages=3744-3756&author=L.+P.+Kilauthor=M.+J.+W.+de+Bruijnauthor=M.+van+Nimwegenauthor=O.+B.+J.+Cornethauthor=J.+P.+van%0AHamburgauthor=G.+M.+Dingjanauthor=F.+Thaissauthor=G.+F.+Rimmelzwaanauthor=D.+Elewautauthor=D.+Delsingauthor=P.+F.+van+Looauthor=R.+W.+Hendriks&title=Btk+levels+set+the+threshold+for+B-cell+activation+and+negative+selection+of+autoreactive+B+cells+in+mice&doi=10.1182%2Fblood-2011-12-397919"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit9R"><div class="casContent"><span class="casTitleNuber">9</span><div class="casTitle"><span class="NLM_cas:atitle">Btk levels set the threshold for B-cell activation and negative selection of autoreactive B cells in mice</span></div><div class="casAuthors">Kil, Laurens P.; de Bruijn, Marjolein J. W.; van Nimwegen, Menno; Corneth, Odilia B. J.; van Hamburg, Jan Piet; Dingjan, Gemma M.; Thaiss, Friedrich; Rimmelzwaan, Guus F.; Elewaut, Dirk; Delsing, Dianne; van Loo, Pieter Fokko; Hendriks, Rudi W.</div><div class="citationInfo"><span class="NLM_cas:title">Blood</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">119</span>
        (<span class="NLM_cas:issue">16</span>),
    <span class="NLM_cas:pages">3744-3756</span>CODEN:
                <span class="NLM_cas:coden">BLOOAW</span>;
        ISSN:<span class="NLM_cas:issn">0006-4971</span>.
    
            (<span class="NLM_cas:orgname">American Society of Hematology</span>)
        </div><div class="casAbstract">On antigen binding by the B-cell receptor (BCR), B cells up-regulate protein expression of the key downstream signaling mol. Bruton tyrosine kinase (Btk), but the effects of Btk up-regulation on B-cell function are unknown.  Here, we show that transgenic mice overexpressing Btk specifically in B cells spontaneously formed germinal centers and manifested increased plasma cell nos., leading to antinuclear autoantibody prodn. and systemic lupus erythematosus (SLE)-like autoimmune pathol. affecting kidneys, lungs, and salivary glands.  Autoimmunity was fully dependent on Btk kinase activity, because Btk inhibitor treatment (PCI-32765) could normalize B-cell activation and differentiation, and because autoantibodies were absent in Btk transgenic mice overexpressing a kinase inactive Btk mutant.  B cells overexpressing wild-type Btk were selectively hyperresponsive to BCR stimulation and showed enhanced Ca2+ influx, nuclear factor (NF)-κB activation, resistance to Fas-mediated apoptosis, and defective elimination of selfreactive B cells in vivo.  These findings unravel a crucial role for Btk in setting the threshold for B-cell activation and counterselection of autoreactive B cells, making Btk an attractive therapeutic target in systemic autoimmune disease such as SLE.  The finding of in vivo pathol. assocd. with Btk overexpression may have important implications for the development of gene therapy strategies for X-linked agammaglobulinemia, the immunodeficiency assocd. with mutations in BTK.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpCZGtsn4i1lrVg90H21EOLACvtfcHk0lhq9FW90oFhYg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38XmslWms7k%253D&md5=ba36239b826343860580cfecea64c850</span></div><a href="/servlet/linkout?suffix=cit9&amp;dbid=16384&amp;doi=10.1182%2Fblood-2011-12-397919&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1182%252Fblood-2011-12-397919%26sid%3Dliteratum%253Aachs%26aulast%3DKil%26aufirst%3DL.%2BP.%26aulast%3Dde%2BBruijn%26aufirst%3DM.%2BJ.%2BW.%26aulast%3Dvan%2BNimwegen%26aufirst%3DM.%26aulast%3DCorneth%26aufirst%3DO.%2BB.%2BJ.%26aulast%3Dvan%2BHamburg%26aufirst%3DJ.%2BP.%26aulast%3DDingjan%26aufirst%3DG.%2BM.%26aulast%3DThaiss%26aufirst%3DF.%26aulast%3DRimmelzwaan%26aufirst%3DG.%2BF.%26aulast%3DElewaut%26aufirst%3DD.%26aulast%3DDelsing%26aufirst%3DD.%26aulast%3Dvan%2BLoo%26aufirst%3DP.%2BF.%26aulast%3DHendriks%26aufirst%3DR.%2BW.%26atitle%3DBtk%2520levels%2520set%2520the%2520threshold%2520for%2520B-cell%2520activation%2520and%2520negative%2520selection%2520of%2520autoreactive%2520B%2520cells%2520in%2520mice%26jtitle%3DBlood%26date%3D2012%26volume%3D119%26spage%3D3744%26epage%3D3756%26doi%3D10.1182%2Fblood-2011-12-397919" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref10"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref10'); return false;" data-citation="" class="refNumLink">10</a></strong><div class="NLM_citation" id="cit10"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Whang, J. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chang, B. Y.</span></span> <span> </span><span class="NLM_article-title">Bruton’s tyrosine kinase inhibitors for the treatment of rheumatoid arthritis</span>. <i>Drug Discovery Today</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>19</i></span>,  <span class="NLM_fpage">1200</span>– <span class="NLM_lpage">1204</span>, <span class="refDoi"> DOI: 10.1016/j.drudis.2014.03.028</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref10/cit10&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00329&amp;key=10.1016%2Fj.drudis.2014.03.028" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref10/cit10&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00329&amp;key=24721226" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref10/cit10&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00329&amp;key=1%3ACAS%3A528%3ADC%252BC2cXmvV2ntLw%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=19&publication_year=2014&pages=1200-1204&author=J.+A.+Whangauthor=B.+Y.+Chang&title=Bruton%E2%80%99s+tyrosine+kinase+inhibitors+for+the+treatment+of+rheumatoid+arthritis&doi=10.1016%2Fj.drudis.2014.03.028"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit10R"><div class="casContent"><span class="casTitleNuber">10</span><div class="casTitle"><span class="NLM_cas:atitle">Bruton's tyrosine kinase inhibitors for the treatment of rheumatoid arthritis</span></div><div class="casAuthors">Whang, Jennifer A.; Chang, Betty Y.</div><div class="citationInfo"><span class="NLM_cas:title">Drug Discovery Today</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">19</span>
        (<span class="NLM_cas:issue">8</span>),
    <span class="NLM_cas:pages">1200-1204</span>CODEN:
                <span class="NLM_cas:coden">DDTOFS</span>;
        ISSN:<span class="NLM_cas:issn">1359-6446</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Ltd.</span>)
        </div><div class="casAbstract">A review.  The function and role of Bruton's tyrosine kinase (BTK) in human B cell development was demonstrated by its assocn. with X-linked agammaglobulinemia (XLA) manifested by a substantial redn. in Igs and B cells.  BTK has a crucial role in pre-B cell receptor (BCR) and BCR signaling during normal B cell development and activation.  Aberrant BCR signaling is assocd. with autoimmune diseases, such as rheumatoid arthritis (RA).  In addn., BTK is also expressed in myeloid cell populations, including monocytes, macrophages, neutrophils and mast cells.  These innate cells infiltrate the synovial cavity and produce inflammatory cytokines, aggravating arthritic symptoms.  In myeloid cell populations, BTK functions downstream of the Fcγ receptors (FcγR) and Fcε receptors (FcεR) [1,2].  In the absence of BTK, FcR-mediated functions, such as cytokine prodn., are impaired.  In addn., Xid mice, which have a mutation in BTK, have decreased susceptibility to developing collagen-induced arthritis (CIA) [3].  Given that BTK is involved in multiple signaling pathways downstream of the BCR and FcR, it is an attractive therapeutic target for RA.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqrfM0cjYRpt7Vg90H21EOLACvtfcHk0lifEONQMsEwEA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXmvV2ntLw%253D&md5=59de1ccd677bb64001719daf5e83952e</span></div><a href="/servlet/linkout?suffix=cit10&amp;dbid=16384&amp;doi=10.1016%2Fj.drudis.2014.03.028&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.drudis.2014.03.028%26sid%3Dliteratum%253Aachs%26aulast%3DWhang%26aufirst%3DJ.%2BA.%26aulast%3DChang%26aufirst%3DB.%2BY.%26atitle%3DBruton%25E2%2580%2599s%2520tyrosine%2520kinase%2520inhibitors%2520for%2520the%2520treatment%2520of%2520rheumatoid%2520arthritis%26jtitle%3DDrug%2520Discovery%2520Today%26date%3D2014%26volume%3D19%26spage%3D1200%26epage%3D1204%26doi%3D10.1016%2Fj.drudis.2014.03.028" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref11"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref11'); return false;" data-citation="" class="refNumLink">11</a></strong><div class="NLM_citation" id="cit11"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Norman, P.</span></span> <span> </span><span class="NLM_article-title">Investigational Bruton’s tyrosine kinase inhibitors for the treatment of rheumatoid arthritis</span>. <i>Expert Opin. Invest. Drugs</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>25</i></span>,  <span class="NLM_fpage">891</span>– <span class="NLM_lpage">899</span>, <span class="refDoi"> DOI: 10.1080/13543784.2016.1182499</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref11/cit11&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00329&amp;key=10.1080%2F13543784.2016.1182499" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref11/cit11&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00329&amp;key=27148767" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref11/cit11&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00329&amp;key=1%3ACAS%3A528%3ADC%252BC28Xnslentb0%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=25&publication_year=2016&pages=891-899&author=P.+Norman&title=Investigational+Bruton%E2%80%99s+tyrosine+kinase+inhibitors+for+the+treatment+of+rheumatoid+arthritis&doi=10.1080%2F13543784.2016.1182499"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit11R"><div class="casContent"><span class="casTitleNuber">11</span><div class="casTitle"><span class="NLM_cas:atitle">Investigational Bruton's tyrosine kinase inhibitors for the treatment of rheumatoid arthritis</span></div><div class="casAuthors">Norman, Peter</div><div class="citationInfo"><span class="NLM_cas:title">Expert Opinion on Investigational Drugs</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">25</span>
        (<span class="NLM_cas:issue">8</span>),
    <span class="NLM_cas:pages">891-899</span>CODEN:
                <span class="NLM_cas:coden">EOIDER</span>;
        ISSN:<span class="NLM_cas:issn">1354-3784</span>.
    
            (<span class="NLM_cas:orgname">Taylor & Francis Ltd.</span>)
        </div><div class="casAbstract">The Tec family of non-receptor tyrosine kinases comprises five members.  The cellular expression and function of these kinases has implicated them as potential drug targets for the treatment of both malignant and autoimmune diseases.  Most attention has focused on inhibitors of BTK kinase with ibrutinib already approved for the treatment of mantle cell lymphoma and chronic lymphocytic leukemia.  Multiple BTK inhibitors are being developed for both oncol. and autoimmune disease indications.  BTK inhibitors being evaluated in rheumatoid arthritis are considered.  Both inhibitors which have progressed to early clin. development, and those demonstrating activity in rodent models of arthritis are reviewed.  These include both reversible and irreversible inhibitors of the kinase, most of which target the cysteine-481 residue of BTK.  The selectivity of these inhibitors for Tec family kinases is considered.  Developing inhibitors of any kinase to treat of rheumatoid arthritis has proved problematic with regard to both efficacy and selectivity.  It is anticipated that the more selective BTK inhibitors may prove more useful in treating arthritis, with the use of reversible inhibitors possibly offering a better strategy.  Chronic dosing may exacerbate the emergence of drug resistance, with resistant mutations already obsd. in ibrutinib-treated patients.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoQsRSjuYxYa7Vg90H21EOLACvtfcHk0lifEONQMsEwEA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28Xnslentb0%253D&md5=037f60be680ad282725fe8f7619f1212</span></div><a href="/servlet/linkout?suffix=cit11&amp;dbid=16384&amp;doi=10.1080%2F13543784.2016.1182499&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1080%252F13543784.2016.1182499%26sid%3Dliteratum%253Aachs%26aulast%3DNorman%26aufirst%3DP.%26atitle%3DInvestigational%2520Bruton%25E2%2580%2599s%2520tyrosine%2520kinase%2520inhibitors%2520for%2520the%2520treatment%2520of%2520rheumatoid%2520arthritis%26jtitle%3DExpert%2520Opin.%2520Invest.%2520Drugs%26date%3D2016%26volume%3D25%26spage%3D891%26epage%3D899%26doi%3D10.1080%2F13543784.2016.1182499" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref12"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref12'); return false;" data-citation="" class="refNumLink">12</a></strong><div class="NLM_citation" id="cit12"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Lou, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Owens, T. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kuglstatter, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kondru, R. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Goldstein, D. M.</span></span> <span> </span><span class="NLM_article-title">Bruton’s Tyrosine Kinase Inhibitors: Approaches to Potent and Selective Inhibition, Preclinical and Clinical Evaluation for Inflammatory Diseases and B Cell Malignancies</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2012</span>,  <span class="NLM_volume"><i>55</i></span>,  <span class="NLM_fpage">4539</span>– <span class="NLM_lpage">4550</span>, <span class="refDoi"> DOI: 10.1021/jm300035p</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm300035p" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref12/cit12&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00329&amp;key=1%3ACAS%3A528%3ADC%252BC38XjsVChsb8%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=55&publication_year=2012&pages=4539-4550&author=Y.+Louauthor=T.+D.+Owensauthor=A.+Kuglstatterauthor=R.+K.+Kondruauthor=D.+M.+Goldstein&title=Bruton%E2%80%99s+Tyrosine+Kinase+Inhibitors%3A+Approaches+to+Potent+and+Selective+Inhibition%2C+Preclinical+and+Clinical+Evaluation+for+Inflammatory+Diseases+and+B+Cell+Malignancies&doi=10.1021%2Fjm300035p"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit12R"><div class="casContent"><span class="casTitleNuber">12</span><div class="casTitle"><span class="NLM_cas:atitle">Bruton's Tyrosine Kinase Inhibitors: Approaches to Potent and Selective Inhibition, Preclinical and Clinical Evaluation for Inflammatory Diseases and B Cell Malignancies</span></div><div class="casAuthors">Lou, Yan; Owens, Timothy D.; Kuglstatter, Andreas; Kondru, Rama K.; Goldstein, David M.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">55</span>
        (<span class="NLM_cas:issue">10</span>),
    <span class="NLM_cas:pages">4539-4550</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">A review.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoRzAwa4gtFprVg90H21EOLACvtfcHk0lifEONQMsEwEA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38XjsVChsb8%253D&md5=b470ba4ec4867e4bfb8d1cfa92b1cc6d</span></div><a href="/servlet/linkout?suffix=cit12&amp;dbid=16384&amp;doi=10.1021%2Fjm300035p&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm300035p%26sid%3Dliteratum%253Aachs%26aulast%3DLou%26aufirst%3DY.%26aulast%3DOwens%26aufirst%3DT.%2BD.%26aulast%3DKuglstatter%26aufirst%3DA.%26aulast%3DKondru%26aufirst%3DR.%2BK.%26aulast%3DGoldstein%26aufirst%3DD.%2BM.%26atitle%3DBruton%25E2%2580%2599s%2520Tyrosine%2520Kinase%2520Inhibitors%253A%2520Approaches%2520to%2520Potent%2520and%2520Selective%2520Inhibition%252C%2520Preclinical%2520and%2520Clinical%2520Evaluation%2520for%2520Inflammatory%2520Diseases%2520and%2520B%2520Cell%2520Malignancies%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2012%26volume%3D55%26spage%3D4539%26epage%3D4550%26doi%3D10.1021%2Fjm300035p" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref13"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref13'); return false;" data-citation="" class="refNumLink">13</a></strong><div class="NLM_citation" id="cit13"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Hendriks, R. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yuvaraj, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kil, L. P.</span></span> <span> </span><span class="NLM_article-title">Targeting Bruton’s tyrosine kinase in B cell malignancies</span>. <i>Nat. Rev. Cancer</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>14</i></span>,  <span class="NLM_fpage">219</span>– <span class="NLM_lpage">232</span>, <span class="refDoi"> DOI: 10.1038/nrc3702</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref13/cit13&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00329&amp;key=10.1038%2Fnrc3702" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref13/cit13&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00329&amp;key=24658273" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref13/cit13&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00329&amp;key=1%3ACAS%3A528%3ADC%252BC2cXkslCqsL4%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=14&publication_year=2014&pages=219-232&author=R.+W.+Hendriksauthor=S.+Yuvarajauthor=L.+P.+Kil&title=Targeting+Bruton%E2%80%99s+tyrosine+kinase+in+B+cell+malignancies&doi=10.1038%2Fnrc3702"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit13R"><div class="casContent"><span class="casTitleNuber">13</span><div class="casTitle"><span class="NLM_cas:atitle">Targeting Bruton's tyrosine kinase in B cell malignancies</span></div><div class="casAuthors">Hendriks, Rudi W.; Yuvaraj, Saravanan; Kil, Laurens P.</div><div class="citationInfo"><span class="NLM_cas:title">Nature Reviews Cancer</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">14</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">219-232</span>CODEN:
                <span class="NLM_cas:coden">NRCAC4</span>;
        ISSN:<span class="NLM_cas:issn">1474-175X</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">A review.  Bruton's tyrosine kinase (BTK) is a key component of B cell receptor (BCR) signalling and functions as an important regulator of cell proliferation and cell survival in various B cell malignancies.  Small-mol. inhibitors of BTK have shown antitumor activity in animal models and, recently, in clin. studies.  High response rates were reported in patients with chronic lymphocytic leukemia and mantle cell lymphoma.  Remarkably, BTK inhibitors have mol. effects that cannot be explained by the classic role of BTK in BCR signalling.  In this Review, we highlight the importance of BTK in various signalling pathways in the context of its therapeutic inhibition.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGo9z_6SqjcVYLVg90H21EOLACvtfcHk0lhLIpQ7PQBn6g"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXkslCqsL4%253D&md5=ed615772c752b64360d0b5c51780e93e</span></div><a href="/servlet/linkout?suffix=cit13&amp;dbid=16384&amp;doi=10.1038%2Fnrc3702&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnrc3702%26sid%3Dliteratum%253Aachs%26aulast%3DHendriks%26aufirst%3DR.%2BW.%26aulast%3DYuvaraj%26aufirst%3DS.%26aulast%3DKil%26aufirst%3DL.%2BP.%26atitle%3DTargeting%2520Bruton%25E2%2580%2599s%2520tyrosine%2520kinase%2520in%2520B%2520cell%2520malignancies%26jtitle%3DNat.%2520Rev.%2520Cancer%26date%3D2014%26volume%3D14%26spage%3D219%26epage%3D232%26doi%3D10.1038%2Fnrc3702" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref14"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref14'); return false;" data-citation="" class="refNumLink">14</a></strong><div class="NLM_citation" id="cit14"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Liang, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tian, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ren, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ding, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jia, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xin, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Thareja, S.</span></span> <span> </span><span class="NLM_article-title">The development of Bruton’s tyrosine kinase (BTK) inhibitors from 2012 to 2017: A mini-review</span>. <i>Eur. J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>151</i></span>,  <span class="NLM_fpage">315</span>– <span class="NLM_lpage">326</span>, <span class="refDoi"> DOI: 10.1016/j.ejmech.2018.03.062</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref14/cit14&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00329&amp;key=10.1016%2Fj.ejmech.2018.03.062" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref14/cit14&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00329&amp;key=29631132" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref14/cit14&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00329&amp;key=1%3ACAS%3A528%3ADC%252BC1cXnt1ehtL0%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=151&publication_year=2018&pages=315-326&author=C.+Liangauthor=D.+Tianauthor=X.+Renauthor=S.+Dingauthor=M.+Jiaauthor=M.+Xinauthor=S.+Thareja&title=The+development+of+Bruton%E2%80%99s+tyrosine+kinase+%28BTK%29+inhibitors+from+2012+to+2017%3A+A+mini-review&doi=10.1016%2Fj.ejmech.2018.03.062"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit14R"><div class="casContent"><span class="casTitleNuber">14</span><div class="casTitle"><span class="NLM_cas:atitle">The development of Bruton's tyrosine kinase (BTK) inhibitors from 2012 to 2017: A mini-review</span></div><div class="casAuthors">Liang, Chengyuan; Tian, Danni; Ren, Xiaodong; Ding, Shunjun; Jia, Minyi; Xin, Minhang; Thareja, Suresh</div><div class="citationInfo"><span class="NLM_cas:title">European Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">151</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">315-326</span>CODEN:
                <span class="NLM_cas:coden">EJMCA5</span>;
        ISSN:<span class="NLM_cas:issn">0223-5234</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Masson SAS</span>)
        </div><div class="casAbstract">A review.  Bruton's tyrosine kinase (BTK) has emerged as a promising drug target for multiple diseases, particularly hematopoietic malignancies and autoimmune diseases related to B lymphocytes.  This review focuses on the diverse, small-mol. inhibitors of BTK kinase that have shown good prospects for clin. application.  Individual examples of these inhibitors, including both reversible and irreversible inhibitors and a recently developed reversible covalent inhibitor of BTK, are discussed.  Considerable progress has been made in the development of irreversible inhibitors, most of which target the SH3 pocket and the cysteine 481 residue of BTK.  The present review also surveys the pharmacol. advantages and deficiencies of both reversible and irreversible BTK drugs, with a focus on the structure-activity relationship (SARs) and binding modes of representative drugs, which could inspire crit. thinking and new ideas for developing potent BTK inhibitors with less unwanted off-target effects.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGptNAsX0qwSHLVg90H21EOLACvtfcHk0lhLIpQ7PQBn6g"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXnt1ehtL0%253D&md5=1ea0bf36d8ebadbfba624f858911b182</span></div><a href="/servlet/linkout?suffix=cit14&amp;dbid=16384&amp;doi=10.1016%2Fj.ejmech.2018.03.062&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.ejmech.2018.03.062%26sid%3Dliteratum%253Aachs%26aulast%3DLiang%26aufirst%3DC.%26aulast%3DTian%26aufirst%3DD.%26aulast%3DRen%26aufirst%3DX.%26aulast%3DDing%26aufirst%3DS.%26aulast%3DJia%26aufirst%3DM.%26aulast%3DXin%26aufirst%3DM.%26aulast%3DThareja%26aufirst%3DS.%26atitle%3DThe%2520development%2520of%2520Bruton%25E2%2580%2599s%2520tyrosine%2520kinase%2520%2528BTK%2529%2520inhibitors%2520from%25202012%2520to%25202017%253A%2520A%2520mini-review%26jtitle%3DEur.%2520J.%2520Med.%2520Chem.%26date%3D2018%26volume%3D151%26spage%3D315%26epage%3D326%26doi%3D10.1016%2Fj.ejmech.2018.03.062" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref15"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref15'); return false;" data-citation="" class="refNumLink">15</a></strong><div class="NLM_citation" id="cit15"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Xue, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Song, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Song, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tong, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Geng, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ding, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, Q.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sun, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xie, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, A.</span></span> <span> </span><span class="NLM_article-title">Discovery of 4,7-Diamino-5-(4-phenoxyphenyl)-6-methylene-pyrimido[5,4-b]pyrrolizines as Novel Bruton’s Tyrosine Kinase Inhibitors</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>61</i></span>,  <span class="NLM_fpage">4608</span>– <span class="NLM_lpage">4627</span>, <span class="refDoi"> DOI: 10.1021/acs.jmedchem.8b00441</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.jmedchem.8b00441" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref15/cit15&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00329&amp;key=1%3ACAS%3A528%3ADC%252BC1cXoslymsbg%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=61&publication_year=2018&pages=4608-4627&author=Y.+Xueauthor=P.+Songauthor=Z.+Songauthor=A.+Wangauthor=L.+Tongauthor=M.+Gengauthor=J.+Dingauthor=Q.+Liuauthor=L.+Sunauthor=H.+Xieauthor=A.+Zhang&title=Discovery+of+4%2C7-Diamino-5-%284-phenoxyphenyl%29-6-methylene-pyrimido%5B5%2C4-b%5Dpyrrolizines+as+Novel+Bruton%E2%80%99s+Tyrosine+Kinase+Inhibitors&doi=10.1021%2Facs.jmedchem.8b00441"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit15R"><div class="casContent"><span class="casTitleNuber">15</span><div class="casTitle"><span class="NLM_cas:atitle">Discovery of 4,7-Diamino-5-(4-phenoxyphenyl)-6-methylene-pyrimido[5,4-b]pyrrolizines as Novel Bruton's Tyrosine Kinase Inhibitors</span></div><div class="casAuthors">Xue, Yu; Song, Peiran; Song, Zilan; Wang, Aoli; Tong, Linjiang; Geng, Meiyu; Ding, Jian; Liu, Qingsong; Sun, Liping; Xie, Hua; Zhang, Ao</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">61</span>
        (<span class="NLM_cas:issue">10</span>),
    <span class="NLM_cas:pages">4608-4627</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Unsatd. amide-substituted pyrimidopyrrolizines such as I were prepd. as analogs of the Bruton's tyrosine kinase (BTK) inhibitor ibrutinib for potential use as antitumor agents.  I was the potent of the analogs prepd., inhibiting BTK with an IC50 value of 0.4 nM and inhibiting the growth of BTK-dependent TMD8 cancer cells with an IC50 value of 16 nM.  I was slightly more selective than ibrutinib for BTK with strong inhibition on the B-cell receptor signaling pathway.  In a TMD8 cell-derived animal xenograft model, I (15 mg/kg, once daily) decreased tumor vol. more effectively than ibrutinib (25 mg/kg, once daily).</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGo9FMOaU6TWUrVg90H21EOLACvtfcHk0lhLIpQ7PQBn6g"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXoslymsbg%253D&md5=1993e1f867d26aedd8d2c719b52667c8</span></div><a href="/servlet/linkout?suffix=cit15&amp;dbid=16384&amp;doi=10.1021%2Facs.jmedchem.8b00441&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.jmedchem.8b00441%26sid%3Dliteratum%253Aachs%26aulast%3DXue%26aufirst%3DY.%26aulast%3DSong%26aufirst%3DP.%26aulast%3DSong%26aufirst%3DZ.%26aulast%3DWang%26aufirst%3DA.%26aulast%3DTong%26aufirst%3DL.%26aulast%3DGeng%26aufirst%3DM.%26aulast%3DDing%26aufirst%3DJ.%26aulast%3DLiu%26aufirst%3DQ.%26aulast%3DSun%26aufirst%3DL.%26aulast%3DXie%26aufirst%3DH.%26aulast%3DZhang%26aufirst%3DA.%26atitle%3DDiscovery%2520of%25204%252C7-Diamino-5-%25284-phenoxyphenyl%2529-6-methylene-pyrimido%255B5%252C4-b%255Dpyrrolizines%2520as%2520Novel%2520Bruton%25E2%2580%2599s%2520Tyrosine%2520Kinase%2520Inhibitors%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2018%26volume%3D61%26spage%3D4608%26epage%3D4627%26doi%3D10.1021%2Facs.jmedchem.8b00441" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref16"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref16'); return false;" data-citation="" class="refNumLink">16</a></strong><div class="NLM_citation" id="cit16"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Pan, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Scheerens, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, S.-J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schultz, B. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sprengeler, P. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Burrill, L. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mendonca, R. V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sweeney, M. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Scott, K. C. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Grothaus, P. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jeffery, D. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Spoerke, J. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Honigberg, L. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Young, P. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dalrymple, S. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Palmer, J. T.</span></span> <span> </span><span class="NLM_article-title">Discovery of Selective Irreversible Inhibitors for Bruton’s Tyrosine Kinase</span>. <i>ChemMedChem</i> <span class="NLM_year" style="font-weight: bold;">2007</span>,  <span class="NLM_volume"><i>2</i></span>,  <span class="NLM_fpage">58</span>– <span class="NLM_lpage">61</span>, <span class="refDoi"> DOI: 10.1002/cmdc.200600221</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref16/cit16&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00329&amp;key=10.1002%2Fcmdc.200600221" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref16/cit16&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00329&amp;key=17154430" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref16/cit16&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00329&amp;key=1%3ACAS%3A528%3ADC%252BD2sXjsVWjsbg%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=2&publication_year=2007&pages=58-61&author=Z.+Panauthor=H.+Scheerensauthor=S.-J.+Liauthor=B.+E.+Schultzauthor=P.+A.+Sprengelerauthor=L.+C.+Burrillauthor=R.+V.+Mendoncaauthor=M.+D.+Sweeneyauthor=K.+C.+K.+Scottauthor=P.+G.+Grothausauthor=D.+A.+Jefferyauthor=J.+M.+Spoerkeauthor=L.+A.+Honigbergauthor=P.+R.+Youngauthor=S.+A.+Dalrympleauthor=J.+T.+Palmer&title=Discovery+of+Selective+Irreversible+Inhibitors+for+Bruton%E2%80%99s+Tyrosine+Kinase&doi=10.1002%2Fcmdc.200600221"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit16R"><div class="casContent"><span class="casTitleNuber">16</span><div class="casTitle"><span class="NLM_cas:atitle">Discovery of selective irreversible inhibitors for bruton's tyrosine kinase</span></div><div class="casAuthors">Pan, Zhengying; Scheerens, Heleen; Li, Shyr-Jiann; Schultz, Brian E.; Sprengeler, Paul A.; Burrill, L. Chuck; Mendonca, Rohan V.; Sweeney, Michael D.; Scott, Keana C. K.; Grothaus, Paul G.; Jeffery, Douglas A.; Spoerke, Jill M.; Honigberg, Lee A.; Young, Peter R.; Dalrymple, Stacie A.; Palmer, James T.</div><div class="citationInfo"><span class="NLM_cas:title">ChemMedChem</span>
        (<span class="NLM_cas:date">2007</span>),
    <span class="NLM_cas:volume">2</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">58-61</span>CODEN:
                <span class="NLM_cas:coden">CHEMGX</span>;
        ISSN:<span class="NLM_cas:issn">1860-7179</span>.
    
            (<span class="NLM_cas:orgname">Wiley-VCH Verlag GmbH & Co. KGaA</span>)
        </div><div class="casAbstract">Synthesis and pharmacol. evaluation of a series of peptidomimetic quinoline derivs. was undertaken to evaluate their efficacy in acting as selective irreversible inhibitors of Bruton's tyrosine kinase (Btk).  With the relative scarcity of knowledge on the inhibition of Btk it is crucial to discover a potent and selective tool compd. for this kinase.  Herein is described the discovery of selective irreversible Btk inhibitors and their efficacy in a mouse RA model.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGovT3kBCYECdbVg90H21EOLACvtfcHk0ljLuenVCmk2LQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2sXjsVWjsbg%253D&md5=023ba8bca9942ad0127d7cf32293e9d2</span></div><a href="/servlet/linkout?suffix=cit16&amp;dbid=16384&amp;doi=10.1002%2Fcmdc.200600221&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fcmdc.200600221%26sid%3Dliteratum%253Aachs%26aulast%3DPan%26aufirst%3DZ.%26aulast%3DScheerens%26aufirst%3DH.%26aulast%3DLi%26aufirst%3DS.-J.%26aulast%3DSchultz%26aufirst%3DB.%2BE.%26aulast%3DSprengeler%26aufirst%3DP.%2BA.%26aulast%3DBurrill%26aufirst%3DL.%2BC.%26aulast%3DMendonca%26aufirst%3DR.%2BV.%26aulast%3DSweeney%26aufirst%3DM.%2BD.%26aulast%3DScott%26aufirst%3DK.%2BC.%2BK.%26aulast%3DGrothaus%26aufirst%3DP.%2BG.%26aulast%3DJeffery%26aufirst%3DD.%2BA.%26aulast%3DSpoerke%26aufirst%3DJ.%2BM.%26aulast%3DHonigberg%26aufirst%3DL.%2BA.%26aulast%3DYoung%26aufirst%3DP.%2BR.%26aulast%3DDalrymple%26aufirst%3DS.%2BA.%26aulast%3DPalmer%26aufirst%3DJ.%2BT.%26atitle%3DDiscovery%2520of%2520Selective%2520Irreversible%2520Inhibitors%2520for%2520Bruton%25E2%2580%2599s%2520Tyrosine%2520Kinase%26jtitle%3DChemMedChem%26date%3D2007%26volume%3D2%26spage%3D58%26epage%3D61%26doi%3D10.1002%2Fcmdc.200600221" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref17"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref17'); return false;" data-citation="" class="refNumLink">17</a></strong><div class="NLM_citation" id="cit17"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Honigberg, L. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Smith, A. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sirisawad, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Verner, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Loury, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chang, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pan, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Thamm, D. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Miller, R. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Buggy, J. J.</span></span> <span> </span><span class="NLM_article-title">The Bruton tyrosine kinase inhibitor PCI-32565 blocks B-cell activation and is efficacious in models of autoimmune disease and B-cell malignancy</span>. <i>Proc. Natl. Acad. Sci. U.S.A.</i> <span class="NLM_year" style="font-weight: bold;">2010</span>,  <span class="NLM_volume"><i>107</i></span>,  <span class="NLM_fpage">12575</span>– <span class="NLM_lpage">12580</span>, <span class="refDoi"> DOI: 10.1073/pnas.1004594107</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref17/cit17&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00329&amp;key=10.1073%2Fpnas.1004594107" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=107&publication_year=2010&pages=12575-12580&author=L.+A.+Honigbergauthor=A.+M.+Smithauthor=M.+Sirisawadauthor=E.+Vernerauthor=D.+Louryauthor=B.+Changauthor=S.+Liauthor=Z.+Panauthor=D.+H.+Thammauthor=R.+A.+Millerauthor=J.+J.+Buggy&title=The+Bruton+tyrosine+kinase+inhibitor+PCI-32565+blocks+B-cell+activation+and+is+efficacious+in+models+of+autoimmune+disease+and+B-cell+malignancy&doi=10.1073%2Fpnas.1004594107"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit17&amp;dbid=16384&amp;doi=10.1073%2Fpnas.1004594107&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1073%252Fpnas.1004594107%26sid%3Dliteratum%253Aachs%26aulast%3DHonigberg%26aufirst%3DL.%2BA.%26aulast%3DSmith%26aufirst%3DA.%2BM.%26aulast%3DSirisawad%26aufirst%3DM.%26aulast%3DVerner%26aufirst%3DE.%26aulast%3DLoury%26aufirst%3DD.%26aulast%3DChang%26aufirst%3DB.%26aulast%3DLi%26aufirst%3DS.%26aulast%3DPan%26aufirst%3DZ.%26aulast%3DThamm%26aufirst%3DD.%2BH.%26aulast%3DMiller%26aufirst%3DR.%2BA.%26aulast%3DBuggy%26aufirst%3DJ.%2BJ.%26atitle%3DThe%2520Bruton%2520tyrosine%2520kinase%2520inhibitor%2520PCI-32565%2520blocks%2520B-cell%2520activation%2520and%2520is%2520efficacious%2520in%2520models%2520of%2520autoimmune%2520disease%2520and%2520B-cell%2520malignancy%26jtitle%3DProc.%2520Natl.%2520Acad.%2520Sci.%2520U.S.A.%26date%3D2010%26volume%3D107%26spage%3D12575%26epage%3D12580%26doi%3D10.1073%2Fpnas.1004594107" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref18"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref18'); return false;" data-citation="" class="refNumLink">18</a></strong><div class="NLM_citation" id="cit18"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Advani, R. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Buggy, J. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sharman, J. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Smith, S. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Boyd, T. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Grant, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kolibaba, K. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Furman, R. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rodriguez, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chang, B. Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sukbuntherng, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Izumi, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hamdy, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hedrick, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fowler, N. H.</span></span> <span> </span><span class="NLM_article-title">Bruton Tyrosine Kinase Inhibitor Ibrutinib (PCI-32765) Has Significant Activity in Patients With Relapsed/Refractory B-Cell Malignancies</span>. <i>J. Clin. Oncol.</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>31</i></span>,  <span class="NLM_fpage">88</span>– <span class="NLM_lpage">94</span>, <span class="refDoi"> DOI: 10.1200/jco.2012.42.7906</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref18/cit18&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00329&amp;key=10.1200%2Fjco.2012.42.7906" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref18/cit18&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00329&amp;key=23045577" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref18/cit18&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00329&amp;key=1%3ACAS%3A528%3ADC%252BC3sXitFaltLg%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=31&publication_year=2013&pages=88-94&author=R.+H.+Advaniauthor=J.+J.+Buggyauthor=J.+P.+Sharmanauthor=S.+M.+Smithauthor=T.+E.+Boydauthor=B.+Grantauthor=K.+S.+Kolibabaauthor=R.+R.+Furmanauthor=S.+Rodriguezauthor=B.+Y.+Changauthor=J.+Sukbuntherngauthor=R.+Izumiauthor=A.+Hamdyauthor=E.+Hedrickauthor=N.+H.+Fowler&title=Bruton+Tyrosine+Kinase+Inhibitor+Ibrutinib+%28PCI-32765%29+Has+Significant+Activity+in+Patients+With+Relapsed%2FRefractory+B-Cell+Malignancies&doi=10.1200%2Fjco.2012.42.7906"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit18R"><div class="casContent"><span class="casTitleNuber">18</span><div class="casTitle"><span class="NLM_cas:atitle">Bruton tyrosine kinase inhibitor ibrutinib (PCI-32765) has significant activity in patients with relapsed/refractory B-cell malignancies</span></div><div class="casAuthors">Advani, Ranjana H.; Buggy, Joseph J.; Sharman, Jeff P.; Smith, Sonali M.; Boyd, Thomas E.; Grant, Barbara; Kolibaba, Kathryn S.; Furman, Richard R.; Rodriguez, Sara; Chang, Betty Y.; Sukbuntherng, Juthamas; Izumi, Raquel; Hamdy, Ahmed; Hedrick, Eric; Fowler, Nathan H.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Clinical Oncology</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">31</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">88-94</span>CODEN:
                <span class="NLM_cas:coden">JCONDN</span>;
        ISSN:<span class="NLM_cas:issn">0732-183X</span>.
    
            (<span class="NLM_cas:orgname">American Society of Clinical Oncology</span>)
        </div><div class="casAbstract">Purpose Survival and progression of mature B-cell malignancies depend on signals from the B-cell antigen receptor, and Bruton tyrosine kinase (BTK) is a crit. signaling kinase in this pathway.  We evaluated ibrutinib (PCI-32765), a small-mol. irreversible inhibitor of BTK, in patients with B-cell malignancies.  Patients and Methods Patients with relapsed or refractory B-cell lymphoma and chronic lymphocytic leukemia received escalating oral doses of ibrutinib.  Two schedules were evaluated: one, 28 days on, 7 days off; and two, once-daily continuous dosing.  Occupancy of BTK by ibrutinib in peripheral blood was monitored using a fluorescent affinity probe.  Dose escalation proceeded until either the max.-tolerated dose (MTD) was achieved or, in the absence of MTD, until three dose levels above full BTK occupancy by ibrutinib.  Response was evaluated every two cycles.  Results Fifty-six patients with a variety of B-cell malignancies were treated over seven cohorts.  Most adverse events were grade 1 and 2 in severity and self-limited.  Dose-limiting events were not obsd., even with prolonged dosing.  Full occupancy of the BTK active site occurred at 2.5 mg/kg per day, and dose escalation continued to 12.5 mg/kg per day without reaching MTD.  Pharmacokinetic data indicated rapid absorption and elimination, yet BTK occupancy was maintained for at least 24 h, consistent with the irreversible mechanism.  Objective response rate in 50 evaluable patients was 60%, including complete response of 16%.  Median progression-free survival in all patients was 13.6 mo.  Conclusion Ibrutinib, a novel BTK-targeting inhibitor, is well tolerated, with substantial activity across B-cell histologies.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoqj_UZPM0nBrVg90H21EOLACvtfcHk0ljLuenVCmk2LQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXitFaltLg%253D&md5=e955490a02af9a321823033b9e258cb6</span></div><a href="/servlet/linkout?suffix=cit18&amp;dbid=16384&amp;doi=10.1200%2Fjco.2012.42.7906&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1200%252Fjco.2012.42.7906%26sid%3Dliteratum%253Aachs%26aulast%3DAdvani%26aufirst%3DR.%2BH.%26aulast%3DBuggy%26aufirst%3DJ.%2BJ.%26aulast%3DSharman%26aufirst%3DJ.%2BP.%26aulast%3DSmith%26aufirst%3DS.%2BM.%26aulast%3DBoyd%26aufirst%3DT.%2BE.%26aulast%3DGrant%26aufirst%3DB.%26aulast%3DKolibaba%26aufirst%3DK.%2BS.%26aulast%3DFurman%26aufirst%3DR.%2BR.%26aulast%3DRodriguez%26aufirst%3DS.%26aulast%3DChang%26aufirst%3DB.%2BY.%26aulast%3DSukbuntherng%26aufirst%3DJ.%26aulast%3DIzumi%26aufirst%3DR.%26aulast%3DHamdy%26aufirst%3DA.%26aulast%3DHedrick%26aufirst%3DE.%26aulast%3DFowler%26aufirst%3DN.%2BH.%26atitle%3DBruton%2520Tyrosine%2520Kinase%2520Inhibitor%2520Ibrutinib%2520%2528PCI-32765%2529%2520Has%2520Significant%2520Activity%2520in%2520Patients%2520With%2520Relapsed%252FRefractory%2520B-Cell%2520Malignancies%26jtitle%3DJ.%2520Clin.%2520Oncol.%26date%3D2013%26volume%3D31%26spage%3D88%26epage%3D94%26doi%3D10.1200%2Fjco.2012.42.7906" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref19"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref19'); return false;" data-citation="" class="refNumLink">19</a></strong><div class="NLM_citation" id="cit19"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Byrd, J. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Furman, R. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Coutre, S. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Flinn, I. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Burger, J. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Blum, K. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Grant, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sharman, J. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Coleman, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wierda, W. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jones, J. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhao, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Heerema, N. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Johnson, A. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sukbuntherng, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chang, B. Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Clow, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hedrick, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Buggy, J. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">James, D. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">O’Brien, S.</span></span> <span> </span><span class="NLM_article-title">Targeting BTK with ibrutinib in relapsed chronic lymphocytic leukemia</span>. <i>N. Engl. J. Med.</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>369</i></span>,  <span class="NLM_fpage">32</span>– <span class="NLM_lpage">42</span>, <span class="refDoi"> DOI: 10.1056/nejmoa1215637</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref19/cit19&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00329&amp;key=10.1056%2Fnejmoa1215637" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref19/cit19&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00329&amp;key=23782158" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref19/cit19&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00329&amp;key=1%3ACAS%3A528%3ADC%252BC3sXhtFygu7zN" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=369&publication_year=2013&pages=32-42&author=J.+C.+Byrdauthor=R.+R.+Furmanauthor=S.+E.+Coutreauthor=I.+W.+Flinnauthor=J.+A.+Burgerauthor=K.+A.+Blumauthor=B.+Grantauthor=J.+P.+Sharmanauthor=M.+Colemanauthor=W.+G.+Wierdaauthor=J.+A.+Jonesauthor=W.+Zhaoauthor=N.+A.+Heeremaauthor=A.+J.+Johnsonauthor=J.+Sukbuntherngauthor=B.+Y.+Changauthor=F.+Clowauthor=E.+Hedrickauthor=J.+J.+Buggyauthor=D.+F.+Jamesauthor=S.+O%E2%80%99Brien&title=Targeting+BTK+with+ibrutinib+in+relapsed+chronic+lymphocytic+leukemia&doi=10.1056%2Fnejmoa1215637"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit19R"><div class="casContent"><span class="casTitleNuber">19</span><div class="casTitle"><span class="NLM_cas:atitle">Targeting BTK with ibrutinib in relapsed chronic lymphocytic leukemia</span></div><div class="casAuthors">Byrd, John C.; Furman, Richard R.; Coutre, Steven E.; Flinn, Ian W.; Burger, Jan A.; Blum, Kristie A.; Grant, Barbara; Sharman, Jeff P.; Coleman, Morton; Wierda, William G.; Jones, Jeffrey A.; Zhao, Weiqiang; Heerema, Nyla A.; Johnson, Amy J.; Sukbuntherng, Juthamas; Chang, Betty Y.; Clow, Fong; Hedrick, Eric; Buggy, Joseph J.; James, Danelle F.; O'Brien, Susan</div><div class="citationInfo"><span class="NLM_cas:title">New England Journal of Medicine</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">369</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">32-42</span>CODEN:
                <span class="NLM_cas:coden">NEJMAG</span>;
        ISSN:<span class="NLM_cas:issn">0028-4793</span>.
    
            (<span class="NLM_cas:orgname">Massachusetts Medical Society</span>)
        </div><div class="casAbstract">Background The treatment of relapsed chronic lymphocytic leukemia (CLL) has resulted in few durable remissions.  Bruton's tyrosine kinase (BTK), an essential component of B-cell-receptor signaling, mediates interactions with the tumor microenvironment and promotes the survival and proliferation of CLL cells.  Methods We conducted a phase 1b-2 multicenter study to assess the safety, efficacy, pharmacokinetics, and pharmacodynamics of ibrutinib (PCI-32765), a first-in-class, oral covalent inhibitor of BTK designed for treatment of B-cell cancers, in patients with relapsed or refractory CLL or small lymphocytic lymphoma.  A total of 85 patients, the majority of whom were considered to have high-risk disease, received ibrutinib orally once daily; 51 received 420 mg, and 34 received 840 mg.  Results Toxic effects were predominantly grade 1 or 2 and included transient diarrhea, fatigue, and upper respiratory tract infection; thus, patients could receive extended treatment with minimal hematol. toxic effects.  The overall response rate was the same in the group that received 420 mg and the group that received 840 mg (71%), and an addnl. 20% and 15% of patients in the resp. groups had a partial response with lymphocytosis.  The response was independent of clin. and genomic risk factors present before treatment, including advanced-stage disease, the no. of previous therapies, and the 17p13.1 deletion.  At 26 mo, the estd. progression-free survival rate was 75% and the rate of overall survival was 83%.  Conclusions Ibrutinib was assocd. with a high frequency of durable remissions in patients with relapsed or refractory CLL and small lymphocytic lymphoma, including patients with high-risk genetic lesions.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGp1EhPQxMRz7rVg90H21EOLACvtfcHk0lhqJ8AXSqrSZQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXhtFygu7zN&md5=32a5eb6ab06beeecf64d9ada84139925</span></div><a href="/servlet/linkout?suffix=cit19&amp;dbid=16384&amp;doi=10.1056%2Fnejmoa1215637&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1056%252Fnejmoa1215637%26sid%3Dliteratum%253Aachs%26aulast%3DByrd%26aufirst%3DJ.%2BC.%26aulast%3DFurman%26aufirst%3DR.%2BR.%26aulast%3DCoutre%26aufirst%3DS.%2BE.%26aulast%3DFlinn%26aufirst%3DI.%2BW.%26aulast%3DBurger%26aufirst%3DJ.%2BA.%26aulast%3DBlum%26aufirst%3DK.%2BA.%26aulast%3DGrant%26aufirst%3DB.%26aulast%3DSharman%26aufirst%3DJ.%2BP.%26aulast%3DColeman%26aufirst%3DM.%26aulast%3DWierda%26aufirst%3DW.%2BG.%26aulast%3DJones%26aufirst%3DJ.%2BA.%26aulast%3DZhao%26aufirst%3DW.%26aulast%3DHeerema%26aufirst%3DN.%2BA.%26aulast%3DJohnson%26aufirst%3DA.%2BJ.%26aulast%3DSukbuntherng%26aufirst%3DJ.%26aulast%3DChang%26aufirst%3DB.%2BY.%26aulast%3DClow%26aufirst%3DF.%26aulast%3DHedrick%26aufirst%3DE.%26aulast%3DBuggy%26aufirst%3DJ.%2BJ.%26aulast%3DJames%26aufirst%3DD.%2BF.%26aulast%3DO%25E2%2580%2599Brien%26aufirst%3DS.%26atitle%3DTargeting%2520BTK%2520with%2520ibrutinib%2520in%2520relapsed%2520chronic%2520lymphocytic%2520leukemia%26jtitle%3DN.%2520Engl.%2520J.%2520Med.%26date%3D2013%26volume%3D369%26spage%3D32%26epage%3D42%26doi%3D10.1056%2Fnejmoa1215637" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref20"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref20'); return false;" data-citation="" class="refNumLink">20</a></strong><div class="NLM_citation" id="cit20"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Wang, M. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rule, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Martin, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Goy, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Auer, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kahl, B. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jurczak, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Advani, R. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Romaguera, J. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Williams, M. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Barrientos, J. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chmielowska, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Radford, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stilgenbauer, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dreyling, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jedrzejczak, W. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Johnson, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Spurgeon, S. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Newberry, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ou, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cheng, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fang, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">McGreivy, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Clow, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Buggy, J. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chang, B. Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Beaupre, D. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kunkel, L. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Blum, K. A.</span></span> <span> </span><span class="NLM_article-title">Targeting BTK with ibrutinib in relapsed or refractory mantle-cell lymphoma</span>. <i>N. Engl. J. Med.</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>369</i></span>,  <span class="NLM_fpage">507</span>– <span class="NLM_lpage">516</span>, <span class="refDoi"> DOI: 10.1056/nejmoa1306220</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref20/cit20&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00329&amp;key=10.1056%2Fnejmoa1306220" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref20/cit20&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00329&amp;key=23782157" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref20/cit20&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00329&amp;key=1%3ACAS%3A528%3ADC%252BC3sXht1OgtL%252FF" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=369&publication_year=2013&pages=507-516&author=M.+L.+Wangauthor=S.+Ruleauthor=P.+Martinauthor=A.+Goyauthor=R.+Auerauthor=B.+S.+Kahlauthor=W.+Jurczakauthor=R.+H.+Advaniauthor=J.+E.+Romagueraauthor=M.+E.+Williamsauthor=J.+C.+Barrientosauthor=E.+Chmielowskaauthor=J.+Radfordauthor=S.+Stilgenbauerauthor=M.+Dreylingauthor=W.+W.+Jedrzejczakauthor=P.+Johnsonauthor=S.+E.+Spurgeonauthor=L.+Liauthor=L.+Zhangauthor=K.+Newberryauthor=Z.+Ouauthor=N.+Chengauthor=B.+Fangauthor=J.+McGreivyauthor=F.+Clowauthor=J.+J.+Buggyauthor=B.+Y.+Changauthor=D.+M.+Beaupreauthor=L.+A.+Kunkelauthor=K.+A.+Blum&title=Targeting+BTK+with+ibrutinib+in+relapsed+or+refractory+mantle-cell+lymphoma&doi=10.1056%2Fnejmoa1306220"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit20R"><div class="casContent"><span class="casTitleNuber">20</span><div class="casTitle"><span class="NLM_cas:atitle">Targeting BTK with ibrutinib in relapsed or refractory mantle-cell lymphoma</span></div><div class="casAuthors">Wang, Michael L.; Rule, Simon; Martin, Peter; Goy, Andre; Auer, Rebecca; Kahl, Brad S.; Jurczak, Wojciech; Advani, Ranjana H.; Romaguera, Jorge E.; Williams, Michael E.; Barrientos, Jacqueline C.; Chmielowska, Ewa; Radford, John; Stilgenbauer, Stephan; Dreyling, Martin; Jedrzejczak, Wieslaw Wiktor; Johnson, Peter; Spurgeon, Stephen E.; Li, Lei; Zhang, Liang; Newberry, Kate; Ou, Zhishuo; Cheng, Nancy; Fang, Bingliang; McGreivy, Jesse; Clow, Fong; Buggy, Joseph J.; Chang, Betty Y.; Beaupre, Darrin M.; Kunkel, Lori A.; Blum, Kristie A.</div><div class="citationInfo"><span class="NLM_cas:title">New England Journal of Medicine</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">369</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">507-516</span>CODEN:
                <span class="NLM_cas:coden">NEJMAG</span>;
        ISSN:<span class="NLM_cas:issn">0028-4793</span>.
    
            (<span class="NLM_cas:orgname">Massachusetts Medical Society</span>)
        </div><div class="casAbstract">BACKGROUND: Bruton's tyrosine kinase (BTK) is a mediator of the B-cell-receptor signaling pathway implicated in the pathogenesis of B-cell cancers.  In a phase 1 study, ibrutinib, a BTK inhibitor, showed antitumor activity in several types of non-Hodgkin's lymphoma, including mantle-cell lymphoma.  METHODS: In this phase 2 study, we investigated oral ibrutinib, at a daily dose of 560 mg, in 111 patients with relapsed or refractory mantle-cell lymphoma.  Patients were enrolled into two groups: those who had previously received at least 2 cycles of bortezomib therapy and those who had received less than 2 complete cycles of bortezomib or had received no prior bortezomib therapy.  The primary end point was the overall response rate.  Secondary end points were duration of response, progression-free survival, overall survival, and safety.  RESULTS: The median age was 68 years, and 86% of patients had intermediate-risk or high-risk mantle-cell lymphoma according to clin. prognostic factors.  Patients had received a median of three prior therapies.  The most common treatment-related adverse events were mild or moderate diarrhea, fatigue, and nausea.  Grade 3 or higher hematol. events were infrequent and included neutropenia (in 16% of patients), thrombocytopenia (in 11%), and anemia (in 10%).  A response rate of 68% (75 patients) was obsd., with a complete response rate of 21% and a partial response rate of 47%; prior treatment with bortezomib had no effect on the response rate.  With an estd. median follow-up of 15.3 mo, the estd. median response duration was 17.5 mo (95% confidence interval [CI], 15.8 to not reached), the estd. median progression-free survival was 13.9 mo (95% CI, 7.0 to not reached), and the median overall survival was not reached.  The estd. rate of overall survival was 58% at 18 mo.  CONCLUSIONS: Ibrutinib shows durable single-agent efficacy in relapsed or refractory mantle-cell lymphoma.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGovUuOKvHS0NrVg90H21EOLACvtfcHk0lhqJ8AXSqrSZQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXht1OgtL%252FF&md5=7a92bbd5acf86e614cea96f44503e12b</span></div><a href="/servlet/linkout?suffix=cit20&amp;dbid=16384&amp;doi=10.1056%2Fnejmoa1306220&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1056%252Fnejmoa1306220%26sid%3Dliteratum%253Aachs%26aulast%3DWang%26aufirst%3DM.%2BL.%26aulast%3DRule%26aufirst%3DS.%26aulast%3DMartin%26aufirst%3DP.%26aulast%3DGoy%26aufirst%3DA.%26aulast%3DAuer%26aufirst%3DR.%26aulast%3DKahl%26aufirst%3DB.%2BS.%26aulast%3DJurczak%26aufirst%3DW.%26aulast%3DAdvani%26aufirst%3DR.%2BH.%26aulast%3DRomaguera%26aufirst%3DJ.%2BE.%26aulast%3DWilliams%26aufirst%3DM.%2BE.%26aulast%3DBarrientos%26aufirst%3DJ.%2BC.%26aulast%3DChmielowska%26aufirst%3DE.%26aulast%3DRadford%26aufirst%3DJ.%26aulast%3DStilgenbauer%26aufirst%3DS.%26aulast%3DDreyling%26aufirst%3DM.%26aulast%3DJedrzejczak%26aufirst%3DW.%2BW.%26aulast%3DJohnson%26aufirst%3DP.%26aulast%3DSpurgeon%26aufirst%3DS.%2BE.%26aulast%3DLi%26aufirst%3DL.%26aulast%3DZhang%26aufirst%3DL.%26aulast%3DNewberry%26aufirst%3DK.%26aulast%3DOu%26aufirst%3DZ.%26aulast%3DCheng%26aufirst%3DN.%26aulast%3DFang%26aufirst%3DB.%26aulast%3DMcGreivy%26aufirst%3DJ.%26aulast%3DClow%26aufirst%3DF.%26aulast%3DBuggy%26aufirst%3DJ.%2BJ.%26aulast%3DChang%26aufirst%3DB.%2BY.%26aulast%3DBeaupre%26aufirst%3DD.%2BM.%26aulast%3DKunkel%26aufirst%3DL.%2BA.%26aulast%3DBlum%26aufirst%3DK.%2BA.%26atitle%3DTargeting%2520BTK%2520with%2520ibrutinib%2520in%2520relapsed%2520or%2520refractory%2520mantle-cell%2520lymphoma%26jtitle%3DN.%2520Engl.%2520J.%2520Med.%26date%3D2013%26volume%3D369%26spage%3D507%26epage%3D516%26doi%3D10.1056%2Fnejmoa1306220" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref21"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref21'); return false;" data-citation="" class="refNumLink">21</a></strong><div class="NLM_citation" id="cit21"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Treon, S. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tripsas, C. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Meid, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Warren, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Varma, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Green, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Argyropoulos, K. V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yang, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cao, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xu, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Patterson, C. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rodig, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zehnder, J. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Aster, J. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Harris, N. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kanan, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ghobrial, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Castillo, J. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Laubach, J. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hunter, Z. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Salman, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cheng, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Clow, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Graef, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Palomba, M. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Advani, R. H.</span></span> <span> </span><span class="NLM_article-title">Ibrutinib in previously treated Waldenstrom’s macroglobulinemia</span>. <i>N. Engl. J. Med.</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>372</i></span>,  <span class="NLM_fpage">1425</span>– <span class="NLM_lpage">1440</span>, <span class="refDoi"> DOI: 10.1056/nejmoa1501548</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref21/cit21&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00329&amp;key=10.1056%2Fnejmoa1501548" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=372&publication_year=2015&pages=1425-1440&author=S.+P.+Treonauthor=C.+K.+Tripsasauthor=K.+Meidauthor=D.+Warrenauthor=G.+Varmaauthor=R.+Greenauthor=K.+V.+Argyropoulosauthor=G.+Yangauthor=Y.+Caoauthor=L.+Xuauthor=C.+J.+Pattersonauthor=S.+Rodigauthor=J.+L.+Zehnderauthor=J.+C.+Asterauthor=N.+L.+Harrisauthor=S.+Kananauthor=I.+Ghobrialauthor=J.+J.+Castilloauthor=J.+P.+Laubachauthor=Z.+R.+Hunterauthor=Z.+Salmanauthor=J.+Liauthor=M.+Chengauthor=F.+Clowauthor=T.+Graefauthor=M.+L.+Palombaauthor=R.+H.+Advani&title=Ibrutinib+in+previously+treated+Waldenstrom%E2%80%99s+macroglobulinemia&doi=10.1056%2Fnejmoa1501548"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit21&amp;dbid=16384&amp;doi=10.1056%2Fnejmoa1501548&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1056%252Fnejmoa1501548%26sid%3Dliteratum%253Aachs%26aulast%3DTreon%26aufirst%3DS.%2BP.%26aulast%3DTripsas%26aufirst%3DC.%2BK.%26aulast%3DMeid%26aufirst%3DK.%26aulast%3DWarren%26aufirst%3DD.%26aulast%3DVarma%26aufirst%3DG.%26aulast%3DGreen%26aufirst%3DR.%26aulast%3DArgyropoulos%26aufirst%3DK.%2BV.%26aulast%3DYang%26aufirst%3DG.%26aulast%3DCao%26aufirst%3DY.%26aulast%3DXu%26aufirst%3DL.%26aulast%3DPatterson%26aufirst%3DC.%2BJ.%26aulast%3DRodig%26aufirst%3DS.%26aulast%3DZehnder%26aufirst%3DJ.%2BL.%26aulast%3DAster%26aufirst%3DJ.%2BC.%26aulast%3DHarris%26aufirst%3DN.%2BL.%26aulast%3DKanan%26aufirst%3DS.%26aulast%3DGhobrial%26aufirst%3DI.%26aulast%3DCastillo%26aufirst%3DJ.%2BJ.%26aulast%3DLaubach%26aufirst%3DJ.%2BP.%26aulast%3DHunter%26aufirst%3DZ.%2BR.%26aulast%3DSalman%26aufirst%3DZ.%26aulast%3DLi%26aufirst%3DJ.%26aulast%3DCheng%26aufirst%3DM.%26aulast%3DClow%26aufirst%3DF.%26aulast%3DGraef%26aufirst%3DT.%26aulast%3DPalomba%26aufirst%3DM.%2BL.%26aulast%3DAdvani%26aufirst%3DR.%2BH.%26atitle%3DIbrutinib%2520in%2520previously%2520treated%2520Waldenstrom%25E2%2580%2599s%2520macroglobulinemia%26jtitle%3DN.%2520Engl.%2520J.%2520Med.%26date%3D2015%26volume%3D372%26spage%3D1425%26epage%3D1440%26doi%3D10.1056%2Fnejmoa1501548" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref22"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref22'); return false;" data-citation="" class="refNumLink">22</a></strong><div class="NLM_citation" id="cit22"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Noy, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">de Vos, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Thieblemont, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Martin, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Flowers, C. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Morschhauser, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Collins, G. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ma, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Coleman, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Peles, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Smith, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Barrientos, J. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Smith, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Munneke, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dimery, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Beaupre, D. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, R.</span></span> <span> </span><span class="NLM_article-title">Targeting Bruton tyrosine kinase with ibrutinib in relapsed/refractory marginal zone lymphoma</span>. <i>Blood</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>129</i></span>,  <span class="NLM_fpage">2224</span>– <span class="NLM_lpage">2232</span>, <span class="refDoi"> DOI: 10.1182/blood-2016-10-747345</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref22/cit22&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00329&amp;key=10.1182%2Fblood-2016-10-747345" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref22/cit22&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00329&amp;key=28167659" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref22/cit22&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00329&amp;key=1%3ACAS%3A528%3ADC%252BC2sXhtFertLvL" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=129&publication_year=2017&pages=2224-2232&author=A.+Noyauthor=S.+de+Vosauthor=C.+Thieblemontauthor=P.+Martinauthor=C.+R.+Flowersauthor=F.+Morschhauserauthor=G.+P.+Collinsauthor=S.+Maauthor=M.+Colemanauthor=S.+Pelesauthor=S.+Smithauthor=J.+C.+Barrientosauthor=A.+Smithauthor=B.+Munnekeauthor=I.+Dimeryauthor=D.+M.+Beaupreauthor=R.+Chen&title=Targeting+Bruton+tyrosine+kinase+with+ibrutinib+in+relapsed%2Frefractory+marginal+zone+lymphoma&doi=10.1182%2Fblood-2016-10-747345"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit22R"><div class="casContent"><span class="casTitleNuber">22</span><div class="casTitle"><span class="NLM_cas:atitle">Targeting Bruton tyrosine kinase with ibrutinib in relapsed/refractory marginal zone lymphoma</span></div><div class="casAuthors">Noy, Ariela; de Vos, Sven; Thieblemont, Catherine; Martin, Peter; Flowers, Christopher R.; Morschhauser, Franck; Collins, Graham P.; Ma, Shuo; Coleman, Morton; Peles, Shachar; Smith, Stephen; Barrientos, Jacqueline C.; Smith, Alina; Munneke, Brian; Dimery, Isaiah; Beaupre, Darrin M.; Chen, Robert</div><div class="citationInfo"><span class="NLM_cas:title">Blood</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">129</span>
        (<span class="NLM_cas:issue">16</span>),
    <span class="NLM_cas:pages">2224-2232</span>CODEN:
                <span class="NLM_cas:coden">BLOOAW</span>;
        ISSN:<span class="NLM_cas:issn">1528-0020</span>.
    
            (<span class="NLM_cas:orgname">American Society of Hematology</span>)
        </div><div class="casAbstract">Marginal zone lymphoma (MZL) is a heterogeneous B-cell malignancy for which no std. treatment exists.  MZL is frequently linked to chronic infection, which may induce B-cell receptor (BCR) signaling, resulting in aberrant B-cell survival and proliferation.  We conducted a multicenter, open-label, phase 2 study to evaluate the efficacy and safety of ibrutinib in previously treated MZL.  Patients with histol. confirmed MZL of all subtypes who received ≥1 prior therapy with an anti-CD20 antibody-contg. regimen were treated with 560 mg ibrutinib orally once daily until progression or unacceptable toxicity.  The primary end point was independent review committee-assessed overall response rate (ORR) by 2007 International Working Group criteria.  Among 63 enrolled patients, median age was 66 years (range, 30-92).  Median no. of prior systemic therapies was 2 (range, 1-9), and 63% received -1 prior chemoimmunotherapy.  In 60 evaluable patients, ORR was 48% (95% confidence interval [CI], 35-62).  With median follow-up of 19.4 mo, median duration of response was not reached (95% CI, 16.7 to not estimable), and median progression-free survival was 14.2 mo (95% CI, 8.3 to not estimable).  Grade ≥3 adverse events (AEs; >5%) included anemia, pneumonia, and fatigue.  Serious AEs of any grade occurred in 44%, with grade 3-4 pneumonia being the most common (8%).  Rates of discontinuation and dose redns. due to AEs were 17% and 10%, resp.  Single-agent ibrutinib induced durable responses with a favorable benefit-risk profile in patients with previously treated MZL, confirming the role of BCR signaling in this malignancy.  As the only approved therapy, ibrutinib provides a treatment option without chemotherapy for MZL.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrPJsWo_0vgV7Vg90H21EOLACvtfcHk0lhwUf7cUn3n_Q"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXhtFertLvL&md5=d40fbb28f38efaddc5b6516f152a5018</span></div><a href="/servlet/linkout?suffix=cit22&amp;dbid=16384&amp;doi=10.1182%2Fblood-2016-10-747345&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1182%252Fblood-2016-10-747345%26sid%3Dliteratum%253Aachs%26aulast%3DNoy%26aufirst%3DA.%26aulast%3Dde%2BVos%26aufirst%3DS.%26aulast%3DThieblemont%26aufirst%3DC.%26aulast%3DMartin%26aufirst%3DP.%26aulast%3DFlowers%26aufirst%3DC.%2BR.%26aulast%3DMorschhauser%26aufirst%3DF.%26aulast%3DCollins%26aufirst%3DG.%2BP.%26aulast%3DMa%26aufirst%3DS.%26aulast%3DColeman%26aufirst%3DM.%26aulast%3DPeles%26aufirst%3DS.%26aulast%3DSmith%26aufirst%3DS.%26aulast%3DBarrientos%26aufirst%3DJ.%2BC.%26aulast%3DSmith%26aufirst%3DA.%26aulast%3DMunneke%26aufirst%3DB.%26aulast%3DDimery%26aufirst%3DI.%26aulast%3DBeaupre%26aufirst%3DD.%2BM.%26aulast%3DChen%26aufirst%3DR.%26atitle%3DTargeting%2520Bruton%2520tyrosine%2520kinase%2520with%2520ibrutinib%2520in%2520relapsed%252Frefractory%2520marginal%2520zone%2520lymphoma%26jtitle%3DBlood%26date%3D2017%26volume%3D129%26spage%3D2224%26epage%3D2232%26doi%3D10.1182%2Fblood-2016-10-747345" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref23"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref23'); return false;" data-citation="" class="refNumLink">23</a></strong><div class="NLM_citation" id="cit23"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Evans, E. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tester, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Aslanian, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Karp, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sheets, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Labenski, M. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Witowski, S. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lounsbury, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chaturvedi, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mazdiyasni, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhu, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nacht, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Freed, M. I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Petter, R. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dubrovskiy, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Singh, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Westlin, W. F.</span></span> <span> </span><span class="NLM_article-title">Inhibition of Btk with CC-292 provides early pharmacodynamic assessment of activity in mice and humans</span>. <i>J. Pharmacol. Exp. Ther.</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>346</i></span>,  <span class="NLM_fpage">219</span>– <span class="NLM_lpage">228</span>, <span class="refDoi"> DOI: 10.1124/jpet.113.203489</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref23/cit23&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00329&amp;key=10.1124%2Fjpet.113.203489" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref23/cit23&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00329&amp;key=23709115" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref23/cit23&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00329&amp;key=1%3ACAS%3A528%3ADC%252BC3sXhtFOjsbbM" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=346&publication_year=2013&pages=219-228&author=E.+K.+Evansauthor=R.+Testerauthor=S.+Aslanianauthor=R.+Karpauthor=M.+Sheetsauthor=M.+T.+Labenskiauthor=S.+R.+Witowskiauthor=H.+Lounsburyauthor=P.+Chaturvediauthor=H.+Mazdiyasniauthor=Z.+Zhuauthor=M.+Nachtauthor=M.+I.+Freedauthor=R.+C.+Petterauthor=A.+Dubrovskiyauthor=J.+Singhauthor=W.+F.+Westlin&title=Inhibition+of+Btk+with+CC-292+provides+early+pharmacodynamic+assessment+of+activity+in+mice+and+humans&doi=10.1124%2Fjpet.113.203489"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit23R"><div class="casContent"><span class="casTitleNuber">23</span><div class="casTitle"><span class="NLM_cas:atitle">Inhibition of Btk with CC-292 provides early pharmacodynamic assessment of activity in mice and humans</span></div><div class="casAuthors">Evans, Erica K.; Tester, Richland; Aslanian, Sharon; Karp, Russell; Sheets, Michael; Labenski, Matthew T.; Witowski, Steven R.; Lounsbury, Heather; Chaturvedi, Prasoon; Mazdiyasni, Hormoz; Zhu, Zhendong; Nacht, Mariana; Freed, Martin I.; Petter, Russell C.; Dubrovskiy, Alex; Singh, Juswinder; Westlin, William F.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Pharmacology and Experimental Therapeutics</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">346</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">219-228</span>CODEN:
                <span class="NLM_cas:coden">JPETAB</span>;
        ISSN:<span class="NLM_cas:issn">1521-0103</span>.
    
            (<span class="NLM_cas:orgname">American Society for Pharmacology and Experimental Therapeutics</span>)
        </div><div class="casAbstract">Targeted therapies that suppress B cell receptor (BCR) signaling have emerged as promising agents in autoimmune disease and B cell malignancies.  Bruton's tyrosine kinase (Btk) plays a crucial role in B cell development and activation through the BCR signaling pathway and represents a new target for diseases characterized by inappropriate B cell activity.  N-(3-(5-fluoro-2-(4-(2-methoxyethoxy)phenylamino)pyrimidin-4-ylamino)phenyl)acrylamide (CC-292) is a highly selective, covalent Btk inhibitor and a sensitive and quant. assay that measures CC-292-Btk engagement has been developed.  This translational pharmacodynamic assay has accompanied CC-292 through each step of drug discovery and development.  These studies demonstrate the quantity of Btk bound by CC-292 correlates with the efficacy of CC-292 in vitro and in the collagen-induced arthritis model of autoimmune disease.  Recently, CC-292 has entered human clin. trials with a trial design that has provided rapid insight into safety, pharmacokinetics, and pharmacodynamics.  This first-in-human healthy volunteer trial has demonstrated that a single oral dose of 2 mg/kg CC-292 consistently engaged all circulating Btk protein and provides the basis for rational dose selection in future clin. trials.  This targeted covalent drug design approach has enabled the discovery and early clin. development of CC-292 and has provided support for Btk as a valuable drug target for B-cell mediated disorders.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrN2l8ZCVqCFLVg90H21EOLACvtfcHk0lhwUf7cUn3n_Q"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXhtFOjsbbM&md5=95fac997a246e59d943dd554af358a65</span></div><a href="/servlet/linkout?suffix=cit23&amp;dbid=16384&amp;doi=10.1124%2Fjpet.113.203489&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1124%252Fjpet.113.203489%26sid%3Dliteratum%253Aachs%26aulast%3DEvans%26aufirst%3DE.%2BK.%26aulast%3DTester%26aufirst%3DR.%26aulast%3DAslanian%26aufirst%3DS.%26aulast%3DKarp%26aufirst%3DR.%26aulast%3DSheets%26aufirst%3DM.%26aulast%3DLabenski%26aufirst%3DM.%2BT.%26aulast%3DWitowski%26aufirst%3DS.%2BR.%26aulast%3DLounsbury%26aufirst%3DH.%26aulast%3DChaturvedi%26aufirst%3DP.%26aulast%3DMazdiyasni%26aufirst%3DH.%26aulast%3DZhu%26aufirst%3DZ.%26aulast%3DNacht%26aufirst%3DM.%26aulast%3DFreed%26aufirst%3DM.%2BI.%26aulast%3DPetter%26aufirst%3DR.%2BC.%26aulast%3DDubrovskiy%26aufirst%3DA.%26aulast%3DSingh%26aufirst%3DJ.%26aulast%3DWestlin%26aufirst%3DW.%2BF.%26atitle%3DInhibition%2520of%2520Btk%2520with%2520CC-292%2520provides%2520early%2520pharmacodynamic%2520assessment%2520of%2520activity%2520in%2520mice%2520and%2520humans%26jtitle%3DJ.%2520Pharmacol.%2520Exp.%2520Ther.%26date%3D2013%26volume%3D346%26spage%3D219%26epage%3D228%26doi%3D10.1124%2Fjpet.113.203489" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref24"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref24'); return false;" data-citation="" class="refNumLink">24</a></strong><div class="NLM_citation" id="cit24"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Wu, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, D.</span></span> <span> </span><span class="NLM_article-title">Acalabrutinib (ACP-196): a selective second-generation BTK inhibitor</span>. <i>J. Hematol. Oncol.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>9</i></span>,  <span class="NLM_fpage">21</span>, <span class="refDoi"> DOI: 10.1186/s13045-016-0250-9</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref24/cit24&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00329&amp;key=10.1186%2Fs13045-016-0250-9" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref24/cit24&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00329&amp;key=26957112" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref24/cit24&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00329&amp;key=1%3ACAS%3A528%3ADC%252BC2sXis1eisrw%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=9&publication_year=2016&pages=21&author=J.+Wuauthor=M.+Zhangauthor=D.+Liu&title=Acalabrutinib+%28ACP-196%29%3A+a+selective+second-generation+BTK+inhibitor&doi=10.1186%2Fs13045-016-0250-9"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit24R"><div class="casContent"><span class="casTitleNuber">24</span><div class="casTitle"><span class="NLM_cas:atitle">Acalabrutinib (ACP-196): a selective second-generation BTK inhibitor</span></div><div class="casAuthors">Wu, Jingjing; Zhang, Mingzhi; Liu, Delong</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Hematology & Oncology</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">9</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">21/1-21/4</span>CODEN:
                <span class="NLM_cas:coden">JHOOAO</span>;
        ISSN:<span class="NLM_cas:issn">1756-8722</span>.
    
            (<span class="NLM_cas:orgname">BioMed Central Ltd.</span>)
        </div><div class="casAbstract">More and more targeted agents become available for B cell malignancies with increasing precision and potency.  The first-in-class Bruton's tyrosine kinase (BTK) inhibitor, ibrutinib, has been in clin. use for the treatment of chronic lymphocytic leukemia, mantle cell lymphoma, and Waldenstrom's macroglobulinemia.  More selective BTK inhibitors (ACP-196, ONO/GS-4059, BGB-3111, CC-292) are being explored.  Acalabrutinib (ACP-196) is a novel irreversible second-generation BTK inhibitor that was shown to be more potent and selective than ibrutinib.  This review summarized the preclin. research and clin. data of acalabrutinib.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpAU072sMxzmLVg90H21EOLACvtfcHk0lgq5RxUYwyRiQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXis1eisrw%253D&md5=a6a8f9b9236abe7ef1054a41e1c71e5a</span></div><a href="/servlet/linkout?suffix=cit24&amp;dbid=16384&amp;doi=10.1186%2Fs13045-016-0250-9&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1186%252Fs13045-016-0250-9%26sid%3Dliteratum%253Aachs%26aulast%3DWu%26aufirst%3DJ.%26aulast%3DZhang%26aufirst%3DM.%26aulast%3DLiu%26aufirst%3DD.%26atitle%3DAcalabrutinib%2520%2528ACP-196%2529%253A%2520a%2520selective%2520second-generation%2520BTK%2520inhibitor%26jtitle%3DJ.%2520Hematol.%2520Oncol.%26date%3D2016%26volume%3D9%26spage%3D21%26doi%3D10.1186%2Fs13045-016-0250-9" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref25"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref25'); return false;" data-citation="" class="refNumLink">25</a></strong><div class="NLM_citation" id="cit25"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Herman, S. E. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Montraveta, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Niemann, C. U.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mora-Jensen, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gulrajani, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Krantz, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mantel, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Smith, L. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">McClanahan, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Harrington, B. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Colomer, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Covey, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Byrd, J. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Izumi, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kaptein, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ulrich, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Johnson, A. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lannutti, B. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wiestner, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Woyach, J. A.</span></span> <span> </span><span class="NLM_article-title">The Bruton tyrosine kinase (BTK) inhibitor Acalabrutinib demonstrates potent on-target effects and efficacy in two mouse models of chronic lymphocytic leukemia</span>. <i>Clin. Cancer Res.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>23</i></span>,  <span class="NLM_fpage">2831</span>– <span class="NLM_lpage">2841</span>, <span class="refDoi"> DOI: 10.1158/1078-0432.ccr-16-0463</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref25/cit25&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00329&amp;key=10.1158%2F1078-0432.ccr-16-0463" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref25/cit25&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00329&amp;key=27903679" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref25/cit25&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00329&amp;key=1%3ACAS%3A528%3ADC%252BC2sXpt1Sms74%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=23&publication_year=2017&pages=2831-2841&author=S.+E.+M.+Hermanauthor=A.+Montravetaauthor=C.+U.+Niemannauthor=H.+Mora-Jensenauthor=M.+Gulrajaniauthor=F.+Krantzauthor=R.+Mantelauthor=L.+L.+Smithauthor=F.+McClanahanauthor=B.+K.+Harringtonauthor=D.+Colomerauthor=T.+Coveyauthor=J.+C.+Byrdauthor=R.+Izumiauthor=A.+Kapteinauthor=R.+Ulrichauthor=A.+J.+Johnsonauthor=B.+J.+Lannuttiauthor=A.+Wiestnerauthor=J.+A.+Woyach&title=The+Bruton+tyrosine+kinase+%28BTK%29+inhibitor+Acalabrutinib+demonstrates+potent+on-target+effects+and+efficacy+in+two+mouse+models+of+chronic+lymphocytic+leukemia&doi=10.1158%2F1078-0432.ccr-16-0463"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit25R"><div class="casContent"><span class="casTitleNuber">25</span><div class="casTitle"><span class="NLM_cas:atitle">The Bruton Tyrosine Kinase (BTK) Inhibitor Acalabrutinib Demonstrates Potent On-Target Effects and Efficacy in Two Mouse Models of Chronic Lymphocytic Leukemia</span></div><div class="casAuthors">Herman, Sarah E. M.; Montraveta, Arnau; Niemann, Carsten U.; Mora-Jensen, Helena; Gulrajani, Michael; Krantz, Fanny; Mantel, Rose; Smith, Lisa L.; McClanahan, Fabienne; Harrington, Bonnie K.; Colomer, Dolors; Covey, Todd; Byrd, John C.; Izumi, Raquel; Kaptein, Allard; Ulrich, Roger; Johnson, Amy J.; Lannutti, Brian J.; Wiestner, Adrian; Woyach, Jennifer A.</div><div class="citationInfo"><span class="NLM_cas:title">Clinical Cancer Research</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">23</span>
        (<span class="NLM_cas:issue">11</span>),
    <span class="NLM_cas:pages">2831-2841</span>CODEN:
                <span class="NLM_cas:coden">CCREF4</span>;
        ISSN:<span class="NLM_cas:issn">1078-0432</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">Purpose: Acalabrutinib (ACP-196) is a novel, potent, and highly selective Bruton tyrosine kinase (BTK) inhibitor, which binds covalently to Cys481 in the ATP-binding pocket of BTK.  We sought to evaluate the antitumor effects of acalabrutinib treatment in two established mouse models of chronic lymphocytic leukemia (CLL).  Exptl. Design: Two distinct mouse models were used, the TCL1 adoptive transfer model where leukemic cells from Eμ-TCL1 transgenic mice are transplanted into C57BL/6 mice, and the human NSG primary CLL xenograft model.  Mice received either vehicle or acalabrutinib formulated into the drinking water.  Results: Utilizing biochem. assays, we demonstrate that acalabrutinib is a highly selective BTK inhibitor as compared with ibrutinib.  In the human CLL NSG xenograft model, treatment with acalabrutinib demonstrated on-target effects, including decreased phosphorylation of PLCγ2, ERK, and significant inhibition of CLL cell proliferation.  Furthermore, tumor burden in the spleen of the mice treated with acalabrutinib was significantly decreased compared with vehicle-treated mice.  Similarly, in the TCL1 adoptive transfer model, decreased phosphorylation of BTK, PLCγ2, and S6 was obsd.  Most notably, treatment with acalabrutinib resulted in a significant increase in survival compared with mice receiving vehicle.  Conclusions: Treatment with acalabrutinib potently inhibits BTK in vivo, leading to on-target decreases in the activation of key signaling mols. (including BTK, PLCγ2, S6, and ERK).  In two complementary mouse models of CLL, acalabrutinib significantly reduced tumor burden and increased survival compared with vehicle treatment.  Overall, acalabrutinib showed increased BTK selectivity compared with ibrutinib while demonstrating significant antitumor efficacy in vivo on par with ibrutinib.  Clin Cancer Res; 23(11); 2831-41. ©2016 AACR.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoD7ESW1IqIY7Vg90H21EOLACvtfcHk0lgfHX73Dqxp7Q"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXpt1Sms74%253D&md5=a3c89f6918d1ed1195f4d439f33c17d7</span></div><a href="/servlet/linkout?suffix=cit25&amp;dbid=16384&amp;doi=10.1158%2F1078-0432.ccr-16-0463&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F1078-0432.ccr-16-0463%26sid%3Dliteratum%253Aachs%26aulast%3DHerman%26aufirst%3DS.%2BE.%2BM.%26aulast%3DMontraveta%26aufirst%3DA.%26aulast%3DNiemann%26aufirst%3DC.%2BU.%26aulast%3DMora-Jensen%26aufirst%3DH.%26aulast%3DGulrajani%26aufirst%3DM.%26aulast%3DKrantz%26aufirst%3DF.%26aulast%3DMantel%26aufirst%3DR.%26aulast%3DSmith%26aufirst%3DL.%2BL.%26aulast%3DMcClanahan%26aufirst%3DF.%26aulast%3DHarrington%26aufirst%3DB.%2BK.%26aulast%3DColomer%26aufirst%3DD.%26aulast%3DCovey%26aufirst%3DT.%26aulast%3DByrd%26aufirst%3DJ.%2BC.%26aulast%3DIzumi%26aufirst%3DR.%26aulast%3DKaptein%26aufirst%3DA.%26aulast%3DUlrich%26aufirst%3DR.%26aulast%3DJohnson%26aufirst%3DA.%2BJ.%26aulast%3DLannutti%26aufirst%3DB.%2BJ.%26aulast%3DWiestner%26aufirst%3DA.%26aulast%3DWoyach%26aufirst%3DJ.%2BA.%26atitle%3DThe%2520Bruton%2520tyrosine%2520kinase%2520%2528BTK%2529%2520inhibitor%2520Acalabrutinib%2520demonstrates%2520potent%2520on-target%2520effects%2520and%2520efficacy%2520in%2520two%2520mouse%2520models%2520of%2520chronic%2520lymphocytic%2520leukemia%26jtitle%3DClin.%2520Cancer%2520Res.%26date%3D2017%26volume%3D23%26spage%3D2831%26epage%3D2841%26doi%3D10.1158%2F1078-0432.ccr-16-0463" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref26"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref26'); return false;" data-citation="" class="refNumLink">26</a></strong><div class="NLM_citation" id="cit26"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Liu, Q.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sabnis, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhao, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Buhrlage, S. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jones, L. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gray, N. S.</span></span> <span> </span><span class="NLM_article-title">Developing irreversible inhibitors of the protein kinase cysteinome</span>. <i>Chem. Biol.</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>20</i></span>,  <span class="NLM_fpage">146</span>– <span class="NLM_lpage">159</span>, <span class="refDoi"> DOI: 10.1016/j.chembiol.2012.12.006</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref26/cit26&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00329&amp;key=10.1016%2Fj.chembiol.2012.12.006" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref26/cit26&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00329&amp;key=23438744" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref26/cit26&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00329&amp;key=1%3ACAS%3A528%3ADC%252BC3sXjtFWitbs%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=20&publication_year=2013&pages=146-159&author=Q.+Liuauthor=Y.+Sabnisauthor=Z.+Zhaoauthor=T.+Zhangauthor=S.+J.+Buhrlageauthor=L.+H.+Jonesauthor=N.+S.+Gray&title=Developing+irreversible+inhibitors+of+the+protein+kinase+cysteinome&doi=10.1016%2Fj.chembiol.2012.12.006"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit26R"><div class="casContent"><span class="casTitleNuber">26</span><div class="casTitle"><span class="NLM_cas:atitle">Developing Irreversible Inhibitors of the Protein Kinase Cysteinome</span></div><div class="casAuthors">Liu, Qingsong; Sabnis, Yogesh; Zhao, Zheng; Zhang, Tinghu; Buhrlage, Sara J.; Jones, Lyn H.; Gray, Nathanael S.</div><div class="citationInfo"><span class="NLM_cas:title">Chemistry & Biology (Oxford, United Kingdom)</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">20</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">146-159</span>CODEN:
                <span class="NLM_cas:coden">CBOLE2</span>;
        ISSN:<span class="NLM_cas:issn">1074-5521</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Ltd.</span>)
        </div><div class="casAbstract">A review.  Protein kinases are a large family of approx. 530 highly conserved enzymes that transfer a γ-phosphate group from ATP to a variety of amino acid residues, such as tyrosine, serine, and threonine, that serves as a ubiquitous mechanism for cellular signal transduction.  The clin. success of a no. of kinase-directed drugs and the frequent observation of disease causing mutations in protein kinases suggest that a large no. of kinases may represent therapeutically relevant targets.  To date, the majority of clin. and preclin. kinase inhibitors are ATP competitive, noncovalent inhibitors that achieve selectivity through recognition of unique features of particular protein kinases.  Recently, there has been renewed interest in the development of irreversible inhibitors that form covalent bonds with cysteine or other nucleophilic residues in the ATP-binding pocket.  Irreversible kinase inhibitors have a no. of potential advantages including prolonged pharmacodynamics, suitability for rational design, high potency, and ability to validate pharmacol. specificity through mutation of the reactive cysteine residue.  Here, we review recent efforts to develop cysteine-targeted irreversible protein kinase inhibitors and discuss their modes of recognizing the ATP-binding pocket and their biol. activity profiles.  In addn., we provided an informatics assessment of the potential "kinase cysteinome" and discuss strategies for the efficient development of new covalent inhibitors.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrVGD7TX3oIeLVg90H21EOLACvtfcHk0lgfHX73Dqxp7Q"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXjtFWitbs%253D&md5=cef80823123bae88362e816a0a638133</span></div><a href="/servlet/linkout?suffix=cit26&amp;dbid=16384&amp;doi=10.1016%2Fj.chembiol.2012.12.006&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.chembiol.2012.12.006%26sid%3Dliteratum%253Aachs%26aulast%3DLiu%26aufirst%3DQ.%26aulast%3DSabnis%26aufirst%3DY.%26aulast%3DZhao%26aufirst%3DZ.%26aulast%3DZhang%26aufirst%3DT.%26aulast%3DBuhrlage%26aufirst%3DS.%2BJ.%26aulast%3DJones%26aufirst%3DL.%2BH.%26aulast%3DGray%26aufirst%3DN.%2BS.%26atitle%3DDeveloping%2520irreversible%2520inhibitors%2520of%2520the%2520protein%2520kinase%2520cysteinome%26jtitle%3DChem.%2520Biol.%26date%3D2013%26volume%3D20%26spage%3D146%26epage%3D159%26doi%3D10.1016%2Fj.chembiol.2012.12.006" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref27"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref27'); return false;" data-citation="" class="refNumLink">27</a></strong><div class="NLM_citation" id="cit27"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Liu, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Di Paolo, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Barbosa, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rong, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Reif, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wong, H.</span></span> <span> </span><span class="NLM_article-title">Antiarthritis effect of a novel Bruton’s tyrosine kinase (BTK) inhibitor in rat collagen-induced arthritis and mechanism-based pharmacokinetic/pharmacodynamic modeling: relationships between inhibition of BTK phosphorylation and efficacy</span>. <i>J. Pharmacol. Exp. Ther.</i> <span class="NLM_year" style="font-weight: bold;">2011</span>,  <span class="NLM_volume"><i>338</i></span>,  <span class="NLM_fpage">154</span>– <span class="NLM_lpage">163</span>, <span class="refDoi"> DOI: 10.1124/jpet.111.181545</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref27/cit27&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00329&amp;key=10.1124%2Fjpet.111.181545" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref27/cit27&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00329&amp;key=21521773" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref27/cit27&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00329&amp;key=1%3ACAS%3A528%3ADC%252BC3MXosFCiu7w%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=338&publication_year=2011&pages=154-163&author=L.+Liuauthor=J.+Di+Paoloauthor=J.+Barbosaauthor=H.+Rongauthor=K.+Reifauthor=H.+Wong&title=Antiarthritis+effect+of+a+novel+Bruton%E2%80%99s+tyrosine+kinase+%28BTK%29+inhibitor+in+rat+collagen-induced+arthritis+and+mechanism-based+pharmacokinetic%2Fpharmacodynamic+modeling%3A+relationships+between+inhibition+of+BTK+phosphorylation+and+efficacy&doi=10.1124%2Fjpet.111.181545"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit27R"><div class="casContent"><span class="casTitleNuber">27</span><div class="casTitle"><span class="NLM_cas:atitle">Antiarthritis effect of a novel Bruton's tyrosine kinase (BTK) inhibitor in rat collagen-induced arthritis and mechanism-based pharmacokinetic/pharmacodynamic modeling: relationships between inhibition of BTK phosphorylation and efficacy</span></div><div class="casAuthors">Liu, Lichuan; Di Paolo, Julie; Barbosa, Jim; Rong, Hong; Reif, Karin; Wong, Harvey</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Pharmacology and Experimental Therapeutics</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">338</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">154-163</span>CODEN:
                <span class="NLM_cas:coden">JPETAB</span>;
        ISSN:<span class="NLM_cas:issn">0022-3565</span>.
    
            (<span class="NLM_cas:orgname">American Society for Pharmacology and Experimental Therapeutics</span>)
        </div><div class="casAbstract">Bruton's tyrosine kinase (BTK) plays a crit. role in the development, differentiation, and proliferation of B-lineage cells, making it an attractive target for the treatment of rheumatoid arthritis.  The objective of this study was to evaluate the antiarthritis effect of GDC-0834 [R-N-(3-(6-(4-(1,4-dimethyl-3-oxopiperazin-2-yl)phenylamino)-4-methyl-5-oxo-4,5-dihydropyrazin-2-yl)-2-methylphenyl)-4,5,6,7-tetrahydrobenzo[b]thiophene-2-carboxamide], a potent and selective BTK inhibitor, and characterize the relationship between inhibition of BTK phosphorylation (pBTK) and efficacy.  GDC-0834 inhibited BTK with an in vitro IC50 of 5.9 and 6.4 nM in biochem. and cellular assays, resp., and in vivo IC50 of 1.1 and 5.6 μM in mouse and rat, resp.  Administration of GDC-0834 (30-100 mg/kg) in a rat collagen-induced arthritis (CIA) model resulted in a dose-dependent decrease of ankle swelling and redn. of morphol. pathol.  An integrated disease progression pharmacokinetic/pharmacodynamic model where efficacy is driven by pBTK inhibition was fit to ankle-diam. time-course data.  This model incorporated a transit model to characterize nondrug-related decreases in ankle swelling occurring at later stages of disease progression in CIA rats.  The time course of ankle swelling in vehicle animals was described well by the base model.  Simultaneous fitting of data from vehicle- and GDC-0834-treated groups showed that overall 73% inhibition of pBTK was needed to decrease the rate const. describing the ankle swelling increase (kin) by half.  These findings suggest a high degree of pBTK inhibition is required for maximal activity of the pathway on inflammatory arthritis in rats.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpUtceutx0oDrVg90H21EOLACvtfcHk0lgfHX73Dqxp7Q"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXosFCiu7w%253D&md5=52ec6f33d9fc743036baea87a2d6bce1</span></div><a href="/servlet/linkout?suffix=cit27&amp;dbid=16384&amp;doi=10.1124%2Fjpet.111.181545&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1124%252Fjpet.111.181545%26sid%3Dliteratum%253Aachs%26aulast%3DLiu%26aufirst%3DL.%26aulast%3DDi%2BPaolo%26aufirst%3DJ.%26aulast%3DBarbosa%26aufirst%3DJ.%26aulast%3DRong%26aufirst%3DH.%26aulast%3DReif%26aufirst%3DK.%26aulast%3DWong%26aufirst%3DH.%26atitle%3DAntiarthritis%2520effect%2520of%2520a%2520novel%2520Bruton%25E2%2580%2599s%2520tyrosine%2520kinase%2520%2528BTK%2529%2520inhibitor%2520in%2520rat%2520collagen-induced%2520arthritis%2520and%2520mechanism-based%2520pharmacokinetic%252Fpharmacodynamic%2520modeling%253A%2520relationships%2520between%2520inhibition%2520of%2520BTK%2520phosphorylation%2520and%2520efficacy%26jtitle%3DJ.%2520Pharmacol.%2520Exp.%2520Ther.%26date%3D2011%26volume%3D338%26spage%3D154%26epage%3D163%26doi%3D10.1124%2Fjpet.111.181545" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref28"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref28'); return false;" data-citation="" class="refNumLink">28</a></strong><div class="NLM_citation" id="cit28"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Di
Paolo, J. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Huang, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Balazs, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Barbosa, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Barck, K. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bravo, B. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Carano, R. A. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Darrow, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Davies, D. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">DeForge, L. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Diehl, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ferrando, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gallion, S. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Giannetti, A. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gribling, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hurez, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hymowitz, S. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jones, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kropf, J. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lee, W. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Maciejewski, P. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mitchell, S. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rong, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Staker, B. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Whitney, J. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yeh, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Young, W. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yu, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Reif, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Currie, K. S.</span></span> <span> </span><span class="NLM_article-title">Specific Btk inhibition suppresses B cell- and myeloid cell-mediated arthritis</span>. <i>Nat. Chem. Biol.</i> <span class="NLM_year" style="font-weight: bold;">2011</span>,  <span class="NLM_volume"><i>7</i></span>,  <span class="NLM_fpage">41</span>– <span class="NLM_lpage">50</span>, <span class="refDoi"> DOI: 10.1038/nchembio.481</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref28/cit28&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00329&amp;key=10.1038%2Fnchembio.481" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref28/cit28&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00329&amp;key=21113169" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref28/cit28&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00329&amp;key=1%3ACAS%3A528%3ADC%252BC3cXhsVOrsLjP" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=7&publication_year=2011&pages=41-50&author=J.+A.+Di%0APaoloauthor=T.+Huangauthor=M.+Balazsauthor=J.+Barbosaauthor=K.+H.+Barckauthor=B.+J.+Bravoauthor=R.+A.+D.+Caranoauthor=J.+Darrowauthor=D.+R.+Daviesauthor=L.+E.+DeForgeauthor=L.+Diehlauthor=R.+Ferrandoauthor=S.+L.+Gallionauthor=A.+M.+Giannettiauthor=P.+Griblingauthor=V.+Hurezauthor=S.+G.+Hymowitzauthor=R.+Jonesauthor=J.+E.+Kropfauthor=W.+P.+Leeauthor=P.+M.+Maciejewskiauthor=S.+A.+Mitchellauthor=H.+Rongauthor=B.+L.+Stakerauthor=J.+A.+Whitneyauthor=S.+Yehauthor=W.+B.+Youngauthor=C.+Yuauthor=J.+Zhangauthor=K.+Reifauthor=K.+S.+Currie&title=Specific+Btk+inhibition+suppresses+B+cell-+and+myeloid+cell-mediated+arthritis&doi=10.1038%2Fnchembio.481"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit28R"><div class="casContent"><span class="casTitleNuber">28</span><div class="casTitle"><span class="NLM_cas:atitle">Specific Btk inhibition suppresses B cell- and myeloid cell-mediated arthritis</span></div><div class="casAuthors">Di Paolo, Julie A.; Huang, Tao; Balazs, Mercedesz; Barbosa, James; Barck, Kai H.; Bravo, Brandon J.; Carano, Richard A. D.; Darrow, James; Davies, Douglas R.; DeForge, Laura E.; Diehl, Lauri; Ferrando, Ronald; Gallion, Steven L.; Giannetti, Anthony M.; Gribling, Peter; Hurez, Vincent; Hymowitz, Sarah G.; Jones, Randall; Kropf, Jeffrey E.; Lee, Wyne P.; Maciejewski, Patricia M.; Mitchell, Scott A.; Rong, Hong; Staker, Bart L.; Whitney, J. Andrew; Yeh, Sherry; Young, Wendy B.; Yu, Christine; Zhang, Juan; Reif, Karin; Currie, Kevin S.</div><div class="citationInfo"><span class="NLM_cas:title">Nature Chemical Biology</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">7</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">41-50</span>CODEN:
                <span class="NLM_cas:coden">NCBABT</span>;
        ISSN:<span class="NLM_cas:issn">1552-4450</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">Bruton's tyrosine kinase (Btk) is a therapeutic target for rheumatoid arthritis, but the cellular and mol. mechanisms by which Btk mediates inflammation are poorly understood.  Here we describe the discovery of CGI1746, a small-mol. Btk inhibitor chemotype with a new binding mode that stabilizes an inactive nonphosphorylated enzyme conformation.  CGI1746 has exquisite selectivity for Btk and inhibits both auto- and transphosphorylation steps necessary for enzyme activation.  Using CGI1746, we demonstrate that Btk regulates inflammatory arthritis by two distinct mechanisms.  CGI1746 blocks B cell receptor-dependent B cell proliferation and in prophylactic regimens reduces autoantibody levels in collagen-induced arthritis.  In macrophages, Btk inhibition abolishes FcγRIII-induced TNFα, IL-1β and IL-6 prodn.  Accordingly, in myeloid- and FcγR-dependent autoantibody-induced arthritis, CGI1746 decreases cytokine levels within joints and ameliorates disease.  These results provide new understanding of the function of Btk in both B cell- or myeloid cell-driven disease processes and provide a compelling rationale for targeting Btk in rheumatoid arthritis.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoegiZYoitP57Vg90H21EOLACvtfcHk0ljc-CARMWpJHA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXhsVOrsLjP&md5=99d925c71bc1b201191ebde0f1c0b50f</span></div><a href="/servlet/linkout?suffix=cit28&amp;dbid=16384&amp;doi=10.1038%2Fnchembio.481&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnchembio.481%26sid%3Dliteratum%253Aachs%26aulast%3DDi%2BPaolo%26aufirst%3DJ.%2BA.%26aulast%3DHuang%26aufirst%3DT.%26aulast%3DBalazs%26aufirst%3DM.%26aulast%3DBarbosa%26aufirst%3DJ.%26aulast%3DBarck%26aufirst%3DK.%2BH.%26aulast%3DBravo%26aufirst%3DB.%2BJ.%26aulast%3DCarano%26aufirst%3DR.%2BA.%2BD.%26aulast%3DDarrow%26aufirst%3DJ.%26aulast%3DDavies%26aufirst%3DD.%2BR.%26aulast%3DDeForge%26aufirst%3DL.%2BE.%26aulast%3DDiehl%26aufirst%3DL.%26aulast%3DFerrando%26aufirst%3DR.%26aulast%3DGallion%26aufirst%3DS.%2BL.%26aulast%3DGiannetti%26aufirst%3DA.%2BM.%26aulast%3DGribling%26aufirst%3DP.%26aulast%3DHurez%26aufirst%3DV.%26aulast%3DHymowitz%26aufirst%3DS.%2BG.%26aulast%3DJones%26aufirst%3DR.%26aulast%3DKropf%26aufirst%3DJ.%2BE.%26aulast%3DLee%26aufirst%3DW.%2BP.%26aulast%3DMaciejewski%26aufirst%3DP.%2BM.%26aulast%3DMitchell%26aufirst%3DS.%2BA.%26aulast%3DRong%26aufirst%3DH.%26aulast%3DStaker%26aufirst%3DB.%2BL.%26aulast%3DWhitney%26aufirst%3DJ.%2BA.%26aulast%3DYeh%26aufirst%3DS.%26aulast%3DYoung%26aufirst%3DW.%2BB.%26aulast%3DYu%26aufirst%3DC.%26aulast%3DZhang%26aufirst%3DJ.%26aulast%3DReif%26aufirst%3DK.%26aulast%3DCurrie%26aufirst%3DK.%2BS.%26atitle%3DSpecific%2520Btk%2520inhibition%2520suppresses%2520B%2520cell-%2520and%2520myeloid%2520cell-mediated%2520arthritis%26jtitle%3DNat.%2520Chem.%2520Biol.%26date%3D2011%26volume%3D7%26spage%3D41%26epage%3D50%26doi%3D10.1038%2Fnchembio.481" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref29"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref29'); return false;" data-citation="" class="refNumLink">29</a></strong><div class="NLM_citation" id="cit29"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Xu, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kim, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Postelnek, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vu, M. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hu, D.-Q.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liao, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bradshaw, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hsu, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pashine, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Srinivasan, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Woods, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Levin, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">O’Mahony, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Owens, T. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lou, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hill, R. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Narula, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">DeMartino, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fine, J. S.</span></span> <span> </span><span class="NLM_article-title">RN486, a selective Bruton’s tyrosine kinase inhibitor, abrogates immune hypersensitivity responses and arthritis in rodents</span>. <i>J. Pharmacol. Exp. Ther.</i> <span class="NLM_year" style="font-weight: bold;">2012</span>,  <span class="NLM_volume"><i>341</i></span>,  <span class="NLM_fpage">90</span>– <span class="NLM_lpage">103</span>, <span class="refDoi"> DOI: 10.1124/jpet.111.187740</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref29/cit29&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00329&amp;key=10.1124%2Fjpet.111.187740" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref29/cit29&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00329&amp;key=22228807" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref29/cit29&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00329&amp;key=1%3ACAS%3A528%3ADC%252BC38XltVagt7g%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=341&publication_year=2012&pages=90-103&author=D.+Xuauthor=Y.+Kimauthor=J.+Postelnekauthor=M.+D.+Vuauthor=D.-Q.+Huauthor=C.+Liaoauthor=M.+Bradshawauthor=J.+Hsuauthor=J.+Zhangauthor=A.+Pashineauthor=D.+Srinivasanauthor=J.+Woodsauthor=A.+Levinauthor=A.+O%E2%80%99Mahonyauthor=T.+D.+Owensauthor=Y.+Louauthor=R.+J.+Hillauthor=S.+Narulaauthor=J.+DeMartinoauthor=J.+S.+Fine&title=RN486%2C+a+selective+Bruton%E2%80%99s+tyrosine+kinase+inhibitor%2C+abrogates+immune+hypersensitivity+responses+and+arthritis+in+rodents&doi=10.1124%2Fjpet.111.187740"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit29R"><div class="casContent"><span class="casTitleNuber">29</span><div class="casTitle"><span class="NLM_cas:atitle">RN486, a selective Bruton's tyrosine kinase inhibitor, abrogates immune hypersensitivity responses and arthritis in rodents</span></div><div class="casAuthors">Xu, Daigen; Kim, Yong; Postelnek, Jennifer; Vu, Minh Diem; Hu, Dong-Qing; Liao, Cheng; Bradshaw, Mike; Hsu, Jonathan; Zhang, Jun; Pashine, Achal; Srinivasan, Dinesh; Woods, John; Levin, Anita; O'Mahony, Alison; Owens, Timothy D.; Lou, Yan; Hill, Ronald J.; Narula, Satwant; DeMartino, Julie; Fine, Jay S.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Pharmacology and Experimental Therapeutics</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">341</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">90-103</span>CODEN:
                <span class="NLM_cas:coden">JPETAB</span>;
        ISSN:<span class="NLM_cas:issn">1521-0103</span>.
    
            (<span class="NLM_cas:orgname">American Society for Pharmacology and Experimental Therapeutics</span>)
        </div><div class="casAbstract">Genetic mutation and pharmacol. inhibition of Bruton's tyrosine kinase (Btk) both have been shown to prevent the development of collagen-induced arthritis (CIA) in mice, providing a rationale for the development of Btk inhibitors for treating rheumatoid arthritis (RA).  In the present study, we characterized a novel Btk inhibitor, 6-cyclopropyl-8-fluoro-2-(2-hydroxymethyl-3-{1-methyl-5-[5-(4-methyl-piperazin-1-yl)-pyridin-2-ylamino]-6-oxo-1,6-dihydro-pyridin-3-yl}-phenyl)-2H-isoquinolin-1-one (RN486), in vitro and in rodent models of immune hypersensitivity and arthritis.  We demonstrated that RN486 not only potently and selectively inhibited the Btk enzyme, but also displayed functional activities in human cell-based assays in multiple cell types, blocking Fcε receptor crosslinking-induced degranulation in mast cells (IC50 = 2.9 nM), Fcγ receptor engagement-mediated tumor necrosis factor α prodn. in monocytes (IC50 = 7.0 nM), and B cell antigen receptor-induced expression of an activation marker, CD69, in B cells in whole blood (IC50 = 21.0 nM).  RN486 displayed similar functional activities in rodent models, effectively preventing type I and type III hypersensitivity responses.  More importantly, RN486 produced robust anti-inflammatory and bone-protective effects in mouse CIA and rat adjuvant-induced arthritis (AIA) models.  In the AIA model, RN486 inhibited both joint and systemic inflammation either alone or in combination with methotrexate, reducing both paw swelling and inflammatory markers in the blood.  Together, our findings not only demonstrate that Btk plays an essential and conserved role in regulating immunoreceptor-mediated immune responses in both humans and rodents, but also provide evidence and mechanistic insights to support the development of selective Btk inhibitors as small-mol. disease-modifying drugs for RA and potentially other autoimmune diseases.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqXBTQENfl5RbVg90H21EOLACvtfcHk0ljc-CARMWpJHA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38XltVagt7g%253D&md5=06be56a47afd2eb09e0871710c1d2b47</span></div><a href="/servlet/linkout?suffix=cit29&amp;dbid=16384&amp;doi=10.1124%2Fjpet.111.187740&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1124%252Fjpet.111.187740%26sid%3Dliteratum%253Aachs%26aulast%3DXu%26aufirst%3DD.%26aulast%3DKim%26aufirst%3DY.%26aulast%3DPostelnek%26aufirst%3DJ.%26aulast%3DVu%26aufirst%3DM.%2BD.%26aulast%3DHu%26aufirst%3DD.-Q.%26aulast%3DLiao%26aufirst%3DC.%26aulast%3DBradshaw%26aufirst%3DM.%26aulast%3DHsu%26aufirst%3DJ.%26aulast%3DZhang%26aufirst%3DJ.%26aulast%3DPashine%26aufirst%3DA.%26aulast%3DSrinivasan%26aufirst%3DD.%26aulast%3DWoods%26aufirst%3DJ.%26aulast%3DLevin%26aufirst%3DA.%26aulast%3DO%25E2%2580%2599Mahony%26aufirst%3DA.%26aulast%3DOwens%26aufirst%3DT.%2BD.%26aulast%3DLou%26aufirst%3DY.%26aulast%3DHill%26aufirst%3DR.%2BJ.%26aulast%3DNarula%26aufirst%3DS.%26aulast%3DDeMartino%26aufirst%3DJ.%26aulast%3DFine%26aufirst%3DJ.%2BS.%26atitle%3DRN486%252C%2520a%2520selective%2520Bruton%25E2%2580%2599s%2520tyrosine%2520kinase%2520inhibitor%252C%2520abrogates%2520immune%2520hypersensitivity%2520responses%2520and%2520arthritis%2520in%2520rodents%26jtitle%3DJ.%2520Pharmacol.%2520Exp.%2520Ther.%26date%3D2012%26volume%3D341%26spage%3D90%26epage%3D103%26doi%3D10.1124%2Fjpet.111.187740" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref30"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref30'); return false;" data-citation="" class="refNumLink">30</a></strong><div class="NLM_citation" id="cit30"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Rankin, A. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Seth, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Keegan, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Andreyeva, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cook, T. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Edmonds, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mathialagan, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Benson, M. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Syed, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhan, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Benoit, S. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Miyashiro, J. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wood, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mohan, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Peeva, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ramaiah, S. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Messing, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Homer, B. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dunussi-Joannopoulos, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nickerson-Nutter, C. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schnute, M. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Douhan, J.</span></span> <span> </span><span class="NLM_article-title">Selective inhibition of BTK prevents murine lupus and antibody-mediated glomerulonephritis</span>. <i>J. Immunol.</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>191</i></span>,  <span class="NLM_fpage">4540</span>– <span class="NLM_lpage">4550</span>, <span class="refDoi"> DOI: 10.4049/jimmunol.1301553</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref30/cit30&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00329&amp;key=10.4049%2Fjimmunol.1301553" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref30/cit30&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00329&amp;key=24068666" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref30/cit30&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00329&amp;key=1%3ACAS%3A528%3ADC%252BC3sXhs1eqs7zE" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=191&publication_year=2013&pages=4540-4550&author=A.+L.+Rankinauthor=N.+Sethauthor=S.+Keeganauthor=T.+Andreyevaauthor=T.+A.+Cookauthor=J.+Edmondsauthor=N.+Mathialaganauthor=M.+J.+Bensonauthor=J.+Syedauthor=Y.+Zhanauthor=S.+E.+Benoitauthor=J.+S.+Miyashiroauthor=N.+Woodauthor=S.+Mohanauthor=E.+Peevaauthor=S.+K.+Ramaiahauthor=D.+Messingauthor=B.+L.+Homerauthor=K.+Dunussi-Joannopoulosauthor=C.+L.+Nickerson-Nutterauthor=M.+E.+Schnuteauthor=J.+Douhan&title=Selective+inhibition+of+BTK+prevents+murine+lupus+and+antibody-mediated+glomerulonephritis&doi=10.4049%2Fjimmunol.1301553"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit30R"><div class="casContent"><span class="casTitleNuber">30</span><div class="casTitle"><span class="NLM_cas:atitle">Selective Inhibition of BTK Prevents Murine Lupus and Antibody-Mediated Glomerulonephritis</span></div><div class="casAuthors">Rankin, Andrew L.; Seth, Nilufer; Keegan, Sean; Andreyeva, Tatyana; Cook, Tim A.; Edmonds, Jason; Mathialagan, Nagappan; Benson, Micah J.; Syed, Jameel; Zhan, Yutian; Benoit, Stephen E.; Miyashiro, Joy S.; Wood, Nancy; Mohan, Shashi; Peeva, Elena; Ramaiah, Shashi K.; Messing, Dean; Homer, Bruce L.; Dunussi-Joannopoulos, Kyri; Nickerson-Nutter, Cheryl L.; Schnute, Mark E.; Douhan, John, III</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Immunology</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">191</span>
        (<span class="NLM_cas:issue">9</span>),
    <span class="NLM_cas:pages">4540-4550</span>CODEN:
                <span class="NLM_cas:coden">JOIMA3</span>;
        ISSN:<span class="NLM_cas:issn">0022-1767</span>.
    
            (<span class="NLM_cas:orgname">American Association of Immunologists</span>)
        </div><div class="casAbstract">Autoantibody prodn. and immune complex deposition within the kidney promote renal disease in patients with lupus nephritis.  Thus, therapeutics that inhibit these pathways may be efficacious in the treatment of systemic lupus erythematosus.  Bruton's tyrosine kinase (BTK) is a crit. signaling component of both BCR and FcR signaling.  We sought to assess the efficacy of inhibiting BTK in the development of lupus-like disease, and in this article describe (R)-5-amino-1-(1-cyanopiperidin-3-yl)-3-(4-[2,4-difluorophenoxy]phenyl)-1H-pyrazole-4-carboxamide (PF-06250112), a novel highly selective and potent BTK inhibitor.  We demonstrate in vitro that PF-06250112 inhibits both BCR-mediated signaling and proliferation, as well as FcR-mediated activation.  To assess the therapeutic impact of BTK inhibition, we treated aged NZBxWF1 mice with PF-06250112 and demonstrate that PF-06250112 significantly limits the spontaneous accumulation of splenic germinal center B cells and plasma cells.  Correspondingly, anti-dsDNA and autoantibody levels were reduced in a dose-dependent manner.  Moreover, administration of PF-06250112 prevented the development of proteinuria and improved glomerular pathol. scores in all treatment groups.  Strikingly, this therapeutic effect could occur with only a modest redn. obsd. in anti-dsDNA titers, implying a crit. role for BTK signaling in disease pathogenesis beyond inhibition of autoantibody prodn.  We subsequently demonstrate that PF-06250112 prevents proteinuria in an FcR-dependent, Ab-mediated model of glomerulonephritis.  Importantly, these results highlight that BTK inhibition potently limits the development of glomerulonephritis by impacting both cell- and effector mol.-mediated pathways.  These data provide support for evaluating the efficacy of BTK inhibition in systemic lupus erythematosus patients.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpBldekay4INLVg90H21EOLACvtfcHk0lit5V1_1RHRBg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXhs1eqs7zE&md5=7abfb074bf422aa3fb63aa0bc3d8cf58</span></div><a href="/servlet/linkout?suffix=cit30&amp;dbid=16384&amp;doi=10.4049%2Fjimmunol.1301553&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.4049%252Fjimmunol.1301553%26sid%3Dliteratum%253Aachs%26aulast%3DRankin%26aufirst%3DA.%2BL.%26aulast%3DSeth%26aufirst%3DN.%26aulast%3DKeegan%26aufirst%3DS.%26aulast%3DAndreyeva%26aufirst%3DT.%26aulast%3DCook%26aufirst%3DT.%2BA.%26aulast%3DEdmonds%26aufirst%3DJ.%26aulast%3DMathialagan%26aufirst%3DN.%26aulast%3DBenson%26aufirst%3DM.%2BJ.%26aulast%3DSyed%26aufirst%3DJ.%26aulast%3DZhan%26aufirst%3DY.%26aulast%3DBenoit%26aufirst%3DS.%2BE.%26aulast%3DMiyashiro%26aufirst%3DJ.%2BS.%26aulast%3DWood%26aufirst%3DN.%26aulast%3DMohan%26aufirst%3DS.%26aulast%3DPeeva%26aufirst%3DE.%26aulast%3DRamaiah%26aufirst%3DS.%2BK.%26aulast%3DMessing%26aufirst%3DD.%26aulast%3DHomer%26aufirst%3DB.%2BL.%26aulast%3DDunussi-Joannopoulos%26aufirst%3DK.%26aulast%3DNickerson-Nutter%26aufirst%3DC.%2BL.%26aulast%3DSchnute%26aufirst%3DM.%2BE.%26aulast%3DDouhan%26aufirst%3DJ.%26atitle%3DSelective%2520inhibition%2520of%2520BTK%2520prevents%2520murine%2520lupus%2520and%2520antibody-mediated%2520glomerulonephritis%26jtitle%3DJ.%2520Immunol.%26date%3D2013%26volume%3D191%26spage%3D4540%26epage%3D4550%26doi%3D10.4049%2Fjimmunol.1301553" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref31"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref31'); return false;" data-citation="" class="refNumLink">31</a></strong><div class="NLM_citation" id="cit31"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Shi, Q.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tebben, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dyckman, A. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lin, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Spergel, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Burke, J. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">McIntyre, K. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Olini, G. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Strnad, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Surti, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Muckelbauer, J. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chang, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">An, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cheng, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ruan, Q.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Leftheris, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Carter, P. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tino, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">De Lucca, G. V.</span></span> <span> </span><span class="NLM_article-title">Purine derivatives as potent Bruton’s tyrosine kinase (BTK) inhibitors for autoimmune diseases</span>. <i>Bioorg. Med. Chem. Lett.</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>24</i></span>,  <span class="NLM_fpage">2206</span>– <span class="NLM_lpage">2211</span>, <span class="refDoi"> DOI: 10.1016/j.bmcl.2014.02.075</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref31/cit31&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00329&amp;key=10.1016%2Fj.bmcl.2014.02.075" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref31/cit31&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00329&amp;key=24685542" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref31/cit31&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00329&amp;key=1%3ACAS%3A528%3ADC%252BC2cXltFOgsL8%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=24&publication_year=2014&pages=2206-2211&author=Q.+Shiauthor=A.+Tebbenauthor=A.+J.+Dyckmanauthor=H.+Liauthor=C.+Liuauthor=J.+Linauthor=S.+Spergelauthor=J.+R.+Burkeauthor=K.+W.+McIntyreauthor=G.+C.+Oliniauthor=J.+Strnadauthor=N.+Surtiauthor=J.+K.+Muckelbauerauthor=C.+Changauthor=Y.+Anauthor=L.+Chengauthor=Q.+Ruanauthor=K.+Leftherisauthor=P.+H.+Carterauthor=J.+Tinoauthor=G.+V.+De+Lucca&title=Purine+derivatives+as+potent+Bruton%E2%80%99s+tyrosine+kinase+%28BTK%29+inhibitors+for+autoimmune+diseases&doi=10.1016%2Fj.bmcl.2014.02.075"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit31R"><div class="casContent"><span class="casTitleNuber">31</span><div class="casTitle"><span class="NLM_cas:atitle">Purine derivatives as potent Bruton's tyrosine kinase (BTK) inhibitors for autoimmune diseases</span></div><div class="casAuthors">Shi, Qing; Tebben, Andrew; Dyckman, Alaric J.; Li, Hedy; Liu, Chunjian; Lin, James; Spergel, Steve; Burke, James R.; McIntyre, Kim W.; Olini, Gilbert C.; Strnad, Joann; Surti, Neha; Muckelbauer, Jodi K.; Chang, Chiehying; An, Yongmi; Cheng, Lin; Ruan, Qian; Leftheris, Katerina; Carter, Percy H.; Tino, Joseph; De Lucca, George V.</div><div class="citationInfo"><span class="NLM_cas:title">Bioorganic & Medicinal Chemistry Letters</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">24</span>
        (<span class="NLM_cas:issue">9</span>),
    <span class="NLM_cas:pages">2206-2211</span>CODEN:
                <span class="NLM_cas:coden">BMCLE8</span>;
        ISSN:<span class="NLM_cas:issn">0960-894X</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">Investigation of various heterocyclic core isosteres of imidazopyrazines 1 & 2 yielded purine derivs. 3 & 8 as potent and selective BTK inhibitors.  Subsequent SAR studies of the purine series led to the discovery of 20 as a leading compd.  Compd. 20 is very selective when screened against a panel of 400 kinases and is a potent inhibitor in cellular assays of human B cell function including B-Cell proliferation and CD86 cell surface expression and exhibited in vivo efficacy in a mouse PCA model.  Its X-ray co-crystal structure with BTK shows that the high selectivity is gained from filling a BTK specific lipophilic pocket.  However, phys. and ADME properties leading to low oral exposure hindered further development.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGobsHsC5Hi6lbVg90H21EOLACvtfcHk0lit5V1_1RHRBg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXltFOgsL8%253D&md5=1b1649221d615d9805d5cc197a39e05a</span></div><a href="/servlet/linkout?suffix=cit31&amp;dbid=16384&amp;doi=10.1016%2Fj.bmcl.2014.02.075&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bmcl.2014.02.075%26sid%3Dliteratum%253Aachs%26aulast%3DShi%26aufirst%3DQ.%26aulast%3DTebben%26aufirst%3DA.%26aulast%3DDyckman%26aufirst%3DA.%2BJ.%26aulast%3DLi%26aufirst%3DH.%26aulast%3DLiu%26aufirst%3DC.%26aulast%3DLin%26aufirst%3DJ.%26aulast%3DSpergel%26aufirst%3DS.%26aulast%3DBurke%26aufirst%3DJ.%2BR.%26aulast%3DMcIntyre%26aufirst%3DK.%2BW.%26aulast%3DOlini%26aufirst%3DG.%2BC.%26aulast%3DStrnad%26aufirst%3DJ.%26aulast%3DSurti%26aufirst%3DN.%26aulast%3DMuckelbauer%26aufirst%3DJ.%2BK.%26aulast%3DChang%26aufirst%3DC.%26aulast%3DAn%26aufirst%3DY.%26aulast%3DCheng%26aufirst%3DL.%26aulast%3DRuan%26aufirst%3DQ.%26aulast%3DLeftheris%26aufirst%3DK.%26aulast%3DCarter%26aufirst%3DP.%2BH.%26aulast%3DTino%26aufirst%3DJ.%26aulast%3DDe%2BLucca%26aufirst%3DG.%2BV.%26atitle%3DPurine%2520derivatives%2520as%2520potent%2520Bruton%25E2%2580%2599s%2520tyrosine%2520kinase%2520%2528BTK%2529%2520inhibitors%2520for%2520autoimmune%2520diseases%26jtitle%3DBioorg.%2520Med.%2520Chem.%2520Lett.%26date%3D2014%26volume%3D24%26spage%3D2206%26epage%3D2211%26doi%3D10.1016%2Fj.bmcl.2014.02.075" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref32"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref32'); return false;" data-citation="" class="refNumLink">32</a></strong><div class="NLM_citation" id="cit32"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Lou, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Han, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kuglstatter, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kondru, R. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sweeney, Z. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Soth, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">McIntosh, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Litman, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Suh, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kocer, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Davis, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Park, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Frauchiger, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dewdney, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zecic, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Taygerly, J. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sarma, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hong, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hill, R. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gabriel, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Goldstein, D. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Owens, T. D.</span></span> <span> </span><span class="NLM_article-title">Structure-Based Drug Design of RN486, a Potent and Selective Bruton’s Tyrosine Kinase (BTK) Inhibitor, for the Treatment of Rheumatoid Arthritis</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>58</i></span>,  <span class="NLM_fpage">512</span>– <span class="NLM_lpage">516</span>, <span class="refDoi"> DOI: 10.1021/jm500305p</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm500305p" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=58&publication_year=2014&pages=512-516&author=Y.+Louauthor=X.+Hanauthor=A.+Kuglstatterauthor=R.+K.+Kondruauthor=Z.+K.+Sweeneyauthor=M.+Sothauthor=J.+McIntoshauthor=R.+Litmanauthor=J.+Suhauthor=B.+Kocerauthor=D.+Davisauthor=J.+Parkauthor=S.+Frauchigerauthor=N.+Dewdneyauthor=H.+Zecicauthor=J.+P.+Taygerlyauthor=K.+Sarmaauthor=J.+Hongauthor=R.+J.+Hillauthor=T.+Gabrielauthor=D.+M.+Goldsteinauthor=T.+D.+Owens&title=Structure-Based+Drug+Design+of+RN486%2C+a+Potent+and+Selective+Bruton%E2%80%99s+Tyrosine+Kinase+%28BTK%29+Inhibitor%2C+for+the+Treatment+of+Rheumatoid+Arthritis&doi=10.1021%2Fjm500305p"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit32&amp;dbid=16384&amp;doi=10.1021%2Fjm500305p&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm500305p%26sid%3Dliteratum%253Aachs%26aulast%3DLou%26aufirst%3DY.%26aulast%3DHan%26aufirst%3DX.%26aulast%3DKuglstatter%26aufirst%3DA.%26aulast%3DKondru%26aufirst%3DR.%2BK.%26aulast%3DSweeney%26aufirst%3DZ.%2BK.%26aulast%3DSoth%26aufirst%3DM.%26aulast%3DMcIntosh%26aufirst%3DJ.%26aulast%3DLitman%26aufirst%3DR.%26aulast%3DSuh%26aufirst%3DJ.%26aulast%3DKocer%26aufirst%3DB.%26aulast%3DDavis%26aufirst%3DD.%26aulast%3DPark%26aufirst%3DJ.%26aulast%3DFrauchiger%26aufirst%3DS.%26aulast%3DDewdney%26aufirst%3DN.%26aulast%3DZecic%26aufirst%3DH.%26aulast%3DTaygerly%26aufirst%3DJ.%2BP.%26aulast%3DSarma%26aufirst%3DK.%26aulast%3DHong%26aufirst%3DJ.%26aulast%3DHill%26aufirst%3DR.%2BJ.%26aulast%3DGabriel%26aufirst%3DT.%26aulast%3DGoldstein%26aufirst%3DD.%2BM.%26aulast%3DOwens%26aufirst%3DT.%2BD.%26atitle%3DStructure-Based%2520Drug%2520Design%2520of%2520RN486%252C%2520a%2520Potent%2520and%2520Selective%2520Bruton%25E2%2580%2599s%2520Tyrosine%2520Kinase%2520%2528BTK%2529%2520Inhibitor%252C%2520for%2520the%2520Treatment%2520of%2520Rheumatoid%2520Arthritis%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2014%26volume%3D58%26spage%3D512%26epage%3D516%26doi%3D10.1021%2Fjm500305p" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref33"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref33'); return false;" data-citation="" class="refNumLink">33</a></strong><div class="NLM_citation" id="cit33"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Liu, Q.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Batt, D. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lippy, J. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Surti, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tebben, A. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Muckelbauer, J. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">An, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chang, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pokross, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yang, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Burke, J. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Carter, P. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tino, J. A.</span></span> <span> </span><span class="NLM_article-title">Design and synthesis of carbazole carboxamides as promising inhibitors of Bruton’s tyrosine kinase (BTK) and Janus kinase 2 (JAK2)</span>. <i>Bioorg. Med. Chem. Lett.</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>25</i></span>,  <span class="NLM_fpage">4265</span>– <span class="NLM_lpage">4269</span>, <span class="refDoi"> DOI: 10.1016/j.bmcl.2015.07.102</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref33/cit33&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00329&amp;key=10.1016%2Fj.bmcl.2015.07.102" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref33/cit33&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00329&amp;key=26320619" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref33/cit33&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00329&amp;key=1%3ACAS%3A528%3ADC%252BC2MXhtlSlsLvF" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=25&publication_year=2015&pages=4265-4269&author=Q.+Liuauthor=D.+G.+Battauthor=J.+S.+Lippyauthor=N.+Surtiauthor=A.+J.+Tebbenauthor=J.+K.+Muckelbauerauthor=L.+Chenauthor=Y.+Anauthor=C.+Changauthor=M.+Pokrossauthor=Z.+Yangauthor=H.+Wangauthor=J.+R.+Burkeauthor=P.+H.+Carterauthor=J.+A.+Tino&title=Design+and+synthesis+of+carbazole+carboxamides+as+promising+inhibitors+of+Bruton%E2%80%99s+tyrosine+kinase+%28BTK%29+and+Janus+kinase+2+%28JAK2%29&doi=10.1016%2Fj.bmcl.2015.07.102"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit33R"><div class="casContent"><span class="casTitleNuber">33</span><div class="casTitle"><span class="NLM_cas:atitle">Design and synthesis of carbazole carboxamides as promising inhibitors of Bruton's tyrosine kinase (BTK) and Janus kinase 2 (JAK2)</span></div><div class="casAuthors">Liu, Qingjie; Batt, Douglas G.; Lippy, Jonathan S.; Surti, Neha; Tebben, Andrew J.; Muckelbauer, Jodi K.; Chen, Lin; An, Yongmi; Chang, Chiehying; Pokross, Matt; Yang, Zheng; Wang, Haiqing; Burke, James R.; Carter, Percy H.; Tino, Joseph A.</div><div class="citationInfo"><span class="NLM_cas:title">Bioorganic & Medicinal Chemistry Letters</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">25</span>
        (<span class="NLM_cas:issue">19</span>),
    <span class="NLM_cas:pages">4265-4269</span>CODEN:
                <span class="NLM_cas:coden">BMCLE8</span>;
        ISSN:<span class="NLM_cas:issn">0960-894X</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">Four series of disubstituted carbazole-1-carboxamides, e.g. I [R = 2-F, 3-MeO, 2-Me, etc.] were designed and synthesized as inhibitors of Bruton's tyrosine kinase.  4,7- And 4,6-Disubstituted carbazole-1-carboxamides were potent and selective inhibitors of BTK, while 3,7- and 3,6-disubstituted carbazole-1-carboxamides were potent and selective inhibitors of Janus kinase 2.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoD3SZfBfD4ZbVg90H21EOLACvtfcHk0lhZczSH7haEjg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXhtlSlsLvF&md5=3558c8ca9a9c29bb38ef98936f61200a</span></div><a href="/servlet/linkout?suffix=cit33&amp;dbid=16384&amp;doi=10.1016%2Fj.bmcl.2015.07.102&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bmcl.2015.07.102%26sid%3Dliteratum%253Aachs%26aulast%3DLiu%26aufirst%3DQ.%26aulast%3DBatt%26aufirst%3DD.%2BG.%26aulast%3DLippy%26aufirst%3DJ.%2BS.%26aulast%3DSurti%26aufirst%3DN.%26aulast%3DTebben%26aufirst%3DA.%2BJ.%26aulast%3DMuckelbauer%26aufirst%3DJ.%2BK.%26aulast%3DChen%26aufirst%3DL.%26aulast%3DAn%26aufirst%3DY.%26aulast%3DChang%26aufirst%3DC.%26aulast%3DPokross%26aufirst%3DM.%26aulast%3DYang%26aufirst%3DZ.%26aulast%3DWang%26aufirst%3DH.%26aulast%3DBurke%26aufirst%3DJ.%2BR.%26aulast%3DCarter%26aufirst%3DP.%2BH.%26aulast%3DTino%26aufirst%3DJ.%2BA.%26atitle%3DDesign%2520and%2520synthesis%2520of%2520carbazole%2520carboxamides%2520as%2520promising%2520inhibitors%2520of%2520Bruton%25E2%2580%2599s%2520tyrosine%2520kinase%2520%2528BTK%2529%2520and%2520Janus%2520kinase%25202%2520%2528JAK2%2529%26jtitle%3DBioorg.%2520Med.%2520Chem.%2520Lett.%26date%3D2015%26volume%3D25%26spage%3D4265%26epage%3D4269%26doi%3D10.1016%2Fj.bmcl.2015.07.102" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref34"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref34'); return false;" data-citation="" class="refNumLink">34</a></strong><div class="NLM_citation" id="cit34"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Zhao, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xin, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Huang, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ren, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jin, Q.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tang, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jiang, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yang, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mo, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xiang, H.</span></span> <span> </span><span class="NLM_article-title">Design, synthesis and evaluation of novel 5-phenylpyridin-2(1H)-one derivatives as potent reversible Bruton’s tyrosine kinase inhibitors</span>. <i>Bioorg. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>23</i></span>,  <span class="NLM_fpage">348</span>– <span class="NLM_lpage">364</span>, <span class="refDoi"> DOI: 10.1016/j.bmc.2014.11.006</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref34/cit34&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00329&amp;key=10.1016%2Fj.bmc.2014.11.006" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref34/cit34&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00329&amp;key=25515957" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref34/cit34&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00329&amp;key=1%3ACAS%3A528%3ADC%252BC2cXhvFWgsL3E" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=23&publication_year=2015&pages=348-364&author=X.+Zhaoauthor=M.+Xinauthor=W.+Huangauthor=Y.+Renauthor=Q.+Jinauthor=F.+Tangauthor=H.+Jiangauthor=Y.+Wangauthor=J.+Yangauthor=S.+Moauthor=H.+Xiang&title=Design%2C+synthesis+and+evaluation+of+novel+5-phenylpyridin-2%281H%29-one+derivatives+as+potent+reversible+Bruton%E2%80%99s+tyrosine+kinase+inhibitors&doi=10.1016%2Fj.bmc.2014.11.006"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit34R"><div class="casContent"><span class="casTitleNuber">34</span><div class="casTitle"><span class="NLM_cas:atitle">Design, synthesis and evaluation of novel 5-phenylpyridin-2(1H)-one derivatives as potent reversible Bruton's tyrosine kinase inhibitors</span></div><div class="casAuthors">Zhao, Xinge; Xin, Minhang; Huang, Wei; Ren, Yanliang; Jin, Qiu; Tang, Feng; Jiang, Hailong; Wang, Yazhou; Yang, Jie; Mo, Shifu; Xiang, Hua</div><div class="citationInfo"><span class="NLM_cas:title">Bioorganic & Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">23</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">348-364</span>CODEN:
                <span class="NLM_cas:coden">BMECEP</span>;
        ISSN:<span class="NLM_cas:issn">0968-0896</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">A series of novel reversible Btk inhibitors has been designed based on the structure of the recently reported preclin. drug RN486.  The synthesis and SAR of these compds. are described.  Among these derivs., compd. (I) was identified to be a potent and orally available reversible agent with satisfactory Btk enzymic and cellular inhibition in vitro, as well as favorable PK properties and inhibition of arthritis in vivo.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoW10EA7bZCLbVg90H21EOLACvtfcHk0lhZczSH7haEjg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXhvFWgsL3E&md5=6281a58160a4bc86e4eef85e3269e801</span></div><a href="/servlet/linkout?suffix=cit34&amp;dbid=16384&amp;doi=10.1016%2Fj.bmc.2014.11.006&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bmc.2014.11.006%26sid%3Dliteratum%253Aachs%26aulast%3DZhao%26aufirst%3DX.%26aulast%3DXin%26aufirst%3DM.%26aulast%3DHuang%26aufirst%3DW.%26aulast%3DRen%26aufirst%3DY.%26aulast%3DJin%26aufirst%3DQ.%26aulast%3DTang%26aufirst%3DF.%26aulast%3DJiang%26aufirst%3DH.%26aulast%3DWang%26aufirst%3DY.%26aulast%3DYang%26aufirst%3DJ.%26aulast%3DMo%26aufirst%3DS.%26aulast%3DXiang%26aufirst%3DH.%26atitle%3DDesign%252C%2520synthesis%2520and%2520evaluation%2520of%2520novel%25205-phenylpyridin-2%25281H%2529-one%2520derivatives%2520as%2520potent%2520reversible%2520Bruton%25E2%2580%2599s%2520tyrosine%2520kinase%2520inhibitors%26jtitle%3DBioorg.%2520Med.%2520Chem.%26date%3D2015%26volume%3D23%26spage%3D348%26epage%3D364%26doi%3D10.1016%2Fj.bmc.2014.11.006" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref35"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref35'); return false;" data-citation="" class="refNumLink">35</a></strong><div class="NLM_citation" id="cit35"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Smith, C. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dougan, D. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Komandla, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kanouni, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Knight, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lawson, J. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sabat, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Taylor, E. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vu, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wyrick, C.</span></span> <span> </span><span class="NLM_article-title">Fragment-Based Discovery of a Small Molecule Inhibitor of Bruton’s Tyrosine Kinase</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>58</i></span>,  <span class="NLM_fpage">5437</span>– <span class="NLM_lpage">5444</span>, <span class="refDoi"> DOI: 10.1021/acs.jmedchem.5b00734</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.jmedchem.5b00734" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref35/cit35&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00329&amp;key=1%3ACAS%3A528%3ADC%252BC2MXhtVans7rF" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=58&publication_year=2015&pages=5437-5444&author=C.+R.+Smithauthor=D.+R.+Douganauthor=M.+Komandlaauthor=T.+Kanouniauthor=B.+Knightauthor=J.+D.+Lawsonauthor=M.+Sabatauthor=E.+R.+Taylorauthor=P.+Vuauthor=C.+Wyrick&title=Fragment-Based+Discovery+of+a+Small+Molecule+Inhibitor+of+Bruton%E2%80%99s+Tyrosine+Kinase&doi=10.1021%2Facs.jmedchem.5b00734"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit35R"><div class="casContent"><span class="casTitleNuber">35</span><div class="casTitle"><span class="NLM_cas:atitle">Fragment-Based Discovery of a Small Molecule Inhibitor of Bruton's Tyrosine Kinase</span></div><div class="casAuthors">Smith, Christopher R.; Dougan, Douglas R.; Komandla, Mallareddy; Kanouni, Toufike; Knight, Beverly; Lawson, J. David; Sabat, Mark; Taylor, Ewan R.; Vu, Phong; Wyrick, Corey</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">58</span>
        (<span class="NLM_cas:issue">14</span>),
    <span class="NLM_cas:pages">5437-5444</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">The discovery and optimization of a series of 4-aminocinnoline-3-carboxamide inhibitors of Bruton's tyrosine kinase are reported.  A fragment-based screening approach incorporating x-ray cocrystallog. was used to identify a cinnoline fragment and characterize its binding mode in the ATP binding site of Btk.  Optimization of the fragment hit resulted in the identification of a lead compd. I which reduced paw swelling in a dose- and exposure-dependent fashion in a rat model of collagen-induced arthritis.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGozENTW7pHlFrVg90H21EOLACvtfcHk0lhZczSH7haEjg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXhtVans7rF&md5=d6626fabcc3e2aa6a9180dc702a5030c</span></div><a href="/servlet/linkout?suffix=cit35&amp;dbid=16384&amp;doi=10.1021%2Facs.jmedchem.5b00734&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.jmedchem.5b00734%26sid%3Dliteratum%253Aachs%26aulast%3DSmith%26aufirst%3DC.%2BR.%26aulast%3DDougan%26aufirst%3DD.%2BR.%26aulast%3DKomandla%26aufirst%3DM.%26aulast%3DKanouni%26aufirst%3DT.%26aulast%3DKnight%26aufirst%3DB.%26aulast%3DLawson%26aufirst%3DJ.%2BD.%26aulast%3DSabat%26aufirst%3DM.%26aulast%3DTaylor%26aufirst%3DE.%2BR.%26aulast%3DVu%26aufirst%3DP.%26aulast%3DWyrick%26aufirst%3DC.%26atitle%3DFragment-Based%2520Discovery%2520of%2520a%2520Small%2520Molecule%2520Inhibitor%2520of%2520Bruton%25E2%2580%2599s%2520Tyrosine%2520Kinase%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2015%26volume%3D58%26spage%3D5437%26epage%3D5444%26doi%3D10.1021%2Facs.jmedchem.5b00734" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref36"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref36'); return false;" data-citation="" class="refNumLink">36</a></strong><div class="NLM_citation" id="cit36"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Young, W. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Barbosa, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Blomgren, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bremer, M. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Crawford, J. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dambach, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gallion, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hymowitz, S. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kropf, J. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lee, S. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lubach, J. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Macaluso, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Maciejewski, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Maurer, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mitchell, S. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ortwine, D. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Di Paolo, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Reif, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Scheerens, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schmitt, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sowell, C. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wong, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xiong, J.-M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xu, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhao, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Currie, K. S.</span></span> <span> </span><span class="NLM_article-title">Potent and selective Bruton’s tyrosine kinase inhibitors: Discovery of GDC-0834</span>. <i>Bioorg. Med. Chem. Lett.</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>25</i></span>,  <span class="NLM_fpage">1333</span>– <span class="NLM_lpage">1337</span>, <span class="refDoi"> DOI: 10.1016/j.bmcl.2015.01.032</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref36/cit36&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00329&amp;key=10.1016%2Fj.bmcl.2015.01.032" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref36/cit36&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00329&amp;key=25701252" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref36/cit36&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00329&amp;key=1%3ACAS%3A528%3ADC%252BC2MXisVSit7w%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=25&publication_year=2015&pages=1333-1337&author=W.+B.+Youngauthor=J.+Barbosaauthor=P.+Blomgrenauthor=M.+C.+Bremerauthor=J.+J.+Crawfordauthor=D.+Dambachauthor=S.+Gallionauthor=S.+G.+Hymowitzauthor=J.+E.+Kropfauthor=S.+H.+Leeauthor=L.+Liuauthor=J.+W.+Lubachauthor=J.+Macalusoauthor=P.+Maciejewskiauthor=B.+Maurerauthor=S.+A.+Mitchellauthor=D.+F.+Ortwineauthor=J.+Di+Paoloauthor=K.+Reifauthor=H.+Scheerensauthor=A.+Schmittauthor=C.+G.+Sowellauthor=X.+Wangauthor=H.+Wongauthor=J.-M.+Xiongauthor=J.+Xuauthor=Z.+Zhaoauthor=K.+S.+Currie&title=Potent+and+selective+Bruton%E2%80%99s+tyrosine+kinase+inhibitors%3A+Discovery+of+GDC-0834&doi=10.1016%2Fj.bmcl.2015.01.032"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit36R"><div class="casContent"><span class="casTitleNuber">36</span><div class="casTitle"><span class="NLM_cas:atitle">Potent and selective Bruton's tyrosine kinase inhibitors: Discovery of GDC-0834</span></div><div class="casAuthors">Young, Wendy B.; Barbosa, James; Blomgren, Peter; Bremer, Meire C.; Crawford, James J.; Dambach, Donna; Gallion, Steve; Hymowitz, Sarah G.; Kropf, Jeffrey E.; Lee, Seung H.; Liu, Lichuan; Lubach, Joseph W.; Macaluso, Jen; Maciejewski, Pat; Maurer, Brigitte; Mitchell, Scott A.; Ortwine, Daniel F.; Di Paolo, Julie; Reif, Karin; Scheerens, Heleen; Schmitt, Aaron; Sowell, C. Gregory; Wang, Xiaojing; Wong, Harvey; Xiong, Jin-Ming; Xu, Jianjun; Zhao, Zhongdong; Currie, Kevin S.</div><div class="citationInfo"><span class="NLM_cas:title">Bioorganic & Medicinal Chemistry Letters</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">25</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">1333-1337</span>CODEN:
                <span class="NLM_cas:coden">BMCLE8</span>;
        ISSN:<span class="NLM_cas:issn">0960-894X</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">SAR studies focused on improving the pharmacokinetic (PK) properties of the previously reported potent and selective Btk inhibitor CGI-1746 resulted in the clin. candidate GDC-0834, which retained the potency and selectivity of CGI-1746, but with much improved PK in preclin. animal models.  Structure based design efforts drove this work as modifications to CGI-1746 were investigated at both the solvent exposed region as well as 'H3 binding pocket'.  However, in vitro metabolic evaluation of GDC-0834 revealed a non CYP-mediated metabolic process that was more prevalent in human than preclin. species (mouse, rat, dog, cyno), leading to a high-level of uncertainly in predicting human pharmacokinetics.  Due to its promising potency, selectivity, and preclin. efficacy, a single dose IND was filed and GDC-0834 was taken in to a single dose phase I trial in healthy volunteers to quickly evaluate the human pharmacokinetics.  In human, GDC-0834 was found to be highly labile at the exo-cyclic amide bond that links the tetrahydrobenzothiophene moiety to the central aniline ring, resulting in insufficient parent drug exposure.  This information informed the back-up program and discovery of improved inhibitors.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrhL04eYDiT3bVg90H21EOLACvtfcHk0ljPnJByREgxGA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXisVSit7w%253D&md5=fdebc0199c8222e093cfb9583244bce3</span></div><a href="/servlet/linkout?suffix=cit36&amp;dbid=16384&amp;doi=10.1016%2Fj.bmcl.2015.01.032&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bmcl.2015.01.032%26sid%3Dliteratum%253Aachs%26aulast%3DYoung%26aufirst%3DW.%2BB.%26aulast%3DBarbosa%26aufirst%3DJ.%26aulast%3DBlomgren%26aufirst%3DP.%26aulast%3DBremer%26aufirst%3DM.%2BC.%26aulast%3DCrawford%26aufirst%3DJ.%2BJ.%26aulast%3DDambach%26aufirst%3DD.%26aulast%3DGallion%26aufirst%3DS.%26aulast%3DHymowitz%26aufirst%3DS.%2BG.%26aulast%3DKropf%26aufirst%3DJ.%2BE.%26aulast%3DLee%26aufirst%3DS.%2BH.%26aulast%3DLiu%26aufirst%3DL.%26aulast%3DLubach%26aufirst%3DJ.%2BW.%26aulast%3DMacaluso%26aufirst%3DJ.%26aulast%3DMaciejewski%26aufirst%3DP.%26aulast%3DMaurer%26aufirst%3DB.%26aulast%3DMitchell%26aufirst%3DS.%2BA.%26aulast%3DOrtwine%26aufirst%3DD.%2BF.%26aulast%3DDi%2BPaolo%26aufirst%3DJ.%26aulast%3DReif%26aufirst%3DK.%26aulast%3DScheerens%26aufirst%3DH.%26aulast%3DSchmitt%26aufirst%3DA.%26aulast%3DSowell%26aufirst%3DC.%2BG.%26aulast%3DWang%26aufirst%3DX.%26aulast%3DWong%26aufirst%3DH.%26aulast%3DXiong%26aufirst%3DJ.-M.%26aulast%3DXu%26aufirst%3DJ.%26aulast%3DZhao%26aufirst%3DZ.%26aulast%3DCurrie%26aufirst%3DK.%2BS.%26atitle%3DPotent%2520and%2520selective%2520Bruton%25E2%2580%2599s%2520tyrosine%2520kinase%2520inhibitors%253A%2520Discovery%2520of%2520GDC-0834%26jtitle%3DBioorg.%2520Med.%2520Chem.%2520Lett.%26date%3D2015%26volume%3D25%26spage%3D1333%26epage%3D1337%26doi%3D10.1016%2Fj.bmcl.2015.01.032" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref37"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref37'); return false;" data-citation="" class="refNumLink">37</a></strong><div class="NLM_citation" id="cit37"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Liu, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Guiadeen, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Krikorian, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gao, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Boga, S. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Alhassan, A.-B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yu, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vaccaro, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yang, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wu, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cooper, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">de Man, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kaptein, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Maloney, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hornak, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gao, Y.-D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fischmann, T. O.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Raaijmakers, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vu-Pham, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Presland, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mansueto, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xu, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Leccese, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang-Hoover, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Knemeyer, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Garlisi, C. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bays, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stivers, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Brandish, P. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hicks, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kim, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kozlowski, J. A.</span></span> <span> </span><span class="NLM_article-title">Discovery of 8-amino-imidazo[1,5-<i>a</i>]pyrazines as reversible BTK inhibitors for the treatment of rheumatoid arthritis</span>. <i>ACS Med. Chem. Lett.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>7</i></span>,  <span class="NLM_fpage">198</span>– <span class="NLM_lpage">203</span>, <span class="refDoi"> DOI: 10.1021/acsmedchemlett.5b00463</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acsmedchemlett.5b00463" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref37/cit37&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00329&amp;key=1%3ACAS%3A528%3ADC%252BC2MXitVGrs7bJ" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=7&publication_year=2016&pages=198-203&author=J.+Liuauthor=D.+Guiadeenauthor=A.+Krikorianauthor=X.+Gaoauthor=J.+Wangauthor=S.+B.+Bogaauthor=A.-B.+Alhassanauthor=Y.+Yuauthor=H.+Vaccaroauthor=S.+Liuauthor=C.+Yangauthor=H.+Wuauthor=A.+Cooperauthor=J.+de+Manauthor=A.+Kapteinauthor=K.+Maloneyauthor=V.+Hornakauthor=Y.-D.+Gaoauthor=T.+O.+Fischmannauthor=H.+Raaijmakersauthor=D.+Vu-Phamauthor=J.+Preslandauthor=M.+Mansuetoauthor=Z.+Xuauthor=E.+Lecceseauthor=J.+Zhang-Hooverauthor=I.+Knemeyerauthor=C.+G.+Garlisiauthor=N.+Baysauthor=P.+Stiversauthor=P.+E.+Brandishauthor=A.+Hicksauthor=R.+Kimauthor=J.+A.+Kozlowski&title=Discovery+of+8-amino-imidazo%5B1%2C5-a%5Dpyrazines+as+reversible+BTK+inhibitors+for+the+treatment+of+rheumatoid+arthritis&doi=10.1021%2Facsmedchemlett.5b00463"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit37R"><div class="casContent"><span class="casTitleNuber">37</span><div class="casTitle"><span class="NLM_cas:atitle">Discovery of 8-Amino-imidazo[1,5-a]pyrazines as Reversible BTK Inhibitors for the Treatment of Rheumatoid Arthritis</span></div><div class="casAuthors">Liu, Jian; Guiadeen, Deodial; Krikorian, Arto; Gao, Xiaolei; Wang, James; Boga, Sobhana Babu; Alhassan, Abdul-Basit; Yu, Younong; Vaccaro, Henry; Liu, Shilan; Yang, Chundao; Wu, Hao; Cooper, Alan; de Man, Jos; Kaptein, Allard; Maloney, Kevin; Hornak, Viktor; Gao, Ying-Duo; Fischmann, Thierry O.; Raaijmakers, Hans; Vu-Pham, Diep; Presland, Jeremy; Mansueto, My; Xu, Zangwei; Leccese, Erica; Zhang-Hoover, Jie; Knemeyer, Ian; Garlisi, Charles G.; Bays, Nathan; Stivers, Peter; Brandish, Philip E.; Hicks, Alexandra; Kim, Ronald; Kozlowski, Joseph A.</div><div class="citationInfo"><span class="NLM_cas:title">ACS Medicinal Chemistry Letters</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">7</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">198-203</span>CODEN:
                <span class="NLM_cas:coden">AMCLCT</span>;
        ISSN:<span class="NLM_cas:issn">1948-5875</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Bruton's tyrosine kinase (BTK) is a Tec family kinase with a well-defined role in the B cell receptor (BCR) pathway.  It has become an attractive kinase target for selective B cell inhibition and for the treatment of B cell related diseases.  We report a series of compds. based on 8-amino-imidazo[1,5-a]pyrazine that are potent reversible BTK inhibitors with excellent kinase selectivity.  Selectivity is achieved through specific interactions of the ligand with the kinase hinge and driven by aminopyridine hydrogen bondings with Ser538 and Asp539, and by hydrophobic interaction of trifluoropyridine in the back pocket.  These interactions are evident in the X-ray crystal structure of the lead compds. 1 and 3 in the complex with the BTK enzyme.  Our lead compds. show desirable PK profiles and efficacy in the preclin. rat collagen induced arthritis model.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoDNSbzZ9EmurVg90H21EOLACvtfcHk0ljPnJByREgxGA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXitVGrs7bJ&md5=62031c18108d12d36cb7f8e3c35888b7</span></div><a href="/servlet/linkout?suffix=cit37&amp;dbid=16384&amp;doi=10.1021%2Facsmedchemlett.5b00463&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facsmedchemlett.5b00463%26sid%3Dliteratum%253Aachs%26aulast%3DLiu%26aufirst%3DJ.%26aulast%3DGuiadeen%26aufirst%3DD.%26aulast%3DKrikorian%26aufirst%3DA.%26aulast%3DGao%26aufirst%3DX.%26aulast%3DWang%26aufirst%3DJ.%26aulast%3DBoga%26aufirst%3DS.%2BB.%26aulast%3DAlhassan%26aufirst%3DA.-B.%26aulast%3DYu%26aufirst%3DY.%26aulast%3DVaccaro%26aufirst%3DH.%26aulast%3DLiu%26aufirst%3DS.%26aulast%3DYang%26aufirst%3DC.%26aulast%3DWu%26aufirst%3DH.%26aulast%3DCooper%26aufirst%3DA.%26aulast%3Dde%2BMan%26aufirst%3DJ.%26aulast%3DKaptein%26aufirst%3DA.%26aulast%3DMaloney%26aufirst%3DK.%26aulast%3DHornak%26aufirst%3DV.%26aulast%3DGao%26aufirst%3DY.-D.%26aulast%3DFischmann%26aufirst%3DT.%2BO.%26aulast%3DRaaijmakers%26aufirst%3DH.%26aulast%3DVu-Pham%26aufirst%3DD.%26aulast%3DPresland%26aufirst%3DJ.%26aulast%3DMansueto%26aufirst%3DM.%26aulast%3DXu%26aufirst%3DZ.%26aulast%3DLeccese%26aufirst%3DE.%26aulast%3DZhang-Hoover%26aufirst%3DJ.%26aulast%3DKnemeyer%26aufirst%3DI.%26aulast%3DGarlisi%26aufirst%3DC.%2BG.%26aulast%3DBays%26aufirst%3DN.%26aulast%3DStivers%26aufirst%3DP.%26aulast%3DBrandish%26aufirst%3DP.%2BE.%26aulast%3DHicks%26aufirst%3DA.%26aulast%3DKim%26aufirst%3DR.%26aulast%3DKozlowski%26aufirst%3DJ.%2BA.%26atitle%3DDiscovery%2520of%25208-amino-imidazo%255B1%252C5-a%255Dpyrazines%2520as%2520reversible%2520BTK%2520inhibitors%2520for%2520the%2520treatment%2520of%2520rheumatoid%2520arthritis%26jtitle%3DACS%2520Med.%2520Chem.%2520Lett.%26date%3D2016%26volume%3D7%26spage%3D198%26epage%3D203%26doi%3D10.1021%2Facsmedchemlett.5b00463" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref38"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref38'); return false;" data-citation="" class="refNumLink">38</a></strong><div class="NLM_citation" id="cit38"><span><span class="NLM_contrib-group"><span class="NLM_string-name">De
Lucca, G. V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shi, Q.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, Q.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Batt, D. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Beaudoin Bertrand, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rampulla, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mathur, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Discenza, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">D’Arienzo, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dai, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Obermeier, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vickery, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yang, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Marathe, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tebben, A. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Muckelbauer, J. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chang, C. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gillooly, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Taylor, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pattoli, M. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Skala, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kukral, D. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">McIntyre, K. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Salter-Cid, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fura, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Burke, J. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Barrish, J. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Carter, P. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tino, J. A.</span></span> <span> </span><span class="NLM_article-title">Small Molecule Reversible Inhibitors of Bruton’s Tyrosine Kinase (BTK): Structure-Activity Relationships Leading to the Identification of 7-(2-Hydroxypropan-2-yl)-4-[2-methyl-3-(4-oxo-3,4-dihydroquinazolin-3-yl)phenyl]-9H-carbazole-1-carboxamide (BMS-935177)</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>59</i></span>,  <span class="NLM_fpage">7915</span>– <span class="NLM_lpage">7935</span>, <span class="refDoi"> DOI: 10.1021/acs.jmedchem.6b00722</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.jmedchem.6b00722" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref38/cit38&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00329&amp;key=1%3ACAS%3A528%3ADC%252BC28XhtlCrsL3M" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=59&publication_year=2016&pages=7915-7935&author=G.+V.+De%0ALuccaauthor=Q.+Shiauthor=Q.+Liuauthor=D.+G.+Battauthor=M.+Beaudoin+Bertrandauthor=R.+Rampullaauthor=A.+Mathurauthor=L.+Discenzaauthor=C.+D%E2%80%99Arienzoauthor=J.+Daiauthor=M.+Obermeierauthor=R.+Vickeryauthor=Y.+Zhangauthor=Z.+Yangauthor=P.+Maratheauthor=A.+J.+Tebbenauthor=J.+K.+Muckelbauerauthor=C.+J.+Changauthor=H.+Zhangauthor=K.+Gilloolyauthor=T.+Taylorauthor=M.+A.+Pattoliauthor=S.+Skalaauthor=D.+W.+Kukralauthor=K.+W.+McIntyreauthor=L.+Salter-Cidauthor=A.+Furaauthor=J.+R.+Burkeauthor=J.+C.+Barrishauthor=P.+H.+Carterauthor=J.+A.+Tino&title=Small+Molecule+Reversible+Inhibitors+of+Bruton%E2%80%99s+Tyrosine+Kinase+%28BTK%29%3A+Structure-Activity+Relationships+Leading+to+the+Identification+of+7-%282-Hydroxypropan-2-yl%29-4-%5B2-methyl-3-%284-oxo-3%2C4-dihydroquinazolin-3-yl%29phenyl%5D-9H-carbazole-1-carboxamide+%28BMS-935177%29&doi=10.1021%2Facs.jmedchem.6b00722"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit38R"><div class="casContent"><span class="casTitleNuber">38</span><div class="casTitle"><span class="NLM_cas:atitle">Small Molecule Reversible Inhibitors of Bruton's Tyrosine Kinase (BTK): Structure-Activity Relationships Leading to the Identification of 7-(2-Hydroxypropan-2-yl)-4-[2-methyl-3-(4-oxo-3,4-dihydroquinazolin-3-yl)phenyl]-9H-carbazole-1-carboxamide (BMS-935177)</span></div><div class="casAuthors">De Lucca, George V.; Shi, Qing; Liu, Qingjie; Batt, Douglas G.; Beaudoin Bertrand, Myra; Rampulla, Rick; Mathur, Arvind; Discenza, Lorell; D'Arienzo, Celia; Dai, Jun; Obermeier, Mary; Vickery, Rodney; Zhang, Yingru; Yang, Zheng; Marathe, Punit; Tebben, Andrew J.; Muckelbauer, Jodi K.; Chang, ChiehYing J.; Zhang, Huiping; Gillooly, Kathleen; Taylor, Tracy; Pattoli, Mark A.; Skala, Stacey; Kukral, Daniel W.; McIntyre, Kim W.; Salter-Cid, Luisa; Fura, Aberra; Burke, James R.; Barrish, Joel C.; Carter, Percy H.; Tino, Joseph A.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">59</span>
        (<span class="NLM_cas:issue">17</span>),
    <span class="NLM_cas:pages">7915-7935</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Bruton's tyrosine kinase (BTK) belongs to the TEC family of nonreceptor tyrosine kinases and plays a crit. role in multiple cell types responsible for numerous autoimmune diseases.  This article will detail the structure-activity relationships (SARs) leading to a novel second generation series of potent and selective reversible carbazole inhibitors of BTK.  With an excellent pharmacokinetic profile as well as demonstrated in vivo activity and an acceptable safety profile, 7-(2-hydroxypropan-2-yl)-4-[2-methyl-3-(4-oxo-3,4-dihydroquinazolin-3-yl)phenyl]-9H-carbazole-1-carboxamide 6 (BMS-935177) was selected to advance into clin. development.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGo1HUwZaRn_w7Vg90H21EOLACvtfcHk0lgZXNpksPS1Cg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28XhtlCrsL3M&md5=7c7ec1a52121c541753c045c1cbf758b</span></div><a href="/servlet/linkout?suffix=cit38&amp;dbid=16384&amp;doi=10.1021%2Facs.jmedchem.6b00722&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.jmedchem.6b00722%26sid%3Dliteratum%253Aachs%26aulast%3DDe%2BLucca%26aufirst%3DG.%2BV.%26aulast%3DShi%26aufirst%3DQ.%26aulast%3DLiu%26aufirst%3DQ.%26aulast%3DBatt%26aufirst%3DD.%2BG.%26aulast%3DBeaudoin%2BBertrand%26aufirst%3DM.%26aulast%3DRampulla%26aufirst%3DR.%26aulast%3DMathur%26aufirst%3DA.%26aulast%3DDiscenza%26aufirst%3DL.%26aulast%3DD%25E2%2580%2599Arienzo%26aufirst%3DC.%26aulast%3DDai%26aufirst%3DJ.%26aulast%3DObermeier%26aufirst%3DM.%26aulast%3DVickery%26aufirst%3DR.%26aulast%3DZhang%26aufirst%3DY.%26aulast%3DYang%26aufirst%3DZ.%26aulast%3DMarathe%26aufirst%3DP.%26aulast%3DTebben%26aufirst%3DA.%2BJ.%26aulast%3DMuckelbauer%26aufirst%3DJ.%2BK.%26aulast%3DChang%26aufirst%3DC.%2BJ.%26aulast%3DZhang%26aufirst%3DH.%26aulast%3DGillooly%26aufirst%3DK.%26aulast%3DTaylor%26aufirst%3DT.%26aulast%3DPattoli%26aufirst%3DM.%2BA.%26aulast%3DSkala%26aufirst%3DS.%26aulast%3DKukral%26aufirst%3DD.%2BW.%26aulast%3DMcIntyre%26aufirst%3DK.%2BW.%26aulast%3DSalter-Cid%26aufirst%3DL.%26aulast%3DFura%26aufirst%3DA.%26aulast%3DBurke%26aufirst%3DJ.%2BR.%26aulast%3DBarrish%26aufirst%3DJ.%2BC.%26aulast%3DCarter%26aufirst%3DP.%2BH.%26aulast%3DTino%26aufirst%3DJ.%2BA.%26atitle%3DSmall%2520Molecule%2520Reversible%2520Inhibitors%2520of%2520Bruton%25E2%2580%2599s%2520Tyrosine%2520Kinase%2520%2528BTK%2529%253A%2520Structure-Activity%2520Relationships%2520Leading%2520to%2520the%2520Identification%2520of%25207-%25282-Hydroxypropan-2-yl%2529-4-%255B2-methyl-3-%25284-oxo-3%252C4-dihydroquinazolin-3-yl%2529phenyl%255D-9H-carbazole-1-carboxamide%2520%2528BMS-935177%2529%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2016%26volume%3D59%26spage%3D7915%26epage%3D7935%26doi%3D10.1021%2Facs.jmedchem.6b00722" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref39"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref39'); return false;" data-citation="" class="refNumLink">39</a></strong><div class="NLM_citation" id="cit39"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Katewa, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hackney, J. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Huang, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Suto, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ramamoorthi, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Austin, C. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bremer, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, J. Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Crawford, J. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Currie, K. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Blomgren, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">DeVoss, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">DiPaolo, J. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hau, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Johnson, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lesch, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">DeForge, L. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lin, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liimatta, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lubach, J. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">McVay, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Modrusan, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nguyen, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Poon, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lee, W. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wong, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Young, W. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Townsend, M. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Reif, K.</span></span> <span> </span><span class="NLM_article-title">Btk-specific inhibition blocks pathogenic plasma cell signatures and myeloid cell-associated damage in IFNα-driven lupus nephritis</span>. <i>JCI Insight</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>2</i></span>, <span class="NLM_elocation-id">e90111</span> <span class="refDoi"> DOI: 10.1172/jci.insight.90111</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref39/cit39&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00329&amp;key=10.1172%2Fjci.insight.90111" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref39/cit39&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00329&amp;key=28405610" title="">PubMed</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=2&publication_year=2017&author=A.+Katewaauthor=Y.+Wangauthor=J.+A.+Hackneyauthor=T.+Huangauthor=E.+Sutoauthor=N.+Ramamoorthiauthor=C.+D.+Austinauthor=M.+Bremerauthor=J.+Z.+Chenauthor=J.+J.+Crawfordauthor=K.+S.+Currieauthor=P.+Blomgrenauthor=J.+DeVossauthor=J.+A.+DiPaoloauthor=J.+Hauauthor=A.+Johnsonauthor=J.+Leschauthor=L.+E.+DeForgeauthor=Z.+Linauthor=M.+Liimattaauthor=J.+W.+Lubachauthor=S.+McVayauthor=Z.+Modrusanauthor=A.+Nguyenauthor=C.+Poonauthor=J.+Wangauthor=L.+Liuauthor=W.+P.+Leeauthor=H.+Wongauthor=W.+B.+Youngauthor=M.+J.+Townsendauthor=K.+Reif&title=Btk-specific+inhibition+blocks+pathogenic+plasma+cell+signatures+and+myeloid+cell-associated+damage+in+IFN%CE%B1-driven+lupus+nephritis&doi=10.1172%2Fjci.insight.90111"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit39&amp;dbid=16384&amp;doi=10.1172%2Fjci.insight.90111&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1172%252Fjci.insight.90111%26sid%3Dliteratum%253Aachs%26aulast%3DKatewa%26aufirst%3DA.%26aulast%3DWang%26aufirst%3DY.%26aulast%3DHackney%26aufirst%3DJ.%2BA.%26aulast%3DHuang%26aufirst%3DT.%26aulast%3DSuto%26aufirst%3DE.%26aulast%3DRamamoorthi%26aufirst%3DN.%26aulast%3DAustin%26aufirst%3DC.%2BD.%26aulast%3DBremer%26aufirst%3DM.%26aulast%3DChen%26aufirst%3DJ.%2BZ.%26aulast%3DCrawford%26aufirst%3DJ.%2BJ.%26aulast%3DCurrie%26aufirst%3DK.%2BS.%26aulast%3DBlomgren%26aufirst%3DP.%26aulast%3DDeVoss%26aufirst%3DJ.%26aulast%3DDiPaolo%26aufirst%3DJ.%2BA.%26aulast%3DHau%26aufirst%3DJ.%26aulast%3DJohnson%26aufirst%3DA.%26aulast%3DLesch%26aufirst%3DJ.%26aulast%3DDeForge%26aufirst%3DL.%2BE.%26aulast%3DLin%26aufirst%3DZ.%26aulast%3DLiimatta%26aufirst%3DM.%26aulast%3DLubach%26aufirst%3DJ.%2BW.%26aulast%3DMcVay%26aufirst%3DS.%26aulast%3DModrusan%26aufirst%3DZ.%26aulast%3DNguyen%26aufirst%3DA.%26aulast%3DPoon%26aufirst%3DC.%26aulast%3DWang%26aufirst%3DJ.%26aulast%3DLiu%26aufirst%3DL.%26aulast%3DLee%26aufirst%3DW.%2BP.%26aulast%3DWong%26aufirst%3DH.%26aulast%3DYoung%26aufirst%3DW.%2BB.%26aulast%3DTownsend%26aufirst%3DM.%2BJ.%26aulast%3DReif%26aufirst%3DK.%26atitle%3DBtk-specific%2520inhibition%2520blocks%2520pathogenic%2520plasma%2520cell%2520signatures%2520and%2520myeloid%2520cell-associated%2520damage%2520in%2520IFN%25CE%25B1-driven%2520lupus%2520nephritis%26jtitle%3DJCI%2520Insight%26date%3D2017%26volume%3D2%26doi%3D10.1172%2Fjci.insight.90111" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref40"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref40'); return false;" data-citation="" class="refNumLink">40</a></strong><div class="NLM_citation" id="cit40"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Kawahata, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Asami, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Irie, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sawa, M.</span></span> <span> </span><span class="NLM_article-title">Design and synthesis of novel pyrimidine analogs as highly selective, non-covalent BTK inhibitors</span>. <i>Bioorg. Med. Chem. Lett.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>28</i></span>,  <span class="NLM_fpage">145</span>– <span class="NLM_lpage">151</span>, <span class="refDoi"> DOI: 10.1016/j.bmcl.2017.11.037</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref40/cit40&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00329&amp;key=10.1016%2Fj.bmcl.2017.11.037" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref40/cit40&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00329&amp;key=29198867" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref40/cit40&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00329&amp;key=1%3ACAS%3A528%3ADC%252BC2sXhvFWhur7I" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=28&publication_year=2018&pages=145-151&author=W.+Kawahataauthor=T.+Asamiauthor=T.+Irieauthor=M.+Sawa&title=Design+and+synthesis+of+novel+pyrimidine+analogs+as+highly+selective%2C+non-covalent+BTK+inhibitors&doi=10.1016%2Fj.bmcl.2017.11.037"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit40R"><div class="casContent"><span class="casTitleNuber">40</span><div class="casTitle"><span class="NLM_cas:atitle">Design and synthesis of novel pyrimidine analogs as highly selective, non-covalent BTK inhibitors</span></div><div class="casAuthors">Kawahata, Wataru; Asami, Tokiko; Irie, Takayuki; Sawa, Masaaki</div><div class="citationInfo"><span class="NLM_cas:title">Bioorganic & Medicinal Chemistry Letters</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">28</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">145-151</span>CODEN:
                <span class="NLM_cas:coden">BMCLE8</span>;
        ISSN:<span class="NLM_cas:issn">0960-894X</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">BTK is a promising target for the treatment of multiple diseases such as B cell malignances, asthma, and rheumatoid arthritis.  Here, the authors report the discovery of a series of novel pyrimidine analogs as potent, highly selective, non-covalent inhibitors of BTK.  Compd. I demonstrated higher affinity to an unactivated conformation of BTK that resulted in an excellent kinase selectivity.  Compd. I showed a good oral bioavailability in mice, and significantly inhibits the PCA reaction in mice.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqpVaSuT25WJ7Vg90H21EOLACvtfcHk0lgZXNpksPS1Cg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXhvFWhur7I&md5=f77ce613ad2c95fe4d34abb41f5c5ea9</span></div><a href="/servlet/linkout?suffix=cit40&amp;dbid=16384&amp;doi=10.1016%2Fj.bmcl.2017.11.037&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bmcl.2017.11.037%26sid%3Dliteratum%253Aachs%26aulast%3DKawahata%26aufirst%3DW.%26aulast%3DAsami%26aufirst%3DT.%26aulast%3DIrie%26aufirst%3DT.%26aulast%3DSawa%26aufirst%3DM.%26atitle%3DDesign%2520and%2520synthesis%2520of%2520novel%2520pyrimidine%2520analogs%2520as%2520highly%2520selective%252C%2520non-covalent%2520BTK%2520inhibitors%26jtitle%3DBioorg.%2520Med.%2520Chem.%2520Lett.%26date%3D2018%26volume%3D28%26spage%3D145%26epage%3D151%26doi%3D10.1016%2Fj.bmcl.2017.11.037" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref41"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref41'); return false;" data-citation="" class="refNumLink">41</a></strong><div class="NLM_citation" id="cit41"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Crawford, J. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Johnson, A. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Misner, D. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Belmont, L. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Castanedo, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Choy, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Coraggio, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dong, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Eigenbrot, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Erickson, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ghilardi, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hau, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Katewa, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kohli, P. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lee, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lubach, J. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">McKenzie, B. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ortwine, D. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schutt, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tay, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wei, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Reif, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wong, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Young, W. B.</span></span> <span> </span><span class="NLM_article-title">Discovery of GDC-0853: A potent, selective, and noncovalent Bruton’s tyrosine kinase inhibitor in early clinical development</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>61</i></span>,  <span class="NLM_fpage">2227</span>– <span class="NLM_lpage">2245</span>, <span class="refDoi"> DOI: 10.1021/acs.jmedchem.7b01712</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.jmedchem.7b01712" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref41/cit41&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00329&amp;key=1%3ACAS%3A528%3ADC%252BC1cXivFCnt7c%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=61&publication_year=2018&pages=2227-2245&author=J.+J.+Crawfordauthor=A.+R.+Johnsonauthor=D.+L.+Misnerauthor=L.+D.+Belmontauthor=G.+Castanedoauthor=R.+Choyauthor=M.+Coraggioauthor=L.+Dongauthor=C.+Eigenbrotauthor=R.+Ericksonauthor=N.+Ghilardiauthor=J.+Hauauthor=A.+Katewaauthor=P.+B.+Kohliauthor=W.+Leeauthor=J.+W.+Lubachauthor=B.+S.+McKenzieauthor=D.+F.+Ortwineauthor=L.+Schuttauthor=S.+Tayauthor=B.+Weiauthor=K.+Reifauthor=L.+Liuauthor=H.+Wongauthor=W.+B.+Young&title=Discovery+of+GDC-0853%3A+A+potent%2C+selective%2C+and+noncovalent+Bruton%E2%80%99s+tyrosine+kinase+inhibitor+in+early+clinical+development&doi=10.1021%2Facs.jmedchem.7b01712"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit41R"><div class="casContent"><span class="casTitleNuber">41</span><div class="casTitle"><span class="NLM_cas:atitle">Discovery of GDC-0853: A Potent, Selective, and Noncovalent Bruton's Tyrosine Kinase Inhibitor in Early Clinical Development</span></div><div class="casAuthors">Crawford, James J.; Johnson, Adam R.; Misner, Dinah L.; Belmont, Lisa D.; Castanedo, Georgette; Choy, Regina; Coraggio, Melis; Dong, Liming; Eigenbrot, Charles; Erickson, Rebecca; Ghilardi, Nico; Hau, Jonathan; Katewa, Arna; Kohli, Pawan Bir; Lee, Wendy; Lubach, Joseph W.; McKenzie, Brent S.; Ortwine, Daniel F.; Schutt, Leah; Tay, Suzanne; Wei, BinQing; Reif, Karin; Liu, Lichuan; Wong, Harvey; Young, Wendy B.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">61</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">2227-2245</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Bruton's tyrosine kinase (Btk) is a nonreceptor cytoplasmic tyrosine kinase involved in B-cell and myeloid cell activation, downstream of B-cell and Fcγ receptors, resp.  Preclin. studies have indicated that inhibition of Btk activity might offer a potential therapy in autoimmune diseases such as rheumatoid arthritis and systemic lupus erythematosus.  Here we disclose the discovery and preclin. characterization of a potent, selective, and noncovalent Btk inhibitor currently in clin. development.  GDC-0853 (29) suppresses B cell- and myeloid cell-mediated components of disease and demonstrates dose-dependent activity in an in vivo rat model of inflammatory arthritis.  It demonstrates highly favorable safety, pharmacokinetic (PK), and pharmacodynamic (PD) profiles in preclin. and Phase 2 studies ongoing in patients with rheumatoid arthritis, lupus, and chronic spontaneous urticaria.  On the basis of its potency, selectivity, long target residence time, and noncovalent mode of inhibition, 29 has the potential to be a best-in-class Btk inhibitor for a wide range of immunol. indications.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqOUJgTOFJ-o7Vg90H21EOLACvtfcHk0lhKzp0qIR_Cvw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXivFCnt7c%253D&md5=eddbd31f387fe86827a7469e8be45430</span></div><a href="/servlet/linkout?suffix=cit41&amp;dbid=16384&amp;doi=10.1021%2Facs.jmedchem.7b01712&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.jmedchem.7b01712%26sid%3Dliteratum%253Aachs%26aulast%3DCrawford%26aufirst%3DJ.%2BJ.%26aulast%3DJohnson%26aufirst%3DA.%2BR.%26aulast%3DMisner%26aufirst%3DD.%2BL.%26aulast%3DBelmont%26aufirst%3DL.%2BD.%26aulast%3DCastanedo%26aufirst%3DG.%26aulast%3DChoy%26aufirst%3DR.%26aulast%3DCoraggio%26aufirst%3DM.%26aulast%3DDong%26aufirst%3DL.%26aulast%3DEigenbrot%26aufirst%3DC.%26aulast%3DErickson%26aufirst%3DR.%26aulast%3DGhilardi%26aufirst%3DN.%26aulast%3DHau%26aufirst%3DJ.%26aulast%3DKatewa%26aufirst%3DA.%26aulast%3DKohli%26aufirst%3DP.%2BB.%26aulast%3DLee%26aufirst%3DW.%26aulast%3DLubach%26aufirst%3DJ.%2BW.%26aulast%3DMcKenzie%26aufirst%3DB.%2BS.%26aulast%3DOrtwine%26aufirst%3DD.%2BF.%26aulast%3DSchutt%26aufirst%3DL.%26aulast%3DTay%26aufirst%3DS.%26aulast%3DWei%26aufirst%3DB.%26aulast%3DReif%26aufirst%3DK.%26aulast%3DLiu%26aufirst%3DL.%26aulast%3DWong%26aufirst%3DH.%26aulast%3DYoung%26aufirst%3DW.%2BB.%26atitle%3DDiscovery%2520of%2520GDC-0853%253A%2520A%2520potent%252C%2520selective%252C%2520and%2520noncovalent%2520Bruton%25E2%2580%2599s%2520tyrosine%2520kinase%2520inhibitor%2520in%2520early%2520clinical%2520development%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2018%26volume%3D61%26spage%3D2227%26epage%3D2245%26doi%3D10.1021%2Facs.jmedchem.7b01712" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref42"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref42'); return false;" data-citation="" class="refNumLink">42</a></strong><div class="NLM_citation" id="cit42"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Liu, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Halladay, J. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shin, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wong, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Coraggio, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">La, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Baumgardner, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Le, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gopaul, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Boggs, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kuebler, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Davis, J. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liao, X. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lubach, J. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Deese, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sowell, C. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Currie, K. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Young, W. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Khojasteh, S. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hop, C. E. C. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wong, H.</span></span> <span> </span><span class="NLM_article-title">Significant species difference in amide hydrolysis of GDC-0834, a novel potent and selective Bruton’s tyrosine kinase inhibitor</span>. <i>Drug Metab. Dispos.</i> <span class="NLM_year" style="font-weight: bold;">2011</span>,  <span class="NLM_volume"><i>39</i></span>,  <span class="NLM_fpage">1840</span>– <span class="NLM_lpage">1849</span>, <span class="refDoi"> DOI: 10.1124/dmd.111.040840</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref42/cit42&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00329&amp;key=10.1124%2Fdmd.111.040840" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref42/cit42&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00329&amp;key=21742900" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref42/cit42&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00329&amp;key=1%3ACAS%3A528%3ADC%252BC3MXhs1ekurnE" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=39&publication_year=2011&pages=1840-1849&author=L.+Liuauthor=J.+S.+Halladayauthor=Y.+Shinauthor=S.+Wongauthor=M.+Coraggioauthor=H.+Laauthor=M.+Baumgardnerauthor=H.+Leauthor=S.+Gopaulauthor=J.+Boggsauthor=P.+Kueblerauthor=J.+C.+Davisauthor=X.+C.+Liaoauthor=J.+W.+Lubachauthor=A.+Deeseauthor=C.+G.+Sowellauthor=K.+S.+Currieauthor=W.+B.+Youngauthor=S.+C.+Khojastehauthor=C.+E.+C.+A.+Hopauthor=H.+Wong&title=Significant+species+difference+in+amide+hydrolysis+of+GDC-0834%2C+a+novel+potent+and+selective+Bruton%E2%80%99s+tyrosine+kinase+inhibitor&doi=10.1124%2Fdmd.111.040840"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit42R"><div class="casContent"><span class="casTitleNuber">42</span><div class="casTitle"><span class="NLM_cas:atitle">Significant species difference in amide hydrolysis of GDC-0834, a novel potent and selective Bruton's tyrosine kinase inhibitor</span></div><div class="casAuthors">Liu, Lichuan; Halladay, Jason S.; Shin, Young; Wong, Susan; Coraggio, Melis; La, Hank; Baumgardner, Matthew; Le, Hoa; Gopaul, Sashi; Boggs, Jason; Kuebler, Peter; Davis, John C., Jr.; Liao, X. Charlene; Lubach, Joseph W.; Deese, Alan; Sowell, C. Gregory; Currie, Kevin S.; Young, Wendy B.; Khojasteh, S. Cyrus; Hop, Cornelis E. C. A.; Wong, Harvey</div><div class="citationInfo"><span class="NLM_cas:title">Drug Metabolism and Disposition</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">39</span>
        (<span class="NLM_cas:issue">10</span>),
    <span class="NLM_cas:pages">1840-1849</span>CODEN:
                <span class="NLM_cas:coden">DMDSAI</span>;
        ISSN:<span class="NLM_cas:issn">0090-9556</span>.
    
            (<span class="NLM_cas:orgname">American Society for Pharmacology and Experimental Therapeutics</span>)
        </div><div class="casAbstract">(R)-N-(3-(6-(4-(1,4-Dimethyl-3-oxopiperazin-2-yl)phenylamino)-4-methyl-5-oxo-4,5-dihydropyrazin-2-yl)-2-methylphenyl)-4,5,6,7-tetrahydrobenzo[b]thiophene-2-carboxamide (GDC-0834) is a potent and selective inhibitor of Bruton's tyrosine kinase (BTK), investigated as a potential treatment for rheumatoid arthritis.  In vitro metabolite identification studies in hepatocytes revealed predominant formation of an inactive metabolite (M1) via amide hydrolysis in human.  The formation of M1 appeared to be NADPH-independent in human liver microsomes.  M1 was found in only minor to moderate quantities in plasma from preclin. species dosed with GDC-0834.  Human clearance predictions using various methodologies resulted in ests. ranging from low to high.  In addn., GDC-0834 exhibited low clearance in PXB chimeric mice with humanized liver.  Uncertainty in human pharmacokinetic prediction and high interest in a BTK inhibitor for clin. evaluation prompted an investigational new drug strategy, in which GDC-0834 was rapidly advanced to a single-dose human clin. trial.  GDC-0834 plasma concns. in humans were below the limit of quantitation (<1 ng/mL) in most samples from the cohorts dosed orally at 35 and 105 mg.  In contrast, substantial plasma concns. of M1 were obsd.  In human plasma and urine, only M1 and its sequential metabolites were identified.  The formation kinetics of M1 was evaluated in rat, dog, monkey, and human liver microsomes in the absence of NADPH.  The max. rate of M1 formation (Vmax) was substantially higher in human compared with that in other species.  In contrast, the Michaelis-Menten const. (Km) was comparable among species.  Intrinsic clearance (Vmax/Km) of GDC-0834 from M1 formation in human was 23- to 169-fold higher than obsd. in rat, dog, and monkey.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGo_v1aPr50jkLVg90H21EOLACvtfcHk0lhKzp0qIR_Cvw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXhs1ekurnE&md5=976adc37c4d621924276d174318a1a84</span></div><a href="/servlet/linkout?suffix=cit42&amp;dbid=16384&amp;doi=10.1124%2Fdmd.111.040840&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1124%252Fdmd.111.040840%26sid%3Dliteratum%253Aachs%26aulast%3DLiu%26aufirst%3DL.%26aulast%3DHalladay%26aufirst%3DJ.%2BS.%26aulast%3DShin%26aufirst%3DY.%26aulast%3DWong%26aufirst%3DS.%26aulast%3DCoraggio%26aufirst%3DM.%26aulast%3DLa%26aufirst%3DH.%26aulast%3DBaumgardner%26aufirst%3DM.%26aulast%3DLe%26aufirst%3DH.%26aulast%3DGopaul%26aufirst%3DS.%26aulast%3DBoggs%26aufirst%3DJ.%26aulast%3DKuebler%26aufirst%3DP.%26aulast%3DDavis%26aufirst%3DJ.%2BC.%26aulast%3DLiao%26aufirst%3DX.%2BC.%26aulast%3DLubach%26aufirst%3DJ.%2BW.%26aulast%3DDeese%26aufirst%3DA.%26aulast%3DSowell%26aufirst%3DC.%2BG.%26aulast%3DCurrie%26aufirst%3DK.%2BS.%26aulast%3DYoung%26aufirst%3DW.%2BB.%26aulast%3DKhojasteh%26aufirst%3DS.%2BC.%26aulast%3DHop%26aufirst%3DC.%2BE.%2BC.%2BA.%26aulast%3DWong%26aufirst%3DH.%26atitle%3DSignificant%2520species%2520difference%2520in%2520amide%2520hydrolysis%2520of%2520GDC-0834%252C%2520a%2520novel%2520potent%2520and%2520selective%2520Bruton%25E2%2580%2599s%2520tyrosine%2520kinase%2520inhibitor%26jtitle%3DDrug%2520Metab.%2520Dispos.%26date%3D2011%26volume%3D39%26spage%3D1840%26epage%3D1849%26doi%3D10.1124%2Fdmd.111.040840" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref43"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref43'); return false;" data-citation="" class="refNumLink">43</a></strong><div class="NLM_citation" id="cit43"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Wu, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Huang, Q.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Qi, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liang, Q.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dong, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yu, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hu, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Deng, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gray, N. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wei, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, Q.</span></span> <span> </span><span class="NLM_article-title">Irreversible inhibition of BTK kinase by a novel highly selective inhibitor CHMFL-BTK-11 suppresses inflammatory response in rheumatoid arthritis model</span>. <i>Sci. Rep.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>7</i></span>,  <span class="NLM_fpage">466</span>, <span class="refDoi"> DOI: 10.1038/s41598-017-00482-4</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref43/cit43&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00329&amp;key=10.1038%2Fs41598-017-00482-4" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref43/cit43&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00329&amp;key=28352114" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref43/cit43&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00329&amp;key=1%3ACAS%3A280%3ADC%252BC1cvitFSitQ%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=7&publication_year=2017&pages=466&author=H.+Wuauthor=Q.+Huangauthor=Z.+Qiauthor=Y.+Chenauthor=A.+Wangauthor=C.+Chenauthor=Q.+Liangauthor=J.+Wangauthor=W.+Chenauthor=J.+Dongauthor=K.+Yuauthor=C.+Huauthor=W.+Wangauthor=X.+Liuauthor=Y.+Dengauthor=L.+Wangauthor=B.+Wangauthor=X.+Liauthor=N.+S.+Grayauthor=J.+Liuauthor=W.+Weiauthor=Q.+Liu&title=Irreversible+inhibition+of+BTK+kinase+by+a+novel+highly+selective+inhibitor+CHMFL-BTK-11+suppresses+inflammatory+response+in+rheumatoid+arthritis+model&doi=10.1038%2Fs41598-017-00482-4"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit43R"><div class="casContent"><span class="casTitleNuber">43</span><div class="casTitle"><span class="NLM_cas:atitle">Irreversible inhibition of BTK kinase by a novel highly selective inhibitor CHMFL-BTK-11 suppresses inflammatory response in rheumatoid arthritis model</span></div><div class="casAuthors">Wu Hong; Qi Ziping; Chen Yongfei; Wang Aoli; Chen Cheng; Liang Qianmao; Yu Kailin; Hu Chen; Wang Wenchao; Liu Xiaochuan; Deng Yuanxin; Wang Li; Wang Beilei; Liu Jing; Liu Qingsong; Wu Hong; Wang Aoli; Yu Kailin; Hu Chen; Wang Li; Wang Beilei; Liu Qingsong; Huang Qiong; Chen Wensheng; Dong Jin; Wei Wei; Liang Qianmao; Liu Xiaochuan; Wang Jinghua; Gray Nathanael S; Li Xiaoxiang</div><div class="citationInfo"><span class="NLM_cas:title">Scientific reports</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">7</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">466</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">BTK plays a critical role in the B cell receptor mediated inflammatory signaling in the rheumatoid arthritis (RA).  Through a rational design approach we discovered a highly selective and potent BTK kinase inhibitor (CHMFL-BTK-11) which exerted its inhibitory efficacy through a covalent bond with BTK Cys481.  CHMFL-BTK-11 potently blocked the anti-IgM stimulated BCR signaling in the Ramos cell lines and isolated human primary B cells.  It significantly inhibited the LPS stimulated TNF-α production in the human PBMC cells but only weakly affecting the normal PBMC cell proliferation.  In the adjuvant-induced arthritis rat model, CHMFL-BTK-11 ameliorated the inflammatory response through blockage of proliferation of activated B cells, inhibition of the secretion of the inflammatory factors such as IgG1, IgG2, IgM, IL-6 and PMΦ phagocytosis, stimulation of secretion of IL-10.  The high specificity of CHMFL-BTK-11 makes it a useful pharmacological tool to further detect BTK mediated signaling in the pathology of RA.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcRDP66FiFmnMFQKX3ooHxWjfW6udTcc2ebI3FC-Sq6l9bntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC1cvitFSitQ%253D%253D&md5=20590a8506a9f4be4b5c0ba739a000b2</span></div><a href="/servlet/linkout?suffix=cit43&amp;dbid=16384&amp;doi=10.1038%2Fs41598-017-00482-4&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fs41598-017-00482-4%26sid%3Dliteratum%253Aachs%26aulast%3DWu%26aufirst%3DH.%26aulast%3DHuang%26aufirst%3DQ.%26aulast%3DQi%26aufirst%3DZ.%26aulast%3DChen%26aufirst%3DY.%26aulast%3DWang%26aufirst%3DA.%26aulast%3DChen%26aufirst%3DC.%26aulast%3DLiang%26aufirst%3DQ.%26aulast%3DWang%26aufirst%3DJ.%26aulast%3DChen%26aufirst%3DW.%26aulast%3DDong%26aufirst%3DJ.%26aulast%3DYu%26aufirst%3DK.%26aulast%3DHu%26aufirst%3DC.%26aulast%3DWang%26aufirst%3DW.%26aulast%3DLiu%26aufirst%3DX.%26aulast%3DDeng%26aufirst%3DY.%26aulast%3DWang%26aufirst%3DL.%26aulast%3DWang%26aufirst%3DB.%26aulast%3DLi%26aufirst%3DX.%26aulast%3DGray%26aufirst%3DN.%2BS.%26aulast%3DLiu%26aufirst%3DJ.%26aulast%3DWei%26aufirst%3DW.%26aulast%3DLiu%26aufirst%3DQ.%26atitle%3DIrreversible%2520inhibition%2520of%2520BTK%2520kinase%2520by%2520a%2520novel%2520highly%2520selective%2520inhibitor%2520CHMFL-BTK-11%2520suppresses%2520inflammatory%2520response%2520in%2520rheumatoid%2520arthritis%2520model%26jtitle%3DSci.%2520Rep.%26date%3D2017%26volume%3D7%26spage%3D466%26doi%3D10.1038%2Fs41598-017-00482-4" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref44"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref44'); return false;" data-citation="" class="refNumLink">44</a></strong><div class="NLM_citation" id="cit44"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Bradshaw, J. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">McFarland, J. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Paavilainen, V. O.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bisconte, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tam, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Phan, V. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Romanov, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Finkle, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shu, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Patel, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ton, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Loughhead, D. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nunn, P. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Karr, D. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gerritsen, M. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Funk, J. O.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Owens, T. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Verner, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Brameld, K. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hill, R. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Goldstein, D. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Taunton, J.</span></span> <span> </span><span class="NLM_article-title">Prolonged and tunable residence time using reversible covalent kinase inhibitors</span>. <i>Nat. Chem. Biol.</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>11</i></span>,  <span class="NLM_fpage">525</span>– <span class="NLM_lpage">531</span>, <span class="refDoi"> DOI: 10.1038/nchembio.1817</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref44/cit44&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00329&amp;key=10.1038%2Fnchembio.1817" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref44/cit44&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00329&amp;key=26006010" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref44/cit44&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00329&amp;key=1%3ACAS%3A528%3ADC%252BC2MXhtFeju7%252FE" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=11&publication_year=2015&pages=525-531&author=J.+M.+Bradshawauthor=J.+M.+McFarlandauthor=V.+O.+Paavilainenauthor=A.+Bisconteauthor=D.+Tamauthor=V.+T.+Phanauthor=S.+Romanovauthor=D.+Finkleauthor=J.+Shuauthor=V.+Patelauthor=T.+Tonauthor=X.+Liauthor=D.+G.+Loughheadauthor=P.+A.+Nunnauthor=D.+E.+Karrauthor=M.+E.+Gerritsenauthor=J.+O.+Funkauthor=T.+D.+Owensauthor=E.+Vernerauthor=K.+A.+Brameldauthor=R.+J.+Hillauthor=D.+M.+Goldsteinauthor=J.+Taunton&title=Prolonged+and+tunable+residence+time+using+reversible+covalent+kinase+inhibitors&doi=10.1038%2Fnchembio.1817"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit44R"><div class="casContent"><span class="casTitleNuber">44</span><div class="casTitle"><span class="NLM_cas:atitle">Prolonged and tunable residence time using reversible covalent kinase inhibitors</span></div><div class="casAuthors">Bradshaw, J. Michael; McFarland, Jesse M.; Paavilainen, Ville O.; Bisconte, Angelina; Tam, Danny; Phan, Vernon T.; Romanov, Sergei; Finkle, David; Shu, Jin; Patel, Vaishali; Ton, Tony; Li, Xiaoyan; Loughhead, David G.; Nunn, Philip A.; Karr, Dane E.; Gerritsen, Mary E.; Funk, Jens Oliver; Owens, Timothy D.; Verner, Erik; Brameld, Ken A.; Hill, Ronald J.; Goldstein, David M.; Taunton, Jack</div><div class="citationInfo"><span class="NLM_cas:title">Nature Chemical Biology</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">11</span>
        (<span class="NLM_cas:issue">7</span>),
    <span class="NLM_cas:pages">525-531</span>CODEN:
                <span class="NLM_cas:coden">NCBABT</span>;
        ISSN:<span class="NLM_cas:issn">1552-4450</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">Drugs with prolonged on-target residence times often show superior efficacy, yet general strategies for optimizing drug-target residence time are lacking.  Here the authors made progress toward this elusive goal by targeting a noncatalytic cysteine in Bruton's tyrosine kinase (BTK) with reversible covalent inhibitors.  Using an inverted orientation of the cysteine-reactive cyanoacrylamide electrophile, the authors identified potent and selective BTK inhibitors that demonstrated biochem. residence times spanning from minutes to 7 d.  An inverted cyanoacrylamide with prolonged residence time in vivo remained bound to BTK for more than 18 h after clearance from the circulation.  The inverted cyanoacrylamide strategy was further used to discover fibroblast growth factor receptor (FGFR) kinase inhibitors with residence times of several days, demonstrating the generalizability of the approach.  Targeting of noncatalytic cysteines with inverted cyanoacrylamides may serve as a broadly applicable platform that facilitates 'residence time by design', the ability to modulate and improve the duration of target engagement in vivo.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrXCpNprhn6kLVg90H21EOLACvtfcHk0ljm8WK0vmjksA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXhtFeju7%252FE&md5=85a73d9ecd62695d03166f7009c68dd8</span></div><a href="/servlet/linkout?suffix=cit44&amp;dbid=16384&amp;doi=10.1038%2Fnchembio.1817&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnchembio.1817%26sid%3Dliteratum%253Aachs%26aulast%3DBradshaw%26aufirst%3DJ.%2BM.%26aulast%3DMcFarland%26aufirst%3DJ.%2BM.%26aulast%3DPaavilainen%26aufirst%3DV.%2BO.%26aulast%3DBisconte%26aufirst%3DA.%26aulast%3DTam%26aufirst%3DD.%26aulast%3DPhan%26aufirst%3DV.%2BT.%26aulast%3DRomanov%26aufirst%3DS.%26aulast%3DFinkle%26aufirst%3DD.%26aulast%3DShu%26aufirst%3DJ.%26aulast%3DPatel%26aufirst%3DV.%26aulast%3DTon%26aufirst%3DT.%26aulast%3DLi%26aufirst%3DX.%26aulast%3DLoughhead%26aufirst%3DD.%2BG.%26aulast%3DNunn%26aufirst%3DP.%2BA.%26aulast%3DKarr%26aufirst%3DD.%2BE.%26aulast%3DGerritsen%26aufirst%3DM.%2BE.%26aulast%3DFunk%26aufirst%3DJ.%2BO.%26aulast%3DOwens%26aufirst%3DT.%2BD.%26aulast%3DVerner%26aufirst%3DE.%26aulast%3DBrameld%26aufirst%3DK.%2BA.%26aulast%3DHill%26aufirst%3DR.%2BJ.%26aulast%3DGoldstein%26aufirst%3DD.%2BM.%26aulast%3DTaunton%26aufirst%3DJ.%26atitle%3DProlonged%2520and%2520tunable%2520residence%2520time%2520using%2520reversible%2520covalent%2520kinase%2520inhibitors%26jtitle%3DNat.%2520Chem.%2520Biol.%26date%3D2015%26volume%3D11%26spage%3D525%26epage%3D531%26doi%3D10.1038%2Fnchembio.1817" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref45"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref45'); return false;" data-citation="" class="refNumLink">45</a></strong><div class="NLM_citation" id="cit45"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Reiff, S. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Muhowski, E. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Guinn, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lehman, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fabian, C. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cheney, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mantel, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Smith, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Johnson, A. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Young, W. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Johnson, A. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Byrd, J. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Woyach, J. A.</span></span> <span> </span><span class="NLM_article-title">Noncovalent inhibition of C481S Bruton tyrosine kinase by GDC-0853: a new treatment strategy for ibrutinib-resistant CLL</span>. <i>Blood</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>132</i></span>,  <span class="NLM_fpage">1039</span>– <span class="NLM_lpage">1049</span>, <span class="refDoi"> DOI: 10.1182/blood-2017-10-809020</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref45/cit45&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00329&amp;key=10.1182%2Fblood-2017-10-809020" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref45/cit45&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00329&amp;key=30018078" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref45/cit45&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00329&amp;key=1%3ACAS%3A528%3ADC%252BC1cXitVegtrnL" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=132&publication_year=2018&pages=1039-1049&author=S.+D.+Reiffauthor=E.+M.+Muhowskiauthor=D.+Guinnauthor=A.+Lehmanauthor=C.+A.+Fabianauthor=C.+Cheneyauthor=R.+Mantelauthor=L.+Smithauthor=A.+J.+Johnsonauthor=W.+B.+Youngauthor=A.+R.+Johnsonauthor=L.+Liuauthor=J.+C.+Byrdauthor=J.+A.+Woyach&title=Noncovalent+inhibition+of+C481S+Bruton+tyrosine+kinase+by+GDC-0853%3A+a+new+treatment+strategy+for+ibrutinib-resistant+CLL&doi=10.1182%2Fblood-2017-10-809020"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit45R"><div class="casContent"><span class="casTitleNuber">45</span><div class="casTitle"><span class="NLM_cas:atitle">Noncovalent inhibition of C481S Bruton tyrosinekinase by GDC-0853: A new treatment strategy foribrutinib-resistant CLL</span></div><div class="casAuthors">Reiff, Sean D.; Muhowski, Elizabeth M.; Guinn, Daphne; Lehman, Amy; Fabian, Catherine A.; Cheney, Carolyn; Mantel, Rose; Smith, Lisa; Johnson, Amy J.; Young, Wendy B.; Johnson, Adam R.; Liu, Lichuan; Byrd, John C.; Woyach, Jennifer A.</div><div class="citationInfo"><span class="NLM_cas:title">Blood</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">132</span>
        (<span class="NLM_cas:issue">10</span>),
    <span class="NLM_cas:pages">1039-1049</span>CODEN:
                <span class="NLM_cas:coden">BLOOAW</span>;
        ISSN:<span class="NLM_cas:issn">1528-0020</span>.
    
            (<span class="NLM_cas:orgname">American Society of Hematology</span>)
        </div><div class="casAbstract">The clin. success of ibrutinib validates Bruton tyrosine kinase (BTK) inhibition as aneffective strategy for treating hematol. malignancies, including chronic lymphocyticleukemia (CLL).  Despite ibrutinib's ability to produce durable remissions in patients, acquiredresistance can develop, mostly commonly by mutation of C481 of BTK in theibrutinib binding site.  Here, we characterize a novel BTK inhibitor, GDC-0853, to evaluateits preclin. efficacy in ibrutinib-naive and ibrutinib-resistant CLL.  GDC-0853 is uniqueamong reported BTK inhibitors in that it does not rely upon covalent reaction with C481 tostabilize its occupancy within BTK's ATP binding site.  As with ibrutinib,GDC-0853 potently reduces B-cell receptor signaling, viability, NF-κB-dependent transcription,activation, and migration in treatment na.ovrddot.ive CLL cells.  We found that GDC-0853also inhibits the most commonly reported ibrutinib-resistant BTK mutant (C481S) both in abiochem. enzyme activity assay and in a stably transfected 293T cell line and maintainscytotoxicity against patient CLL cells harboring C481S BTK mutations.  Addnl., GDC-0853 does not inhibit endothelial growth factor receptor or ITK, 2 alternative targets ofibrutinib that are likely responsible for some adverse events and may reduce the efficacy of ibrutinib-antibodycombinations, resp.  Our results using GDC-0853 indicate that noncovalent, selective BTK inhibition may beeffective in CLL either as monotherapy or in combination with therapeutic antibodies, esp. among the emergingpopulation of patients with acquired resistance to ibrutinib therapy.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpLuDzLD7FMb7Vg90H21EOLACvtfcHk0li1OWFnCqJezg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXitVegtrnL&md5=f867a4ef8469fb2db96eb45c481a7b76</span></div><a href="/servlet/linkout?suffix=cit45&amp;dbid=16384&amp;doi=10.1182%2Fblood-2017-10-809020&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1182%252Fblood-2017-10-809020%26sid%3Dliteratum%253Aachs%26aulast%3DReiff%26aufirst%3DS.%2BD.%26aulast%3DMuhowski%26aufirst%3DE.%2BM.%26aulast%3DGuinn%26aufirst%3DD.%26aulast%3DLehman%26aufirst%3DA.%26aulast%3DFabian%26aufirst%3DC.%2BA.%26aulast%3DCheney%26aufirst%3DC.%26aulast%3DMantel%26aufirst%3DR.%26aulast%3DSmith%26aufirst%3DL.%26aulast%3DJohnson%26aufirst%3DA.%2BJ.%26aulast%3DYoung%26aufirst%3DW.%2BB.%26aulast%3DJohnson%26aufirst%3DA.%2BR.%26aulast%3DLiu%26aufirst%3DL.%26aulast%3DByrd%26aufirst%3DJ.%2BC.%26aulast%3DWoyach%26aufirst%3DJ.%2BA.%26atitle%3DNoncovalent%2520inhibition%2520of%2520C481S%2520Bruton%2520tyrosine%2520kinase%2520by%2520GDC-0853%253A%2520a%2520new%2520treatment%2520strategy%2520for%2520ibrutinib-resistant%2520CLL%26jtitle%3DBlood%26date%3D2018%26volume%3D132%26spage%3D1039%26epage%3D1049%26doi%3D10.1182%2Fblood-2017-10-809020" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref46"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref46'); return false;" data-citation="" class="refNumLink">46</a></strong><div class="NLM_citation" id="cit46"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Watterson, S. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">De Lucca, G. V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shi, Q.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Langevine, C. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, Q.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Batt, D. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Beaudoin
Bertrand, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gong, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dai, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yip, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sun, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wu, D.-R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Traeger, S. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pattoli, M. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Skala, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cheng, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Obermeier, M. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vickery, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Discenza, L. N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">D’Arienzo, C. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Heimrich, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gillooly, K. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Taylor, T. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pulicicchio, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">McIntyre, K. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Galella, M. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tebben, A. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Muckelbauer, J. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chang, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rampulla, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mathur, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Salter-Cid, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Barrish, J. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Carter, P. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fura, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Burke, J. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tino, J. A.</span></span> <span> </span><span class="NLM_article-title">Discovery of 6-Fluoro-5-(R)-(3-(S)-(8-fluoro-1-methyl-2,4-dioxo-1,2-dihydroquinazolin-3(4H)-yl)-2-methylphenyl)-2-(S)-(2-hydroxypropan-2-yl)-2,3,4,9-tetrahydro-1H-carbazole-8-carboxamide (BMS-986142): A Reversible Inhibitor of Bruton’s Tyrosine Kinase (BTK) Conformationally Constrained by Two Locked Atropisomers</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>59</i></span>,  <span class="NLM_fpage">9173</span>– <span class="NLM_lpage">9200</span>, <span class="refDoi"> DOI: 10.1021/acs.jmedchem.6b01088</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.jmedchem.6b01088" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref46/cit46&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00329&amp;key=1%3ACAS%3A528%3ADC%252BC28XhsVKjsrfF" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=59&publication_year=2016&pages=9173-9200&author=S.+H.+Wattersonauthor=G.+V.+De+Luccaauthor=Q.+Shiauthor=C.+M.+Langevineauthor=Q.+Liuauthor=D.+G.+Battauthor=M.+Beaudoin%0ABertrandauthor=H.+Gongauthor=J.+Daiauthor=S.+Yipauthor=P.+Liauthor=D.+Sunauthor=D.-R.+Wuauthor=C.+Wangauthor=Y.+Zhangauthor=S.+C.+Traegerauthor=M.+A.+Pattoliauthor=S.+Skalaauthor=L.+Chengauthor=M.+T.+Obermeierauthor=R.+Vickeryauthor=L.+N.+Discenzaauthor=C.+J.+D%E2%80%99Arienzoauthor=Y.+Zhangauthor=E.+Heimrichauthor=K.+M.+Gilloolyauthor=T.+L.+Taylorauthor=C.+Pulicicchioauthor=K.+W.+McIntyreauthor=M.+A.+Galellaauthor=A.+J.+Tebbenauthor=J.+K.+Muckelbauerauthor=C.+Changauthor=R.+Rampullaauthor=A.+Mathurauthor=L.+Salter-Cidauthor=J.+C.+Barrishauthor=P.+H.+Carterauthor=A.+Furaauthor=J.+R.+Burkeauthor=J.+A.+Tino&title=Discovery+of+6-Fluoro-5-%28R%29-%283-%28S%29-%288-fluoro-1-methyl-2%2C4-dioxo-1%2C2-dihydroquinazolin-3%284H%29-yl%29-2-methylphenyl%29-2-%28S%29-%282-hydroxypropan-2-yl%29-2%2C3%2C4%2C9-tetrahydro-1H-carbazole-8-carboxamide+%28BMS-986142%29%3A+A+Reversible+Inhibitor+of+Bruton%E2%80%99s+Tyrosine+Kinase+%28BTK%29+Conformationally+Constrained+by+Two+Locked+Atropisomers&doi=10.1021%2Facs.jmedchem.6b01088"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit46R"><div class="casContent"><span class="casTitleNuber">46</span><div class="casTitle"><span class="NLM_cas:atitle">Discovery of 6-Fluoro-5-(R)-(3-(S)-(8-fluoro-1-methyl-2,4-dioxo-1,2-dihydroquinazolin-3(4H)-yl)-2-methylphenyl)-2-(S)-(2-hydroxypropan-2-yl)-2,3,4,9-tetrahydro-1H-carbazole-8-carboxamide (BMS-986142): A Reversible Inhibitor of Bruton's Tyrosine Kinase (BTK) Conformationally Constrained by Two Locked Atropisomers</span></div><div class="casAuthors">Watterson, Scott H.; De Lucca, George V.; Shi, Qing; Langevine, Charles M.; Liu, Qingjie; Batt, Douglas G.; Beaudoin Bertrand, Myra; Gong, Hua; Dai, Jun; Yip, Shiuhang; Li, Peng; Sun, Dawn; Wu, Dauh-Rurng; Wang, Chunlei; Zhang, Yingru; Traeger, Sarah C.; Pattoli, Mark A.; Skala, Stacey; Cheng, Lihong; Obermeier, Mary T.; Vickery, Rodney; Discenza, Lorell N.; D'Arienzo, Celia J.; Zhang, Yifan; Heimrich, Elizabeth; Gillooly, Kathleen M.; Taylor, Tracy L.; Pulicicchio, Claudine; McIntyre, Kim W.; Galella, Michael A.; Tebben, Andy J.; Muckelbauer, Jodi K.; Chang, ChiehYing; Rampulla, Richard; Mathur, Arvind; Salter-Cid, Luisa; Barrish, Joel C.; Carter, Percy H.; Fura, Aberra; Burke, James R.; Tino, Joseph A.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">59</span>
        (<span class="NLM_cas:issue">19</span>),
    <span class="NLM_cas:pages">9173-9200</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Bruton's tyrosine kinase (BTK), a nonreceptor tyrosine kinase, is a member of the Tec family of kinases.  BTK plays an essential role in B cell receptor (BCR)-mediated signaling as well as Fcγ receptor signaling in monocytes and Fcε receptor signaling in mast cells and basophils, all of which have been implicated in the pathophysiol. of autoimmune disease.  As a result, inhibition of BTK is anticipated to provide an effective strategy for the clin. treatment of autoimmune diseases such as lupus and rheumatoid arthritis.  This article details the structure-activity relationships (SAR) leading to a novel series of highly potent and selective carbazole and tetrahydrocarbazole based, reversible inhibitors of BTK.  Of particular interest is that two atropisomeric centers were rotationally locked to provide a single, stable atropisomer, resulting in enhanced potency and selectivity as well as a redn. in safety liabilities.  With significantly enhanced potency and selectivity, excellent in vivo properties and efficacy, and a very desirable tolerability and safety profile, 14f (BMS-986142) was advanced into clin. studies.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpmpBAygRAsYrVg90H21EOLACvtfcHk0li1OWFnCqJezg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28XhsVKjsrfF&md5=91098abc802521b9ad91563d20ac5893</span></div><a href="/servlet/linkout?suffix=cit46&amp;dbid=16384&amp;doi=10.1021%2Facs.jmedchem.6b01088&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.jmedchem.6b01088%26sid%3Dliteratum%253Aachs%26aulast%3DWatterson%26aufirst%3DS.%2BH.%26aulast%3DDe%2BLucca%26aufirst%3DG.%2BV.%26aulast%3DShi%26aufirst%3DQ.%26aulast%3DLangevine%26aufirst%3DC.%2BM.%26aulast%3DLiu%26aufirst%3DQ.%26aulast%3DBatt%26aufirst%3DD.%2BG.%26aulast%3DBeaudoin%2BBertrand%26aufirst%3DM.%26aulast%3DGong%26aufirst%3DH.%26aulast%3DDai%26aufirst%3DJ.%26aulast%3DYip%26aufirst%3DS.%26aulast%3DLi%26aufirst%3DP.%26aulast%3DSun%26aufirst%3DD.%26aulast%3DWu%26aufirst%3DD.-R.%26aulast%3DWang%26aufirst%3DC.%26aulast%3DZhang%26aufirst%3DY.%26aulast%3DTraeger%26aufirst%3DS.%2BC.%26aulast%3DPattoli%26aufirst%3DM.%2BA.%26aulast%3DSkala%26aufirst%3DS.%26aulast%3DCheng%26aufirst%3DL.%26aulast%3DObermeier%26aufirst%3DM.%2BT.%26aulast%3DVickery%26aufirst%3DR.%26aulast%3DDiscenza%26aufirst%3DL.%2BN.%26aulast%3DD%25E2%2580%2599Arienzo%26aufirst%3DC.%2BJ.%26aulast%3DZhang%26aufirst%3DY.%26aulast%3DHeimrich%26aufirst%3DE.%26aulast%3DGillooly%26aufirst%3DK.%2BM.%26aulast%3DTaylor%26aufirst%3DT.%2BL.%26aulast%3DPulicicchio%26aufirst%3DC.%26aulast%3DMcIntyre%26aufirst%3DK.%2BW.%26aulast%3DGalella%26aufirst%3DM.%2BA.%26aulast%3DTebben%26aufirst%3DA.%2BJ.%26aulast%3DMuckelbauer%26aufirst%3DJ.%2BK.%26aulast%3DChang%26aufirst%3DC.%26aulast%3DRampulla%26aufirst%3DR.%26aulast%3DMathur%26aufirst%3DA.%26aulast%3DSalter-Cid%26aufirst%3DL.%26aulast%3DBarrish%26aufirst%3DJ.%2BC.%26aulast%3DCarter%26aufirst%3DP.%2BH.%26aulast%3DFura%26aufirst%3DA.%26aulast%3DBurke%26aufirst%3DJ.%2BR.%26aulast%3DTino%26aufirst%3DJ.%2BA.%26atitle%3DDiscovery%2520of%25206-Fluoro-5-%2528R%2529-%25283-%2528S%2529-%25288-fluoro-1-methyl-2%252C4-dioxo-1%252C2-dihydroquinazolin-3%25284H%2529-yl%2529-2-methylphenyl%2529-2-%2528S%2529-%25282-hydroxypropan-2-yl%2529-2%252C3%252C4%252C9-tetrahydro-1H-carbazole-8-carboxamide%2520%2528BMS-986142%2529%253A%2520A%2520Reversible%2520Inhibitor%2520of%2520Bruton%25E2%2580%2599s%2520Tyrosine%2520Kinase%2520%2528BTK%2529%2520Conformationally%2520Constrained%2520by%2520Two%2520Locked%2520Atropisomers%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2016%26volume%3D59%26spage%3D9173%26epage%3D9200%26doi%3D10.1021%2Facs.jmedchem.6b01088" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref47"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref47'); return false;" data-citation="" class="refNumLink">47</a></strong><div class="NLM_citation" id="cit47"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Neffendorf, J. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gout, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hildebrand, G. D.</span></span> <span> </span><span class="NLM_article-title">Ibrutinib in relapsed chronic lymphocytic leukemia</span>. <i>N. Engl. J. Med.</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>369</i></span>,  <span class="NLM_fpage">1277</span>– <span class="NLM_lpage">1279</span>, <span class="refDoi"> DOI: 10.1056/nejmc1309710</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref47/cit47&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00329&amp;key=10.1056%2Fnejmc1309710" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref47/cit47&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00329&amp;key=24066759" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref47/cit47&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00329&amp;key=1%3ACAS%3A528%3ADC%252BC3sXhsFGktLbM" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=369&publication_year=2013&pages=1277-1279&author=J.+E.+Neffendorfauthor=I.+Goutauthor=G.+D.+Hildebrand&title=Ibrutinib+in+relapsed+chronic+lymphocytic+leukemia&doi=10.1056%2Fnejmc1309710"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit47R"><div class="casContent"><span class="casTitleNuber">47</span><div class="casTitle"><span class="NLM_cas:atitle">Comments on: ibrutinib in relapsed chronic lymphocytic leukemia</span></div><div class="casAuthors">Neffendorf, James E.; Gout, Irina; Hildebrand, G. Darius</div><div class="citationInfo"><span class="NLM_cas:title">New England Journal of Medicine</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">369</span>
        (<span class="NLM_cas:issue">13</span>),
    <span class="NLM_cas:pages">1277-1278</span>CODEN:
                <span class="NLM_cas:coden">NEJMAG</span>;
        ISSN:<span class="NLM_cas:issn">0028-4793</span>.
    
            (<span class="NLM_cas:orgname">Massachusetts Medical Society</span>)
        </div><div class="casAbstract">
                There is no expanded citation for this reference.
            </div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGo-Wf-6sB8Ch7Vg90H21EOLACvtfcHk0li1OWFnCqJezg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXhsFGktLbM&md5=9aecfee27df57c795e046316b3624f33</span></div><a href="/servlet/linkout?suffix=cit47&amp;dbid=16384&amp;doi=10.1056%2Fnejmc1309710&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1056%252Fnejmc1309710%26sid%3Dliteratum%253Aachs%26aulast%3DNeffendorf%26aufirst%3DJ.%2BE.%26aulast%3DGout%26aufirst%3DI.%26aulast%3DHildebrand%26aufirst%3DG.%2BD.%26atitle%3DIbrutinib%2520in%2520relapsed%2520chronic%2520lymphocytic%2520leukemia%26jtitle%3DN.%2520Engl.%2520J.%2520Med.%26date%3D2013%26volume%3D369%26spage%3D1277%26epage%3D1279%26doi%3D10.1056%2Fnejmc1309710" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref48"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref48'); return false;" data-citation="" class="refNumLink">48</a></strong><div class="NLM_citation" id="cit48"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Byrd, J. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Brown, J. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">O’Brien, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Barrientos, J. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kay, N. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Reddy, N. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Coutre, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tam, C. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mulligan, S. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jaeger, U.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Devereux, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Barr, P. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Furman, R. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kipps, T. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cymbalista, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pocock, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Thornton, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Caligaris-Cappio, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Robak, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Delgado, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schuster, S. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Montillo, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schuh, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">de Vos, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gill, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bloor, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dearden, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Moreno, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jones, J. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chu, A. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fardis, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">McGreivy, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Clow, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">James, D. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hillmen, P.</span></span> <span> </span><span class="NLM_article-title">Ibrutinib versus ofatumumab in previously treated chronic lymphoid leukemia</span>. <i>N. Engl. J. Med.</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>371</i></span>,  <span class="NLM_fpage">213</span>– <span class="NLM_lpage">223</span>, <span class="refDoi"> DOI: 10.1056/nejmoa1400376</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref48/cit48&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00329&amp;key=10.1056%2Fnejmoa1400376" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref48/cit48&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00329&amp;key=24881631" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref48/cit48&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00329&amp;key=1%3ACAS%3A528%3ADC%252BC2cXhs1egsbrN" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=371&publication_year=2014&pages=213-223&author=J.+C.+Byrdauthor=J.+R.+Brownauthor=S.+O%E2%80%99Brienauthor=J.+C.+Barrientosauthor=N.+E.+Kayauthor=N.+M.+Reddyauthor=S.+Coutreauthor=C.+S.+Tamauthor=S.+P.+Mulliganauthor=U.+Jaegerauthor=S.+Devereuxauthor=P.+M.+Barrauthor=R.+R.+Furmanauthor=T.+J.+Kippsauthor=F.+Cymbalistaauthor=C.+Pocockauthor=P.+Thorntonauthor=F.+Caligaris-Cappioauthor=T.+Robakauthor=J.+Delgadoauthor=S.+J.+Schusterauthor=M.+Montilloauthor=A.+Schuhauthor=S.+de+Vosauthor=D.+Gillauthor=A.+Bloorauthor=C.+Deardenauthor=C.+Morenoauthor=J.+J.+Jonesauthor=A.+D.+Chuauthor=M.+Fardisauthor=J.+McGreivyauthor=F.+Clowauthor=D.+F.+Jamesauthor=P.+Hillmen&title=Ibrutinib+versus+ofatumumab+in+previously+treated+chronic+lymphoid+leukemia&doi=10.1056%2Fnejmoa1400376"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit48R"><div class="casContent"><span class="casTitleNuber">48</span><div class="casTitle"><span class="NLM_cas:atitle">Ibrutinib versus ofatumumab in previously treated chronic lymphoid leukemia</span></div><div class="casAuthors">Byrd, J. C.; Brown, J. R.; O'Brien, S.; Barrientos, J. C.; Kay, N. E.; Reddy, N. M.; Coutre, S.; Tam, C. S.; Mulligan, S. P.; Jaeger, U.; Devereux, S.; Barr, P. M.; Furman, R. R.; Kipps, T. J.; Cymbalista, F.; Pocock, C.; Thornton, P.; Caligaris-Cappio, F.; Robak, T.; Delgado, J.; Schuster, S. J.; Montillo, M.; Schuh, A.; de Vos, S.; Gill, D.; Bloor, A.; Dearden, C.; Moreno, C.; Jones, J. J.; Chu, A. D.; Fardis, M.; McGreivy, J.; Clow, F.; James, D. F.; Hillmen, P.</div><div class="citationInfo"><span class="NLM_cas:title">New England Journal of Medicine</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">371</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">213-223, 11 pp.</span>CODEN:
                <span class="NLM_cas:coden">NEJMAG</span>;
        ISSN:<span class="NLM_cas:issn">1533-4406</span>.
    
            (<span class="NLM_cas:orgname">Massachusetts Medical Society</span>)
        </div><div class="casAbstract">Background: In patients with chronic lymphoid leukemia (CLL) or small lymphocytic lymphoma (SLL), a short duration of response to therapy or adverse cytogenetic abnormalities are assocd. with a poor outcome.  We evaluated the efficacy of ibrutinib, a covalent inhibitor of Bruton's tyrosine kinase, in patients at risk for a poor outcome.  Methods: In this multicenter, open-label, phase 3 study, we randomly assigned 391 patients with relapsed or refractory CLL or SLL to receive daily ibrutinib or the anti-CD20 antibody ofatumumab.  The primary end point was the duration of progression-free survival, with the duration of overall survival and the overall response rate as secondary end points.  Results: At a median follow-up of 9.4 mo, ibrutinib significantly improved progression-free survival; the median duration was not reached in the ibrutinib group (with a rate of progression-free survival of 88% at 6 mo), as compared with a median of 8.1 mo in the ofatumumab group (hazard ratio for progression or death in the ibrutinib group, 0.22; P < 0.001).  Ibrutinib also significantly improved overall survival (hazard ratio for death, 0.43; P = 0.005).  At 12 mo, the overall survival rate was 90% in the ibrutinib group and 81% in the ofatumumab group.  The overall response rate was significantly higher in the ibrutinib group than in the ofatumumab group (42.6% vs. 4.1%, P < 0.001).  An addnl. 20% of ibrutinib-treated patients had a partial response with lymphocytosis.  Similar effects were obsd. regardless of whether patients had a chromosome 17p13.1 deletion or resistance to purine analogs.  The most frequent nonhematol. adverse events were diarrhea, fatigue, pyrexia, and nausea in the ibrutinib group and fatigue, infusion-related reactions, and cough in the ofatumumab group.  Conclusions: Ibrutinib, as compared with ofatumumab, significantly improved progression-free survival, overall survival, and response rate among patients with previously treated CLL or SLL.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrCuX1vrLZxQLVg90H21EOLACvtfcHk0lj0XYJEElBT0A"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXhs1egsbrN&md5=87b692d35faa0fb8666bb945746fb9b0</span></div><a href="/servlet/linkout?suffix=cit48&amp;dbid=16384&amp;doi=10.1056%2Fnejmoa1400376&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1056%252Fnejmoa1400376%26sid%3Dliteratum%253Aachs%26aulast%3DByrd%26aufirst%3DJ.%2BC.%26aulast%3DBrown%26aufirst%3DJ.%2BR.%26aulast%3DO%25E2%2580%2599Brien%26aufirst%3DS.%26aulast%3DBarrientos%26aufirst%3DJ.%2BC.%26aulast%3DKay%26aufirst%3DN.%2BE.%26aulast%3DReddy%26aufirst%3DN.%2BM.%26aulast%3DCoutre%26aufirst%3DS.%26aulast%3DTam%26aufirst%3DC.%2BS.%26aulast%3DMulligan%26aufirst%3DS.%2BP.%26aulast%3DJaeger%26aufirst%3DU.%26aulast%3DDevereux%26aufirst%3DS.%26aulast%3DBarr%26aufirst%3DP.%2BM.%26aulast%3DFurman%26aufirst%3DR.%2BR.%26aulast%3DKipps%26aufirst%3DT.%2BJ.%26aulast%3DCymbalista%26aufirst%3DF.%26aulast%3DPocock%26aufirst%3DC.%26aulast%3DThornton%26aufirst%3DP.%26aulast%3DCaligaris-Cappio%26aufirst%3DF.%26aulast%3DRobak%26aufirst%3DT.%26aulast%3DDelgado%26aufirst%3DJ.%26aulast%3DSchuster%26aufirst%3DS.%2BJ.%26aulast%3DMontillo%26aufirst%3DM.%26aulast%3DSchuh%26aufirst%3DA.%26aulast%3Dde%2BVos%26aufirst%3DS.%26aulast%3DGill%26aufirst%3DD.%26aulast%3DBloor%26aufirst%3DA.%26aulast%3DDearden%26aufirst%3DC.%26aulast%3DMoreno%26aufirst%3DC.%26aulast%3DJones%26aufirst%3DJ.%2BJ.%26aulast%3DChu%26aufirst%3DA.%2BD.%26aulast%3DFardis%26aufirst%3DM.%26aulast%3DMcGreivy%26aufirst%3DJ.%26aulast%3DClow%26aufirst%3DF.%26aulast%3DJames%26aufirst%3DD.%2BF.%26aulast%3DHillmen%26aufirst%3DP.%26atitle%3DIbrutinib%2520versus%2520ofatumumab%2520in%2520previously%2520treated%2520chronic%2520lymphoid%2520leukemia%26jtitle%3DN.%2520Engl.%2520J.%2520Med.%26date%3D2014%26volume%3D371%26spage%3D213%26epage%3D223%26doi%3D10.1056%2Fnejmoa1400376" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref49"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref49'); return false;" data-citation="" class="refNumLink">49</a></strong><div class="NLM_citation" id="cit49"><span><span class="NLM_contrib-group"><span class="NLM_string-name">O’Brien, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Furman, R. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Coutre, S. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sharman, J. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Burger, J. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Blum, K. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Grant, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Richards, D. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Coleman, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wierda, W. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jones, J. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhao, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Heerema, N. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Johnson, A. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Izumi, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hamdy, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chang, B. Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Graef, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Clow, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Buggy, J. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">James, D. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Byrd, J. C.</span></span> <span> </span><span class="NLM_article-title">Ibrutinib as initial therapy for elderly patients with chronic lymphocytic leukaemia or small lymphocytic lymphoma: an open-label, multicentre, phase 1b/2 trial</span>. <i>Lancet Oncol.</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>15</i></span>,  <span class="NLM_fpage">48</span>– <span class="NLM_lpage">58</span>, <span class="refDoi"> DOI: 10.1016/s1470-2045(13)70513-8</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref49/cit49&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00329&amp;key=10.1016%2Fs1470-2045%2813%2970513-8" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref49/cit49&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00329&amp;key=24332241" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref49/cit49&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00329&amp;key=1%3ACAS%3A528%3ADC%252BC3sXitVWjtrzL" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=15&publication_year=2014&pages=48-58&author=S.+O%E2%80%99Brienauthor=R.+R.+Furmanauthor=S.+E.+Coutreauthor=J.+P.+Sharmanauthor=J.+A.+Burgerauthor=K.+A.+Blumauthor=B.+Grantauthor=D.+A.+Richardsauthor=M.+Colemanauthor=W.+G.+Wierdaauthor=J.+A.+Jonesauthor=W.+Zhaoauthor=N.+A.+Heeremaauthor=A.+J.+Johnsonauthor=R.+Izumiauthor=A.+Hamdyauthor=B.+Y.+Changauthor=T.+Graefauthor=F.+Clowauthor=J.+J.+Buggyauthor=D.+F.+Jamesauthor=J.+C.+Byrd&title=Ibrutinib+as+initial+therapy+for+elderly+patients+with+chronic+lymphocytic+leukaemia+or+small+lymphocytic+lymphoma%3A+an+open-label%2C+multicentre%2C+phase+1b%2F2+trial&doi=10.1016%2Fs1470-2045%2813%2970513-8"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit49R"><div class="casContent"><span class="casTitleNuber">49</span><div class="casTitle"><span class="NLM_cas:atitle">Ibrutinib as initial therapy for elderly patients with chronic lymphocytic leukaemia or small lymphocytic lymphoma: an open-label, multicentre, phase 1b/2 trial</span></div><div class="casAuthors">O'Brien, Susan; Furman, Richard R.; Coutre, Steven E.; Sharman, Jeff P.; Burger, Jan A.; Blum, Kristie A.; Grant, Barbara; Richards, Donald A.; Coleman, Morton; Wierda, William G.; Jones, Jeffrey A.; Zhao, Weiqiang; Heerema, Nyla A.; Johnson, Amy J.; Izumi, Raquel; Hamdy, Ahmed; Chang, Betty Y.; Graef, Thorsten; Clow, Fong; Buggy, Joseph J.; James, Danelle F.; Byrd, John C.</div><div class="citationInfo"><span class="NLM_cas:title">Lancet Oncology</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">15</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">48-58</span>CODEN:
                <span class="NLM_cas:coden">LOANBN</span>;
        ISSN:<span class="NLM_cas:issn">1470-2045</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Ltd.</span>)
        </div><div class="casAbstract">Background: Chemoimmunotherapy has led to improved nos. of patients achieving disease response, and longer overall survival in young patients with chronic lymphocytic leukemia; however, its application in elderly patients has been restricted by substantial myelosuppression and infection.  We aimed to assess safety and activity of ibrutinib, an orally administered covalent inhibitor of Bruton tyrosine kinase (BTK), in treatment-naive patients aged 65 years and older with chronic lymphocytic leukemia.  Methods: In our open-label phase 1b/2 trial, we enrolled previously untreated patients at clin. sites in the USA.  Eligible patients were aged at least 65 years, and had symptomatic chronic lymphocytic leukemia or small lymphocytic lymphoma requiring therapy.  Patients received 28 day cycles of once-daily ibrutinib 420 mg or ibrutinib 840 mg.  The 840 mg dose was discontinued after enrollment had begun because comparable activity of the doses has been shown.  The primary endpoint was the safety of the dose-fixed regimen in terms of frequency and severity of adverse events for all patients who received treatment.  This study is registered with ClinicalTrials.gov, no. NCT01105247.  Findings: Between May 20, 2010, and Dec 18, 2012, we enrolled 29 patients with chronic lymphocytic leukemia and two patients with small lymphocytic lymphoma.  Median age was 71 years (range 65-84), and 23 (74%) patients were at least 70 years old.  Toxicity was mainly of mild-to-moderate severity (grade 1-2). 21 (68%) patients had diarrhea (grade 1 in 14 [45%] patients, grade 2 in three [10%] patients, and grade 3 in four [13%] patients). 15 (48%) patients developed nausea (grade 1 in 12 [39%] patients and grade 2 in three [10%] patients).  Ten (32%) patients developed fatigue (grade 1 in five [16%] patients, grade 2 in four [13%] patients, and grade 3 in one [3%] patient).  Three (10%) patients developed grade 3 infections, although no grade 4 or 5 infections occurred.  One patient developed grade 3 neutropenia, and one developed grade 4 thrombocytopenia.  After a median follow-up of 22·1 mo (IQR 18·4-23·2), 22 (71%) of 31 patients achieved an objective response (95% CI 52·0-85·8); four patients (13%) had a complete response, one patient (3%) had a nodular partial response, and 17 (55%) patients had a partial response.  Interpretation: The safety and activity of ibrutinib in elderly, previously untreated patients with symptomatic chronic lymphocytic leukemia, or small lymphocytic lymphoma is encouraging, and merits further investigation in phase 3 trials.  Funding: Pharmacyclics, Leukemia and Lymphoma Society, D Warren Brown Foundation, Mr and Mrs Michael Thomas, Harry Mangurian Foundation, P50 CA140158 to Prof J C Byrd MD.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpaUFztuMSARrVg90H21EOLACvtfcHk0lj0XYJEElBT0A"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXitVWjtrzL&md5=1f2e48019c275e2e07e41479c7fc3f21</span></div><a href="/servlet/linkout?suffix=cit49&amp;dbid=16384&amp;doi=10.1016%2Fs1470-2045%2813%2970513-8&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fs1470-2045%252813%252970513-8%26sid%3Dliteratum%253Aachs%26aulast%3DO%25E2%2580%2599Brien%26aufirst%3DS.%26aulast%3DFurman%26aufirst%3DR.%2BR.%26aulast%3DCoutre%26aufirst%3DS.%2BE.%26aulast%3DSharman%26aufirst%3DJ.%2BP.%26aulast%3DBurger%26aufirst%3DJ.%2BA.%26aulast%3DBlum%26aufirst%3DK.%2BA.%26aulast%3DGrant%26aufirst%3DB.%26aulast%3DRichards%26aufirst%3DD.%2BA.%26aulast%3DColeman%26aufirst%3DM.%26aulast%3DWierda%26aufirst%3DW.%2BG.%26aulast%3DJones%26aufirst%3DJ.%2BA.%26aulast%3DZhao%26aufirst%3DW.%26aulast%3DHeerema%26aufirst%3DN.%2BA.%26aulast%3DJohnson%26aufirst%3DA.%2BJ.%26aulast%3DIzumi%26aufirst%3DR.%26aulast%3DHamdy%26aufirst%3DA.%26aulast%3DChang%26aufirst%3DB.%2BY.%26aulast%3DGraef%26aufirst%3DT.%26aulast%3DClow%26aufirst%3DF.%26aulast%3DBuggy%26aufirst%3DJ.%2BJ.%26aulast%3DJames%26aufirst%3DD.%2BF.%26aulast%3DByrd%26aufirst%3DJ.%2BC.%26atitle%3DIbrutinib%2520as%2520initial%2520therapy%2520for%2520elderly%2520patients%2520with%2520chronic%2520lymphocytic%2520leukaemia%2520or%2520small%2520lymphocytic%2520lymphoma%253A%2520an%2520open-label%252C%2520multicentre%252C%2520phase%25201b%252F2%2520trial%26jtitle%3DLancet%2520Oncol.%26date%3D2014%26volume%3D15%26spage%3D48%26epage%3D58%26doi%3D10.1016%2Fs1470-2045%2813%2970513-8" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref50"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref50'); return false;" data-citation="" class="refNumLink">50</a></strong><div class="NLM_citation" id="cit50"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Lu, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chambers, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wipf, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xie, X.-Q.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Englert, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Weber, S.</span></span> <span> </span><span class="NLM_article-title">Lipophilicity screening of novel drug-like compounds and comparison to clogP</span>. <i>J. Chromatogr. A</i> <span class="NLM_year" style="font-weight: bold;">2012</span>,  <span class="NLM_volume"><i>1258</i></span>,  <span class="NLM_fpage">161</span>– <span class="NLM_lpage">167</span>, <span class="refDoi"> DOI: 10.1016/j.chroma.2012.07.078</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref50/cit50&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00329&amp;key=10.1016%2Fj.chroma.2012.07.078" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref50/cit50&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00329&amp;key=22939208" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref50/cit50&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00329&amp;key=1%3ACAS%3A528%3ADC%252BC38XhtlKltL%252FM" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=1258&publication_year=2012&pages=161-167&author=D.+Luauthor=P.+Chambersauthor=P.+Wipfauthor=X.-Q.+Xieauthor=D.+Englertauthor=S.+Weber&title=Lipophilicity+screening+of+novel+drug-like+compounds+and+comparison+to+clogP&doi=10.1016%2Fj.chroma.2012.07.078"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit50R"><div class="casContent"><span class="casTitleNuber">50</span><div class="casTitle"><span class="NLM_cas:atitle">Lipophilicity screening of novel drug-like compounds and comparison to clog P</span></div><div class="casAuthors">Lu, Dujuan; Chambers, Peter; Wipf, Peter; Xie, Xiang-Qun; Englert, Danielle; Weber, Stephen</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Chromatography A</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">1258</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">161-167</span>CODEN:
                <span class="NLM_cas:coden">JCRAEY</span>;
        ISSN:<span class="NLM_cas:issn">0021-9673</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">We detd. the distribution coeffs. of solutes between a polymer film phase (polyvinyl chloride (PVC) with 67% (wt./wt.) dioctyl sebacate (DOS)) and an aq. phase in a 96-well format.  The parallel measurement approach is efficient and uses very little material.  Polymer-water distribution coeffs. (D pw) at different pH values yield the pKa and polymer-water partition coeff. values (P pw) of the solutes. log P pw of a prominent drug-like compd., 2H-1,2,6-thiadiazine, 3-methyl-5-phenyl-,1,1-dioxide, is in good agreement with clog P, while the pK a value is substantially different from calcd. values.  This method has been also successfully applied to a library of novel drug-like compds. log D pw values (at pH 4.0, 7.0, 10.0) of 24 novel drug-like compds. have been detd. with good reproducibility with the 96-well plate approach.  Differences between exptl. values and a variety of available calcd. values are significant.  This emphasizes the need for lab. sepns.-based measurements of log D.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrVeCs5QNEEWrVg90H21EOLACvtfcHk0lgf24jYADyHbQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38XhtlKltL%252FM&md5=8e49487d24015204688baf5d6efc91f7</span></div><a href="/servlet/linkout?suffix=cit50&amp;dbid=16384&amp;doi=10.1016%2Fj.chroma.2012.07.078&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.chroma.2012.07.078%26sid%3Dliteratum%253Aachs%26aulast%3DLu%26aufirst%3DD.%26aulast%3DChambers%26aufirst%3DP.%26aulast%3DWipf%26aufirst%3DP.%26aulast%3DXie%26aufirst%3DX.-Q.%26aulast%3DEnglert%26aufirst%3DD.%26aulast%3DWeber%26aufirst%3DS.%26atitle%3DLipophilicity%2520screening%2520of%2520novel%2520drug-like%2520compounds%2520and%2520comparison%2520to%2520clogP%26jtitle%3DJ.%2520Chromatogr.%2520A%26date%3D2012%26volume%3D1258%26spage%3D161%26epage%3D167%26doi%3D10.1016%2Fj.chroma.2012.07.078" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref51"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref51'); return false;" data-citation="" class="refNumLink">51</a></strong><div class="NLM_citation" id="cit51"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Böhm, H.-J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Banner, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bendels, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kansy, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kuhn, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Müller, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Obst-Sander, U.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stahl, M.</span></span> <span> </span><span class="NLM_article-title">Fluorine in medicinal chemistry</span>. <i>ChemBioChem</i> <span class="NLM_year" style="font-weight: bold;">2004</span>,  <span class="NLM_volume"><i>5</i></span>,  <span class="NLM_fpage">637</span>– <span class="NLM_lpage">643</span>, <span class="refDoi"> DOI: 10.1002/cbic.200301023</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref51/cit51&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00329&amp;key=10.1002%2Fcbic.200301023" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref51/cit51&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00329&amp;key=15122635" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref51/cit51&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00329&amp;key=1%3ACAS%3A280%3ADC%252BD2c3it1egug%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=5&publication_year=2004&pages=637-643&author=H.-J.+B%C3%B6hmauthor=D.+Bannerauthor=S.+Bendelsauthor=M.+Kansyauthor=B.+Kuhnauthor=K.+M%C3%BCllerauthor=U.+Obst-Sanderauthor=M.+Stahl&title=Fluorine+in+medicinal+chemistry&doi=10.1002%2Fcbic.200301023"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit51R"><div class="casContent"><span class="casTitleNuber">51</span><div class="casTitle"><span class="NLM_cas:atitle">Fluorine in medicinal chemistry</span></div><div class="casAuthors">Bohm Hans-Joachim; Banner David; Bendels Stefanie; Kansy Manfred; Kuhn Bernd; Muller Klaus; Obst-Sander Ulrike; Stahl Martin</div><div class="citationInfo"><span class="NLM_cas:title">Chembiochem : a European journal of chemical biology</span>
        (<span class="NLM_cas:date">2004</span>),
    <span class="NLM_cas:volume">5</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">637-43</span>
        ISSN:<span class="NLM_cas:issn">1439-4227</span>.
    </div><div class="casAbstract">Fluorinated compounds are synthesized in pharmaceutical research on a routine basis and many marketed compounds contain fluorine.  The present review summarizes some of the most frequently employed strategies for using fluorine substituents in medicinal chemistry.  Quite often, fluorine is introduced to improve the metabolic stability by blocking metabolically labile sites.  However, fluorine can also be used to modulate the physicochemical properties, such as lipophilicity or basicity.  It may exert a substantial effect on the conformation of a molecule.  Increasingly, fluorine is used to enhance the binding affinity to the target protein.  Recent 3D-structure determinations of protein complexes with bound fluorinated ligands have led to an improved understanding of the nonbonding protein-ligand interactions that involve fluorine.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcQ4zDG_wo1YGtts4TFFB11gfW6udTcc2ebuzt-nY7VeFrntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BD2c3it1egug%253D%253D&md5=fa5ca2cfc278b83c80d5c96b18dfe312</span></div><a href="/servlet/linkout?suffix=cit51&amp;dbid=16384&amp;doi=10.1002%2Fcbic.200301023&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fcbic.200301023%26sid%3Dliteratum%253Aachs%26aulast%3DB%25C3%25B6hm%26aufirst%3DH.-J.%26aulast%3DBanner%26aufirst%3DD.%26aulast%3DBendels%26aufirst%3DS.%26aulast%3DKansy%26aufirst%3DM.%26aulast%3DKuhn%26aufirst%3DB.%26aulast%3DM%25C3%25BCller%26aufirst%3DK.%26aulast%3DObst-Sander%26aufirst%3DU.%26aulast%3DStahl%26aufirst%3DM.%26atitle%3DFluorine%2520in%2520medicinal%2520chemistry%26jtitle%3DChemBioChem%26date%3D2004%26volume%3D5%26spage%3D637%26epage%3D643%26doi%3D10.1002%2Fcbic.200301023" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref52"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref52'); return false;" data-citation="" class="refNumLink">52</a></strong><div class="NLM_citation" id="cit52"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Boucheron, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ellmeier, W.</span></span> <span> </span><span class="NLM_article-title">The Role of Tec family kinases in the regulation of T-helper-cell differentiation</span>. <i>Int. Rev. Immunol.</i> <span class="NLM_year" style="font-weight: bold;">2012</span>,  <span class="NLM_volume"><i>31</i></span>,  <span class="NLM_fpage">133</span>– <span class="NLM_lpage">154</span>, <span class="refDoi"> DOI: 10.3109/08830185.2012.664798</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref52/cit52&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00329&amp;key=10.3109%2F08830185.2012.664798" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref52/cit52&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00329&amp;key=22449074" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref52/cit52&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00329&amp;key=1%3ACAS%3A528%3ADC%252BC38Xks1Omu7w%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=31&publication_year=2012&pages=133-154&author=N.+Boucheronauthor=W.+Ellmeier&title=The+Role+of+Tec+family+kinases+in+the+regulation+of+T-helper-cell+differentiation&doi=10.3109%2F08830185.2012.664798"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit52R"><div class="casContent"><span class="casTitleNuber">52</span><div class="casTitle"><span class="NLM_cas:atitle">The Role of Tec Family Kinases in the Regulation of T-helper-cell Differentiation</span></div><div class="casAuthors">Boucheron, Nicole; Ellmeier, Wilfried</div><div class="citationInfo"><span class="NLM_cas:title">International Reviews of Immunology</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">31</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">133-154</span>CODEN:
                <span class="NLM_cas:coden">IRIMEH</span>;
        ISSN:<span class="NLM_cas:issn">0883-0185</span>.
    
            (<span class="NLM_cas:orgname">Informa Healthcare</span>)
        </div><div class="casAbstract">A review.  Members of the Tec kinase family (Tec, Btk, Itk, Rlk, and Bmx) play an important role during innate and adaptive immune responses, and mutations in Tec family kinases are linked with immunodeficiencies in humans and mice.  Three members of the Tec kinase family are expressed in T cells (Tec, Itk, and Rlk), and biochem. and genetic studies have revealed important roles for Tec family kinases during T-cell development and in the control of T-cell function.  Here the authors review the role of Tec family kinases in the regulation of T-helper-cell differentiation.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpv3IOWbLRvJ7Vg90H21EOLACvtfcHk0lgf24jYADyHbQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38Xks1Omu7w%253D&md5=c5b80129819a6e6b29de0b30f8875b1e</span></div><a href="/servlet/linkout?suffix=cit52&amp;dbid=16384&amp;doi=10.3109%2F08830185.2012.664798&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.3109%252F08830185.2012.664798%26sid%3Dliteratum%253Aachs%26aulast%3DBoucheron%26aufirst%3DN.%26aulast%3DEllmeier%26aufirst%3DW.%26atitle%3DThe%2520Role%2520of%2520Tec%2520family%2520kinases%2520in%2520the%2520regulation%2520of%2520T-helper-cell%2520differentiation%26jtitle%3DInt.%2520Rev.%2520Immunol.%26date%3D2012%26volume%3D31%26spage%3D133%26epage%3D154%26doi%3D10.3109%2F08830185.2012.664798" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li></ol></div><script data-cfasync="false" src="/cdn-cgi/scripts/5c5dd728/cloudflare-static/email-decode.min.js"></script><script type="text/javascript">window.refViewer={'ref1':['cit1'],'ref2':['cit2'],'ref3':['cit3'],'ref4':['cit4'],'ref5':['cit5'],'ref6':['cit6'],'ref7':['cit7'],'ref8':['cit8'],'ref9':['cit9'],'ref10':['cit10'],'ref11':['cit11'],'ref12':['cit12'],'ref13':['cit13'],'ref14':['cit14'],'ref15':['cit15'],'ref16':['cit16'],'ref17':['cit17'],'ref18':['cit18'],'ref19':['cit19'],'ref20':['cit20'],'ref21':['cit21'],'ref22':['cit22'],'ref23':['cit23'],'ref24':['cit24'],'ref25':['cit25'],'ref26':['cit26'],'ref27':['cit27'],'ref28':['cit28'],'ref29':['cit29'],'ref30':['cit30'],'ref31':['cit31'],'ref32':['cit32'],'ref33':['cit33'],'ref34':['cit34'],'ref35':['cit35'],'ref36':['cit36'],'ref37':['cit37'],'ref38':['cit38'],'ref39':['cit39'],'ref40':['cit40'],'ref41':['cit41'],'ref42':['cit42'],'ref43':['cit43'],'ref44':['cit44'],'ref45':['cit45'],'ref46':['cit46'],'ref47':['cit47'],'ref48':['cit48'],'ref49':['cit49'],'ref50':['cit50'],'ref51':['cit51'],'ref52':['cit52']}</script><div class="articleCitedByDropzone" data-pb-dropzone="articleCitedByDropzone"><div class="cited-by"><div class="article_content-header cited-content_header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="citeThis">Cited By</h2></div></div></div><hr/></hr><div class="cited-by__content"><div class="cited-content hlFld-Abstract"><p>This article is cited by 6 publications.</p><ol class="cited-content_cbyCitation"><li><span class="cited-content_cbyCitation_article-contributors">Zhouling Xie, Xiaoxiao Yang, Yajun Duan, Jihong Han, <span class="NLM_string-name hlFld-ContribAuthor">Chenzhong Liao</span>. </span><span class="cited-content_cbyCitation_article-title">Small-Molecule Kinase Inhibitors for the Treatment of Nononcologic Diseases. </span><span class="cited-content_cbyCitation_journal-name">Journal of Medicinal Chemistry</span><span> <strong>2021,</strong> <em>64 </em>
                                    (3)
                                     , 1283-1345. <a href="https://doi.org/10.1021/acs.jmedchem.0c01511" title="DOI URL">https://doi.org/10.1021/acs.jmedchem.0c01511</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/acs.jmedchem.0c01511&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Facs.jmedchem.0c01511%26sid%3Dliteratum%253Aachs%26jtitle%3DJournal%2520of%2520Medicinal%2520Chemistry%26atitle%3DSmall-Molecule%252BKinase%252BInhibitors%252Bfor%252Bthe%252BTreatment%252Bof%252BNononcologic%252BDiseases%26aulast%3DXie%26aufirst%3DZhouling%26date%3D2021%26date%3D2021%26date%3D2020%26date%3D29082020%26date%3D22012021%26volume%3D64%26issue%3D3%26spage%3D1283%26epage%3D1345" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors">Mookda Pattarawarapan, Dolnapa Yamano, Nittaya Wiriya, Saranphong Yimklan, <span class="NLM_string-name hlFld-ContribAuthor">Wong Phakhodee</span>. </span><span class="cited-content_cbyCitation_article-title">Simultaneous Formation and Functionalization of Aryliminophosphoranes Using 1,3-Dihydro-1H-benzimidazol-2-ones as Precursors. </span><span class="cited-content_cbyCitation_journal-name">The Journal of Organic Chemistry</span><span> <strong>2020,</strong> <em>85 </em>
                                    (20)
                                     , 13330-13338. <a href="https://doi.org/10.1021/acs.joc.0c01979" title="DOI URL">https://doi.org/10.1021/acs.joc.0c01979</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/acs.joc.0c01979&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Facs.joc.0c01979%26sid%3Dliteratum%253Aachs%26jtitle%3DThe%2520Journal%2520of%2520Organic%2520Chemistry%26atitle%3DSimultaneous%252BFormation%252Band%252BFunctionalization%252Bof%252BAryliminophosphoranes%252BUsing%252B1%25252C3-Dihydro-1H-benzimidazol-2-ones%252Bas%252BPrecursors%26aulast%3DPattarawarapan%26aufirst%3DMookda%26date%3D2020%26date%3D2020%26date%3D2020%26date%3D17082020%26date%3D02102020%26volume%3D85%26issue%3D20%26spage%3D13330%26epage%3D13338" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors">Xuejun Zhang, Xijun Sheng, Jie Shen, Shoubo Zhang, Wenjie Sun, Chunli Shen, Yi Li, Jun Wang, Huqiang Lv, Minghui Cui, Yuchuan Zhu, Lei Huang, Dongling Hao, Zhibo Qi, Guanglong Sun, Weifeng Mao, Yan Pan, Liang Shen, Xin Li, Guoping Hu, Zhen Gong, Shuhua Han, Jian Li, Shuhui Chen, Ronghua Tu, Xuehai Wang, <span class="NLM_string-name hlFld-ContribAuthor">Chengde Wu</span>. </span><span class="cited-content_cbyCitation_article-title">Discovery and Evaluation of Pyrazolo[3,4-d]pyridazinone as a Potent and Orally Active Irreversible BTK Inhibitor. </span><span class="cited-content_cbyCitation_journal-name">ACS Medicinal Chemistry Letters</span><span> <strong>2020,</strong> <em>11 </em>
                                    (10)
                                     , 1863-1868. <a href="https://doi.org/10.1021/acsmedchemlett.9b00395" title="DOI URL">https://doi.org/10.1021/acsmedchemlett.9b00395</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/acsmedchemlett.9b00395&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Facsmedchemlett.9b00395%26sid%3Dliteratum%253Aachs%26jtitle%3DACS%2520Medicinal%2520Chemistry%2520Letters%26atitle%3DDiscovery%252Band%252BEvaluation%252Bof%252BPyrazolo%25255B3%25252C4-d%25255Dpyridazinone%252Bas%252Ba%252BPotent%252Band%252BOrally%252BActive%252BIrreversible%252BBTK%252BInhibitor%26aulast%3DZhang%26aufirst%3DXuejun%26date%3D2020%26date%3D2019%26date%3D2019%26date%3D2019%26date%3D23082019%26date%3D11122019%26date%3D16122019%26date%3D11122019%26volume%3D11%26issue%3D10%26spage%3D1863%26epage%3D1868" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Shuqiang  Chen</span>, <span class="hlFld-ContribAuthor ">Kaijian  Bi</span>, <span class="hlFld-ContribAuthor ">Shanchao  Wu</span>, <span class="hlFld-ContribAuthor ">Yu  Li</span>, <span class="hlFld-ContribAuthor ">Yahui  Huang</span>, <span class="hlFld-ContribAuthor ">Chunquan  Sheng</span>, <span class="hlFld-ContribAuthor ">Guoqiang  Dong</span>. </span><span class="cited-content_cbyCitation_article-title">Water-soluble derivatives of evodiamine: Discovery of evodiamine-10-phosphate as an orally active antitumor lead compound. </span><span class="cited-content_cbyCitation_journal-name">European Journal of Medicinal Chemistry</span><span> <strong>2021,</strong> <em>220 </em>, 113544. <a href="https://doi.org/10.1016/j.ejmech.2021.113544" title="DOI URL">https://doi.org/10.1016/j.ejmech.2021.113544</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.ejmech.2021.113544&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.ejmech.2021.113544%26sid%3Dliteratum%253Aachs%26jtitle%3DEuropean%2520Journal%2520of%2520Medicinal%2520Chemistry%26atitle%3DWater-soluble%252Bderivatives%252Bof%252Bevodiamine%25253A%252BDiscovery%252Bof%252Bevodiamine-10-phosphate%252Bas%252Ban%252Borally%252Bactive%252Bantitumor%252Blead%252Bcompound%26aulast%3DChen%26aufirst%3DShuqiang%26date%3D2021%26volume%3D220%26spage%3D113544" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Jiakuo  Liu</span>, <span class="hlFld-ContribAuthor ">Chengjuan  Chen</span>, <span class="hlFld-ContribAuthor ">Dongmei  Wang</span>, <span class="hlFld-ContribAuthor ">Jie  Zhang</span>, <span class="hlFld-ContribAuthor ">Tiantai  Zhang</span>. </span><span class="cited-content_cbyCitation_article-title">Emerging small-molecule inhibitors of the Bruton’s tyrosine kinase (BTK): Current development. </span><span class="cited-content_cbyCitation_journal-name">European Journal of Medicinal Chemistry</span><span> <strong>2021,</strong> <em>217 </em>, 113329. <a href="https://doi.org/10.1016/j.ejmech.2021.113329" title="DOI URL">https://doi.org/10.1016/j.ejmech.2021.113329</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.ejmech.2021.113329&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.ejmech.2021.113329%26sid%3Dliteratum%253Aachs%26jtitle%3DEuropean%2520Journal%2520of%2520Medicinal%2520Chemistry%26atitle%3DEmerging%252Bsmall-molecule%252Binhibitors%252Bof%252Bthe%252BBruton%2525E2%252580%252599s%252Btyrosine%252Bkinase%252B%252528BTK%252529%25253A%252BCurrent%252Bdevelopment%26aulast%3DLiu%26aufirst%3DJiakuo%26date%3D2021%26volume%3D217%26spage%3D113329" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Jiamin  Zheng</span>, <span class="hlFld-ContribAuthor ">Jun  Wu</span>, <span class="hlFld-ContribAuthor ">Xiao  Ding</span>, <span class="hlFld-ContribAuthor ">Hong C.  Shen</span>, <span class="hlFld-ContribAuthor ">Ge  Zou</span>. </span><span class="cited-content_cbyCitation_article-title">Small molecule approaches to treat autoimmune and inflammatory diseases (Part I): Kinase inhibitors. </span><span class="cited-content_cbyCitation_journal-name">Bioorganic & Medicinal Chemistry Letters</span><span> <strong>2021,</strong> <em>38 </em>, 127862. <a href="https://doi.org/10.1016/j.bmcl.2021.127862" title="DOI URL">https://doi.org/10.1016/j.bmcl.2021.127862</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.bmcl.2021.127862&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.bmcl.2021.127862%26sid%3Dliteratum%253Aachs%26jtitle%3DBioorganic%2520%2526%2520Medicinal%2520Chemistry%2520Letters%26atitle%3DSmall%252Bmolecule%252Bapproaches%252Bto%252Btreat%252Bautoimmune%252Band%252Binflammatory%252Bdiseases%252B%252528Part%252BI%252529%25253A%252BKinase%252Binhibitors%26aulast%3DZheng%26aufirst%3DJiamin%26date%3D2021%26volume%3D38%26spage%3D127862" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li></ol></div></div></div></div></div><div class="article_content-right" id="article_content-right" tabindex="0"><div class="tab tab--flex"><div class="tab__close"><i class="icon-close" tabindex="0" aria-label="close the sidebar."></i></div><ul role="tablist" class="rlist tab__nav"><li role="presentation" class="active"><a id="pane-m1con" href="#pane-m1" aria-controls="pane-m1" role="tab" data-toggle="tab" title="Figures" aria-selected="true" class="active empty" aria-label="Figures"><i class="icon-image"></i><span>Figures</span></a></li><li role="presentation"><a id="pane-m2con" href="#pane-m2" aria-controls="pane-m2" role="tab" data-toggle="tab" title="References" aria-selected="false" class="empty"><i class="icon-link"></i><span>References</span></a></li><li role="presentation"><a id="pane-m3con" href="#pane-m3" aria-controls="pane-m3" role="tab" data-toggle="tab" title="Support Info" aria-selected="false" class="empty tab__nav-suppInfo"><i class="icon-supporting-info"></i><span>Support Info</span></a></li></ul><div class="paneContainer"><ul class="rlist tab__content"><li id="pane-m1" aria-labelledby="pane-m1" class="tab__pane tab__pane-figures active empty"><figure data-id="_i1" data-index="0" class="article__inlineFigure"><h2 class="fig-label">Abstract</h2><img class="rightTab-fig internalNav" src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-14/acs.jmedchem.9b00329/20190719/images/medium/jm-2019-00329v_0016.gif" alt="" id="tgr1" /></img><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-14/acs.jmedchem.9b00329/20190719/images/large/jm-2019-00329v_0016.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.9b00329&amp;id=_i1"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig1" data-index="1" class="article__inlineFigure"><h2 class="fig-label">Figure 1</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-14/acs.jmedchem.9b00329/20190719/images/medium/jm-2019-00329v_0001.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-14/acs.jmedchem.9b00329/20190719/images/large/jm-2019-00329v_0001.jpeg" id="rightTab-gr1" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 1. Well-known BTK inhibitors.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-14/acs.jmedchem.9b00329/20190719/images/large/jm-2019-00329v_0001.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.9b00329&amp;id=fig1"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig2" data-index="2" class="article__inlineFigure"><h2 class="fig-label">Figure 2</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-14/acs.jmedchem.9b00329/20190719/images/medium/jm-2019-00329v_0002.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-14/acs.jmedchem.9b00329/20190719/images/large/jm-2019-00329v_0002.jpeg" id="rightTab-gr2" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 2. (A) Putative binding mode of compound <b>7</b>. The red arrow points out the extended orientation for the hydrophobic groups to grow toward the H3 pocket. Selected residues are displayed in stick representation. Orange dashes represent hydrogen bonds. (B) Docking structure of BTK bound to compound <b>7</b> (green and blue) superimposed on the X-ray cocrystal structure of BTK bound to RN-486 (PDB code: <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=4OTR">4OTR</a>, gray and yellow). RN-486 had a hydrophobic interaction with the H3 pocket which induced a significant position change of key activating tyrosine Tyr551 such that it was in the unphosphorylated state and sequestered from solvent.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-14/acs.jmedchem.9b00329/20190719/images/large/jm-2019-00329v_0002.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.9b00329&amp;id=fig2"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig3" data-index="3" class="article__inlineFigure"><h2 class="fig-label">Figure 3</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-14/acs.jmedchem.9b00329/20190719/images/medium/jm-2019-00329v_0003.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-14/acs.jmedchem.9b00329/20190719/images/large/jm-2019-00329v_0003.jpeg" id="rightTab-gr3" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 3. BTK inhibitors blocked autophosphorylation of Tyr223. (A) Concentration-dependent inhibition by compound <b>6</b>, <b>17</b>, and <b>25</b> in Ramos cells of pervanadate-mediated phosphorylation of BTK Tyr223. The phosphorylation levels of BTK (Tyr223) and total BTK protein levels were analyzed by western blotting. (B) EC<sub>50</sub> curves of compound <b>25</b> and <b>6</b>. Data are mean ± SD of three independent experiments.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-14/acs.jmedchem.9b00329/20190719/images/large/jm-2019-00329v_0003.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.9b00329&amp;id=fig3"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig4" data-index="4" class="article__inlineFigure"><h2 class="fig-label">Figure 4</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-14/acs.jmedchem.9b00329/20190719/images/medium/jm-2019-00329v_0004.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-14/acs.jmedchem.9b00329/20190719/images/large/jm-2019-00329v_0004.jpeg" id="rightTab-gr4" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 4. Docking study of 4-aminoquinoline-3-carboxamide derivatives. (A) Putative binding modes of compound <b>7</b> (orange) and <b>25</b> (green) in the BTK kinase domain (yellow cartoon). Selected residues are shown in stick representation. (B) Summary of receptor interactions with compound <b>25</b>. Dark blue ball (positive charged interaction); cyan and red ball (polar interaction); green ball (hydrophobic interaction); purple arrow (H-bond); red line (π–cation interaction).</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-14/acs.jmedchem.9b00329/20190719/images/large/jm-2019-00329v_0004.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.9b00329&amp;id=fig4"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig5" data-index="5" class="article__inlineFigure"><h2 class="fig-label">Figure 5</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-14/acs.jmedchem.9b00329/20190719/images/medium/jm-2019-00329v_0005.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-14/acs.jmedchem.9b00329/20190719/images/large/jm-2019-00329v_0005.jpeg" id="rightTab-gr5" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 5. Compound <b>25</b> binds to the kinase domain of BTK with a different manner of the existing ATP-mimetic covalent inhibitors. (A) Superposition of the cocrystal structure of Ibrutinib (orange, PDB code: <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=5P9J">5P9J</a>) and docking pose of <b>25</b> (blue). Ibrutinib forms a covalent bond with residue Cys481 and occupies the hydrophobic pocket behind the gatekeeper residue Thr474; <b>25</b> does neither. Residue Cys481 is shown in stick representation. (B) IC<sub>50</sub> values of <b>25</b> and ACP-196 against BTK, BTK<sup><i>C481S</i></sup>, EGFR, and TEC kinases.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-14/acs.jmedchem.9b00329/20190719/images/large/jm-2019-00329v_0005.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.9b00329&amp;id=fig5"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig6" data-index="6" class="article__inlineFigure"><h2 class="fig-label">Figure 6</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-14/acs.jmedchem.9b00329/20190719/images/medium/jm-2019-00329v_0006.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-14/acs.jmedchem.9b00329/20190719/images/large/jm-2019-00329v_0006.jpeg" id="rightTab-gr6" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 6. Efficacy of compound <b>25</b> in the rodent CIA model. (A) Paw swelling rate of four groups, including vehicle, <b>25</b> (10 mg/kg, QD), DXMS (0.2 mg/kg, QD) and naive, male DBA/1 mice, <i>n</i> = 6. Data are represented as mean ± SEM in the graphs. ***<i>P</i> < 0.001, ****<i>P</i> < 0.0001 vs vehicle control by Dunnett’s test. (B) Average body weights of the mice over study days.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-14/acs.jmedchem.9b00329/20190719/images/large/jm-2019-00329v_0006.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.9b00329&amp;id=fig6"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="sch1" data-index="7" class="article__inlineFigure"><h2 class="fig-label">Scheme 1</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-14/acs.jmedchem.9b00329/20190719/images/medium/jm-2019-00329v_0007.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-14/acs.jmedchem.9b00329/20190719/images/large/jm-2019-00329v_0007.jpeg" id="rightTab-gr7" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 1. Synthesis of Quinoline Intermediates<sup>a</sup></div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-14/acs.jmedchem.9b00329/20190719/images/large/jm-2019-00329v_0007.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.9b00329&amp;id=sch1"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label"><sup>a</sup></span>Reagents and conditions: (a) (i) diethyl ethoxymethylenemalonate, 100 °C, 2 h, (ii) Dowtherm A, 250 °C, 4–12 h, 40–60% (b) LiOH, THF/EtOH/H<sub>2</sub>O = 4:4:2, 55 °C, 4–8 h, 75–82%; (c) (i) SOCl<sub>2</sub>, DMF, 70 °C, 3–6 h, (ii) NH<sub>3</sub>·H<sub>2</sub>O, DCM, 0 °C—rt, 1 h, 40–60%; (d) 7 M NH<sub>3</sub> in MeOH, 80 °C, overnight, 50–55%.</p></p></figure><figure data-id="sch2" data-index="8" class="article__inlineFigure"><h2 class="fig-label">Scheme 2</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-14/acs.jmedchem.9b00329/20190719/images/medium/jm-2019-00329v_0008.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-14/acs.jmedchem.9b00329/20190719/images/large/jm-2019-00329v_0008.jpeg" id="rightTab-gr8" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 2. Synthetic Route of Title Compounds <b>9–16</b><sup>a</sup></div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-14/acs.jmedchem.9b00329/20190719/images/large/jm-2019-00329v_0008.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.9b00329&amp;id=sch2"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label"><sup>a</sup></span>Reagents and conditions: (a) diisopropylamine, <i>n</i>-butyllithium, DMF, anhydrous THF, −78 °C—rt, 3 h, 50%; (b) R<sub>1</sub>YH, K<sub>2</sub>CO<sub>3</sub>, DMA, 100 °C, 3–8 h, 35–61%; (c) N<sub>2</sub>H<sub>4</sub>·H<sub>2</sub>O/DME 1:1, 170–200 °C, 24–48 h, 20–62%; (d) <i>t</i>-buLi, tributyl borate, anhydrous THF, −78 °C—rt, overnight, 21–62%; (e) Pd(dppf)Cl<sub>2</sub>, 2 M Na<sub>2</sub>CO<sub>3</sub>, 1,4-dioxane, microwave, 140 °C, 1–2 h, 23–84%</p></p></figure><figure data-id="sch3" data-index="9" class="article__inlineFigure"><h2 class="fig-label">Scheme 3</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-14/acs.jmedchem.9b00329/20190719/images/medium/jm-2019-00329v_0009.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-14/acs.jmedchem.9b00329/20190719/images/large/jm-2019-00329v_0009.jpeg" id="rightTab-gr9" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 3. Synthetic Route of Title Compounds <b>7</b>, <b>25</b>, and <b>17–20</b><sup>a</sup></div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-14/acs.jmedchem.9b00329/20190719/images/large/jm-2019-00329v_0009.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.9b00329&amp;id=sch3"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label"><sup>a</sup></span>Reagents and conditions: (a) Fe, NH<sub>4</sub>Cl, EtOH/H<sub>2</sub>O 3:1, 80 °C, 1 h, 80–90%; (b) (i) 50% HBF<sub>4</sub>, NaNO<sub>2</sub>, H<sub>2</sub>O, 0 °C, 3 h; (ii) AcOK, 18-crown-6, CHCl<sub>3</sub>, rt, 3 h; (iii) Boc<sub>2</sub>O, DMAP, Et<sub>3</sub>N, MeCN, rt, 1 h, 25–35%; (c) (i) Pd(dppf)Cl<sub>2</sub>, B<sub>2</sub>pin<sub>2</sub>, KOAc, 1,4-dioxane, 90 °C, overnight; (ii) TFA/DCM 1:1, rt, 2 h, 55–60%; (d) Pd(dppf)Cl<sub>2</sub>, 2 M Na<sub>2</sub>CO<sub>3</sub>, 1,4-dioxane, 140 °C, microwave, 1–2 h, 44–65%.</p></p></figure><figure data-id="sch4" data-index="10" class="article__inlineFigure"><h2 class="fig-label">Scheme 4</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-14/acs.jmedchem.9b00329/20190719/images/medium/jm-2019-00329v_0010.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-14/acs.jmedchem.9b00329/20190719/images/large/jm-2019-00329v_0010.jpeg" id="rightTab-gr10" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 4. Synthetic Route of Title Compounds <b>21–24</b><sup>a</sup></div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-14/acs.jmedchem.9b00329/20190719/images/large/jm-2019-00329v_0010.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.9b00329&amp;id=sch4"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label"><sup>a</sup></span>Reagents and conditions: (a) <i>N</i>,<i>N</i>′-carbonyldiimidazole, rt, overnight, 75–78%; (b) Pd(dppf)Cl<sub>2</sub>, B<sub>2</sub>pin<sub>2</sub>, KOAc, 1,4-dioxane, 90 °C, 6 h, 80–83%; (c) Pd(dppf)Cl<sub>2</sub>, 2 M Na<sub>2</sub>CO<sub>3</sub>, 1,4-dioxane, microwave, 140 °C, 2 h, 43–51%.</p></p></figure></li><li id="pane-m2" aria-labelledby="pane-m2" class="tab__pane tab__pane-references empty"><div class="refs-header-label"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="rightTab-_i80">References</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_12260" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_12260" class="dropBlock__holder"></div></div></div></div></div><hr /></hr></div><p class="rightTab-references-count">
            This article references 52 other publications.
        </p><ol id="rightTab-references" class="useLabel"><li id="rightTab-ref1"><div class="reference"><strong class="refLabel"><a href="#ref1" class="rightTabRefNumLink">1</a></strong><div class="NLM_citation" id="rightTab-cit1"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Mcinnes, I. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schett, G.</span></span> <span> </span><span class="NLM_article-title">The pathogenesis of rheumatoid arthritis</span>. <i>N. Engl. J. Med.</i> <span class="NLM_year" style="font-weight: bold;">2011</span>,  <span class="NLM_volume"><i>365</i></span>,  <span class="NLM_fpage">2205</span>– <span class="NLM_lpage">2219</span>, <span class="refDoi"> DOI: 10.1056/nejmra1004965</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref1/cit1&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00329&amp;key=10.1056%2Fnejmra1004965" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref1/cit1&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00329&amp;key=22150039" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref1/cit1&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00329&amp;key=1%3ACAS%3A528%3ADC%252BC3MXhs1ajsrrM" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=365&publication_year=2011&pages=2205-2219&author=I.+B.+Mcinnesauthor=G.+Schett&title=The+pathogenesis+of+rheumatoid+arthritis&doi=10.1056%2Fnejmra1004965"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit1R"><div class="casContent"><span class="casTitleNuber">1</span><div class="casTitle"><span class="NLM_cas:atitle">The pathogenesis of rheumatoid arthritis</span></div><div class="casAuthors">McInnes, Lain B.; Schett, Georg</div><div class="citationInfo"><span class="NLM_cas:title">New England Journal of Medicine</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">365</span>
        (<span class="NLM_cas:issue">23</span>),
    <span class="NLM_cas:pages">2205-2219</span>CODEN:
                <span class="NLM_cas:coden">NEJMAG</span>;
        ISSN:<span class="NLM_cas:issn">0028-4793</span>.
    
            (<span class="NLM_cas:orgname">Massachusetts Medical Society</span>)
        </div><div class="casAbstract">A review discusses key pathogenic advances in rheumatoid arthritis, genetics, environmental factors, immunol. processes, inflammation, and structural damage.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrJslDVaG7MxbVg90H21EOLACvtfcHk0lhqxEXuaoh7-A"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXhs1ajsrrM&md5=31a79ccb05bca03f207b15f934b2d52d</span></div><a href="/servlet/linkout?suffix=cit1&amp;dbid=16384&amp;doi=10.1056%2Fnejmra1004965&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1056%252Fnejmra1004965%26sid%3Dliteratum%253Aachs%26aulast%3DMcinnes%26aufirst%3DI.%2BB.%26aulast%3DSchett%26aufirst%3DG.%26atitle%3DThe%2520pathogenesis%2520of%2520rheumatoid%2520arthritis%26jtitle%3DN.%2520Engl.%2520J.%2520Med.%26date%3D2011%26volume%3D365%26spage%3D2205%26epage%3D2219%26doi%3D10.1056%2Fnejmra1004965" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref2"><div class="reference"><strong class="refLabel"><a href="#ref2" class="rightTabRefNumLink">2</a></strong><div class="NLM_citation" id="rightTab-cit2"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Smolen, J. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Aletaha, D.</span></span> <span> </span><span class="NLM_article-title">Rheumatoid arthritis therapy reappraisal: strategies, opportunities and challenges</span>. <i>Nat. Rev. Rheumatol.</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>11</i></span>,  <span class="NLM_fpage">256</span>– <span class="NLM_lpage">289</span>, <span class="refDoi"> DOI: 10.1038/nrrheum.2015.8</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref2/cit2&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00329&amp;key=10.1038%2Fnrrheum.2015.8" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=11&publication_year=2015&pages=256-289&author=J.+S.+Smolenauthor=D.+Aletaha&title=Rheumatoid+arthritis+therapy+reappraisal%3A+strategies%2C+opportunities+and+challenges&doi=10.1038%2Fnrrheum.2015.8"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit2&amp;dbid=16384&amp;doi=10.1038%2Fnrrheum.2015.8&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnrrheum.2015.8%26sid%3Dliteratum%253Aachs%26aulast%3DSmolen%26aufirst%3DJ.%2BS.%26aulast%3DAletaha%26aufirst%3DD.%26atitle%3DRheumatoid%2520arthritis%2520therapy%2520reappraisal%253A%2520strategies%252C%2520opportunities%2520and%2520challenges%26jtitle%3DNat.%2520Rev.%2520Rheumatol.%26date%3D2015%26volume%3D11%26spage%3D256%26epage%3D289%26doi%3D10.1038%2Fnrrheum.2015.8" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref3"><div class="reference"><strong class="refLabel"><a href="#ref3" class="rightTabRefNumLink">3</a></strong><div class="NLM_citation" id="rightTab-cit3"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Kremer, J. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bloom, B. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Breedveld, F. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Coombs, J. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fletcher, M. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gruben, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Krishnaswami, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Burgos-Vargas, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wilkinson, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zerbini, C. A. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zwillich, S. H.</span></span> <span> </span><span class="NLM_article-title">The safety and efficacy of a JAK inhibitor in patients with active rheumatoid arthritis: Results of a double-blind, placebo-controlled phase IIa trial of three dosage levels of CP-690,550 versus placebo</span>. <i>Arthritis Rheum.</i> <span class="NLM_year" style="font-weight: bold;">2009</span>,  <span class="NLM_volume"><i>60</i></span>,  <span class="NLM_fpage">1895</span>– <span class="NLM_lpage">1905</span>, <span class="refDoi"> DOI: 10.1002/art.24567</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref3/cit3&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00329&amp;key=10.1002%2Fart.24567" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref3/cit3&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00329&amp;key=19565475" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref3/cit3&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00329&amp;key=1%3ACAS%3A528%3ADC%252BD1MXptlKktLg%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=60&publication_year=2009&pages=1895-1905&author=J.+M.+Kremerauthor=B.+J.+Bloomauthor=F.+C.+Breedveldauthor=J.+H.+Coombsauthor=M.+P.+Fletcherauthor=D.+Grubenauthor=S.+Krishnaswamiauthor=R.+Burgos-Vargasauthor=B.+Wilkinsonauthor=C.+A.+F.+Zerbiniauthor=S.+H.+Zwillich&title=The+safety+and+efficacy+of+a+JAK+inhibitor+in+patients+with+active+rheumatoid+arthritis%3A+Results+of+a+double-blind%2C+placebo-controlled+phase+IIa+trial+of+three+dosage+levels+of+CP-690%2C550+versus+placebo&doi=10.1002%2Fart.24567"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit3R"><div class="casContent"><span class="casTitleNuber">3</span><div class="casTitle"><span class="NLM_cas:atitle">The safety and efficacy of a JAK inhibitor in patients with active rheumatoid arthritis: results of a double-blind, placebo-controlled phase IIa trial of three dosage levels of CP-690,550 versus placebo</span></div><div class="casAuthors">Kremer, Joel M.; Bloom, Bradley J.; Breedveld, Ferdinand C.; Coombs, John H.; Fletcher, Mark P.; Gruben, David; Krishnaswami, Sriram; Burgos-Vargas, Ruben; Wilkinson, Bethanie; Zerbini, Cristiano A. F.; Zwillich, Samuel H.</div><div class="citationInfo"><span class="NLM_cas:title">Arthritis & Rheumatism</span>
        (<span class="NLM_cas:date">2009</span>),
    <span class="NLM_cas:volume">60</span>
        (<span class="NLM_cas:issue">7</span>),
    <span class="NLM_cas:pages">1895-1905</span>CODEN:
                <span class="NLM_cas:coden">ARHEAW</span>;
        ISSN:<span class="NLM_cas:issn">0004-3591</span>.
    
            (<span class="NLM_cas:orgname">John Wiley & Sons, Inc.</span>)
        </div><div class="casAbstract">To det. the efficacy, safety, and tolerability of 3 different dosages of CP-690,550, a potent, orally active JAK inhibitor, in patients with active rheumatoid arthritis (RA) in whom methotrexate, etanercept, infliximab, or adalimumab caused an inadequate or toxic response.  Patients (n = 264) were randomized equally to receive placebo, 5 mg of CP-690,550,15 mg of CP-690,550, or 30 mg of CP-690,550 twice daily for 6 wk, and were followed up for an addnl. 6 wk after treatment.  The primary efficacy end point was the American College of Rheumatol. 20% improvement criteria (ACR20) response rate at 6 wk.  By week 6, the ACR20 response rates were 70.5%, 81.2%, and 76.8% in the 5 mg, 15 mg, and 30 mg twice daily groups, resp., compared with 29.2% in the placebo group (P < 0.001).  Improvements in disease activity in CP-690,550-treated patients compared with placebo were seen in all treatment groups as early as week 1.  ACR50 and ACR70 response rates significantly improved in all treatment groups by week 4.  The most common adverse events reported were headache and nausea.  The infection rate in both the 15 mg twice daily group and the 30 mg twice daily group was 30.4% (vs. 26.2% in the placebo group).  No opportunistic infections or deaths occurred.  Increases in mean low-d. lipoprotein cholesterol and high-d. lipoprotein cholesterol levels, and increases in mean serum creatinine level (0.04-0.06 mg/dL) were seen in all CP-690,550 treatment arms.  Our findings indicate that CP-690,550 is efficacious in the treatment of RA, resulting in rapid, statistically significant, and clin. meaningful redns. in the signs and symptoms of RA.  Further studies of CP-690,550 in RA are warranted.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoBhxBhh_mG7rVg90H21EOLACvtfcHk0lhqxEXuaoh7-A"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1MXptlKktLg%253D&md5=ab5fb34e43d8643871560c67bbbca07d</span></div><a href="/servlet/linkout?suffix=cit3&amp;dbid=16384&amp;doi=10.1002%2Fart.24567&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fart.24567%26sid%3Dliteratum%253Aachs%26aulast%3DKremer%26aufirst%3DJ.%2BM.%26aulast%3DBloom%26aufirst%3DB.%2BJ.%26aulast%3DBreedveld%26aufirst%3DF.%2BC.%26aulast%3DCoombs%26aufirst%3DJ.%2BH.%26aulast%3DFletcher%26aufirst%3DM.%2BP.%26aulast%3DGruben%26aufirst%3DD.%26aulast%3DKrishnaswami%26aufirst%3DS.%26aulast%3DBurgos-Vargas%26aufirst%3DR.%26aulast%3DWilkinson%26aufirst%3DB.%26aulast%3DZerbini%26aufirst%3DC.%2BA.%2BF.%26aulast%3DZwillich%26aufirst%3DS.%2BH.%26atitle%3DThe%2520safety%2520and%2520efficacy%2520of%2520a%2520JAK%2520inhibitor%2520in%2520patients%2520with%2520active%2520rheumatoid%2520arthritis%253A%2520Results%2520of%2520a%2520double-blind%252C%2520placebo-controlled%2520phase%2520IIa%2520trial%2520of%2520three%2520dosage%2520levels%2520of%2520CP-690%252C550%2520versus%2520placebo%26jtitle%3DArthritis%2520Rheum.%26date%3D2009%26volume%3D60%26spage%3D1895%26epage%3D1905%26doi%3D10.1002%2Fart.24567" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref4"><div class="reference"><strong class="refLabel"><a href="#ref4" class="rightTabRefNumLink">4</a></strong><div class="NLM_citation" id="rightTab-cit4"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Gadina, M.</span></span> <span> </span><span class="NLM_article-title">Advances in kinase inhibition</span>. <i>Curr. Opin. Rheumatol.</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>26</i></span>,  <span class="NLM_fpage">237</span>– <span class="NLM_lpage">243</span>, <span class="refDoi"> DOI: 10.1097/bor.0000000000000023</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref4/cit4&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00329&amp;key=10.1097%2Fbor.0000000000000023" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref4/cit4&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00329&amp;key=24419749" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref4/cit4&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00329&amp;key=1%3ACAS%3A528%3ADC%252BC2cXitFWmtbs%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=26&publication_year=2014&pages=237-243&author=M.+Gadina&title=Advances+in+kinase+inhibition&doi=10.1097%2Fbor.0000000000000023"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit4R"><div class="casContent"><span class="casTitleNuber">4</span><div class="casTitle"><span class="NLM_cas:atitle">Advances in kinase inhibition: treating rheumatic diseases and beyond</span></div><div class="casAuthors">Gadina, Massimo</div><div class="citationInfo"><span class="NLM_cas:title">Current Opinion in Rheumatology</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">26</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">237-243</span>CODEN:
                <span class="NLM_cas:coden">CORHES</span>;
        ISSN:<span class="NLM_cas:issn">1040-8711</span>.
    
            (<span class="NLM_cas:orgname">Lippincott Williams & Wilkins</span>)
        </div><div class="casAbstract">Purpose of review: Kinases inhibitors are now used for the treatment of autoimmune diseases.  Here, the most recent findings related to their mechanism of action and some of the newest mols. and targets which are being investigated for autoimmune and inflammatory disorders are reviewed.  Recent findings: Similarly to p38 inhibitors, current spleen tyrosine kinase inhibitors have not fulfilled the expectations of researchers and clinicians, and will likely not be used therapeutically in autoimmunity.  Bruton's tyrosine kinase inhibitors remain in the preclin. phase.  Studies on the mechanism of action of successful Janus kinase (Jak) inhibitors have revealed that, apart from T and B cells, bone cells such as osteoclasts and innate immunity cells such as dendritic cells are pos. affected.  More specific, novel Jak inhibitors are now in clin. trials and newer Jak inhibitors are being developed.  Other kinases are emerging from basic studies as potentially druggable and will surely be investigated.  Summary: First-generation pan-Jak inhibitors can be useful for a wide variety of diseases.  They act on adaptive as well as innate immune cells and can promote tolerance.  More specific inhibitors will soon be available and these may be used in a disease-specific manner.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGr4w_eWCaCWi7Vg90H21EOLACvtfcHk0lhqxEXuaoh7-A"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXitFWmtbs%253D&md5=1e84017807d214979d8fce85e796157d</span></div><a href="/servlet/linkout?suffix=cit4&amp;dbid=16384&amp;doi=10.1097%2Fbor.0000000000000023&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1097%252Fbor.0000000000000023%26sid%3Dliteratum%253Aachs%26aulast%3DGadina%26aufirst%3DM.%26atitle%3DAdvances%2520in%2520kinase%2520inhibition%26jtitle%3DCurr.%2520Opin.%2520Rheumatol.%26date%3D2014%26volume%3D26%26spage%3D237%26epage%3D243%26doi%3D10.1097%2Fbor.0000000000000023" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref5"><div class="reference"><strong class="refLabel"><a href="#ref5" class="rightTabRefNumLink">5</a></strong><div class="NLM_citation" id="rightTab-cit5"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Whyburn, L. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Halcomb, K. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Contreras, C. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lowell, C. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Witte, O. N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Satterthwaite, A. B.</span></span> <span> </span><span class="NLM_article-title">Reduced Dosage of Bruton’s Tyrosine Kinase Uncouples B Cell Hyperresponsiveness from Autoimmunity in lyn–/– Mice</span>. <i>J. Immunol.</i> <span class="NLM_year" style="font-weight: bold;">2003</span>,  <span class="NLM_volume"><i>171</i></span>,  <span class="NLM_fpage">1850</span>– <span class="NLM_lpage">1858</span>, <span class="refDoi"> DOI: 10.4049/jimmunol.171.4.1850</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref5/cit5&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00329&amp;key=10.4049%2Fjimmunol.171.4.1850" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref5/cit5&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00329&amp;key=12902486" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref5/cit5&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00329&amp;key=1%3ACAS%3A528%3ADC%252BD3sXmtVWntbc%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=171&publication_year=2003&pages=1850-1858&author=L.+R.+Whyburnauthor=K.+E.+Halcombauthor=C.+M.+Contrerasauthor=C.+A.+Lowellauthor=O.+N.+Witteauthor=A.+B.+Satterthwaite&title=Reduced+Dosage+of+Bruton%E2%80%99s+Tyrosine+Kinase+Uncouples+B+Cell+Hyperresponsiveness+from+Autoimmunity+in+lyn%E2%80%93%2F%E2%80%93+Mice&doi=10.4049%2Fjimmunol.171.4.1850"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit5R"><div class="casContent"><span class="casTitleNuber">5</span><div class="casTitle"><span class="NLM_cas:atitle">Reduced Dosage of Bruton's Tyrosine Kinase Uncouples B Cell Hyperresponsiveness from Autoimmunity in lyn-/- Mice</span></div><div class="casAuthors">Whyburn, Lindsey R.; Halcomb, Kristina E.; Contreras, Cristina M.; Lowell, Clifford A.; Witte, Owen N.; Satterthwaite, Anne B.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Immunology</span>
        (<span class="NLM_cas:date">2003</span>),
    <span class="NLM_cas:volume">171</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">1850-1858</span>CODEN:
                <span class="NLM_cas:coden">JOIMA3</span>;
        ISSN:<span class="NLM_cas:issn">0022-1767</span>.
    
            (<span class="NLM_cas:orgname">American Association of Immunologists</span>)
        </div><div class="casAbstract">The development of autoimmunity is correlated with heightened sensitivity of B cells to B cell Ag receptor (BCR) crosslinking.  BCR signals are down-regulated by Lyn, which phosphorylates inhibitory receptors.  Lyn-/- mice have reduced BCR signaling thresholds and develop autoantibodies, glomerulonephritis, splenomegaly due to myeloid hyperplasia, and increased B-1 cell nos.  Bruton's tyrosine kinase (Btk), a crit. component of BCR signaling pathways, is required for autoantibody prodn. in lyn-/- mice.  It is unclear whether Btk mediates autoimmunity at the level of BCR signal transduction or B cell development, given that lyn-/-Btk-/- mice have a severe redn. in conventional B and B-1 cell nos.  To address this issue, we crossed a transgene expressing a low dosage of Btk (Btklow) in B cells to lyn-/-Btk-/- mice.  Conventional B cell populations were restored to levels similar to those in lyn-/- mice.  These cells were as hypersensitive to BCR crosslinking as lyn-/- B cells as measured by proliferation, Ca2+ flux, and activation of extracellular signal-regulated kinase and Akt.  However, lyn-/-Btklow mice did not produce anti-ssDNA, anti-dsDNA, anti-histone, or anti-histone/DNA IgM or IgG.  They also lacked B-1 cells and did not exhibit splenomegaly.  Thus, B cell hyperresponsiveness is insufficient for autoimmunity in lyn-/- mice.  These studies implicate B-1 and/or myeloid cells as key contributors to the lyn-/- autoimmune phenotype.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqfv6aQDPmpNbVg90H21EOLACvtfcHk0lh2Uuhyy5_7CQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3sXmtVWntbc%253D&md5=4a83a9bb23bec2c63db3447c519da533</span></div><a href="/servlet/linkout?suffix=cit5&amp;dbid=16384&amp;doi=10.4049%2Fjimmunol.171.4.1850&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.4049%252Fjimmunol.171.4.1850%26sid%3Dliteratum%253Aachs%26aulast%3DWhyburn%26aufirst%3DL.%2BR.%26aulast%3DHalcomb%26aufirst%3DK.%2BE.%26aulast%3DContreras%26aufirst%3DC.%2BM.%26aulast%3DLowell%26aufirst%3DC.%2BA.%26aulast%3DWitte%26aufirst%3DO.%2BN.%26aulast%3DSatterthwaite%26aufirst%3DA.%2BB.%26atitle%3DReduced%2520Dosage%2520of%2520Bruton%25E2%2580%2599s%2520Tyrosine%2520Kinase%2520Uncouples%2520B%2520Cell%2520Hyperresponsiveness%2520from%2520Autoimmunity%2520in%2520lyn%25E2%2580%2593%252F%25E2%2580%2593%2520Mice%26jtitle%3DJ.%2520Immunol.%26date%3D2003%26volume%3D171%26spage%3D1850%26epage%3D1858%26doi%3D10.4049%2Fjimmunol.171.4.1850" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref6"><div class="reference"><strong class="refLabel"><a href="#ref6" class="rightTabRefNumLink">6</a></strong><div class="NLM_citation" id="rightTab-cit6"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Brunner, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Müller, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wirth, T.</span></span> <span> </span><span class="NLM_article-title">Bruton’s Tyrosine Kinase is involved in innate and adaptive immunity</span>. <i>Histol. Histopathol.</i> <span class="NLM_year" style="font-weight: bold;">2005</span>,  <span class="NLM_volume"><i>20</i></span>,  <span class="NLM_fpage">945</span>, <span class="refDoi"> DOI: 10.14670/HH-20.945</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref6/cit6&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00329&amp;key=10.14670%2FHH-20.945" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref6/cit6&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00329&amp;key=15944945" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref6/cit6&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00329&amp;key=1%3ACAS%3A528%3ADC%252BD2MXpsFKjtL4%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=20&publication_year=2005&pages=945&author=C.+Brunnerauthor=B.+M%C3%BCllerauthor=T.+Wirth&title=Bruton%E2%80%99s+Tyrosine+Kinase+is+involved+in+innate+and+adaptive+immunity&doi=10.14670%2FHH-20.945"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit6R"><div class="casContent"><span class="casTitleNuber">6</span><div class="casTitle"><span class="NLM_cas:atitle">Bruton's Tyrosine Kinase is involved in innate and adaptive immunity</span></div><div class="casAuthors">Brunner, C.; Mueller, B.; Wirth, T.</div><div class="citationInfo"><span class="NLM_cas:title">Histology and Histopathology</span>
        (<span class="NLM_cas:date">2005</span>),
    <span class="NLM_cas:volume">20</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">945-955</span>CODEN:
                <span class="NLM_cas:coden">HIHIES</span>;
        ISSN:<span class="NLM_cas:issn">0213-3911</span>.
    
            (<span class="NLM_cas:orgname">Jimenez Godoy, S.A.</span>)
        </div><div class="casAbstract">A review.  Btk is a cytoplasmic tyrosine kinase, which is mainly involved in B cell receptor signaling.  Gene targeting expts. revealed that Btk is important for B cell development and function.  However, Btk is not only expressed in B cells, but also in most other hematopoietic lineages except for T cells and plasma cells.  Recently we found that Btk is involved in Toll-like receptor signaling.  Toll-like receptors play an important role in innate immunity.  They are highly expressed on mast cells, macrophages and dendritic cells, which are essential for the recognition and consequently for the elimination of microbial pathogens.  Therefore Btk might play an important role for the function of immunocompetent cells of innate as well as adaptive immunity.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqQA-9NFdeNr7Vg90H21EOLACvtfcHk0lh2Uuhyy5_7CQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2MXpsFKjtL4%253D&md5=97cbcc5df2704d4b58933085ab8ff929</span></div><a href="/servlet/linkout?suffix=cit6&amp;dbid=16384&amp;doi=10.14670%2FHH-20.945&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.14670%252FHH-20.945%26sid%3Dliteratum%253Aachs%26aulast%3DBrunner%26aufirst%3DC.%26aulast%3DM%25C3%25BCller%26aufirst%3DB.%26aulast%3DWirth%26aufirst%3DT.%26atitle%3DBruton%25E2%2580%2599s%2520Tyrosine%2520Kinase%2520is%2520involved%2520in%2520innate%2520and%2520adaptive%2520immunity%26jtitle%3DHistol.%2520Histopathol.%26date%3D2005%26volume%3D20%26spage%3D945%26doi%3D10.14670%2FHH-20.945" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref7"><div class="reference"><strong class="refLabel"><a href="#ref7" class="rightTabRefNumLink">7</a></strong><div class="NLM_citation" id="rightTab-cit7"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Satterthwaite, A. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Witte, O. N.</span></span> <span> </span><span class="NLM_article-title">Btk function in B cell development and response</span>. <i>Semin. Immunol.</i> <span class="NLM_year" style="font-weight: bold;">1998</span>,  <span class="NLM_volume"><i>10</i></span>,  <span class="NLM_fpage">309</span>– <span class="NLM_lpage">316</span>, <span class="refDoi"> DOI: 10.1006/smim.1998.0123</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref7/cit7&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00329&amp;key=10.1006%2Fsmim.1998.0123" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref7/cit7&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00329&amp;key=9695187" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref7/cit7&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00329&amp;key=1%3ACAS%3A528%3ADyaK1cXltlCiuro%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=10&publication_year=1998&pages=309-316&author=A.+B.+Satterthwaiteauthor=Z.+Liauthor=O.+N.+Witte&title=Btk+function+in+B+cell+development+and+response&doi=10.1006%2Fsmim.1998.0123"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit7R"><div class="casContent"><span class="casTitleNuber">7</span><div class="casTitle"><span class="NLM_cas:atitle">Btk function in B cell development and response</span></div><div class="casAuthors">Satterthwaite, Anne B.; Li, Zuomei; Witte, Owen N.</div><div class="citationInfo"><span class="NLM_cas:title">Seminars in Immunology</span>
        (<span class="NLM_cas:date">1998</span>),
    <span class="NLM_cas:volume">10</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">309-316</span>CODEN:
                <span class="NLM_cas:coden">SEIME2</span>;
        ISSN:<span class="NLM_cas:issn">1044-5323</span>.
    
            (<span class="NLM_cas:orgname">Academic Press</span>)
        </div><div class="casAbstract">A review with 85 refs.  Mutations in Bruton's tyrosine kinase (Btk) result in the B cell immunodeficiencies XLA (X-linked agammaglobulinemia) in humans and Xid (X-linked immunodeficiency) in mice.  Both the maintenance of peripheral B cell nos. and their response to B cell antigen receptor (BCR) crosslinking depend on Btk.  Btk integrates signals from multiple cell surface receptors, including BCR and G-protein coupled receptors.  These Btk dependent signals control B cell proliferation and survival by mediating Ca2+ flux, activating JNK and p38 and inducing cell cycle regulatory genes.  (c) 1998 Academic Press.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqVrVOyUeT25bVg90H21EOLACvtfcHk0lj_Eb-c5g2Tmg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK1cXltlCiuro%253D&md5=f03605bc9f39d663d28794c7b7e40138</span></div><a href="/servlet/linkout?suffix=cit7&amp;dbid=16384&amp;doi=10.1006%2Fsmim.1998.0123&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1006%252Fsmim.1998.0123%26sid%3Dliteratum%253Aachs%26aulast%3DSatterthwaite%26aufirst%3DA.%2BB.%26aulast%3DLi%26aufirst%3DZ.%26aulast%3DWitte%26aufirst%3DO.%2BN.%26atitle%3DBtk%2520function%2520in%2520B%2520cell%2520development%2520and%2520response%26jtitle%3DSemin.%2520Immunol.%26date%3D1998%26volume%3D10%26spage%3D309%26epage%3D316%26doi%3D10.1006%2Fsmim.1998.0123" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref8"><div class="reference"><strong class="refLabel"><a href="#ref8" class="rightTabRefNumLink">8</a></strong><div class="NLM_citation" id="rightTab-cit8"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Khan, W. N.</span></span> <span> </span><span class="NLM_article-title">Regulation of B lymphocyte development and activation by Bruton’s tyrosine kinase</span>. <i>Immunol. Res.</i> <span class="NLM_year" style="font-weight: bold;">2001</span>,  <span class="NLM_volume"><i>23</i></span>,  <span class="NLM_fpage">147</span>– <span class="NLM_lpage">156</span>, <span class="refDoi"> DOI: 10.1385/ir:23:2-3:147</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref8/cit8&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00329&amp;key=10.1385%2Fir%3A23%3A2-3%3A147" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref8/cit8&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00329&amp;key=11444380" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref8/cit8&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00329&amp;key=1%3ACAS%3A528%3ADC%252BD3MXltFWqsb0%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=23&publication_year=2001&pages=147-156&author=W.+N.+Khan&title=Regulation+of+B+lymphocyte+development+and+activation+by+Bruton%E2%80%99s+tyrosine+kinase&doi=10.1385%2Fir%3A23%3A2-3%3A147"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit8R"><div class="casContent"><span class="casTitleNuber">8</span><div class="casTitle"><span class="NLM_cas:atitle">Regulation of B lymphocyte development and activation by Bruton's tyrosine kinase</span></div><div class="casAuthors">Khan, Wasif N.</div><div class="citationInfo"><span class="NLM_cas:title">Immunologic Research</span>
        (<span class="NLM_cas:date">2001</span>),
    <span class="NLM_cas:volume">23</span>
        (<span class="NLM_cas:issue">2 & 3</span>),
    <span class="NLM_cas:pages">147-156</span>CODEN:
                <span class="NLM_cas:coden">IMRSEB</span>;
        ISSN:<span class="NLM_cas:issn">0257-277X</span>.
    
            (<span class="NLM_cas:orgname">Humana Press Inc.</span>)
        </div><div class="casAbstract">A review discussed the role of Bruton's tyrosine kinase in B lymphocyte development and activation.  The generation and maintenance of B lymphocytes is controlled by biochem. signals transmitted by the B cell antigen receptor (BCR) complex.  These signals are transduced by multiple cytoplasmic protein tyrosine kinases (PTKs) including Lyn, Syk, and Bruton's tyrosine kinase (BTK).  Upon BCR engagement, these PTKs activate downstream effectors, including transcription factors that modulate gene expression.  In turn, activation of downstream effectors is crit. for B cell survival, cell cycle progression, and antibody prodn.  Our studies focus on the role of BTK in these biol. responses.  We have discovered that BTK is required for activation of the BCR-responsive transcription factor, NF-κB.  Furthermore, BTK-dependent activation of NF-κB is essential for reprogramming the expression of genes that control B cell survival and proliferation.  The biochem. mechanisms by which BTK regulates signaling components that activate NF-κB, and the identification of BTK-responsive genes are under investigation.  Elucidation of these regulatory mechanisms is expected to reveal new therapeutic targets for B cell pathologies involving defects in BTK, including X-linked agammaglobulinemia (XLA).</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrx0btKIFSX9LVg90H21EOLACvtfcHk0lj_Eb-c5g2Tmg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3MXltFWqsb0%253D&md5=564d950f06ab14daff2b45f5a3d863f4</span></div><a href="/servlet/linkout?suffix=cit8&amp;dbid=16384&amp;doi=10.1385%2Fir%3A23%3A2-3%3A147&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1385%252Fir%253A23%253A2-3%253A147%26sid%3Dliteratum%253Aachs%26aulast%3DKhan%26aufirst%3DW.%2BN.%26atitle%3DRegulation%2520of%2520B%2520lymphocyte%2520development%2520and%2520activation%2520by%2520Bruton%25E2%2580%2599s%2520tyrosine%2520kinase%26jtitle%3DImmunol.%2520Res.%26date%3D2001%26volume%3D23%26spage%3D147%26epage%3D156%26doi%3D10.1385%2Fir%3A23%3A2-3%3A147" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref9"><div class="reference"><strong class="refLabel"><a href="#ref9" class="rightTabRefNumLink">9</a></strong><div class="NLM_citation" id="rightTab-cit9"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Kil, L. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">de Bruijn, M. J. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">van Nimwegen, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Corneth, O. B. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">van
Hamburg, J. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dingjan, G. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Thaiss, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rimmelzwaan, G. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Elewaut, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Delsing, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">van Loo, P. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hendriks, R. W.</span></span> <span> </span><span class="NLM_article-title">Btk levels set the threshold for B-cell activation and negative selection of autoreactive B cells in mice</span>. <i>Blood</i> <span class="NLM_year" style="font-weight: bold;">2012</span>,  <span class="NLM_volume"><i>119</i></span>,  <span class="NLM_fpage">3744</span>– <span class="NLM_lpage">3756</span>, <span class="refDoi"> DOI: 10.1182/blood-2011-12-397919</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref9/cit9&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00329&amp;key=10.1182%2Fblood-2011-12-397919" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref9/cit9&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00329&amp;key=22383797" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref9/cit9&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00329&amp;key=1%3ACAS%3A528%3ADC%252BC38XmslWms7k%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=119&publication_year=2012&pages=3744-3756&author=L.+P.+Kilauthor=M.+J.+W.+de+Bruijnauthor=M.+van+Nimwegenauthor=O.+B.+J.+Cornethauthor=J.+P.+van%0AHamburgauthor=G.+M.+Dingjanauthor=F.+Thaissauthor=G.+F.+Rimmelzwaanauthor=D.+Elewautauthor=D.+Delsingauthor=P.+F.+van+Looauthor=R.+W.+Hendriks&title=Btk+levels+set+the+threshold+for+B-cell+activation+and+negative+selection+of+autoreactive+B+cells+in+mice&doi=10.1182%2Fblood-2011-12-397919"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit9R"><div class="casContent"><span class="casTitleNuber">9</span><div class="casTitle"><span class="NLM_cas:atitle">Btk levels set the threshold for B-cell activation and negative selection of autoreactive B cells in mice</span></div><div class="casAuthors">Kil, Laurens P.; de Bruijn, Marjolein J. W.; van Nimwegen, Menno; Corneth, Odilia B. J.; van Hamburg, Jan Piet; Dingjan, Gemma M.; Thaiss, Friedrich; Rimmelzwaan, Guus F.; Elewaut, Dirk; Delsing, Dianne; van Loo, Pieter Fokko; Hendriks, Rudi W.</div><div class="citationInfo"><span class="NLM_cas:title">Blood</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">119</span>
        (<span class="NLM_cas:issue">16</span>),
    <span class="NLM_cas:pages">3744-3756</span>CODEN:
                <span class="NLM_cas:coden">BLOOAW</span>;
        ISSN:<span class="NLM_cas:issn">0006-4971</span>.
    
            (<span class="NLM_cas:orgname">American Society of Hematology</span>)
        </div><div class="casAbstract">On antigen binding by the B-cell receptor (BCR), B cells up-regulate protein expression of the key downstream signaling mol. Bruton tyrosine kinase (Btk), but the effects of Btk up-regulation on B-cell function are unknown.  Here, we show that transgenic mice overexpressing Btk specifically in B cells spontaneously formed germinal centers and manifested increased plasma cell nos., leading to antinuclear autoantibody prodn. and systemic lupus erythematosus (SLE)-like autoimmune pathol. affecting kidneys, lungs, and salivary glands.  Autoimmunity was fully dependent on Btk kinase activity, because Btk inhibitor treatment (PCI-32765) could normalize B-cell activation and differentiation, and because autoantibodies were absent in Btk transgenic mice overexpressing a kinase inactive Btk mutant.  B cells overexpressing wild-type Btk were selectively hyperresponsive to BCR stimulation and showed enhanced Ca2+ influx, nuclear factor (NF)-κB activation, resistance to Fas-mediated apoptosis, and defective elimination of selfreactive B cells in vivo.  These findings unravel a crucial role for Btk in setting the threshold for B-cell activation and counterselection of autoreactive B cells, making Btk an attractive therapeutic target in systemic autoimmune disease such as SLE.  The finding of in vivo pathol. assocd. with Btk overexpression may have important implications for the development of gene therapy strategies for X-linked agammaglobulinemia, the immunodeficiency assocd. with mutations in BTK.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpCZGtsn4i1lrVg90H21EOLACvtfcHk0lj_Eb-c5g2Tmg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38XmslWms7k%253D&md5=ba36239b826343860580cfecea64c850</span></div><a href="/servlet/linkout?suffix=cit9&amp;dbid=16384&amp;doi=10.1182%2Fblood-2011-12-397919&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1182%252Fblood-2011-12-397919%26sid%3Dliteratum%253Aachs%26aulast%3DKil%26aufirst%3DL.%2BP.%26aulast%3Dde%2BBruijn%26aufirst%3DM.%2BJ.%2BW.%26aulast%3Dvan%2BNimwegen%26aufirst%3DM.%26aulast%3DCorneth%26aufirst%3DO.%2BB.%2BJ.%26aulast%3Dvan%2BHamburg%26aufirst%3DJ.%2BP.%26aulast%3DDingjan%26aufirst%3DG.%2BM.%26aulast%3DThaiss%26aufirst%3DF.%26aulast%3DRimmelzwaan%26aufirst%3DG.%2BF.%26aulast%3DElewaut%26aufirst%3DD.%26aulast%3DDelsing%26aufirst%3DD.%26aulast%3Dvan%2BLoo%26aufirst%3DP.%2BF.%26aulast%3DHendriks%26aufirst%3DR.%2BW.%26atitle%3DBtk%2520levels%2520set%2520the%2520threshold%2520for%2520B-cell%2520activation%2520and%2520negative%2520selection%2520of%2520autoreactive%2520B%2520cells%2520in%2520mice%26jtitle%3DBlood%26date%3D2012%26volume%3D119%26spage%3D3744%26epage%3D3756%26doi%3D10.1182%2Fblood-2011-12-397919" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref10"><div class="reference"><strong class="refLabel"><a href="#ref10" class="rightTabRefNumLink">10</a></strong><div class="NLM_citation" id="rightTab-cit10"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Whang, J. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chang, B. Y.</span></span> <span> </span><span class="NLM_article-title">Bruton’s tyrosine kinase inhibitors for the treatment of rheumatoid arthritis</span>. <i>Drug Discovery Today</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>19</i></span>,  <span class="NLM_fpage">1200</span>– <span class="NLM_lpage">1204</span>, <span class="refDoi"> DOI: 10.1016/j.drudis.2014.03.028</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref10/cit10&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00329&amp;key=10.1016%2Fj.drudis.2014.03.028" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref10/cit10&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00329&amp;key=24721226" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref10/cit10&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00329&amp;key=1%3ACAS%3A528%3ADC%252BC2cXmvV2ntLw%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=19&publication_year=2014&pages=1200-1204&author=J.+A.+Whangauthor=B.+Y.+Chang&title=Bruton%E2%80%99s+tyrosine+kinase+inhibitors+for+the+treatment+of+rheumatoid+arthritis&doi=10.1016%2Fj.drudis.2014.03.028"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit10R"><div class="casContent"><span class="casTitleNuber">10</span><div class="casTitle"><span class="NLM_cas:atitle">Bruton's tyrosine kinase inhibitors for the treatment of rheumatoid arthritis</span></div><div class="casAuthors">Whang, Jennifer A.; Chang, Betty Y.</div><div class="citationInfo"><span class="NLM_cas:title">Drug Discovery Today</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">19</span>
        (<span class="NLM_cas:issue">8</span>),
    <span class="NLM_cas:pages">1200-1204</span>CODEN:
                <span class="NLM_cas:coden">DDTOFS</span>;
        ISSN:<span class="NLM_cas:issn">1359-6446</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Ltd.</span>)
        </div><div class="casAbstract">A review.  The function and role of Bruton's tyrosine kinase (BTK) in human B cell development was demonstrated by its assocn. with X-linked agammaglobulinemia (XLA) manifested by a substantial redn. in Igs and B cells.  BTK has a crucial role in pre-B cell receptor (BCR) and BCR signaling during normal B cell development and activation.  Aberrant BCR signaling is assocd. with autoimmune diseases, such as rheumatoid arthritis (RA).  In addn., BTK is also expressed in myeloid cell populations, including monocytes, macrophages, neutrophils and mast cells.  These innate cells infiltrate the synovial cavity and produce inflammatory cytokines, aggravating arthritic symptoms.  In myeloid cell populations, BTK functions downstream of the Fcγ receptors (FcγR) and Fcε receptors (FcεR) [1,2].  In the absence of BTK, FcR-mediated functions, such as cytokine prodn., are impaired.  In addn., Xid mice, which have a mutation in BTK, have decreased susceptibility to developing collagen-induced arthritis (CIA) [3].  Given that BTK is involved in multiple signaling pathways downstream of the BCR and FcR, it is an attractive therapeutic target for RA.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqrfM0cjYRpt7Vg90H21EOLACvtfcHk0liExPduqseCEg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXmvV2ntLw%253D&md5=59de1ccd677bb64001719daf5e83952e</span></div><a href="/servlet/linkout?suffix=cit10&amp;dbid=16384&amp;doi=10.1016%2Fj.drudis.2014.03.028&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.drudis.2014.03.028%26sid%3Dliteratum%253Aachs%26aulast%3DWhang%26aufirst%3DJ.%2BA.%26aulast%3DChang%26aufirst%3DB.%2BY.%26atitle%3DBruton%25E2%2580%2599s%2520tyrosine%2520kinase%2520inhibitors%2520for%2520the%2520treatment%2520of%2520rheumatoid%2520arthritis%26jtitle%3DDrug%2520Discovery%2520Today%26date%3D2014%26volume%3D19%26spage%3D1200%26epage%3D1204%26doi%3D10.1016%2Fj.drudis.2014.03.028" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref11"><div class="reference"><strong class="refLabel"><a href="#ref11" class="rightTabRefNumLink">11</a></strong><div class="NLM_citation" id="rightTab-cit11"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Norman, P.</span></span> <span> </span><span class="NLM_article-title">Investigational Bruton’s tyrosine kinase inhibitors for the treatment of rheumatoid arthritis</span>. <i>Expert Opin. Invest. Drugs</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>25</i></span>,  <span class="NLM_fpage">891</span>– <span class="NLM_lpage">899</span>, <span class="refDoi"> DOI: 10.1080/13543784.2016.1182499</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref11/cit11&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00329&amp;key=10.1080%2F13543784.2016.1182499" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref11/cit11&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00329&amp;key=27148767" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref11/cit11&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00329&amp;key=1%3ACAS%3A528%3ADC%252BC28Xnslentb0%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=25&publication_year=2016&pages=891-899&author=P.+Norman&title=Investigational+Bruton%E2%80%99s+tyrosine+kinase+inhibitors+for+the+treatment+of+rheumatoid+arthritis&doi=10.1080%2F13543784.2016.1182499"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit11R"><div class="casContent"><span class="casTitleNuber">11</span><div class="casTitle"><span class="NLM_cas:atitle">Investigational Bruton's tyrosine kinase inhibitors for the treatment of rheumatoid arthritis</span></div><div class="casAuthors">Norman, Peter</div><div class="citationInfo"><span class="NLM_cas:title">Expert Opinion on Investigational Drugs</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">25</span>
        (<span class="NLM_cas:issue">8</span>),
    <span class="NLM_cas:pages">891-899</span>CODEN:
                <span class="NLM_cas:coden">EOIDER</span>;
        ISSN:<span class="NLM_cas:issn">1354-3784</span>.
    
            (<span class="NLM_cas:orgname">Taylor & Francis Ltd.</span>)
        </div><div class="casAbstract">The Tec family of non-receptor tyrosine kinases comprises five members.  The cellular expression and function of these kinases has implicated them as potential drug targets for the treatment of both malignant and autoimmune diseases.  Most attention has focused on inhibitors of BTK kinase with ibrutinib already approved for the treatment of mantle cell lymphoma and chronic lymphocytic leukemia.  Multiple BTK inhibitors are being developed for both oncol. and autoimmune disease indications.  BTK inhibitors being evaluated in rheumatoid arthritis are considered.  Both inhibitors which have progressed to early clin. development, and those demonstrating activity in rodent models of arthritis are reviewed.  These include both reversible and irreversible inhibitors of the kinase, most of which target the cysteine-481 residue of BTK.  The selectivity of these inhibitors for Tec family kinases is considered.  Developing inhibitors of any kinase to treat of rheumatoid arthritis has proved problematic with regard to both efficacy and selectivity.  It is anticipated that the more selective BTK inhibitors may prove more useful in treating arthritis, with the use of reversible inhibitors possibly offering a better strategy.  Chronic dosing may exacerbate the emergence of drug resistance, with resistant mutations already obsd. in ibrutinib-treated patients.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoQsRSjuYxYa7Vg90H21EOLACvtfcHk0liExPduqseCEg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28Xnslentb0%253D&md5=037f60be680ad282725fe8f7619f1212</span></div><a href="/servlet/linkout?suffix=cit11&amp;dbid=16384&amp;doi=10.1080%2F13543784.2016.1182499&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1080%252F13543784.2016.1182499%26sid%3Dliteratum%253Aachs%26aulast%3DNorman%26aufirst%3DP.%26atitle%3DInvestigational%2520Bruton%25E2%2580%2599s%2520tyrosine%2520kinase%2520inhibitors%2520for%2520the%2520treatment%2520of%2520rheumatoid%2520arthritis%26jtitle%3DExpert%2520Opin.%2520Invest.%2520Drugs%26date%3D2016%26volume%3D25%26spage%3D891%26epage%3D899%26doi%3D10.1080%2F13543784.2016.1182499" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref12"><div class="reference"><strong class="refLabel"><a href="#ref12" class="rightTabRefNumLink">12</a></strong><div class="NLM_citation" id="rightTab-cit12"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Lou, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Owens, T. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kuglstatter, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kondru, R. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Goldstein, D. M.</span></span> <span> </span><span class="NLM_article-title">Bruton’s Tyrosine Kinase Inhibitors: Approaches to Potent and Selective Inhibition, Preclinical and Clinical Evaluation for Inflammatory Diseases and B Cell Malignancies</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2012</span>,  <span class="NLM_volume"><i>55</i></span>,  <span class="NLM_fpage">4539</span>– <span class="NLM_lpage">4550</span>, <span class="refDoi"> DOI: 10.1021/jm300035p</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm300035p" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref12/cit12&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00329&amp;key=1%3ACAS%3A528%3ADC%252BC38XjsVChsb8%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=55&publication_year=2012&pages=4539-4550&author=Y.+Louauthor=T.+D.+Owensauthor=A.+Kuglstatterauthor=R.+K.+Kondruauthor=D.+M.+Goldstein&title=Bruton%E2%80%99s+Tyrosine+Kinase+Inhibitors%3A+Approaches+to+Potent+and+Selective+Inhibition%2C+Preclinical+and+Clinical+Evaluation+for+Inflammatory+Diseases+and+B+Cell+Malignancies&doi=10.1021%2Fjm300035p"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit12R"><div class="casContent"><span class="casTitleNuber">12</span><div class="casTitle"><span class="NLM_cas:atitle">Bruton's Tyrosine Kinase Inhibitors: Approaches to Potent and Selective Inhibition, Preclinical and Clinical Evaluation for Inflammatory Diseases and B Cell Malignancies</span></div><div class="casAuthors">Lou, Yan; Owens, Timothy D.; Kuglstatter, Andreas; Kondru, Rama K.; Goldstein, David M.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">55</span>
        (<span class="NLM_cas:issue">10</span>),
    <span class="NLM_cas:pages">4539-4550</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">A review.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoRzAwa4gtFprVg90H21EOLACvtfcHk0liExPduqseCEg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38XjsVChsb8%253D&md5=b470ba4ec4867e4bfb8d1cfa92b1cc6d</span></div><a href="/servlet/linkout?suffix=cit12&amp;dbid=16384&amp;doi=10.1021%2Fjm300035p&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm300035p%26sid%3Dliteratum%253Aachs%26aulast%3DLou%26aufirst%3DY.%26aulast%3DOwens%26aufirst%3DT.%2BD.%26aulast%3DKuglstatter%26aufirst%3DA.%26aulast%3DKondru%26aufirst%3DR.%2BK.%26aulast%3DGoldstein%26aufirst%3DD.%2BM.%26atitle%3DBruton%25E2%2580%2599s%2520Tyrosine%2520Kinase%2520Inhibitors%253A%2520Approaches%2520to%2520Potent%2520and%2520Selective%2520Inhibition%252C%2520Preclinical%2520and%2520Clinical%2520Evaluation%2520for%2520Inflammatory%2520Diseases%2520and%2520B%2520Cell%2520Malignancies%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2012%26volume%3D55%26spage%3D4539%26epage%3D4550%26doi%3D10.1021%2Fjm300035p" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref13"><div class="reference"><strong class="refLabel"><a href="#ref13" class="rightTabRefNumLink">13</a></strong><div class="NLM_citation" id="rightTab-cit13"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Hendriks, R. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yuvaraj, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kil, L. P.</span></span> <span> </span><span class="NLM_article-title">Targeting Bruton’s tyrosine kinase in B cell malignancies</span>. <i>Nat. Rev. Cancer</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>14</i></span>,  <span class="NLM_fpage">219</span>– <span class="NLM_lpage">232</span>, <span class="refDoi"> DOI: 10.1038/nrc3702</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref13/cit13&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00329&amp;key=10.1038%2Fnrc3702" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref13/cit13&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00329&amp;key=24658273" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref13/cit13&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00329&amp;key=1%3ACAS%3A528%3ADC%252BC2cXkslCqsL4%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=14&publication_year=2014&pages=219-232&author=R.+W.+Hendriksauthor=S.+Yuvarajauthor=L.+P.+Kil&title=Targeting+Bruton%E2%80%99s+tyrosine+kinase+in+B+cell+malignancies&doi=10.1038%2Fnrc3702"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit13R"><div class="casContent"><span class="casTitleNuber">13</span><div class="casTitle"><span class="NLM_cas:atitle">Targeting Bruton's tyrosine kinase in B cell malignancies</span></div><div class="casAuthors">Hendriks, Rudi W.; Yuvaraj, Saravanan; Kil, Laurens P.</div><div class="citationInfo"><span class="NLM_cas:title">Nature Reviews Cancer</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">14</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">219-232</span>CODEN:
                <span class="NLM_cas:coden">NRCAC4</span>;
        ISSN:<span class="NLM_cas:issn">1474-175X</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">A review.  Bruton's tyrosine kinase (BTK) is a key component of B cell receptor (BCR) signalling and functions as an important regulator of cell proliferation and cell survival in various B cell malignancies.  Small-mol. inhibitors of BTK have shown antitumor activity in animal models and, recently, in clin. studies.  High response rates were reported in patients with chronic lymphocytic leukemia and mantle cell lymphoma.  Remarkably, BTK inhibitors have mol. effects that cannot be explained by the classic role of BTK in BCR signalling.  In this Review, we highlight the importance of BTK in various signalling pathways in the context of its therapeutic inhibition.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGo9z_6SqjcVYLVg90H21EOLACvtfcHk0liGNhwa3WeEZw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXkslCqsL4%253D&md5=ed615772c752b64360d0b5c51780e93e</span></div><a href="/servlet/linkout?suffix=cit13&amp;dbid=16384&amp;doi=10.1038%2Fnrc3702&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnrc3702%26sid%3Dliteratum%253Aachs%26aulast%3DHendriks%26aufirst%3DR.%2BW.%26aulast%3DYuvaraj%26aufirst%3DS.%26aulast%3DKil%26aufirst%3DL.%2BP.%26atitle%3DTargeting%2520Bruton%25E2%2580%2599s%2520tyrosine%2520kinase%2520in%2520B%2520cell%2520malignancies%26jtitle%3DNat.%2520Rev.%2520Cancer%26date%3D2014%26volume%3D14%26spage%3D219%26epage%3D232%26doi%3D10.1038%2Fnrc3702" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref14"><div class="reference"><strong class="refLabel"><a href="#ref14" class="rightTabRefNumLink">14</a></strong><div class="NLM_citation" id="rightTab-cit14"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Liang, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tian, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ren, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ding, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jia, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xin, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Thareja, S.</span></span> <span> </span><span class="NLM_article-title">The development of Bruton’s tyrosine kinase (BTK) inhibitors from 2012 to 2017: A mini-review</span>. <i>Eur. J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>151</i></span>,  <span class="NLM_fpage">315</span>– <span class="NLM_lpage">326</span>, <span class="refDoi"> DOI: 10.1016/j.ejmech.2018.03.062</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref14/cit14&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00329&amp;key=10.1016%2Fj.ejmech.2018.03.062" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref14/cit14&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00329&amp;key=29631132" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref14/cit14&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00329&amp;key=1%3ACAS%3A528%3ADC%252BC1cXnt1ehtL0%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=151&publication_year=2018&pages=315-326&author=C.+Liangauthor=D.+Tianauthor=X.+Renauthor=S.+Dingauthor=M.+Jiaauthor=M.+Xinauthor=S.+Thareja&title=The+development+of+Bruton%E2%80%99s+tyrosine+kinase+%28BTK%29+inhibitors+from+2012+to+2017%3A+A+mini-review&doi=10.1016%2Fj.ejmech.2018.03.062"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit14R"><div class="casContent"><span class="casTitleNuber">14</span><div class="casTitle"><span class="NLM_cas:atitle">The development of Bruton's tyrosine kinase (BTK) inhibitors from 2012 to 2017: A mini-review</span></div><div class="casAuthors">Liang, Chengyuan; Tian, Danni; Ren, Xiaodong; Ding, Shunjun; Jia, Minyi; Xin, Minhang; Thareja, Suresh</div><div class="citationInfo"><span class="NLM_cas:title">European Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">151</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">315-326</span>CODEN:
                <span class="NLM_cas:coden">EJMCA5</span>;
        ISSN:<span class="NLM_cas:issn">0223-5234</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Masson SAS</span>)
        </div><div class="casAbstract">A review.  Bruton's tyrosine kinase (BTK) has emerged as a promising drug target for multiple diseases, particularly hematopoietic malignancies and autoimmune diseases related to B lymphocytes.  This review focuses on the diverse, small-mol. inhibitors of BTK kinase that have shown good prospects for clin. application.  Individual examples of these inhibitors, including both reversible and irreversible inhibitors and a recently developed reversible covalent inhibitor of BTK, are discussed.  Considerable progress has been made in the development of irreversible inhibitors, most of which target the SH3 pocket and the cysteine 481 residue of BTK.  The present review also surveys the pharmacol. advantages and deficiencies of both reversible and irreversible BTK drugs, with a focus on the structure-activity relationship (SARs) and binding modes of representative drugs, which could inspire crit. thinking and new ideas for developing potent BTK inhibitors with less unwanted off-target effects.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGptNAsX0qwSHLVg90H21EOLACvtfcHk0liGNhwa3WeEZw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXnt1ehtL0%253D&md5=1ea0bf36d8ebadbfba624f858911b182</span></div><a href="/servlet/linkout?suffix=cit14&amp;dbid=16384&amp;doi=10.1016%2Fj.ejmech.2018.03.062&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.ejmech.2018.03.062%26sid%3Dliteratum%253Aachs%26aulast%3DLiang%26aufirst%3DC.%26aulast%3DTian%26aufirst%3DD.%26aulast%3DRen%26aufirst%3DX.%26aulast%3DDing%26aufirst%3DS.%26aulast%3DJia%26aufirst%3DM.%26aulast%3DXin%26aufirst%3DM.%26aulast%3DThareja%26aufirst%3DS.%26atitle%3DThe%2520development%2520of%2520Bruton%25E2%2580%2599s%2520tyrosine%2520kinase%2520%2528BTK%2529%2520inhibitors%2520from%25202012%2520to%25202017%253A%2520A%2520mini-review%26jtitle%3DEur.%2520J.%2520Med.%2520Chem.%26date%3D2018%26volume%3D151%26spage%3D315%26epage%3D326%26doi%3D10.1016%2Fj.ejmech.2018.03.062" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref15"><div class="reference"><strong class="refLabel"><a href="#ref15" class="rightTabRefNumLink">15</a></strong><div class="NLM_citation" id="rightTab-cit15"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Xue, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Song, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Song, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tong, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Geng, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ding, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, Q.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sun, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xie, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, A.</span></span> <span> </span><span class="NLM_article-title">Discovery of 4,7-Diamino-5-(4-phenoxyphenyl)-6-methylene-pyrimido[5,4-b]pyrrolizines as Novel Bruton’s Tyrosine Kinase Inhibitors</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>61</i></span>,  <span class="NLM_fpage">4608</span>– <span class="NLM_lpage">4627</span>, <span class="refDoi"> DOI: 10.1021/acs.jmedchem.8b00441</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.jmedchem.8b00441" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref15/cit15&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00329&amp;key=1%3ACAS%3A528%3ADC%252BC1cXoslymsbg%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=61&publication_year=2018&pages=4608-4627&author=Y.+Xueauthor=P.+Songauthor=Z.+Songauthor=A.+Wangauthor=L.+Tongauthor=M.+Gengauthor=J.+Dingauthor=Q.+Liuauthor=L.+Sunauthor=H.+Xieauthor=A.+Zhang&title=Discovery+of+4%2C7-Diamino-5-%284-phenoxyphenyl%29-6-methylene-pyrimido%5B5%2C4-b%5Dpyrrolizines+as+Novel+Bruton%E2%80%99s+Tyrosine+Kinase+Inhibitors&doi=10.1021%2Facs.jmedchem.8b00441"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit15R"><div class="casContent"><span class="casTitleNuber">15</span><div class="casTitle"><span class="NLM_cas:atitle">Discovery of 4,7-Diamino-5-(4-phenoxyphenyl)-6-methylene-pyrimido[5,4-b]pyrrolizines as Novel Bruton's Tyrosine Kinase Inhibitors</span></div><div class="casAuthors">Xue, Yu; Song, Peiran; Song, Zilan; Wang, Aoli; Tong, Linjiang; Geng, Meiyu; Ding, Jian; Liu, Qingsong; Sun, Liping; Xie, Hua; Zhang, Ao</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">61</span>
        (<span class="NLM_cas:issue">10</span>),
    <span class="NLM_cas:pages">4608-4627</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Unsatd. amide-substituted pyrimidopyrrolizines such as I were prepd. as analogs of the Bruton's tyrosine kinase (BTK) inhibitor ibrutinib for potential use as antitumor agents.  I was the potent of the analogs prepd., inhibiting BTK with an IC50 value of 0.4 nM and inhibiting the growth of BTK-dependent TMD8 cancer cells with an IC50 value of 16 nM.  I was slightly more selective than ibrutinib for BTK with strong inhibition on the B-cell receptor signaling pathway.  In a TMD8 cell-derived animal xenograft model, I (15 mg/kg, once daily) decreased tumor vol. more effectively than ibrutinib (25 mg/kg, once daily).</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGo9FMOaU6TWUrVg90H21EOLACvtfcHk0liGNhwa3WeEZw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXoslymsbg%253D&md5=1993e1f867d26aedd8d2c719b52667c8</span></div><a href="/servlet/linkout?suffix=cit15&amp;dbid=16384&amp;doi=10.1021%2Facs.jmedchem.8b00441&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.jmedchem.8b00441%26sid%3Dliteratum%253Aachs%26aulast%3DXue%26aufirst%3DY.%26aulast%3DSong%26aufirst%3DP.%26aulast%3DSong%26aufirst%3DZ.%26aulast%3DWang%26aufirst%3DA.%26aulast%3DTong%26aufirst%3DL.%26aulast%3DGeng%26aufirst%3DM.%26aulast%3DDing%26aufirst%3DJ.%26aulast%3DLiu%26aufirst%3DQ.%26aulast%3DSun%26aufirst%3DL.%26aulast%3DXie%26aufirst%3DH.%26aulast%3DZhang%26aufirst%3DA.%26atitle%3DDiscovery%2520of%25204%252C7-Diamino-5-%25284-phenoxyphenyl%2529-6-methylene-pyrimido%255B5%252C4-b%255Dpyrrolizines%2520as%2520Novel%2520Bruton%25E2%2580%2599s%2520Tyrosine%2520Kinase%2520Inhibitors%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2018%26volume%3D61%26spage%3D4608%26epage%3D4627%26doi%3D10.1021%2Facs.jmedchem.8b00441" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref16"><div class="reference"><strong class="refLabel"><a href="#ref16" class="rightTabRefNumLink">16</a></strong><div class="NLM_citation" id="rightTab-cit16"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Pan, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Scheerens, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, S.-J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schultz, B. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sprengeler, P. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Burrill, L. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mendonca, R. V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sweeney, M. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Scott, K. C. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Grothaus, P. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jeffery, D. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Spoerke, J. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Honigberg, L. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Young, P. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dalrymple, S. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Palmer, J. T.</span></span> <span> </span><span class="NLM_article-title">Discovery of Selective Irreversible Inhibitors for Bruton’s Tyrosine Kinase</span>. <i>ChemMedChem</i> <span class="NLM_year" style="font-weight: bold;">2007</span>,  <span class="NLM_volume"><i>2</i></span>,  <span class="NLM_fpage">58</span>– <span class="NLM_lpage">61</span>, <span class="refDoi"> DOI: 10.1002/cmdc.200600221</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref16/cit16&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00329&amp;key=10.1002%2Fcmdc.200600221" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref16/cit16&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00329&amp;key=17154430" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref16/cit16&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00329&amp;key=1%3ACAS%3A528%3ADC%252BD2sXjsVWjsbg%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=2&publication_year=2007&pages=58-61&author=Z.+Panauthor=H.+Scheerensauthor=S.-J.+Liauthor=B.+E.+Schultzauthor=P.+A.+Sprengelerauthor=L.+C.+Burrillauthor=R.+V.+Mendoncaauthor=M.+D.+Sweeneyauthor=K.+C.+K.+Scottauthor=P.+G.+Grothausauthor=D.+A.+Jefferyauthor=J.+M.+Spoerkeauthor=L.+A.+Honigbergauthor=P.+R.+Youngauthor=S.+A.+Dalrympleauthor=J.+T.+Palmer&title=Discovery+of+Selective+Irreversible+Inhibitors+for+Bruton%E2%80%99s+Tyrosine+Kinase&doi=10.1002%2Fcmdc.200600221"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit16R"><div class="casContent"><span class="casTitleNuber">16</span><div class="casTitle"><span class="NLM_cas:atitle">Discovery of selective irreversible inhibitors for bruton's tyrosine kinase</span></div><div class="casAuthors">Pan, Zhengying; Scheerens, Heleen; Li, Shyr-Jiann; Schultz, Brian E.; Sprengeler, Paul A.; Burrill, L. Chuck; Mendonca, Rohan V.; Sweeney, Michael D.; Scott, Keana C. K.; Grothaus, Paul G.; Jeffery, Douglas A.; Spoerke, Jill M.; Honigberg, Lee A.; Young, Peter R.; Dalrymple, Stacie A.; Palmer, James T.</div><div class="citationInfo"><span class="NLM_cas:title">ChemMedChem</span>
        (<span class="NLM_cas:date">2007</span>),
    <span class="NLM_cas:volume">2</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">58-61</span>CODEN:
                <span class="NLM_cas:coden">CHEMGX</span>;
        ISSN:<span class="NLM_cas:issn">1860-7179</span>.
    
            (<span class="NLM_cas:orgname">Wiley-VCH Verlag GmbH & Co. KGaA</span>)
        </div><div class="casAbstract">Synthesis and pharmacol. evaluation of a series of peptidomimetic quinoline derivs. was undertaken to evaluate their efficacy in acting as selective irreversible inhibitors of Bruton's tyrosine kinase (Btk).  With the relative scarcity of knowledge on the inhibition of Btk it is crucial to discover a potent and selective tool compd. for this kinase.  Herein is described the discovery of selective irreversible Btk inhibitors and their efficacy in a mouse RA model.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGovT3kBCYECdbVg90H21EOLACvtfcHk0lhuA8RIykGAOg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2sXjsVWjsbg%253D&md5=023ba8bca9942ad0127d7cf32293e9d2</span></div><a href="/servlet/linkout?suffix=cit16&amp;dbid=16384&amp;doi=10.1002%2Fcmdc.200600221&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fcmdc.200600221%26sid%3Dliteratum%253Aachs%26aulast%3DPan%26aufirst%3DZ.%26aulast%3DScheerens%26aufirst%3DH.%26aulast%3DLi%26aufirst%3DS.-J.%26aulast%3DSchultz%26aufirst%3DB.%2BE.%26aulast%3DSprengeler%26aufirst%3DP.%2BA.%26aulast%3DBurrill%26aufirst%3DL.%2BC.%26aulast%3DMendonca%26aufirst%3DR.%2BV.%26aulast%3DSweeney%26aufirst%3DM.%2BD.%26aulast%3DScott%26aufirst%3DK.%2BC.%2BK.%26aulast%3DGrothaus%26aufirst%3DP.%2BG.%26aulast%3DJeffery%26aufirst%3DD.%2BA.%26aulast%3DSpoerke%26aufirst%3DJ.%2BM.%26aulast%3DHonigberg%26aufirst%3DL.%2BA.%26aulast%3DYoung%26aufirst%3DP.%2BR.%26aulast%3DDalrymple%26aufirst%3DS.%2BA.%26aulast%3DPalmer%26aufirst%3DJ.%2BT.%26atitle%3DDiscovery%2520of%2520Selective%2520Irreversible%2520Inhibitors%2520for%2520Bruton%25E2%2580%2599s%2520Tyrosine%2520Kinase%26jtitle%3DChemMedChem%26date%3D2007%26volume%3D2%26spage%3D58%26epage%3D61%26doi%3D10.1002%2Fcmdc.200600221" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref17"><div class="reference"><strong class="refLabel"><a href="#ref17" class="rightTabRefNumLink">17</a></strong><div class="NLM_citation" id="rightTab-cit17"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Honigberg, L. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Smith, A. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sirisawad, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Verner, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Loury, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chang, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pan, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Thamm, D. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Miller, R. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Buggy, J. J.</span></span> <span> </span><span class="NLM_article-title">The Bruton tyrosine kinase inhibitor PCI-32565 blocks B-cell activation and is efficacious in models of autoimmune disease and B-cell malignancy</span>. <i>Proc. Natl. Acad. Sci. U.S.A.</i> <span class="NLM_year" style="font-weight: bold;">2010</span>,  <span class="NLM_volume"><i>107</i></span>,  <span class="NLM_fpage">12575</span>– <span class="NLM_lpage">12580</span>, <span class="refDoi"> DOI: 10.1073/pnas.1004594107</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref17/cit17&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00329&amp;key=10.1073%2Fpnas.1004594107" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=107&publication_year=2010&pages=12575-12580&author=L.+A.+Honigbergauthor=A.+M.+Smithauthor=M.+Sirisawadauthor=E.+Vernerauthor=D.+Louryauthor=B.+Changauthor=S.+Liauthor=Z.+Panauthor=D.+H.+Thammauthor=R.+A.+Millerauthor=J.+J.+Buggy&title=The+Bruton+tyrosine+kinase+inhibitor+PCI-32565+blocks+B-cell+activation+and+is+efficacious+in+models+of+autoimmune+disease+and+B-cell+malignancy&doi=10.1073%2Fpnas.1004594107"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit17&amp;dbid=16384&amp;doi=10.1073%2Fpnas.1004594107&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1073%252Fpnas.1004594107%26sid%3Dliteratum%253Aachs%26aulast%3DHonigberg%26aufirst%3DL.%2BA.%26aulast%3DSmith%26aufirst%3DA.%2BM.%26aulast%3DSirisawad%26aufirst%3DM.%26aulast%3DVerner%26aufirst%3DE.%26aulast%3DLoury%26aufirst%3DD.%26aulast%3DChang%26aufirst%3DB.%26aulast%3DLi%26aufirst%3DS.%26aulast%3DPan%26aufirst%3DZ.%26aulast%3DThamm%26aufirst%3DD.%2BH.%26aulast%3DMiller%26aufirst%3DR.%2BA.%26aulast%3DBuggy%26aufirst%3DJ.%2BJ.%26atitle%3DThe%2520Bruton%2520tyrosine%2520kinase%2520inhibitor%2520PCI-32565%2520blocks%2520B-cell%2520activation%2520and%2520is%2520efficacious%2520in%2520models%2520of%2520autoimmune%2520disease%2520and%2520B-cell%2520malignancy%26jtitle%3DProc.%2520Natl.%2520Acad.%2520Sci.%2520U.S.A.%26date%3D2010%26volume%3D107%26spage%3D12575%26epage%3D12580%26doi%3D10.1073%2Fpnas.1004594107" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref18"><div class="reference"><strong class="refLabel"><a href="#ref18" class="rightTabRefNumLink">18</a></strong><div class="NLM_citation" id="rightTab-cit18"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Advani, R. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Buggy, J. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sharman, J. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Smith, S. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Boyd, T. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Grant, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kolibaba, K. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Furman, R. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rodriguez, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chang, B. Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sukbuntherng, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Izumi, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hamdy, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hedrick, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fowler, N. H.</span></span> <span> </span><span class="NLM_article-title">Bruton Tyrosine Kinase Inhibitor Ibrutinib (PCI-32765) Has Significant Activity in Patients With Relapsed/Refractory B-Cell Malignancies</span>. <i>J. Clin. Oncol.</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>31</i></span>,  <span class="NLM_fpage">88</span>– <span class="NLM_lpage">94</span>, <span class="refDoi"> DOI: 10.1200/jco.2012.42.7906</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref18/cit18&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00329&amp;key=10.1200%2Fjco.2012.42.7906" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref18/cit18&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00329&amp;key=23045577" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref18/cit18&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00329&amp;key=1%3ACAS%3A528%3ADC%252BC3sXitFaltLg%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=31&publication_year=2013&pages=88-94&author=R.+H.+Advaniauthor=J.+J.+Buggyauthor=J.+P.+Sharmanauthor=S.+M.+Smithauthor=T.+E.+Boydauthor=B.+Grantauthor=K.+S.+Kolibabaauthor=R.+R.+Furmanauthor=S.+Rodriguezauthor=B.+Y.+Changauthor=J.+Sukbuntherngauthor=R.+Izumiauthor=A.+Hamdyauthor=E.+Hedrickauthor=N.+H.+Fowler&title=Bruton+Tyrosine+Kinase+Inhibitor+Ibrutinib+%28PCI-32765%29+Has+Significant+Activity+in+Patients+With+Relapsed%2FRefractory+B-Cell+Malignancies&doi=10.1200%2Fjco.2012.42.7906"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit18R"><div class="casContent"><span class="casTitleNuber">18</span><div class="casTitle"><span class="NLM_cas:atitle">Bruton tyrosine kinase inhibitor ibrutinib (PCI-32765) has significant activity in patients with relapsed/refractory B-cell malignancies</span></div><div class="casAuthors">Advani, Ranjana H.; Buggy, Joseph J.; Sharman, Jeff P.; Smith, Sonali M.; Boyd, Thomas E.; Grant, Barbara; Kolibaba, Kathryn S.; Furman, Richard R.; Rodriguez, Sara; Chang, Betty Y.; Sukbuntherng, Juthamas; Izumi, Raquel; Hamdy, Ahmed; Hedrick, Eric; Fowler, Nathan H.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Clinical Oncology</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">31</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">88-94</span>CODEN:
                <span class="NLM_cas:coden">JCONDN</span>;
        ISSN:<span class="NLM_cas:issn">0732-183X</span>.
    
            (<span class="NLM_cas:orgname">American Society of Clinical Oncology</span>)
        </div><div class="casAbstract">Purpose Survival and progression of mature B-cell malignancies depend on signals from the B-cell antigen receptor, and Bruton tyrosine kinase (BTK) is a crit. signaling kinase in this pathway.  We evaluated ibrutinib (PCI-32765), a small-mol. irreversible inhibitor of BTK, in patients with B-cell malignancies.  Patients and Methods Patients with relapsed or refractory B-cell lymphoma and chronic lymphocytic leukemia received escalating oral doses of ibrutinib.  Two schedules were evaluated: one, 28 days on, 7 days off; and two, once-daily continuous dosing.  Occupancy of BTK by ibrutinib in peripheral blood was monitored using a fluorescent affinity probe.  Dose escalation proceeded until either the max.-tolerated dose (MTD) was achieved or, in the absence of MTD, until three dose levels above full BTK occupancy by ibrutinib.  Response was evaluated every two cycles.  Results Fifty-six patients with a variety of B-cell malignancies were treated over seven cohorts.  Most adverse events were grade 1 and 2 in severity and self-limited.  Dose-limiting events were not obsd., even with prolonged dosing.  Full occupancy of the BTK active site occurred at 2.5 mg/kg per day, and dose escalation continued to 12.5 mg/kg per day without reaching MTD.  Pharmacokinetic data indicated rapid absorption and elimination, yet BTK occupancy was maintained for at least 24 h, consistent with the irreversible mechanism.  Objective response rate in 50 evaluable patients was 60%, including complete response of 16%.  Median progression-free survival in all patients was 13.6 mo.  Conclusion Ibrutinib, a novel BTK-targeting inhibitor, is well tolerated, with substantial activity across B-cell histologies.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoqj_UZPM0nBrVg90H21EOLACvtfcHk0lhuA8RIykGAOg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXitFaltLg%253D&md5=e955490a02af9a321823033b9e258cb6</span></div><a href="/servlet/linkout?suffix=cit18&amp;dbid=16384&amp;doi=10.1200%2Fjco.2012.42.7906&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1200%252Fjco.2012.42.7906%26sid%3Dliteratum%253Aachs%26aulast%3DAdvani%26aufirst%3DR.%2BH.%26aulast%3DBuggy%26aufirst%3DJ.%2BJ.%26aulast%3DSharman%26aufirst%3DJ.%2BP.%26aulast%3DSmith%26aufirst%3DS.%2BM.%26aulast%3DBoyd%26aufirst%3DT.%2BE.%26aulast%3DGrant%26aufirst%3DB.%26aulast%3DKolibaba%26aufirst%3DK.%2BS.%26aulast%3DFurman%26aufirst%3DR.%2BR.%26aulast%3DRodriguez%26aufirst%3DS.%26aulast%3DChang%26aufirst%3DB.%2BY.%26aulast%3DSukbuntherng%26aufirst%3DJ.%26aulast%3DIzumi%26aufirst%3DR.%26aulast%3DHamdy%26aufirst%3DA.%26aulast%3DHedrick%26aufirst%3DE.%26aulast%3DFowler%26aufirst%3DN.%2BH.%26atitle%3DBruton%2520Tyrosine%2520Kinase%2520Inhibitor%2520Ibrutinib%2520%2528PCI-32765%2529%2520Has%2520Significant%2520Activity%2520in%2520Patients%2520With%2520Relapsed%252FRefractory%2520B-Cell%2520Malignancies%26jtitle%3DJ.%2520Clin.%2520Oncol.%26date%3D2013%26volume%3D31%26spage%3D88%26epage%3D94%26doi%3D10.1200%2Fjco.2012.42.7906" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref19"><div class="reference"><strong class="refLabel"><a href="#ref19" class="rightTabRefNumLink">19</a></strong><div class="NLM_citation" id="rightTab-cit19"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Byrd, J. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Furman, R. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Coutre, S. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Flinn, I. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Burger, J. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Blum, K. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Grant, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sharman, J. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Coleman, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wierda, W. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jones, J. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhao, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Heerema, N. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Johnson, A. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sukbuntherng, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chang, B. Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Clow, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hedrick, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Buggy, J. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">James, D. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">O’Brien, S.</span></span> <span> </span><span class="NLM_article-title">Targeting BTK with ibrutinib in relapsed chronic lymphocytic leukemia</span>. <i>N. Engl. J. Med.</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>369</i></span>,  <span class="NLM_fpage">32</span>– <span class="NLM_lpage">42</span>, <span class="refDoi"> DOI: 10.1056/nejmoa1215637</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref19/cit19&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00329&amp;key=10.1056%2Fnejmoa1215637" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref19/cit19&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00329&amp;key=23782158" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref19/cit19&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00329&amp;key=1%3ACAS%3A528%3ADC%252BC3sXhtFygu7zN" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=369&publication_year=2013&pages=32-42&author=J.+C.+Byrdauthor=R.+R.+Furmanauthor=S.+E.+Coutreauthor=I.+W.+Flinnauthor=J.+A.+Burgerauthor=K.+A.+Blumauthor=B.+Grantauthor=J.+P.+Sharmanauthor=M.+Colemanauthor=W.+G.+Wierdaauthor=J.+A.+Jonesauthor=W.+Zhaoauthor=N.+A.+Heeremaauthor=A.+J.+Johnsonauthor=J.+Sukbuntherngauthor=B.+Y.+Changauthor=F.+Clowauthor=E.+Hedrickauthor=J.+J.+Buggyauthor=D.+F.+Jamesauthor=S.+O%E2%80%99Brien&title=Targeting+BTK+with+ibrutinib+in+relapsed+chronic+lymphocytic+leukemia&doi=10.1056%2Fnejmoa1215637"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit19R"><div class="casContent"><span class="casTitleNuber">19</span><div class="casTitle"><span class="NLM_cas:atitle">Targeting BTK with ibrutinib in relapsed chronic lymphocytic leukemia</span></div><div class="casAuthors">Byrd, John C.; Furman, Richard R.; Coutre, Steven E.; Flinn, Ian W.; Burger, Jan A.; Blum, Kristie A.; Grant, Barbara; Sharman, Jeff P.; Coleman, Morton; Wierda, William G.; Jones, Jeffrey A.; Zhao, Weiqiang; Heerema, Nyla A.; Johnson, Amy J.; Sukbuntherng, Juthamas; Chang, Betty Y.; Clow, Fong; Hedrick, Eric; Buggy, Joseph J.; James, Danelle F.; O'Brien, Susan</div><div class="citationInfo"><span class="NLM_cas:title">New England Journal of Medicine</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">369</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">32-42</span>CODEN:
                <span class="NLM_cas:coden">NEJMAG</span>;
        ISSN:<span class="NLM_cas:issn">0028-4793</span>.
    
            (<span class="NLM_cas:orgname">Massachusetts Medical Society</span>)
        </div><div class="casAbstract">Background The treatment of relapsed chronic lymphocytic leukemia (CLL) has resulted in few durable remissions.  Bruton's tyrosine kinase (BTK), an essential component of B-cell-receptor signaling, mediates interactions with the tumor microenvironment and promotes the survival and proliferation of CLL cells.  Methods We conducted a phase 1b-2 multicenter study to assess the safety, efficacy, pharmacokinetics, and pharmacodynamics of ibrutinib (PCI-32765), a first-in-class, oral covalent inhibitor of BTK designed for treatment of B-cell cancers, in patients with relapsed or refractory CLL or small lymphocytic lymphoma.  A total of 85 patients, the majority of whom were considered to have high-risk disease, received ibrutinib orally once daily; 51 received 420 mg, and 34 received 840 mg.  Results Toxic effects were predominantly grade 1 or 2 and included transient diarrhea, fatigue, and upper respiratory tract infection; thus, patients could receive extended treatment with minimal hematol. toxic effects.  The overall response rate was the same in the group that received 420 mg and the group that received 840 mg (71%), and an addnl. 20% and 15% of patients in the resp. groups had a partial response with lymphocytosis.  The response was independent of clin. and genomic risk factors present before treatment, including advanced-stage disease, the no. of previous therapies, and the 17p13.1 deletion.  At 26 mo, the estd. progression-free survival rate was 75% and the rate of overall survival was 83%.  Conclusions Ibrutinib was assocd. with a high frequency of durable remissions in patients with relapsed or refractory CLL and small lymphocytic lymphoma, including patients with high-risk genetic lesions.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGp1EhPQxMRz7rVg90H21EOLACvtfcHk0ljcB8gj6Zvheg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXhtFygu7zN&md5=32a5eb6ab06beeecf64d9ada84139925</span></div><a href="/servlet/linkout?suffix=cit19&amp;dbid=16384&amp;doi=10.1056%2Fnejmoa1215637&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1056%252Fnejmoa1215637%26sid%3Dliteratum%253Aachs%26aulast%3DByrd%26aufirst%3DJ.%2BC.%26aulast%3DFurman%26aufirst%3DR.%2BR.%26aulast%3DCoutre%26aufirst%3DS.%2BE.%26aulast%3DFlinn%26aufirst%3DI.%2BW.%26aulast%3DBurger%26aufirst%3DJ.%2BA.%26aulast%3DBlum%26aufirst%3DK.%2BA.%26aulast%3DGrant%26aufirst%3DB.%26aulast%3DSharman%26aufirst%3DJ.%2BP.%26aulast%3DColeman%26aufirst%3DM.%26aulast%3DWierda%26aufirst%3DW.%2BG.%26aulast%3DJones%26aufirst%3DJ.%2BA.%26aulast%3DZhao%26aufirst%3DW.%26aulast%3DHeerema%26aufirst%3DN.%2BA.%26aulast%3DJohnson%26aufirst%3DA.%2BJ.%26aulast%3DSukbuntherng%26aufirst%3DJ.%26aulast%3DChang%26aufirst%3DB.%2BY.%26aulast%3DClow%26aufirst%3DF.%26aulast%3DHedrick%26aufirst%3DE.%26aulast%3DBuggy%26aufirst%3DJ.%2BJ.%26aulast%3DJames%26aufirst%3DD.%2BF.%26aulast%3DO%25E2%2580%2599Brien%26aufirst%3DS.%26atitle%3DTargeting%2520BTK%2520with%2520ibrutinib%2520in%2520relapsed%2520chronic%2520lymphocytic%2520leukemia%26jtitle%3DN.%2520Engl.%2520J.%2520Med.%26date%3D2013%26volume%3D369%26spage%3D32%26epage%3D42%26doi%3D10.1056%2Fnejmoa1215637" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref20"><div class="reference"><strong class="refLabel"><a href="#ref20" class="rightTabRefNumLink">20</a></strong><div class="NLM_citation" id="rightTab-cit20"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Wang, M. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rule, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Martin, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Goy, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Auer, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kahl, B. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jurczak, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Advani, R. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Romaguera, J. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Williams, M. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Barrientos, J. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chmielowska, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Radford, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stilgenbauer, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dreyling, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jedrzejczak, W. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Johnson, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Spurgeon, S. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Newberry, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ou, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cheng, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fang, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">McGreivy, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Clow, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Buggy, J. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chang, B. Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Beaupre, D. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kunkel, L. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Blum, K. A.</span></span> <span> </span><span class="NLM_article-title">Targeting BTK with ibrutinib in relapsed or refractory mantle-cell lymphoma</span>. <i>N. Engl. J. Med.</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>369</i></span>,  <span class="NLM_fpage">507</span>– <span class="NLM_lpage">516</span>, <span class="refDoi"> DOI: 10.1056/nejmoa1306220</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref20/cit20&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00329&amp;key=10.1056%2Fnejmoa1306220" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref20/cit20&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00329&amp;key=23782157" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref20/cit20&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00329&amp;key=1%3ACAS%3A528%3ADC%252BC3sXht1OgtL%252FF" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=369&publication_year=2013&pages=507-516&author=M.+L.+Wangauthor=S.+Ruleauthor=P.+Martinauthor=A.+Goyauthor=R.+Auerauthor=B.+S.+Kahlauthor=W.+Jurczakauthor=R.+H.+Advaniauthor=J.+E.+Romagueraauthor=M.+E.+Williamsauthor=J.+C.+Barrientosauthor=E.+Chmielowskaauthor=J.+Radfordauthor=S.+Stilgenbauerauthor=M.+Dreylingauthor=W.+W.+Jedrzejczakauthor=P.+Johnsonauthor=S.+E.+Spurgeonauthor=L.+Liauthor=L.+Zhangauthor=K.+Newberryauthor=Z.+Ouauthor=N.+Chengauthor=B.+Fangauthor=J.+McGreivyauthor=F.+Clowauthor=J.+J.+Buggyauthor=B.+Y.+Changauthor=D.+M.+Beaupreauthor=L.+A.+Kunkelauthor=K.+A.+Blum&title=Targeting+BTK+with+ibrutinib+in+relapsed+or+refractory+mantle-cell+lymphoma&doi=10.1056%2Fnejmoa1306220"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit20R"><div class="casContent"><span class="casTitleNuber">20</span><div class="casTitle"><span class="NLM_cas:atitle">Targeting BTK with ibrutinib in relapsed or refractory mantle-cell lymphoma</span></div><div class="casAuthors">Wang, Michael L.; Rule, Simon; Martin, Peter; Goy, Andre; Auer, Rebecca; Kahl, Brad S.; Jurczak, Wojciech; Advani, Ranjana H.; Romaguera, Jorge E.; Williams, Michael E.; Barrientos, Jacqueline C.; Chmielowska, Ewa; Radford, John; Stilgenbauer, Stephan; Dreyling, Martin; Jedrzejczak, Wieslaw Wiktor; Johnson, Peter; Spurgeon, Stephen E.; Li, Lei; Zhang, Liang; Newberry, Kate; Ou, Zhishuo; Cheng, Nancy; Fang, Bingliang; McGreivy, Jesse; Clow, Fong; Buggy, Joseph J.; Chang, Betty Y.; Beaupre, Darrin M.; Kunkel, Lori A.; Blum, Kristie A.</div><div class="citationInfo"><span class="NLM_cas:title">New England Journal of Medicine</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">369</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">507-516</span>CODEN:
                <span class="NLM_cas:coden">NEJMAG</span>;
        ISSN:<span class="NLM_cas:issn">0028-4793</span>.
    
            (<span class="NLM_cas:orgname">Massachusetts Medical Society</span>)
        </div><div class="casAbstract">BACKGROUND: Bruton's tyrosine kinase (BTK) is a mediator of the B-cell-receptor signaling pathway implicated in the pathogenesis of B-cell cancers.  In a phase 1 study, ibrutinib, a BTK inhibitor, showed antitumor activity in several types of non-Hodgkin's lymphoma, including mantle-cell lymphoma.  METHODS: In this phase 2 study, we investigated oral ibrutinib, at a daily dose of 560 mg, in 111 patients with relapsed or refractory mantle-cell lymphoma.  Patients were enrolled into two groups: those who had previously received at least 2 cycles of bortezomib therapy and those who had received less than 2 complete cycles of bortezomib or had received no prior bortezomib therapy.  The primary end point was the overall response rate.  Secondary end points were duration of response, progression-free survival, overall survival, and safety.  RESULTS: The median age was 68 years, and 86% of patients had intermediate-risk or high-risk mantle-cell lymphoma according to clin. prognostic factors.  Patients had received a median of three prior therapies.  The most common treatment-related adverse events were mild or moderate diarrhea, fatigue, and nausea.  Grade 3 or higher hematol. events were infrequent and included neutropenia (in 16% of patients), thrombocytopenia (in 11%), and anemia (in 10%).  A response rate of 68% (75 patients) was obsd., with a complete response rate of 21% and a partial response rate of 47%; prior treatment with bortezomib had no effect on the response rate.  With an estd. median follow-up of 15.3 mo, the estd. median response duration was 17.5 mo (95% confidence interval [CI], 15.8 to not reached), the estd. median progression-free survival was 13.9 mo (95% CI, 7.0 to not reached), and the median overall survival was not reached.  The estd. rate of overall survival was 58% at 18 mo.  CONCLUSIONS: Ibrutinib shows durable single-agent efficacy in relapsed or refractory mantle-cell lymphoma.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGovUuOKvHS0NrVg90H21EOLACvtfcHk0ljcB8gj6Zvheg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXht1OgtL%252FF&md5=7a92bbd5acf86e614cea96f44503e12b</span></div><a href="/servlet/linkout?suffix=cit20&amp;dbid=16384&amp;doi=10.1056%2Fnejmoa1306220&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1056%252Fnejmoa1306220%26sid%3Dliteratum%253Aachs%26aulast%3DWang%26aufirst%3DM.%2BL.%26aulast%3DRule%26aufirst%3DS.%26aulast%3DMartin%26aufirst%3DP.%26aulast%3DGoy%26aufirst%3DA.%26aulast%3DAuer%26aufirst%3DR.%26aulast%3DKahl%26aufirst%3DB.%2BS.%26aulast%3DJurczak%26aufirst%3DW.%26aulast%3DAdvani%26aufirst%3DR.%2BH.%26aulast%3DRomaguera%26aufirst%3DJ.%2BE.%26aulast%3DWilliams%26aufirst%3DM.%2BE.%26aulast%3DBarrientos%26aufirst%3DJ.%2BC.%26aulast%3DChmielowska%26aufirst%3DE.%26aulast%3DRadford%26aufirst%3DJ.%26aulast%3DStilgenbauer%26aufirst%3DS.%26aulast%3DDreyling%26aufirst%3DM.%26aulast%3DJedrzejczak%26aufirst%3DW.%2BW.%26aulast%3DJohnson%26aufirst%3DP.%26aulast%3DSpurgeon%26aufirst%3DS.%2BE.%26aulast%3DLi%26aufirst%3DL.%26aulast%3DZhang%26aufirst%3DL.%26aulast%3DNewberry%26aufirst%3DK.%26aulast%3DOu%26aufirst%3DZ.%26aulast%3DCheng%26aufirst%3DN.%26aulast%3DFang%26aufirst%3DB.%26aulast%3DMcGreivy%26aufirst%3DJ.%26aulast%3DClow%26aufirst%3DF.%26aulast%3DBuggy%26aufirst%3DJ.%2BJ.%26aulast%3DChang%26aufirst%3DB.%2BY.%26aulast%3DBeaupre%26aufirst%3DD.%2BM.%26aulast%3DKunkel%26aufirst%3DL.%2BA.%26aulast%3DBlum%26aufirst%3DK.%2BA.%26atitle%3DTargeting%2520BTK%2520with%2520ibrutinib%2520in%2520relapsed%2520or%2520refractory%2520mantle-cell%2520lymphoma%26jtitle%3DN.%2520Engl.%2520J.%2520Med.%26date%3D2013%26volume%3D369%26spage%3D507%26epage%3D516%26doi%3D10.1056%2Fnejmoa1306220" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref21"><div class="reference"><strong class="refLabel"><a href="#ref21" class="rightTabRefNumLink">21</a></strong><div class="NLM_citation" id="rightTab-cit21"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Treon, S. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tripsas, C. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Meid, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Warren, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Varma, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Green, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Argyropoulos, K. V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yang, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cao, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xu, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Patterson, C. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rodig, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zehnder, J. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Aster, J. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Harris, N. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kanan, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ghobrial, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Castillo, J. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Laubach, J. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hunter, Z. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Salman, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cheng, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Clow, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Graef, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Palomba, M. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Advani, R. H.</span></span> <span> </span><span class="NLM_article-title">Ibrutinib in previously treated Waldenstrom’s macroglobulinemia</span>. <i>N. Engl. J. Med.</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>372</i></span>,  <span class="NLM_fpage">1425</span>– <span class="NLM_lpage">1440</span>, <span class="refDoi"> DOI: 10.1056/nejmoa1501548</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref21/cit21&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00329&amp;key=10.1056%2Fnejmoa1501548" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=372&publication_year=2015&pages=1425-1440&author=S.+P.+Treonauthor=C.+K.+Tripsasauthor=K.+Meidauthor=D.+Warrenauthor=G.+Varmaauthor=R.+Greenauthor=K.+V.+Argyropoulosauthor=G.+Yangauthor=Y.+Caoauthor=L.+Xuauthor=C.+J.+Pattersonauthor=S.+Rodigauthor=J.+L.+Zehnderauthor=J.+C.+Asterauthor=N.+L.+Harrisauthor=S.+Kananauthor=I.+Ghobrialauthor=J.+J.+Castilloauthor=J.+P.+Laubachauthor=Z.+R.+Hunterauthor=Z.+Salmanauthor=J.+Liauthor=M.+Chengauthor=F.+Clowauthor=T.+Graefauthor=M.+L.+Palombaauthor=R.+H.+Advani&title=Ibrutinib+in+previously+treated+Waldenstrom%E2%80%99s+macroglobulinemia&doi=10.1056%2Fnejmoa1501548"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit21&amp;dbid=16384&amp;doi=10.1056%2Fnejmoa1501548&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1056%252Fnejmoa1501548%26sid%3Dliteratum%253Aachs%26aulast%3DTreon%26aufirst%3DS.%2BP.%26aulast%3DTripsas%26aufirst%3DC.%2BK.%26aulast%3DMeid%26aufirst%3DK.%26aulast%3DWarren%26aufirst%3DD.%26aulast%3DVarma%26aufirst%3DG.%26aulast%3DGreen%26aufirst%3DR.%26aulast%3DArgyropoulos%26aufirst%3DK.%2BV.%26aulast%3DYang%26aufirst%3DG.%26aulast%3DCao%26aufirst%3DY.%26aulast%3DXu%26aufirst%3DL.%26aulast%3DPatterson%26aufirst%3DC.%2BJ.%26aulast%3DRodig%26aufirst%3DS.%26aulast%3DZehnder%26aufirst%3DJ.%2BL.%26aulast%3DAster%26aufirst%3DJ.%2BC.%26aulast%3DHarris%26aufirst%3DN.%2BL.%26aulast%3DKanan%26aufirst%3DS.%26aulast%3DGhobrial%26aufirst%3DI.%26aulast%3DCastillo%26aufirst%3DJ.%2BJ.%26aulast%3DLaubach%26aufirst%3DJ.%2BP.%26aulast%3DHunter%26aufirst%3DZ.%2BR.%26aulast%3DSalman%26aufirst%3DZ.%26aulast%3DLi%26aufirst%3DJ.%26aulast%3DCheng%26aufirst%3DM.%26aulast%3DClow%26aufirst%3DF.%26aulast%3DGraef%26aufirst%3DT.%26aulast%3DPalomba%26aufirst%3DM.%2BL.%26aulast%3DAdvani%26aufirst%3DR.%2BH.%26atitle%3DIbrutinib%2520in%2520previously%2520treated%2520Waldenstrom%25E2%2580%2599s%2520macroglobulinemia%26jtitle%3DN.%2520Engl.%2520J.%2520Med.%26date%3D2015%26volume%3D372%26spage%3D1425%26epage%3D1440%26doi%3D10.1056%2Fnejmoa1501548" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref22"><div class="reference"><strong class="refLabel"><a href="#ref22" class="rightTabRefNumLink">22</a></strong><div class="NLM_citation" id="rightTab-cit22"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Noy, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">de Vos, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Thieblemont, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Martin, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Flowers, C. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Morschhauser, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Collins, G. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ma, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Coleman, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Peles, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Smith, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Barrientos, J. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Smith, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Munneke, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dimery, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Beaupre, D. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, R.</span></span> <span> </span><span class="NLM_article-title">Targeting Bruton tyrosine kinase with ibrutinib in relapsed/refractory marginal zone lymphoma</span>. <i>Blood</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>129</i></span>,  <span class="NLM_fpage">2224</span>– <span class="NLM_lpage">2232</span>, <span class="refDoi"> DOI: 10.1182/blood-2016-10-747345</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref22/cit22&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00329&amp;key=10.1182%2Fblood-2016-10-747345" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref22/cit22&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00329&amp;key=28167659" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref22/cit22&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00329&amp;key=1%3ACAS%3A528%3ADC%252BC2sXhtFertLvL" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=129&publication_year=2017&pages=2224-2232&author=A.+Noyauthor=S.+de+Vosauthor=C.+Thieblemontauthor=P.+Martinauthor=C.+R.+Flowersauthor=F.+Morschhauserauthor=G.+P.+Collinsauthor=S.+Maauthor=M.+Colemanauthor=S.+Pelesauthor=S.+Smithauthor=J.+C.+Barrientosauthor=A.+Smithauthor=B.+Munnekeauthor=I.+Dimeryauthor=D.+M.+Beaupreauthor=R.+Chen&title=Targeting+Bruton+tyrosine+kinase+with+ibrutinib+in+relapsed%2Frefractory+marginal+zone+lymphoma&doi=10.1182%2Fblood-2016-10-747345"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit22R"><div class="casContent"><span class="casTitleNuber">22</span><div class="casTitle"><span class="NLM_cas:atitle">Targeting Bruton tyrosine kinase with ibrutinib in relapsed/refractory marginal zone lymphoma</span></div><div class="casAuthors">Noy, Ariela; de Vos, Sven; Thieblemont, Catherine; Martin, Peter; Flowers, Christopher R.; Morschhauser, Franck; Collins, Graham P.; Ma, Shuo; Coleman, Morton; Peles, Shachar; Smith, Stephen; Barrientos, Jacqueline C.; Smith, Alina; Munneke, Brian; Dimery, Isaiah; Beaupre, Darrin M.; Chen, Robert</div><div class="citationInfo"><span class="NLM_cas:title">Blood</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">129</span>
        (<span class="NLM_cas:issue">16</span>),
    <span class="NLM_cas:pages">2224-2232</span>CODEN:
                <span class="NLM_cas:coden">BLOOAW</span>;
        ISSN:<span class="NLM_cas:issn">1528-0020</span>.
    
            (<span class="NLM_cas:orgname">American Society of Hematology</span>)
        </div><div class="casAbstract">Marginal zone lymphoma (MZL) is a heterogeneous B-cell malignancy for which no std. treatment exists.  MZL is frequently linked to chronic infection, which may induce B-cell receptor (BCR) signaling, resulting in aberrant B-cell survival and proliferation.  We conducted a multicenter, open-label, phase 2 study to evaluate the efficacy and safety of ibrutinib in previously treated MZL.  Patients with histol. confirmed MZL of all subtypes who received ≥1 prior therapy with an anti-CD20 antibody-contg. regimen were treated with 560 mg ibrutinib orally once daily until progression or unacceptable toxicity.  The primary end point was independent review committee-assessed overall response rate (ORR) by 2007 International Working Group criteria.  Among 63 enrolled patients, median age was 66 years (range, 30-92).  Median no. of prior systemic therapies was 2 (range, 1-9), and 63% received -1 prior chemoimmunotherapy.  In 60 evaluable patients, ORR was 48% (95% confidence interval [CI], 35-62).  With median follow-up of 19.4 mo, median duration of response was not reached (95% CI, 16.7 to not estimable), and median progression-free survival was 14.2 mo (95% CI, 8.3 to not estimable).  Grade ≥3 adverse events (AEs; >5%) included anemia, pneumonia, and fatigue.  Serious AEs of any grade occurred in 44%, with grade 3-4 pneumonia being the most common (8%).  Rates of discontinuation and dose redns. due to AEs were 17% and 10%, resp.  Single-agent ibrutinib induced durable responses with a favorable benefit-risk profile in patients with previously treated MZL, confirming the role of BCR signaling in this malignancy.  As the only approved therapy, ibrutinib provides a treatment option without chemotherapy for MZL.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrPJsWo_0vgV7Vg90H21EOLACvtfcHk0liVdBK5B7GlHw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXhtFertLvL&md5=d40fbb28f38efaddc5b6516f152a5018</span></div><a href="/servlet/linkout?suffix=cit22&amp;dbid=16384&amp;doi=10.1182%2Fblood-2016-10-747345&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1182%252Fblood-2016-10-747345%26sid%3Dliteratum%253Aachs%26aulast%3DNoy%26aufirst%3DA.%26aulast%3Dde%2BVos%26aufirst%3DS.%26aulast%3DThieblemont%26aufirst%3DC.%26aulast%3DMartin%26aufirst%3DP.%26aulast%3DFlowers%26aufirst%3DC.%2BR.%26aulast%3DMorschhauser%26aufirst%3DF.%26aulast%3DCollins%26aufirst%3DG.%2BP.%26aulast%3DMa%26aufirst%3DS.%26aulast%3DColeman%26aufirst%3DM.%26aulast%3DPeles%26aufirst%3DS.%26aulast%3DSmith%26aufirst%3DS.%26aulast%3DBarrientos%26aufirst%3DJ.%2BC.%26aulast%3DSmith%26aufirst%3DA.%26aulast%3DMunneke%26aufirst%3DB.%26aulast%3DDimery%26aufirst%3DI.%26aulast%3DBeaupre%26aufirst%3DD.%2BM.%26aulast%3DChen%26aufirst%3DR.%26atitle%3DTargeting%2520Bruton%2520tyrosine%2520kinase%2520with%2520ibrutinib%2520in%2520relapsed%252Frefractory%2520marginal%2520zone%2520lymphoma%26jtitle%3DBlood%26date%3D2017%26volume%3D129%26spage%3D2224%26epage%3D2232%26doi%3D10.1182%2Fblood-2016-10-747345" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref23"><div class="reference"><strong class="refLabel"><a href="#ref23" class="rightTabRefNumLink">23</a></strong><div class="NLM_citation" id="rightTab-cit23"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Evans, E. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tester, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Aslanian, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Karp, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sheets, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Labenski, M. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Witowski, S. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lounsbury, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chaturvedi, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mazdiyasni, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhu, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nacht, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Freed, M. I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Petter, R. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dubrovskiy, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Singh, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Westlin, W. F.</span></span> <span> </span><span class="NLM_article-title">Inhibition of Btk with CC-292 provides early pharmacodynamic assessment of activity in mice and humans</span>. <i>J. Pharmacol. Exp. Ther.</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>346</i></span>,  <span class="NLM_fpage">219</span>– <span class="NLM_lpage">228</span>, <span class="refDoi"> DOI: 10.1124/jpet.113.203489</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref23/cit23&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00329&amp;key=10.1124%2Fjpet.113.203489" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref23/cit23&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00329&amp;key=23709115" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref23/cit23&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00329&amp;key=1%3ACAS%3A528%3ADC%252BC3sXhtFOjsbbM" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=346&publication_year=2013&pages=219-228&author=E.+K.+Evansauthor=R.+Testerauthor=S.+Aslanianauthor=R.+Karpauthor=M.+Sheetsauthor=M.+T.+Labenskiauthor=S.+R.+Witowskiauthor=H.+Lounsburyauthor=P.+Chaturvediauthor=H.+Mazdiyasniauthor=Z.+Zhuauthor=M.+Nachtauthor=M.+I.+Freedauthor=R.+C.+Petterauthor=A.+Dubrovskiyauthor=J.+Singhauthor=W.+F.+Westlin&title=Inhibition+of+Btk+with+CC-292+provides+early+pharmacodynamic+assessment+of+activity+in+mice+and+humans&doi=10.1124%2Fjpet.113.203489"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit23R"><div class="casContent"><span class="casTitleNuber">23</span><div class="casTitle"><span class="NLM_cas:atitle">Inhibition of Btk with CC-292 provides early pharmacodynamic assessment of activity in mice and humans</span></div><div class="casAuthors">Evans, Erica K.; Tester, Richland; Aslanian, Sharon; Karp, Russell; Sheets, Michael; Labenski, Matthew T.; Witowski, Steven R.; Lounsbury, Heather; Chaturvedi, Prasoon; Mazdiyasni, Hormoz; Zhu, Zhendong; Nacht, Mariana; Freed, Martin I.; Petter, Russell C.; Dubrovskiy, Alex; Singh, Juswinder; Westlin, William F.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Pharmacology and Experimental Therapeutics</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">346</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">219-228</span>CODEN:
                <span class="NLM_cas:coden">JPETAB</span>;
        ISSN:<span class="NLM_cas:issn">1521-0103</span>.
    
            (<span class="NLM_cas:orgname">American Society for Pharmacology and Experimental Therapeutics</span>)
        </div><div class="casAbstract">Targeted therapies that suppress B cell receptor (BCR) signaling have emerged as promising agents in autoimmune disease and B cell malignancies.  Bruton's tyrosine kinase (Btk) plays a crucial role in B cell development and activation through the BCR signaling pathway and represents a new target for diseases characterized by inappropriate B cell activity.  N-(3-(5-fluoro-2-(4-(2-methoxyethoxy)phenylamino)pyrimidin-4-ylamino)phenyl)acrylamide (CC-292) is a highly selective, covalent Btk inhibitor and a sensitive and quant. assay that measures CC-292-Btk engagement has been developed.  This translational pharmacodynamic assay has accompanied CC-292 through each step of drug discovery and development.  These studies demonstrate the quantity of Btk bound by CC-292 correlates with the efficacy of CC-292 in vitro and in the collagen-induced arthritis model of autoimmune disease.  Recently, CC-292 has entered human clin. trials with a trial design that has provided rapid insight into safety, pharmacokinetics, and pharmacodynamics.  This first-in-human healthy volunteer trial has demonstrated that a single oral dose of 2 mg/kg CC-292 consistently engaged all circulating Btk protein and provides the basis for rational dose selection in future clin. trials.  This targeted covalent drug design approach has enabled the discovery and early clin. development of CC-292 and has provided support for Btk as a valuable drug target for B-cell mediated disorders.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrN2l8ZCVqCFLVg90H21EOLACvtfcHk0liVdBK5B7GlHw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXhtFOjsbbM&md5=95fac997a246e59d943dd554af358a65</span></div><a href="/servlet/linkout?suffix=cit23&amp;dbid=16384&amp;doi=10.1124%2Fjpet.113.203489&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1124%252Fjpet.113.203489%26sid%3Dliteratum%253Aachs%26aulast%3DEvans%26aufirst%3DE.%2BK.%26aulast%3DTester%26aufirst%3DR.%26aulast%3DAslanian%26aufirst%3DS.%26aulast%3DKarp%26aufirst%3DR.%26aulast%3DSheets%26aufirst%3DM.%26aulast%3DLabenski%26aufirst%3DM.%2BT.%26aulast%3DWitowski%26aufirst%3DS.%2BR.%26aulast%3DLounsbury%26aufirst%3DH.%26aulast%3DChaturvedi%26aufirst%3DP.%26aulast%3DMazdiyasni%26aufirst%3DH.%26aulast%3DZhu%26aufirst%3DZ.%26aulast%3DNacht%26aufirst%3DM.%26aulast%3DFreed%26aufirst%3DM.%2BI.%26aulast%3DPetter%26aufirst%3DR.%2BC.%26aulast%3DDubrovskiy%26aufirst%3DA.%26aulast%3DSingh%26aufirst%3DJ.%26aulast%3DWestlin%26aufirst%3DW.%2BF.%26atitle%3DInhibition%2520of%2520Btk%2520with%2520CC-292%2520provides%2520early%2520pharmacodynamic%2520assessment%2520of%2520activity%2520in%2520mice%2520and%2520humans%26jtitle%3DJ.%2520Pharmacol.%2520Exp.%2520Ther.%26date%3D2013%26volume%3D346%26spage%3D219%26epage%3D228%26doi%3D10.1124%2Fjpet.113.203489" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref24"><div class="reference"><strong class="refLabel"><a href="#ref24" class="rightTabRefNumLink">24</a></strong><div class="NLM_citation" id="rightTab-cit24"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Wu, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, D.</span></span> <span> </span><span class="NLM_article-title">Acalabrutinib (ACP-196): a selective second-generation BTK inhibitor</span>. <i>J. Hematol. Oncol.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>9</i></span>,  <span class="NLM_fpage">21</span>, <span class="refDoi"> DOI: 10.1186/s13045-016-0250-9</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref24/cit24&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00329&amp;key=10.1186%2Fs13045-016-0250-9" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref24/cit24&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00329&amp;key=26957112" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref24/cit24&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00329&amp;key=1%3ACAS%3A528%3ADC%252BC2sXis1eisrw%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=9&publication_year=2016&pages=21&author=J.+Wuauthor=M.+Zhangauthor=D.+Liu&title=Acalabrutinib+%28ACP-196%29%3A+a+selective+second-generation+BTK+inhibitor&doi=10.1186%2Fs13045-016-0250-9"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit24R"><div class="casContent"><span class="casTitleNuber">24</span><div class="casTitle"><span class="NLM_cas:atitle">Acalabrutinib (ACP-196): a selective second-generation BTK inhibitor</span></div><div class="casAuthors">Wu, Jingjing; Zhang, Mingzhi; Liu, Delong</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Hematology & Oncology</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">9</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">21/1-21/4</span>CODEN:
                <span class="NLM_cas:coden">JHOOAO</span>;
        ISSN:<span class="NLM_cas:issn">1756-8722</span>.
    
            (<span class="NLM_cas:orgname">BioMed Central Ltd.</span>)
        </div><div class="casAbstract">More and more targeted agents become available for B cell malignancies with increasing precision and potency.  The first-in-class Bruton's tyrosine kinase (BTK) inhibitor, ibrutinib, has been in clin. use for the treatment of chronic lymphocytic leukemia, mantle cell lymphoma, and Waldenstrom's macroglobulinemia.  More selective BTK inhibitors (ACP-196, ONO/GS-4059, BGB-3111, CC-292) are being explored.  Acalabrutinib (ACP-196) is a novel irreversible second-generation BTK inhibitor that was shown to be more potent and selective than ibrutinib.  This review summarized the preclin. research and clin. data of acalabrutinib.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpAU072sMxzmLVg90H21EOLACvtfcHk0lieL_ibsxAcZQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXis1eisrw%253D&md5=a6a8f9b9236abe7ef1054a41e1c71e5a</span></div><a href="/servlet/linkout?suffix=cit24&amp;dbid=16384&amp;doi=10.1186%2Fs13045-016-0250-9&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1186%252Fs13045-016-0250-9%26sid%3Dliteratum%253Aachs%26aulast%3DWu%26aufirst%3DJ.%26aulast%3DZhang%26aufirst%3DM.%26aulast%3DLiu%26aufirst%3DD.%26atitle%3DAcalabrutinib%2520%2528ACP-196%2529%253A%2520a%2520selective%2520second-generation%2520BTK%2520inhibitor%26jtitle%3DJ.%2520Hematol.%2520Oncol.%26date%3D2016%26volume%3D9%26spage%3D21%26doi%3D10.1186%2Fs13045-016-0250-9" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref25"><div class="reference"><strong class="refLabel"><a href="#ref25" class="rightTabRefNumLink">25</a></strong><div class="NLM_citation" id="rightTab-cit25"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Herman, S. E. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Montraveta, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Niemann, C. U.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mora-Jensen, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gulrajani, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Krantz, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mantel, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Smith, L. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">McClanahan, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Harrington, B. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Colomer, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Covey, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Byrd, J. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Izumi, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kaptein, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ulrich, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Johnson, A. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lannutti, B. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wiestner, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Woyach, J. A.</span></span> <span> </span><span class="NLM_article-title">The Bruton tyrosine kinase (BTK) inhibitor Acalabrutinib demonstrates potent on-target effects and efficacy in two mouse models of chronic lymphocytic leukemia</span>. <i>Clin. Cancer Res.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>23</i></span>,  <span class="NLM_fpage">2831</span>– <span class="NLM_lpage">2841</span>, <span class="refDoi"> DOI: 10.1158/1078-0432.ccr-16-0463</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref25/cit25&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00329&amp;key=10.1158%2F1078-0432.ccr-16-0463" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref25/cit25&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00329&amp;key=27903679" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref25/cit25&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00329&amp;key=1%3ACAS%3A528%3ADC%252BC2sXpt1Sms74%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=23&publication_year=2017&pages=2831-2841&author=S.+E.+M.+Hermanauthor=A.+Montravetaauthor=C.+U.+Niemannauthor=H.+Mora-Jensenauthor=M.+Gulrajaniauthor=F.+Krantzauthor=R.+Mantelauthor=L.+L.+Smithauthor=F.+McClanahanauthor=B.+K.+Harringtonauthor=D.+Colomerauthor=T.+Coveyauthor=J.+C.+Byrdauthor=R.+Izumiauthor=A.+Kapteinauthor=R.+Ulrichauthor=A.+J.+Johnsonauthor=B.+J.+Lannuttiauthor=A.+Wiestnerauthor=J.+A.+Woyach&title=The+Bruton+tyrosine+kinase+%28BTK%29+inhibitor+Acalabrutinib+demonstrates+potent+on-target+effects+and+efficacy+in+two+mouse+models+of+chronic+lymphocytic+leukemia&doi=10.1158%2F1078-0432.ccr-16-0463"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit25R"><div class="casContent"><span class="casTitleNuber">25</span><div class="casTitle"><span class="NLM_cas:atitle">The Bruton Tyrosine Kinase (BTK) Inhibitor Acalabrutinib Demonstrates Potent On-Target Effects and Efficacy in Two Mouse Models of Chronic Lymphocytic Leukemia</span></div><div class="casAuthors">Herman, Sarah E. M.; Montraveta, Arnau; Niemann, Carsten U.; Mora-Jensen, Helena; Gulrajani, Michael; Krantz, Fanny; Mantel, Rose; Smith, Lisa L.; McClanahan, Fabienne; Harrington, Bonnie K.; Colomer, Dolors; Covey, Todd; Byrd, John C.; Izumi, Raquel; Kaptein, Allard; Ulrich, Roger; Johnson, Amy J.; Lannutti, Brian J.; Wiestner, Adrian; Woyach, Jennifer A.</div><div class="citationInfo"><span class="NLM_cas:title">Clinical Cancer Research</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">23</span>
        (<span class="NLM_cas:issue">11</span>),
    <span class="NLM_cas:pages">2831-2841</span>CODEN:
                <span class="NLM_cas:coden">CCREF4</span>;
        ISSN:<span class="NLM_cas:issn">1078-0432</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">Purpose: Acalabrutinib (ACP-196) is a novel, potent, and highly selective Bruton tyrosine kinase (BTK) inhibitor, which binds covalently to Cys481 in the ATP-binding pocket of BTK.  We sought to evaluate the antitumor effects of acalabrutinib treatment in two established mouse models of chronic lymphocytic leukemia (CLL).  Exptl. Design: Two distinct mouse models were used, the TCL1 adoptive transfer model where leukemic cells from Eμ-TCL1 transgenic mice are transplanted into C57BL/6 mice, and the human NSG primary CLL xenograft model.  Mice received either vehicle or acalabrutinib formulated into the drinking water.  Results: Utilizing biochem. assays, we demonstrate that acalabrutinib is a highly selective BTK inhibitor as compared with ibrutinib.  In the human CLL NSG xenograft model, treatment with acalabrutinib demonstrated on-target effects, including decreased phosphorylation of PLCγ2, ERK, and significant inhibition of CLL cell proliferation.  Furthermore, tumor burden in the spleen of the mice treated with acalabrutinib was significantly decreased compared with vehicle-treated mice.  Similarly, in the TCL1 adoptive transfer model, decreased phosphorylation of BTK, PLCγ2, and S6 was obsd.  Most notably, treatment with acalabrutinib resulted in a significant increase in survival compared with mice receiving vehicle.  Conclusions: Treatment with acalabrutinib potently inhibits BTK in vivo, leading to on-target decreases in the activation of key signaling mols. (including BTK, PLCγ2, S6, and ERK).  In two complementary mouse models of CLL, acalabrutinib significantly reduced tumor burden and increased survival compared with vehicle treatment.  Overall, acalabrutinib showed increased BTK selectivity compared with ibrutinib while demonstrating significant antitumor efficacy in vivo on par with ibrutinib.  Clin Cancer Res; 23(11); 2831-41. ©2016 AACR.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoD7ESW1IqIY7Vg90H21EOLACvtfcHk0lieL_ibsxAcZQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXpt1Sms74%253D&md5=a3c89f6918d1ed1195f4d439f33c17d7</span></div><a href="/servlet/linkout?suffix=cit25&amp;dbid=16384&amp;doi=10.1158%2F1078-0432.ccr-16-0463&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F1078-0432.ccr-16-0463%26sid%3Dliteratum%253Aachs%26aulast%3DHerman%26aufirst%3DS.%2BE.%2BM.%26aulast%3DMontraveta%26aufirst%3DA.%26aulast%3DNiemann%26aufirst%3DC.%2BU.%26aulast%3DMora-Jensen%26aufirst%3DH.%26aulast%3DGulrajani%26aufirst%3DM.%26aulast%3DKrantz%26aufirst%3DF.%26aulast%3DMantel%26aufirst%3DR.%26aulast%3DSmith%26aufirst%3DL.%2BL.%26aulast%3DMcClanahan%26aufirst%3DF.%26aulast%3DHarrington%26aufirst%3DB.%2BK.%26aulast%3DColomer%26aufirst%3DD.%26aulast%3DCovey%26aufirst%3DT.%26aulast%3DByrd%26aufirst%3DJ.%2BC.%26aulast%3DIzumi%26aufirst%3DR.%26aulast%3DKaptein%26aufirst%3DA.%26aulast%3DUlrich%26aufirst%3DR.%26aulast%3DJohnson%26aufirst%3DA.%2BJ.%26aulast%3DLannutti%26aufirst%3DB.%2BJ.%26aulast%3DWiestner%26aufirst%3DA.%26aulast%3DWoyach%26aufirst%3DJ.%2BA.%26atitle%3DThe%2520Bruton%2520tyrosine%2520kinase%2520%2528BTK%2529%2520inhibitor%2520Acalabrutinib%2520demonstrates%2520potent%2520on-target%2520effects%2520and%2520efficacy%2520in%2520two%2520mouse%2520models%2520of%2520chronic%2520lymphocytic%2520leukemia%26jtitle%3DClin.%2520Cancer%2520Res.%26date%3D2017%26volume%3D23%26spage%3D2831%26epage%3D2841%26doi%3D10.1158%2F1078-0432.ccr-16-0463" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref26"><div class="reference"><strong class="refLabel"><a href="#ref26" class="rightTabRefNumLink">26</a></strong><div class="NLM_citation" id="rightTab-cit26"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Liu, Q.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sabnis, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhao, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Buhrlage, S. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jones, L. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gray, N. S.</span></span> <span> </span><span class="NLM_article-title">Developing irreversible inhibitors of the protein kinase cysteinome</span>. <i>Chem. Biol.</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>20</i></span>,  <span class="NLM_fpage">146</span>– <span class="NLM_lpage">159</span>, <span class="refDoi"> DOI: 10.1016/j.chembiol.2012.12.006</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref26/cit26&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00329&amp;key=10.1016%2Fj.chembiol.2012.12.006" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref26/cit26&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00329&amp;key=23438744" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref26/cit26&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00329&amp;key=1%3ACAS%3A528%3ADC%252BC3sXjtFWitbs%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=20&publication_year=2013&pages=146-159&author=Q.+Liuauthor=Y.+Sabnisauthor=Z.+Zhaoauthor=T.+Zhangauthor=S.+J.+Buhrlageauthor=L.+H.+Jonesauthor=N.+S.+Gray&title=Developing+irreversible+inhibitors+of+the+protein+kinase+cysteinome&doi=10.1016%2Fj.chembiol.2012.12.006"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit26R"><div class="casContent"><span class="casTitleNuber">26</span><div class="casTitle"><span class="NLM_cas:atitle">Developing Irreversible Inhibitors of the Protein Kinase Cysteinome</span></div><div class="casAuthors">Liu, Qingsong; Sabnis, Yogesh; Zhao, Zheng; Zhang, Tinghu; Buhrlage, Sara J.; Jones, Lyn H.; Gray, Nathanael S.</div><div class="citationInfo"><span class="NLM_cas:title">Chemistry & Biology (Oxford, United Kingdom)</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">20</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">146-159</span>CODEN:
                <span class="NLM_cas:coden">CBOLE2</span>;
        ISSN:<span class="NLM_cas:issn">1074-5521</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Ltd.</span>)
        </div><div class="casAbstract">A review.  Protein kinases are a large family of approx. 530 highly conserved enzymes that transfer a γ-phosphate group from ATP to a variety of amino acid residues, such as tyrosine, serine, and threonine, that serves as a ubiquitous mechanism for cellular signal transduction.  The clin. success of a no. of kinase-directed drugs and the frequent observation of disease causing mutations in protein kinases suggest that a large no. of kinases may represent therapeutically relevant targets.  To date, the majority of clin. and preclin. kinase inhibitors are ATP competitive, noncovalent inhibitors that achieve selectivity through recognition of unique features of particular protein kinases.  Recently, there has been renewed interest in the development of irreversible inhibitors that form covalent bonds with cysteine or other nucleophilic residues in the ATP-binding pocket.  Irreversible kinase inhibitors have a no. of potential advantages including prolonged pharmacodynamics, suitability for rational design, high potency, and ability to validate pharmacol. specificity through mutation of the reactive cysteine residue.  Here, we review recent efforts to develop cysteine-targeted irreversible protein kinase inhibitors and discuss their modes of recognizing the ATP-binding pocket and their biol. activity profiles.  In addn., we provided an informatics assessment of the potential "kinase cysteinome" and discuss strategies for the efficient development of new covalent inhibitors.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrVGD7TX3oIeLVg90H21EOLACvtfcHk0lieL_ibsxAcZQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXjtFWitbs%253D&md5=cef80823123bae88362e816a0a638133</span></div><a href="/servlet/linkout?suffix=cit26&amp;dbid=16384&amp;doi=10.1016%2Fj.chembiol.2012.12.006&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.chembiol.2012.12.006%26sid%3Dliteratum%253Aachs%26aulast%3DLiu%26aufirst%3DQ.%26aulast%3DSabnis%26aufirst%3DY.%26aulast%3DZhao%26aufirst%3DZ.%26aulast%3DZhang%26aufirst%3DT.%26aulast%3DBuhrlage%26aufirst%3DS.%2BJ.%26aulast%3DJones%26aufirst%3DL.%2BH.%26aulast%3DGray%26aufirst%3DN.%2BS.%26atitle%3DDeveloping%2520irreversible%2520inhibitors%2520of%2520the%2520protein%2520kinase%2520cysteinome%26jtitle%3DChem.%2520Biol.%26date%3D2013%26volume%3D20%26spage%3D146%26epage%3D159%26doi%3D10.1016%2Fj.chembiol.2012.12.006" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref27"><div class="reference"><strong class="refLabel"><a href="#ref27" class="rightTabRefNumLink">27</a></strong><div class="NLM_citation" id="rightTab-cit27"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Liu, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Di Paolo, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Barbosa, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rong, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Reif, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wong, H.</span></span> <span> </span><span class="NLM_article-title">Antiarthritis effect of a novel Bruton’s tyrosine kinase (BTK) inhibitor in rat collagen-induced arthritis and mechanism-based pharmacokinetic/pharmacodynamic modeling: relationships between inhibition of BTK phosphorylation and efficacy</span>. <i>J. Pharmacol. Exp. Ther.</i> <span class="NLM_year" style="font-weight: bold;">2011</span>,  <span class="NLM_volume"><i>338</i></span>,  <span class="NLM_fpage">154</span>– <span class="NLM_lpage">163</span>, <span class="refDoi"> DOI: 10.1124/jpet.111.181545</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref27/cit27&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00329&amp;key=10.1124%2Fjpet.111.181545" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref27/cit27&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00329&amp;key=21521773" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref27/cit27&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00329&amp;key=1%3ACAS%3A528%3ADC%252BC3MXosFCiu7w%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=338&publication_year=2011&pages=154-163&author=L.+Liuauthor=J.+Di+Paoloauthor=J.+Barbosaauthor=H.+Rongauthor=K.+Reifauthor=H.+Wong&title=Antiarthritis+effect+of+a+novel+Bruton%E2%80%99s+tyrosine+kinase+%28BTK%29+inhibitor+in+rat+collagen-induced+arthritis+and+mechanism-based+pharmacokinetic%2Fpharmacodynamic+modeling%3A+relationships+between+inhibition+of+BTK+phosphorylation+and+efficacy&doi=10.1124%2Fjpet.111.181545"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit27R"><div class="casContent"><span class="casTitleNuber">27</span><div class="casTitle"><span class="NLM_cas:atitle">Antiarthritis effect of a novel Bruton's tyrosine kinase (BTK) inhibitor in rat collagen-induced arthritis and mechanism-based pharmacokinetic/pharmacodynamic modeling: relationships between inhibition of BTK phosphorylation and efficacy</span></div><div class="casAuthors">Liu, Lichuan; Di Paolo, Julie; Barbosa, Jim; Rong, Hong; Reif, Karin; Wong, Harvey</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Pharmacology and Experimental Therapeutics</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">338</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">154-163</span>CODEN:
                <span class="NLM_cas:coden">JPETAB</span>;
        ISSN:<span class="NLM_cas:issn">0022-3565</span>.
    
            (<span class="NLM_cas:orgname">American Society for Pharmacology and Experimental Therapeutics</span>)
        </div><div class="casAbstract">Bruton's tyrosine kinase (BTK) plays a crit. role in the development, differentiation, and proliferation of B-lineage cells, making it an attractive target for the treatment of rheumatoid arthritis.  The objective of this study was to evaluate the antiarthritis effect of GDC-0834 [R-N-(3-(6-(4-(1,4-dimethyl-3-oxopiperazin-2-yl)phenylamino)-4-methyl-5-oxo-4,5-dihydropyrazin-2-yl)-2-methylphenyl)-4,5,6,7-tetrahydrobenzo[b]thiophene-2-carboxamide], a potent and selective BTK inhibitor, and characterize the relationship between inhibition of BTK phosphorylation (pBTK) and efficacy.  GDC-0834 inhibited BTK with an in vitro IC50 of 5.9 and 6.4 nM in biochem. and cellular assays, resp., and in vivo IC50 of 1.1 and 5.6 μM in mouse and rat, resp.  Administration of GDC-0834 (30-100 mg/kg) in a rat collagen-induced arthritis (CIA) model resulted in a dose-dependent decrease of ankle swelling and redn. of morphol. pathol.  An integrated disease progression pharmacokinetic/pharmacodynamic model where efficacy is driven by pBTK inhibition was fit to ankle-diam. time-course data.  This model incorporated a transit model to characterize nondrug-related decreases in ankle swelling occurring at later stages of disease progression in CIA rats.  The time course of ankle swelling in vehicle animals was described well by the base model.  Simultaneous fitting of data from vehicle- and GDC-0834-treated groups showed that overall 73% inhibition of pBTK was needed to decrease the rate const. describing the ankle swelling increase (kin) by half.  These findings suggest a high degree of pBTK inhibition is required for maximal activity of the pathway on inflammatory arthritis in rats.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpUtceutx0oDrVg90H21EOLACvtfcHk0ljyPHc7O7oSJA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXosFCiu7w%253D&md5=52ec6f33d9fc743036baea87a2d6bce1</span></div><a href="/servlet/linkout?suffix=cit27&amp;dbid=16384&amp;doi=10.1124%2Fjpet.111.181545&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1124%252Fjpet.111.181545%26sid%3Dliteratum%253Aachs%26aulast%3DLiu%26aufirst%3DL.%26aulast%3DDi%2BPaolo%26aufirst%3DJ.%26aulast%3DBarbosa%26aufirst%3DJ.%26aulast%3DRong%26aufirst%3DH.%26aulast%3DReif%26aufirst%3DK.%26aulast%3DWong%26aufirst%3DH.%26atitle%3DAntiarthritis%2520effect%2520of%2520a%2520novel%2520Bruton%25E2%2580%2599s%2520tyrosine%2520kinase%2520%2528BTK%2529%2520inhibitor%2520in%2520rat%2520collagen-induced%2520arthritis%2520and%2520mechanism-based%2520pharmacokinetic%252Fpharmacodynamic%2520modeling%253A%2520relationships%2520between%2520inhibition%2520of%2520BTK%2520phosphorylation%2520and%2520efficacy%26jtitle%3DJ.%2520Pharmacol.%2520Exp.%2520Ther.%26date%3D2011%26volume%3D338%26spage%3D154%26epage%3D163%26doi%3D10.1124%2Fjpet.111.181545" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref28"><div class="reference"><strong class="refLabel"><a href="#ref28" class="rightTabRefNumLink">28</a></strong><div class="NLM_citation" id="rightTab-cit28"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Di
Paolo, J. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Huang, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Balazs, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Barbosa, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Barck, K. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bravo, B. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Carano, R. A. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Darrow, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Davies, D. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">DeForge, L. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Diehl, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ferrando, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gallion, S. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Giannetti, A. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gribling, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hurez, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hymowitz, S. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jones, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kropf, J. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lee, W. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Maciejewski, P. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mitchell, S. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rong, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Staker, B. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Whitney, J. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yeh, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Young, W. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yu, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Reif, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Currie, K. S.</span></span> <span> </span><span class="NLM_article-title">Specific Btk inhibition suppresses B cell- and myeloid cell-mediated arthritis</span>. <i>Nat. Chem. Biol.</i> <span class="NLM_year" style="font-weight: bold;">2011</span>,  <span class="NLM_volume"><i>7</i></span>,  <span class="NLM_fpage">41</span>– <span class="NLM_lpage">50</span>, <span class="refDoi"> DOI: 10.1038/nchembio.481</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref28/cit28&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00329&amp;key=10.1038%2Fnchembio.481" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref28/cit28&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00329&amp;key=21113169" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref28/cit28&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00329&amp;key=1%3ACAS%3A528%3ADC%252BC3cXhsVOrsLjP" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=7&publication_year=2011&pages=41-50&author=J.+A.+Di%0APaoloauthor=T.+Huangauthor=M.+Balazsauthor=J.+Barbosaauthor=K.+H.+Barckauthor=B.+J.+Bravoauthor=R.+A.+D.+Caranoauthor=J.+Darrowauthor=D.+R.+Daviesauthor=L.+E.+DeForgeauthor=L.+Diehlauthor=R.+Ferrandoauthor=S.+L.+Gallionauthor=A.+M.+Giannettiauthor=P.+Griblingauthor=V.+Hurezauthor=S.+G.+Hymowitzauthor=R.+Jonesauthor=J.+E.+Kropfauthor=W.+P.+Leeauthor=P.+M.+Maciejewskiauthor=S.+A.+Mitchellauthor=H.+Rongauthor=B.+L.+Stakerauthor=J.+A.+Whitneyauthor=S.+Yehauthor=W.+B.+Youngauthor=C.+Yuauthor=J.+Zhangauthor=K.+Reifauthor=K.+S.+Currie&title=Specific+Btk+inhibition+suppresses+B+cell-+and+myeloid+cell-mediated+arthritis&doi=10.1038%2Fnchembio.481"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit28R"><div class="casContent"><span class="casTitleNuber">28</span><div class="casTitle"><span class="NLM_cas:atitle">Specific Btk inhibition suppresses B cell- and myeloid cell-mediated arthritis</span></div><div class="casAuthors">Di Paolo, Julie A.; Huang, Tao; Balazs, Mercedesz; Barbosa, James; Barck, Kai H.; Bravo, Brandon J.; Carano, Richard A. D.; Darrow, James; Davies, Douglas R.; DeForge, Laura E.; Diehl, Lauri; Ferrando, Ronald; Gallion, Steven L.; Giannetti, Anthony M.; Gribling, Peter; Hurez, Vincent; Hymowitz, Sarah G.; Jones, Randall; Kropf, Jeffrey E.; Lee, Wyne P.; Maciejewski, Patricia M.; Mitchell, Scott A.; Rong, Hong; Staker, Bart L.; Whitney, J. Andrew; Yeh, Sherry; Young, Wendy B.; Yu, Christine; Zhang, Juan; Reif, Karin; Currie, Kevin S.</div><div class="citationInfo"><span class="NLM_cas:title">Nature Chemical Biology</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">7</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">41-50</span>CODEN:
                <span class="NLM_cas:coden">NCBABT</span>;
        ISSN:<span class="NLM_cas:issn">1552-4450</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">Bruton's tyrosine kinase (Btk) is a therapeutic target for rheumatoid arthritis, but the cellular and mol. mechanisms by which Btk mediates inflammation are poorly understood.  Here we describe the discovery of CGI1746, a small-mol. Btk inhibitor chemotype with a new binding mode that stabilizes an inactive nonphosphorylated enzyme conformation.  CGI1746 has exquisite selectivity for Btk and inhibits both auto- and transphosphorylation steps necessary for enzyme activation.  Using CGI1746, we demonstrate that Btk regulates inflammatory arthritis by two distinct mechanisms.  CGI1746 blocks B cell receptor-dependent B cell proliferation and in prophylactic regimens reduces autoantibody levels in collagen-induced arthritis.  In macrophages, Btk inhibition abolishes FcγRIII-induced TNFα, IL-1β and IL-6 prodn.  Accordingly, in myeloid- and FcγR-dependent autoantibody-induced arthritis, CGI1746 decreases cytokine levels within joints and ameliorates disease.  These results provide new understanding of the function of Btk in both B cell- or myeloid cell-driven disease processes and provide a compelling rationale for targeting Btk in rheumatoid arthritis.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoegiZYoitP57Vg90H21EOLACvtfcHk0ljyPHc7O7oSJA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXhsVOrsLjP&md5=99d925c71bc1b201191ebde0f1c0b50f</span></div><a href="/servlet/linkout?suffix=cit28&amp;dbid=16384&amp;doi=10.1038%2Fnchembio.481&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnchembio.481%26sid%3Dliteratum%253Aachs%26aulast%3DDi%2BPaolo%26aufirst%3DJ.%2BA.%26aulast%3DHuang%26aufirst%3DT.%26aulast%3DBalazs%26aufirst%3DM.%26aulast%3DBarbosa%26aufirst%3DJ.%26aulast%3DBarck%26aufirst%3DK.%2BH.%26aulast%3DBravo%26aufirst%3DB.%2BJ.%26aulast%3DCarano%26aufirst%3DR.%2BA.%2BD.%26aulast%3DDarrow%26aufirst%3DJ.%26aulast%3DDavies%26aufirst%3DD.%2BR.%26aulast%3DDeForge%26aufirst%3DL.%2BE.%26aulast%3DDiehl%26aufirst%3DL.%26aulast%3DFerrando%26aufirst%3DR.%26aulast%3DGallion%26aufirst%3DS.%2BL.%26aulast%3DGiannetti%26aufirst%3DA.%2BM.%26aulast%3DGribling%26aufirst%3DP.%26aulast%3DHurez%26aufirst%3DV.%26aulast%3DHymowitz%26aufirst%3DS.%2BG.%26aulast%3DJones%26aufirst%3DR.%26aulast%3DKropf%26aufirst%3DJ.%2BE.%26aulast%3DLee%26aufirst%3DW.%2BP.%26aulast%3DMaciejewski%26aufirst%3DP.%2BM.%26aulast%3DMitchell%26aufirst%3DS.%2BA.%26aulast%3DRong%26aufirst%3DH.%26aulast%3DStaker%26aufirst%3DB.%2BL.%26aulast%3DWhitney%26aufirst%3DJ.%2BA.%26aulast%3DYeh%26aufirst%3DS.%26aulast%3DYoung%26aufirst%3DW.%2BB.%26aulast%3DYu%26aufirst%3DC.%26aulast%3DZhang%26aufirst%3DJ.%26aulast%3DReif%26aufirst%3DK.%26aulast%3DCurrie%26aufirst%3DK.%2BS.%26atitle%3DSpecific%2520Btk%2520inhibition%2520suppresses%2520B%2520cell-%2520and%2520myeloid%2520cell-mediated%2520arthritis%26jtitle%3DNat.%2520Chem.%2520Biol.%26date%3D2011%26volume%3D7%26spage%3D41%26epage%3D50%26doi%3D10.1038%2Fnchembio.481" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref29"><div class="reference"><strong class="refLabel"><a href="#ref29" class="rightTabRefNumLink">29</a></strong><div class="NLM_citation" id="rightTab-cit29"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Xu, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kim, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Postelnek, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vu, M. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hu, D.-Q.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liao, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bradshaw, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hsu, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pashine, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Srinivasan, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Woods, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Levin, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">O’Mahony, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Owens, T. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lou, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hill, R. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Narula, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">DeMartino, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fine, J. S.</span></span> <span> </span><span class="NLM_article-title">RN486, a selective Bruton’s tyrosine kinase inhibitor, abrogates immune hypersensitivity responses and arthritis in rodents</span>. <i>J. Pharmacol. Exp. Ther.</i> <span class="NLM_year" style="font-weight: bold;">2012</span>,  <span class="NLM_volume"><i>341</i></span>,  <span class="NLM_fpage">90</span>– <span class="NLM_lpage">103</span>, <span class="refDoi"> DOI: 10.1124/jpet.111.187740</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref29/cit29&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00329&amp;key=10.1124%2Fjpet.111.187740" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref29/cit29&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00329&amp;key=22228807" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref29/cit29&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00329&amp;key=1%3ACAS%3A528%3ADC%252BC38XltVagt7g%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=341&publication_year=2012&pages=90-103&author=D.+Xuauthor=Y.+Kimauthor=J.+Postelnekauthor=M.+D.+Vuauthor=D.-Q.+Huauthor=C.+Liaoauthor=M.+Bradshawauthor=J.+Hsuauthor=J.+Zhangauthor=A.+Pashineauthor=D.+Srinivasanauthor=J.+Woodsauthor=A.+Levinauthor=A.+O%E2%80%99Mahonyauthor=T.+D.+Owensauthor=Y.+Louauthor=R.+J.+Hillauthor=S.+Narulaauthor=J.+DeMartinoauthor=J.+S.+Fine&title=RN486%2C+a+selective+Bruton%E2%80%99s+tyrosine+kinase+inhibitor%2C+abrogates+immune+hypersensitivity+responses+and+arthritis+in+rodents&doi=10.1124%2Fjpet.111.187740"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit29R"><div class="casContent"><span class="casTitleNuber">29</span><div class="casTitle"><span class="NLM_cas:atitle">RN486, a selective Bruton's tyrosine kinase inhibitor, abrogates immune hypersensitivity responses and arthritis in rodents</span></div><div class="casAuthors">Xu, Daigen; Kim, Yong; Postelnek, Jennifer; Vu, Minh Diem; Hu, Dong-Qing; Liao, Cheng; Bradshaw, Mike; Hsu, Jonathan; Zhang, Jun; Pashine, Achal; Srinivasan, Dinesh; Woods, John; Levin, Anita; O'Mahony, Alison; Owens, Timothy D.; Lou, Yan; Hill, Ronald J.; Narula, Satwant; DeMartino, Julie; Fine, Jay S.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Pharmacology and Experimental Therapeutics</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">341</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">90-103</span>CODEN:
                <span class="NLM_cas:coden">JPETAB</span>;
        ISSN:<span class="NLM_cas:issn">1521-0103</span>.
    
            (<span class="NLM_cas:orgname">American Society for Pharmacology and Experimental Therapeutics</span>)
        </div><div class="casAbstract">Genetic mutation and pharmacol. inhibition of Bruton's tyrosine kinase (Btk) both have been shown to prevent the development of collagen-induced arthritis (CIA) in mice, providing a rationale for the development of Btk inhibitors for treating rheumatoid arthritis (RA).  In the present study, we characterized a novel Btk inhibitor, 6-cyclopropyl-8-fluoro-2-(2-hydroxymethyl-3-{1-methyl-5-[5-(4-methyl-piperazin-1-yl)-pyridin-2-ylamino]-6-oxo-1,6-dihydro-pyridin-3-yl}-phenyl)-2H-isoquinolin-1-one (RN486), in vitro and in rodent models of immune hypersensitivity and arthritis.  We demonstrated that RN486 not only potently and selectively inhibited the Btk enzyme, but also displayed functional activities in human cell-based assays in multiple cell types, blocking Fcε receptor crosslinking-induced degranulation in mast cells (IC50 = 2.9 nM), Fcγ receptor engagement-mediated tumor necrosis factor α prodn. in monocytes (IC50 = 7.0 nM), and B cell antigen receptor-induced expression of an activation marker, CD69, in B cells in whole blood (IC50 = 21.0 nM).  RN486 displayed similar functional activities in rodent models, effectively preventing type I and type III hypersensitivity responses.  More importantly, RN486 produced robust anti-inflammatory and bone-protective effects in mouse CIA and rat adjuvant-induced arthritis (AIA) models.  In the AIA model, RN486 inhibited both joint and systemic inflammation either alone or in combination with methotrexate, reducing both paw swelling and inflammatory markers in the blood.  Together, our findings not only demonstrate that Btk plays an essential and conserved role in regulating immunoreceptor-mediated immune responses in both humans and rodents, but also provide evidence and mechanistic insights to support the development of selective Btk inhibitors as small-mol. disease-modifying drugs for RA and potentially other autoimmune diseases.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqXBTQENfl5RbVg90H21EOLACvtfcHk0lhSSztYWH0Ohg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38XltVagt7g%253D&md5=06be56a47afd2eb09e0871710c1d2b47</span></div><a href="/servlet/linkout?suffix=cit29&amp;dbid=16384&amp;doi=10.1124%2Fjpet.111.187740&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1124%252Fjpet.111.187740%26sid%3Dliteratum%253Aachs%26aulast%3DXu%26aufirst%3DD.%26aulast%3DKim%26aufirst%3DY.%26aulast%3DPostelnek%26aufirst%3DJ.%26aulast%3DVu%26aufirst%3DM.%2BD.%26aulast%3DHu%26aufirst%3DD.-Q.%26aulast%3DLiao%26aufirst%3DC.%26aulast%3DBradshaw%26aufirst%3DM.%26aulast%3DHsu%26aufirst%3DJ.%26aulast%3DZhang%26aufirst%3DJ.%26aulast%3DPashine%26aufirst%3DA.%26aulast%3DSrinivasan%26aufirst%3DD.%26aulast%3DWoods%26aufirst%3DJ.%26aulast%3DLevin%26aufirst%3DA.%26aulast%3DO%25E2%2580%2599Mahony%26aufirst%3DA.%26aulast%3DOwens%26aufirst%3DT.%2BD.%26aulast%3DLou%26aufirst%3DY.%26aulast%3DHill%26aufirst%3DR.%2BJ.%26aulast%3DNarula%26aufirst%3DS.%26aulast%3DDeMartino%26aufirst%3DJ.%26aulast%3DFine%26aufirst%3DJ.%2BS.%26atitle%3DRN486%252C%2520a%2520selective%2520Bruton%25E2%2580%2599s%2520tyrosine%2520kinase%2520inhibitor%252C%2520abrogates%2520immune%2520hypersensitivity%2520responses%2520and%2520arthritis%2520in%2520rodents%26jtitle%3DJ.%2520Pharmacol.%2520Exp.%2520Ther.%26date%3D2012%26volume%3D341%26spage%3D90%26epage%3D103%26doi%3D10.1124%2Fjpet.111.187740" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref30"><div class="reference"><strong class="refLabel"><a href="#ref30" class="rightTabRefNumLink">30</a></strong><div class="NLM_citation" id="rightTab-cit30"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Rankin, A. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Seth, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Keegan, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Andreyeva, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cook, T. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Edmonds, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mathialagan, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Benson, M. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Syed, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhan, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Benoit, S. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Miyashiro, J. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wood, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mohan, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Peeva, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ramaiah, S. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Messing, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Homer, B. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dunussi-Joannopoulos, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nickerson-Nutter, C. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schnute, M. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Douhan, J.</span></span> <span> </span><span class="NLM_article-title">Selective inhibition of BTK prevents murine lupus and antibody-mediated glomerulonephritis</span>. <i>J. Immunol.</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>191</i></span>,  <span class="NLM_fpage">4540</span>– <span class="NLM_lpage">4550</span>, <span class="refDoi"> DOI: 10.4049/jimmunol.1301553</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref30/cit30&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00329&amp;key=10.4049%2Fjimmunol.1301553" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref30/cit30&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00329&amp;key=24068666" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref30/cit30&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00329&amp;key=1%3ACAS%3A528%3ADC%252BC3sXhs1eqs7zE" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=191&publication_year=2013&pages=4540-4550&author=A.+L.+Rankinauthor=N.+Sethauthor=S.+Keeganauthor=T.+Andreyevaauthor=T.+A.+Cookauthor=J.+Edmondsauthor=N.+Mathialaganauthor=M.+J.+Bensonauthor=J.+Syedauthor=Y.+Zhanauthor=S.+E.+Benoitauthor=J.+S.+Miyashiroauthor=N.+Woodauthor=S.+Mohanauthor=E.+Peevaauthor=S.+K.+Ramaiahauthor=D.+Messingauthor=B.+L.+Homerauthor=K.+Dunussi-Joannopoulosauthor=C.+L.+Nickerson-Nutterauthor=M.+E.+Schnuteauthor=J.+Douhan&title=Selective+inhibition+of+BTK+prevents+murine+lupus+and+antibody-mediated+glomerulonephritis&doi=10.4049%2Fjimmunol.1301553"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit30R"><div class="casContent"><span class="casTitleNuber">30</span><div class="casTitle"><span class="NLM_cas:atitle">Selective Inhibition of BTK Prevents Murine Lupus and Antibody-Mediated Glomerulonephritis</span></div><div class="casAuthors">Rankin, Andrew L.; Seth, Nilufer; Keegan, Sean; Andreyeva, Tatyana; Cook, Tim A.; Edmonds, Jason; Mathialagan, Nagappan; Benson, Micah J.; Syed, Jameel; Zhan, Yutian; Benoit, Stephen E.; Miyashiro, Joy S.; Wood, Nancy; Mohan, Shashi; Peeva, Elena; Ramaiah, Shashi K.; Messing, Dean; Homer, Bruce L.; Dunussi-Joannopoulos, Kyri; Nickerson-Nutter, Cheryl L.; Schnute, Mark E.; Douhan, John, III</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Immunology</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">191</span>
        (<span class="NLM_cas:issue">9</span>),
    <span class="NLM_cas:pages">4540-4550</span>CODEN:
                <span class="NLM_cas:coden">JOIMA3</span>;
        ISSN:<span class="NLM_cas:issn">0022-1767</span>.
    
            (<span class="NLM_cas:orgname">American Association of Immunologists</span>)
        </div><div class="casAbstract">Autoantibody prodn. and immune complex deposition within the kidney promote renal disease in patients with lupus nephritis.  Thus, therapeutics that inhibit these pathways may be efficacious in the treatment of systemic lupus erythematosus.  Bruton's tyrosine kinase (BTK) is a crit. signaling component of both BCR and FcR signaling.  We sought to assess the efficacy of inhibiting BTK in the development of lupus-like disease, and in this article describe (R)-5-amino-1-(1-cyanopiperidin-3-yl)-3-(4-[2,4-difluorophenoxy]phenyl)-1H-pyrazole-4-carboxamide (PF-06250112), a novel highly selective and potent BTK inhibitor.  We demonstrate in vitro that PF-06250112 inhibits both BCR-mediated signaling and proliferation, as well as FcR-mediated activation.  To assess the therapeutic impact of BTK inhibition, we treated aged NZBxWF1 mice with PF-06250112 and demonstrate that PF-06250112 significantly limits the spontaneous accumulation of splenic germinal center B cells and plasma cells.  Correspondingly, anti-dsDNA and autoantibody levels were reduced in a dose-dependent manner.  Moreover, administration of PF-06250112 prevented the development of proteinuria and improved glomerular pathol. scores in all treatment groups.  Strikingly, this therapeutic effect could occur with only a modest redn. obsd. in anti-dsDNA titers, implying a crit. role for BTK signaling in disease pathogenesis beyond inhibition of autoantibody prodn.  We subsequently demonstrate that PF-06250112 prevents proteinuria in an FcR-dependent, Ab-mediated model of glomerulonephritis.  Importantly, these results highlight that BTK inhibition potently limits the development of glomerulonephritis by impacting both cell- and effector mol.-mediated pathways.  These data provide support for evaluating the efficacy of BTK inhibition in systemic lupus erythematosus patients.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpBldekay4INLVg90H21EOLACvtfcHk0lhSSztYWH0Ohg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXhs1eqs7zE&md5=7abfb074bf422aa3fb63aa0bc3d8cf58</span></div><a href="/servlet/linkout?suffix=cit30&amp;dbid=16384&amp;doi=10.4049%2Fjimmunol.1301553&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.4049%252Fjimmunol.1301553%26sid%3Dliteratum%253Aachs%26aulast%3DRankin%26aufirst%3DA.%2BL.%26aulast%3DSeth%26aufirst%3DN.%26aulast%3DKeegan%26aufirst%3DS.%26aulast%3DAndreyeva%26aufirst%3DT.%26aulast%3DCook%26aufirst%3DT.%2BA.%26aulast%3DEdmonds%26aufirst%3DJ.%26aulast%3DMathialagan%26aufirst%3DN.%26aulast%3DBenson%26aufirst%3DM.%2BJ.%26aulast%3DSyed%26aufirst%3DJ.%26aulast%3DZhan%26aufirst%3DY.%26aulast%3DBenoit%26aufirst%3DS.%2BE.%26aulast%3DMiyashiro%26aufirst%3DJ.%2BS.%26aulast%3DWood%26aufirst%3DN.%26aulast%3DMohan%26aufirst%3DS.%26aulast%3DPeeva%26aufirst%3DE.%26aulast%3DRamaiah%26aufirst%3DS.%2BK.%26aulast%3DMessing%26aufirst%3DD.%26aulast%3DHomer%26aufirst%3DB.%2BL.%26aulast%3DDunussi-Joannopoulos%26aufirst%3DK.%26aulast%3DNickerson-Nutter%26aufirst%3DC.%2BL.%26aulast%3DSchnute%26aufirst%3DM.%2BE.%26aulast%3DDouhan%26aufirst%3DJ.%26atitle%3DSelective%2520inhibition%2520of%2520BTK%2520prevents%2520murine%2520lupus%2520and%2520antibody-mediated%2520glomerulonephritis%26jtitle%3DJ.%2520Immunol.%26date%3D2013%26volume%3D191%26spage%3D4540%26epage%3D4550%26doi%3D10.4049%2Fjimmunol.1301553" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref31"><div class="reference"><strong class="refLabel"><a href="#ref31" class="rightTabRefNumLink">31</a></strong><div class="NLM_citation" id="rightTab-cit31"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Shi, Q.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tebben, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dyckman, A. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lin, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Spergel, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Burke, J. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">McIntyre, K. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Olini, G. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Strnad, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Surti, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Muckelbauer, J. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chang, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">An, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cheng, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ruan, Q.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Leftheris, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Carter, P. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tino, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">De Lucca, G. V.</span></span> <span> </span><span class="NLM_article-title">Purine derivatives as potent Bruton’s tyrosine kinase (BTK) inhibitors for autoimmune diseases</span>. <i>Bioorg. Med. Chem. Lett.</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>24</i></span>,  <span class="NLM_fpage">2206</span>– <span class="NLM_lpage">2211</span>, <span class="refDoi"> DOI: 10.1016/j.bmcl.2014.02.075</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref31/cit31&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00329&amp;key=10.1016%2Fj.bmcl.2014.02.075" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref31/cit31&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00329&amp;key=24685542" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref31/cit31&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00329&amp;key=1%3ACAS%3A528%3ADC%252BC2cXltFOgsL8%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=24&publication_year=2014&pages=2206-2211&author=Q.+Shiauthor=A.+Tebbenauthor=A.+J.+Dyckmanauthor=H.+Liauthor=C.+Liuauthor=J.+Linauthor=S.+Spergelauthor=J.+R.+Burkeauthor=K.+W.+McIntyreauthor=G.+C.+Oliniauthor=J.+Strnadauthor=N.+Surtiauthor=J.+K.+Muckelbauerauthor=C.+Changauthor=Y.+Anauthor=L.+Chengauthor=Q.+Ruanauthor=K.+Leftherisauthor=P.+H.+Carterauthor=J.+Tinoauthor=G.+V.+De+Lucca&title=Purine+derivatives+as+potent+Bruton%E2%80%99s+tyrosine+kinase+%28BTK%29+inhibitors+for+autoimmune+diseases&doi=10.1016%2Fj.bmcl.2014.02.075"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit31R"><div class="casContent"><span class="casTitleNuber">31</span><div class="casTitle"><span class="NLM_cas:atitle">Purine derivatives as potent Bruton's tyrosine kinase (BTK) inhibitors for autoimmune diseases</span></div><div class="casAuthors">Shi, Qing; Tebben, Andrew; Dyckman, Alaric J.; Li, Hedy; Liu, Chunjian; Lin, James; Spergel, Steve; Burke, James R.; McIntyre, Kim W.; Olini, Gilbert C.; Strnad, Joann; Surti, Neha; Muckelbauer, Jodi K.; Chang, Chiehying; An, Yongmi; Cheng, Lin; Ruan, Qian; Leftheris, Katerina; Carter, Percy H.; Tino, Joseph; De Lucca, George V.</div><div class="citationInfo"><span class="NLM_cas:title">Bioorganic & Medicinal Chemistry Letters</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">24</span>
        (<span class="NLM_cas:issue">9</span>),
    <span class="NLM_cas:pages">2206-2211</span>CODEN:
                <span class="NLM_cas:coden">BMCLE8</span>;
        ISSN:<span class="NLM_cas:issn">0960-894X</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">Investigation of various heterocyclic core isosteres of imidazopyrazines 1 & 2 yielded purine derivs. 3 & 8 as potent and selective BTK inhibitors.  Subsequent SAR studies of the purine series led to the discovery of 20 as a leading compd.  Compd. 20 is very selective when screened against a panel of 400 kinases and is a potent inhibitor in cellular assays of human B cell function including B-Cell proliferation and CD86 cell surface expression and exhibited in vivo efficacy in a mouse PCA model.  Its X-ray co-crystal structure with BTK shows that the high selectivity is gained from filling a BTK specific lipophilic pocket.  However, phys. and ADME properties leading to low oral exposure hindered further development.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGobsHsC5Hi6lbVg90H21EOLACvtfcHk0lhSSztYWH0Ohg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXltFOgsL8%253D&md5=1b1649221d615d9805d5cc197a39e05a</span></div><a href="/servlet/linkout?suffix=cit31&amp;dbid=16384&amp;doi=10.1016%2Fj.bmcl.2014.02.075&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bmcl.2014.02.075%26sid%3Dliteratum%253Aachs%26aulast%3DShi%26aufirst%3DQ.%26aulast%3DTebben%26aufirst%3DA.%26aulast%3DDyckman%26aufirst%3DA.%2BJ.%26aulast%3DLi%26aufirst%3DH.%26aulast%3DLiu%26aufirst%3DC.%26aulast%3DLin%26aufirst%3DJ.%26aulast%3DSpergel%26aufirst%3DS.%26aulast%3DBurke%26aufirst%3DJ.%2BR.%26aulast%3DMcIntyre%26aufirst%3DK.%2BW.%26aulast%3DOlini%26aufirst%3DG.%2BC.%26aulast%3DStrnad%26aufirst%3DJ.%26aulast%3DSurti%26aufirst%3DN.%26aulast%3DMuckelbauer%26aufirst%3DJ.%2BK.%26aulast%3DChang%26aufirst%3DC.%26aulast%3DAn%26aufirst%3DY.%26aulast%3DCheng%26aufirst%3DL.%26aulast%3DRuan%26aufirst%3DQ.%26aulast%3DLeftheris%26aufirst%3DK.%26aulast%3DCarter%26aufirst%3DP.%2BH.%26aulast%3DTino%26aufirst%3DJ.%26aulast%3DDe%2BLucca%26aufirst%3DG.%2BV.%26atitle%3DPurine%2520derivatives%2520as%2520potent%2520Bruton%25E2%2580%2599s%2520tyrosine%2520kinase%2520%2528BTK%2529%2520inhibitors%2520for%2520autoimmune%2520diseases%26jtitle%3DBioorg.%2520Med.%2520Chem.%2520Lett.%26date%3D2014%26volume%3D24%26spage%3D2206%26epage%3D2211%26doi%3D10.1016%2Fj.bmcl.2014.02.075" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref32"><div class="reference"><strong class="refLabel"><a href="#ref32" class="rightTabRefNumLink">32</a></strong><div class="NLM_citation" id="rightTab-cit32"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Lou, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Han, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kuglstatter, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kondru, R. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sweeney, Z. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Soth, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">McIntosh, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Litman, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Suh, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kocer, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Davis, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Park, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Frauchiger, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dewdney, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zecic, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Taygerly, J. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sarma, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hong, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hill, R. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gabriel, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Goldstein, D. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Owens, T. D.</span></span> <span> </span><span class="NLM_article-title">Structure-Based Drug Design of RN486, a Potent and Selective Bruton’s Tyrosine Kinase (BTK) Inhibitor, for the Treatment of Rheumatoid Arthritis</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>58</i></span>,  <span class="NLM_fpage">512</span>– <span class="NLM_lpage">516</span>, <span class="refDoi"> DOI: 10.1021/jm500305p</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm500305p" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=58&publication_year=2014&pages=512-516&author=Y.+Louauthor=X.+Hanauthor=A.+Kuglstatterauthor=R.+K.+Kondruauthor=Z.+K.+Sweeneyauthor=M.+Sothauthor=J.+McIntoshauthor=R.+Litmanauthor=J.+Suhauthor=B.+Kocerauthor=D.+Davisauthor=J.+Parkauthor=S.+Frauchigerauthor=N.+Dewdneyauthor=H.+Zecicauthor=J.+P.+Taygerlyauthor=K.+Sarmaauthor=J.+Hongauthor=R.+J.+Hillauthor=T.+Gabrielauthor=D.+M.+Goldsteinauthor=T.+D.+Owens&title=Structure-Based+Drug+Design+of+RN486%2C+a+Potent+and+Selective+Bruton%E2%80%99s+Tyrosine+Kinase+%28BTK%29+Inhibitor%2C+for+the+Treatment+of+Rheumatoid+Arthritis&doi=10.1021%2Fjm500305p"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit32&amp;dbid=16384&amp;doi=10.1021%2Fjm500305p&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm500305p%26sid%3Dliteratum%253Aachs%26aulast%3DLou%26aufirst%3DY.%26aulast%3DHan%26aufirst%3DX.%26aulast%3DKuglstatter%26aufirst%3DA.%26aulast%3DKondru%26aufirst%3DR.%2BK.%26aulast%3DSweeney%26aufirst%3DZ.%2BK.%26aulast%3DSoth%26aufirst%3DM.%26aulast%3DMcIntosh%26aufirst%3DJ.%26aulast%3DLitman%26aufirst%3DR.%26aulast%3DSuh%26aufirst%3DJ.%26aulast%3DKocer%26aufirst%3DB.%26aulast%3DDavis%26aufirst%3DD.%26aulast%3DPark%26aufirst%3DJ.%26aulast%3DFrauchiger%26aufirst%3DS.%26aulast%3DDewdney%26aufirst%3DN.%26aulast%3DZecic%26aufirst%3DH.%26aulast%3DTaygerly%26aufirst%3DJ.%2BP.%26aulast%3DSarma%26aufirst%3DK.%26aulast%3DHong%26aufirst%3DJ.%26aulast%3DHill%26aufirst%3DR.%2BJ.%26aulast%3DGabriel%26aufirst%3DT.%26aulast%3DGoldstein%26aufirst%3DD.%2BM.%26aulast%3DOwens%26aufirst%3DT.%2BD.%26atitle%3DStructure-Based%2520Drug%2520Design%2520of%2520RN486%252C%2520a%2520Potent%2520and%2520Selective%2520Bruton%25E2%2580%2599s%2520Tyrosine%2520Kinase%2520%2528BTK%2529%2520Inhibitor%252C%2520for%2520the%2520Treatment%2520of%2520Rheumatoid%2520Arthritis%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2014%26volume%3D58%26spage%3D512%26epage%3D516%26doi%3D10.1021%2Fjm500305p" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref33"><div class="reference"><strong class="refLabel"><a href="#ref33" class="rightTabRefNumLink">33</a></strong><div class="NLM_citation" id="rightTab-cit33"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Liu, Q.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Batt, D. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lippy, J. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Surti, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tebben, A. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Muckelbauer, J. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">An, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chang, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pokross, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yang, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Burke, J. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Carter, P. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tino, J. A.</span></span> <span> </span><span class="NLM_article-title">Design and synthesis of carbazole carboxamides as promising inhibitors of Bruton’s tyrosine kinase (BTK) and Janus kinase 2 (JAK2)</span>. <i>Bioorg. Med. Chem. Lett.</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>25</i></span>,  <span class="NLM_fpage">4265</span>– <span class="NLM_lpage">4269</span>, <span class="refDoi"> DOI: 10.1016/j.bmcl.2015.07.102</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref33/cit33&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00329&amp;key=10.1016%2Fj.bmcl.2015.07.102" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref33/cit33&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00329&amp;key=26320619" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref33/cit33&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00329&amp;key=1%3ACAS%3A528%3ADC%252BC2MXhtlSlsLvF" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=25&publication_year=2015&pages=4265-4269&author=Q.+Liuauthor=D.+G.+Battauthor=J.+S.+Lippyauthor=N.+Surtiauthor=A.+J.+Tebbenauthor=J.+K.+Muckelbauerauthor=L.+Chenauthor=Y.+Anauthor=C.+Changauthor=M.+Pokrossauthor=Z.+Yangauthor=H.+Wangauthor=J.+R.+Burkeauthor=P.+H.+Carterauthor=J.+A.+Tino&title=Design+and+synthesis+of+carbazole+carboxamides+as+promising+inhibitors+of+Bruton%E2%80%99s+tyrosine+kinase+%28BTK%29+and+Janus+kinase+2+%28JAK2%29&doi=10.1016%2Fj.bmcl.2015.07.102"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit33R"><div class="casContent"><span class="casTitleNuber">33</span><div class="casTitle"><span class="NLM_cas:atitle">Design and synthesis of carbazole carboxamides as promising inhibitors of Bruton's tyrosine kinase (BTK) and Janus kinase 2 (JAK2)</span></div><div class="casAuthors">Liu, Qingjie; Batt, Douglas G.; Lippy, Jonathan S.; Surti, Neha; Tebben, Andrew J.; Muckelbauer, Jodi K.; Chen, Lin; An, Yongmi; Chang, Chiehying; Pokross, Matt; Yang, Zheng; Wang, Haiqing; Burke, James R.; Carter, Percy H.; Tino, Joseph A.</div><div class="citationInfo"><span class="NLM_cas:title">Bioorganic & Medicinal Chemistry Letters</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">25</span>
        (<span class="NLM_cas:issue">19</span>),
    <span class="NLM_cas:pages">4265-4269</span>CODEN:
                <span class="NLM_cas:coden">BMCLE8</span>;
        ISSN:<span class="NLM_cas:issn">0960-894X</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">Four series of disubstituted carbazole-1-carboxamides, e.g. I [R = 2-F, 3-MeO, 2-Me, etc.] were designed and synthesized as inhibitors of Bruton's tyrosine kinase.  4,7- And 4,6-Disubstituted carbazole-1-carboxamides were potent and selective inhibitors of BTK, while 3,7- and 3,6-disubstituted carbazole-1-carboxamides were potent and selective inhibitors of Janus kinase 2.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoD3SZfBfD4ZbVg90H21EOLACvtfcHk0lj17sRvtV8CAw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXhtlSlsLvF&md5=3558c8ca9a9c29bb38ef98936f61200a</span></div><a href="/servlet/linkout?suffix=cit33&amp;dbid=16384&amp;doi=10.1016%2Fj.bmcl.2015.07.102&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bmcl.2015.07.102%26sid%3Dliteratum%253Aachs%26aulast%3DLiu%26aufirst%3DQ.%26aulast%3DBatt%26aufirst%3DD.%2BG.%26aulast%3DLippy%26aufirst%3DJ.%2BS.%26aulast%3DSurti%26aufirst%3DN.%26aulast%3DTebben%26aufirst%3DA.%2BJ.%26aulast%3DMuckelbauer%26aufirst%3DJ.%2BK.%26aulast%3DChen%26aufirst%3DL.%26aulast%3DAn%26aufirst%3DY.%26aulast%3DChang%26aufirst%3DC.%26aulast%3DPokross%26aufirst%3DM.%26aulast%3DYang%26aufirst%3DZ.%26aulast%3DWang%26aufirst%3DH.%26aulast%3DBurke%26aufirst%3DJ.%2BR.%26aulast%3DCarter%26aufirst%3DP.%2BH.%26aulast%3DTino%26aufirst%3DJ.%2BA.%26atitle%3DDesign%2520and%2520synthesis%2520of%2520carbazole%2520carboxamides%2520as%2520promising%2520inhibitors%2520of%2520Bruton%25E2%2580%2599s%2520tyrosine%2520kinase%2520%2528BTK%2529%2520and%2520Janus%2520kinase%25202%2520%2528JAK2%2529%26jtitle%3DBioorg.%2520Med.%2520Chem.%2520Lett.%26date%3D2015%26volume%3D25%26spage%3D4265%26epage%3D4269%26doi%3D10.1016%2Fj.bmcl.2015.07.102" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref34"><div class="reference"><strong class="refLabel"><a href="#ref34" class="rightTabRefNumLink">34</a></strong><div class="NLM_citation" id="rightTab-cit34"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Zhao, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xin, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Huang, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ren, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jin, Q.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tang, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jiang, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yang, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mo, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xiang, H.</span></span> <span> </span><span class="NLM_article-title">Design, synthesis and evaluation of novel 5-phenylpyridin-2(1H)-one derivatives as potent reversible Bruton’s tyrosine kinase inhibitors</span>. <i>Bioorg. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>23</i></span>,  <span class="NLM_fpage">348</span>– <span class="NLM_lpage">364</span>, <span class="refDoi"> DOI: 10.1016/j.bmc.2014.11.006</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref34/cit34&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00329&amp;key=10.1016%2Fj.bmc.2014.11.006" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref34/cit34&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00329&amp;key=25515957" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref34/cit34&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00329&amp;key=1%3ACAS%3A528%3ADC%252BC2cXhvFWgsL3E" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=23&publication_year=2015&pages=348-364&author=X.+Zhaoauthor=M.+Xinauthor=W.+Huangauthor=Y.+Renauthor=Q.+Jinauthor=F.+Tangauthor=H.+Jiangauthor=Y.+Wangauthor=J.+Yangauthor=S.+Moauthor=H.+Xiang&title=Design%2C+synthesis+and+evaluation+of+novel+5-phenylpyridin-2%281H%29-one+derivatives+as+potent+reversible+Bruton%E2%80%99s+tyrosine+kinase+inhibitors&doi=10.1016%2Fj.bmc.2014.11.006"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit34R"><div class="casContent"><span class="casTitleNuber">34</span><div class="casTitle"><span class="NLM_cas:atitle">Design, synthesis and evaluation of novel 5-phenylpyridin-2(1H)-one derivatives as potent reversible Bruton's tyrosine kinase inhibitors</span></div><div class="casAuthors">Zhao, Xinge; Xin, Minhang; Huang, Wei; Ren, Yanliang; Jin, Qiu; Tang, Feng; Jiang, Hailong; Wang, Yazhou; Yang, Jie; Mo, Shifu; Xiang, Hua</div><div class="citationInfo"><span class="NLM_cas:title">Bioorganic & Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">23</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">348-364</span>CODEN:
                <span class="NLM_cas:coden">BMECEP</span>;
        ISSN:<span class="NLM_cas:issn">0968-0896</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">A series of novel reversible Btk inhibitors has been designed based on the structure of the recently reported preclin. drug RN486.  The synthesis and SAR of these compds. are described.  Among these derivs., compd. (I) was identified to be a potent and orally available reversible agent with satisfactory Btk enzymic and cellular inhibition in vitro, as well as favorable PK properties and inhibition of arthritis in vivo.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoW10EA7bZCLbVg90H21EOLACvtfcHk0lgWlNPSIYZ4Xg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXhvFWgsL3E&md5=6281a58160a4bc86e4eef85e3269e801</span></div><a href="/servlet/linkout?suffix=cit34&amp;dbid=16384&amp;doi=10.1016%2Fj.bmc.2014.11.006&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bmc.2014.11.006%26sid%3Dliteratum%253Aachs%26aulast%3DZhao%26aufirst%3DX.%26aulast%3DXin%26aufirst%3DM.%26aulast%3DHuang%26aufirst%3DW.%26aulast%3DRen%26aufirst%3DY.%26aulast%3DJin%26aufirst%3DQ.%26aulast%3DTang%26aufirst%3DF.%26aulast%3DJiang%26aufirst%3DH.%26aulast%3DWang%26aufirst%3DY.%26aulast%3DYang%26aufirst%3DJ.%26aulast%3DMo%26aufirst%3DS.%26aulast%3DXiang%26aufirst%3DH.%26atitle%3DDesign%252C%2520synthesis%2520and%2520evaluation%2520of%2520novel%25205-phenylpyridin-2%25281H%2529-one%2520derivatives%2520as%2520potent%2520reversible%2520Bruton%25E2%2580%2599s%2520tyrosine%2520kinase%2520inhibitors%26jtitle%3DBioorg.%2520Med.%2520Chem.%26date%3D2015%26volume%3D23%26spage%3D348%26epage%3D364%26doi%3D10.1016%2Fj.bmc.2014.11.006" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref35"><div class="reference"><strong class="refLabel"><a href="#ref35" class="rightTabRefNumLink">35</a></strong><div class="NLM_citation" id="rightTab-cit35"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Smith, C. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dougan, D. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Komandla, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kanouni, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Knight, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lawson, J. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sabat, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Taylor, E. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vu, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wyrick, C.</span></span> <span> </span><span class="NLM_article-title">Fragment-Based Discovery of a Small Molecule Inhibitor of Bruton’s Tyrosine Kinase</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>58</i></span>,  <span class="NLM_fpage">5437</span>– <span class="NLM_lpage">5444</span>, <span class="refDoi"> DOI: 10.1021/acs.jmedchem.5b00734</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.jmedchem.5b00734" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref35/cit35&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00329&amp;key=1%3ACAS%3A528%3ADC%252BC2MXhtVans7rF" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=58&publication_year=2015&pages=5437-5444&author=C.+R.+Smithauthor=D.+R.+Douganauthor=M.+Komandlaauthor=T.+Kanouniauthor=B.+Knightauthor=J.+D.+Lawsonauthor=M.+Sabatauthor=E.+R.+Taylorauthor=P.+Vuauthor=C.+Wyrick&title=Fragment-Based+Discovery+of+a+Small+Molecule+Inhibitor+of+Bruton%E2%80%99s+Tyrosine+Kinase&doi=10.1021%2Facs.jmedchem.5b00734"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit35R"><div class="casContent"><span class="casTitleNuber">35</span><div class="casTitle"><span class="NLM_cas:atitle">Fragment-Based Discovery of a Small Molecule Inhibitor of Bruton's Tyrosine Kinase</span></div><div class="casAuthors">Smith, Christopher R.; Dougan, Douglas R.; Komandla, Mallareddy; Kanouni, Toufike; Knight, Beverly; Lawson, J. David; Sabat, Mark; Taylor, Ewan R.; Vu, Phong; Wyrick, Corey</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">58</span>
        (<span class="NLM_cas:issue">14</span>),
    <span class="NLM_cas:pages">5437-5444</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">The discovery and optimization of a series of 4-aminocinnoline-3-carboxamide inhibitors of Bruton's tyrosine kinase are reported.  A fragment-based screening approach incorporating x-ray cocrystallog. was used to identify a cinnoline fragment and characterize its binding mode in the ATP binding site of Btk.  Optimization of the fragment hit resulted in the identification of a lead compd. I which reduced paw swelling in a dose- and exposure-dependent fashion in a rat model of collagen-induced arthritis.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGozENTW7pHlFrVg90H21EOLACvtfcHk0lgWlNPSIYZ4Xg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXhtVans7rF&md5=d6626fabcc3e2aa6a9180dc702a5030c</span></div><a href="/servlet/linkout?suffix=cit35&amp;dbid=16384&amp;doi=10.1021%2Facs.jmedchem.5b00734&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.jmedchem.5b00734%26sid%3Dliteratum%253Aachs%26aulast%3DSmith%26aufirst%3DC.%2BR.%26aulast%3DDougan%26aufirst%3DD.%2BR.%26aulast%3DKomandla%26aufirst%3DM.%26aulast%3DKanouni%26aufirst%3DT.%26aulast%3DKnight%26aufirst%3DB.%26aulast%3DLawson%26aufirst%3DJ.%2BD.%26aulast%3DSabat%26aufirst%3DM.%26aulast%3DTaylor%26aufirst%3DE.%2BR.%26aulast%3DVu%26aufirst%3DP.%26aulast%3DWyrick%26aufirst%3DC.%26atitle%3DFragment-Based%2520Discovery%2520of%2520a%2520Small%2520Molecule%2520Inhibitor%2520of%2520Bruton%25E2%2580%2599s%2520Tyrosine%2520Kinase%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2015%26volume%3D58%26spage%3D5437%26epage%3D5444%26doi%3D10.1021%2Facs.jmedchem.5b00734" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref36"><div class="reference"><strong class="refLabel"><a href="#ref36" class="rightTabRefNumLink">36</a></strong><div class="NLM_citation" id="rightTab-cit36"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Young, W. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Barbosa, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Blomgren, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bremer, M. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Crawford, J. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dambach, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gallion, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hymowitz, S. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kropf, J. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lee, S. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lubach, J. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Macaluso, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Maciejewski, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Maurer, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mitchell, S. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ortwine, D. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Di Paolo, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Reif, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Scheerens, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schmitt, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sowell, C. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wong, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xiong, J.-M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xu, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhao, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Currie, K. S.</span></span> <span> </span><span class="NLM_article-title">Potent and selective Bruton’s tyrosine kinase inhibitors: Discovery of GDC-0834</span>. <i>Bioorg. Med. Chem. Lett.</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>25</i></span>,  <span class="NLM_fpage">1333</span>– <span class="NLM_lpage">1337</span>, <span class="refDoi"> DOI: 10.1016/j.bmcl.2015.01.032</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref36/cit36&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00329&amp;key=10.1016%2Fj.bmcl.2015.01.032" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref36/cit36&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00329&amp;key=25701252" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref36/cit36&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00329&amp;key=1%3ACAS%3A528%3ADC%252BC2MXisVSit7w%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=25&publication_year=2015&pages=1333-1337&author=W.+B.+Youngauthor=J.+Barbosaauthor=P.+Blomgrenauthor=M.+C.+Bremerauthor=J.+J.+Crawfordauthor=D.+Dambachauthor=S.+Gallionauthor=S.+G.+Hymowitzauthor=J.+E.+Kropfauthor=S.+H.+Leeauthor=L.+Liuauthor=J.+W.+Lubachauthor=J.+Macalusoauthor=P.+Maciejewskiauthor=B.+Maurerauthor=S.+A.+Mitchellauthor=D.+F.+Ortwineauthor=J.+Di+Paoloauthor=K.+Reifauthor=H.+Scheerensauthor=A.+Schmittauthor=C.+G.+Sowellauthor=X.+Wangauthor=H.+Wongauthor=J.-M.+Xiongauthor=J.+Xuauthor=Z.+Zhaoauthor=K.+S.+Currie&title=Potent+and+selective+Bruton%E2%80%99s+tyrosine+kinase+inhibitors%3A+Discovery+of+GDC-0834&doi=10.1016%2Fj.bmcl.2015.01.032"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit36R"><div class="casContent"><span class="casTitleNuber">36</span><div class="casTitle"><span class="NLM_cas:atitle">Potent and selective Bruton's tyrosine kinase inhibitors: Discovery of GDC-0834</span></div><div class="casAuthors">Young, Wendy B.; Barbosa, James; Blomgren, Peter; Bremer, Meire C.; Crawford, James J.; Dambach, Donna; Gallion, Steve; Hymowitz, Sarah G.; Kropf, Jeffrey E.; Lee, Seung H.; Liu, Lichuan; Lubach, Joseph W.; Macaluso, Jen; Maciejewski, Pat; Maurer, Brigitte; Mitchell, Scott A.; Ortwine, Daniel F.; Di Paolo, Julie; Reif, Karin; Scheerens, Heleen; Schmitt, Aaron; Sowell, C. Gregory; Wang, Xiaojing; Wong, Harvey; Xiong, Jin-Ming; Xu, Jianjun; Zhao, Zhongdong; Currie, Kevin S.</div><div class="citationInfo"><span class="NLM_cas:title">Bioorganic & Medicinal Chemistry Letters</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">25</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">1333-1337</span>CODEN:
                <span class="NLM_cas:coden">BMCLE8</span>;
        ISSN:<span class="NLM_cas:issn">0960-894X</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">SAR studies focused on improving the pharmacokinetic (PK) properties of the previously reported potent and selective Btk inhibitor CGI-1746 resulted in the clin. candidate GDC-0834, which retained the potency and selectivity of CGI-1746, but with much improved PK in preclin. animal models.  Structure based design efforts drove this work as modifications to CGI-1746 were investigated at both the solvent exposed region as well as 'H3 binding pocket'.  However, in vitro metabolic evaluation of GDC-0834 revealed a non CYP-mediated metabolic process that was more prevalent in human than preclin. species (mouse, rat, dog, cyno), leading to a high-level of uncertainly in predicting human pharmacokinetics.  Due to its promising potency, selectivity, and preclin. efficacy, a single dose IND was filed and GDC-0834 was taken in to a single dose phase I trial in healthy volunteers to quickly evaluate the human pharmacokinetics.  In human, GDC-0834 was found to be highly labile at the exo-cyclic amide bond that links the tetrahydrobenzothiophene moiety to the central aniline ring, resulting in insufficient parent drug exposure.  This information informed the back-up program and discovery of improved inhibitors.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrhL04eYDiT3bVg90H21EOLACvtfcHk0lgWlNPSIYZ4Xg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXisVSit7w%253D&md5=fdebc0199c8222e093cfb9583244bce3</span></div><a href="/servlet/linkout?suffix=cit36&amp;dbid=16384&amp;doi=10.1016%2Fj.bmcl.2015.01.032&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bmcl.2015.01.032%26sid%3Dliteratum%253Aachs%26aulast%3DYoung%26aufirst%3DW.%2BB.%26aulast%3DBarbosa%26aufirst%3DJ.%26aulast%3DBlomgren%26aufirst%3DP.%26aulast%3DBremer%26aufirst%3DM.%2BC.%26aulast%3DCrawford%26aufirst%3DJ.%2BJ.%26aulast%3DDambach%26aufirst%3DD.%26aulast%3DGallion%26aufirst%3DS.%26aulast%3DHymowitz%26aufirst%3DS.%2BG.%26aulast%3DKropf%26aufirst%3DJ.%2BE.%26aulast%3DLee%26aufirst%3DS.%2BH.%26aulast%3DLiu%26aufirst%3DL.%26aulast%3DLubach%26aufirst%3DJ.%2BW.%26aulast%3DMacaluso%26aufirst%3DJ.%26aulast%3DMaciejewski%26aufirst%3DP.%26aulast%3DMaurer%26aufirst%3DB.%26aulast%3DMitchell%26aufirst%3DS.%2BA.%26aulast%3DOrtwine%26aufirst%3DD.%2BF.%26aulast%3DDi%2BPaolo%26aufirst%3DJ.%26aulast%3DReif%26aufirst%3DK.%26aulast%3DScheerens%26aufirst%3DH.%26aulast%3DSchmitt%26aufirst%3DA.%26aulast%3DSowell%26aufirst%3DC.%2BG.%26aulast%3DWang%26aufirst%3DX.%26aulast%3DWong%26aufirst%3DH.%26aulast%3DXiong%26aufirst%3DJ.-M.%26aulast%3DXu%26aufirst%3DJ.%26aulast%3DZhao%26aufirst%3DZ.%26aulast%3DCurrie%26aufirst%3DK.%2BS.%26atitle%3DPotent%2520and%2520selective%2520Bruton%25E2%2580%2599s%2520tyrosine%2520kinase%2520inhibitors%253A%2520Discovery%2520of%2520GDC-0834%26jtitle%3DBioorg.%2520Med.%2520Chem.%2520Lett.%26date%3D2015%26volume%3D25%26spage%3D1333%26epage%3D1337%26doi%3D10.1016%2Fj.bmcl.2015.01.032" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref37"><div class="reference"><strong class="refLabel"><a href="#ref37" class="rightTabRefNumLink">37</a></strong><div class="NLM_citation" id="rightTab-cit37"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Liu, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Guiadeen, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Krikorian, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gao, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Boga, S. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Alhassan, A.-B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yu, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vaccaro, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yang, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wu, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cooper, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">de Man, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kaptein, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Maloney, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hornak, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gao, Y.-D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fischmann, T. O.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Raaijmakers, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vu-Pham, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Presland, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mansueto, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xu, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Leccese, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang-Hoover, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Knemeyer, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Garlisi, C. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bays, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stivers, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Brandish, P. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hicks, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kim, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kozlowski, J. A.</span></span> <span> </span><span class="NLM_article-title">Discovery of 8-amino-imidazo[1,5-<i>a</i>]pyrazines as reversible BTK inhibitors for the treatment of rheumatoid arthritis</span>. <i>ACS Med. Chem. Lett.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>7</i></span>,  <span class="NLM_fpage">198</span>– <span class="NLM_lpage">203</span>, <span class="refDoi"> DOI: 10.1021/acsmedchemlett.5b00463</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acsmedchemlett.5b00463" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref37/cit37&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00329&amp;key=1%3ACAS%3A528%3ADC%252BC2MXitVGrs7bJ" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=7&publication_year=2016&pages=198-203&author=J.+Liuauthor=D.+Guiadeenauthor=A.+Krikorianauthor=X.+Gaoauthor=J.+Wangauthor=S.+B.+Bogaauthor=A.-B.+Alhassanauthor=Y.+Yuauthor=H.+Vaccaroauthor=S.+Liuauthor=C.+Yangauthor=H.+Wuauthor=A.+Cooperauthor=J.+de+Manauthor=A.+Kapteinauthor=K.+Maloneyauthor=V.+Hornakauthor=Y.-D.+Gaoauthor=T.+O.+Fischmannauthor=H.+Raaijmakersauthor=D.+Vu-Phamauthor=J.+Preslandauthor=M.+Mansuetoauthor=Z.+Xuauthor=E.+Lecceseauthor=J.+Zhang-Hooverauthor=I.+Knemeyerauthor=C.+G.+Garlisiauthor=N.+Baysauthor=P.+Stiversauthor=P.+E.+Brandishauthor=A.+Hicksauthor=R.+Kimauthor=J.+A.+Kozlowski&title=Discovery+of+8-amino-imidazo%5B1%2C5-a%5Dpyrazines+as+reversible+BTK+inhibitors+for+the+treatment+of+rheumatoid+arthritis&doi=10.1021%2Facsmedchemlett.5b00463"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit37R"><div class="casContent"><span class="casTitleNuber">37</span><div class="casTitle"><span class="NLM_cas:atitle">Discovery of 8-Amino-imidazo[1,5-a]pyrazines as Reversible BTK Inhibitors for the Treatment of Rheumatoid Arthritis</span></div><div class="casAuthors">Liu, Jian; Guiadeen, Deodial; Krikorian, Arto; Gao, Xiaolei; Wang, James; Boga, Sobhana Babu; Alhassan, Abdul-Basit; Yu, Younong; Vaccaro, Henry; Liu, Shilan; Yang, Chundao; Wu, Hao; Cooper, Alan; de Man, Jos; Kaptein, Allard; Maloney, Kevin; Hornak, Viktor; Gao, Ying-Duo; Fischmann, Thierry O.; Raaijmakers, Hans; Vu-Pham, Diep; Presland, Jeremy; Mansueto, My; Xu, Zangwei; Leccese, Erica; Zhang-Hoover, Jie; Knemeyer, Ian; Garlisi, Charles G.; Bays, Nathan; Stivers, Peter; Brandish, Philip E.; Hicks, Alexandra; Kim, Ronald; Kozlowski, Joseph A.</div><div class="citationInfo"><span class="NLM_cas:title">ACS Medicinal Chemistry Letters</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">7</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">198-203</span>CODEN:
                <span class="NLM_cas:coden">AMCLCT</span>;
        ISSN:<span class="NLM_cas:issn">1948-5875</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Bruton's tyrosine kinase (BTK) is a Tec family kinase with a well-defined role in the B cell receptor (BCR) pathway.  It has become an attractive kinase target for selective B cell inhibition and for the treatment of B cell related diseases.  We report a series of compds. based on 8-amino-imidazo[1,5-a]pyrazine that are potent reversible BTK inhibitors with excellent kinase selectivity.  Selectivity is achieved through specific interactions of the ligand with the kinase hinge and driven by aminopyridine hydrogen bondings with Ser538 and Asp539, and by hydrophobic interaction of trifluoropyridine in the back pocket.  These interactions are evident in the X-ray crystal structure of the lead compds. 1 and 3 in the complex with the BTK enzyme.  Our lead compds. show desirable PK profiles and efficacy in the preclin. rat collagen induced arthritis model.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoDNSbzZ9EmurVg90H21EOLACvtfcHk0liWvvTQKpNRCA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXitVGrs7bJ&md5=62031c18108d12d36cb7f8e3c35888b7</span></div><a href="/servlet/linkout?suffix=cit37&amp;dbid=16384&amp;doi=10.1021%2Facsmedchemlett.5b00463&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facsmedchemlett.5b00463%26sid%3Dliteratum%253Aachs%26aulast%3DLiu%26aufirst%3DJ.%26aulast%3DGuiadeen%26aufirst%3DD.%26aulast%3DKrikorian%26aufirst%3DA.%26aulast%3DGao%26aufirst%3DX.%26aulast%3DWang%26aufirst%3DJ.%26aulast%3DBoga%26aufirst%3DS.%2BB.%26aulast%3DAlhassan%26aufirst%3DA.-B.%26aulast%3DYu%26aufirst%3DY.%26aulast%3DVaccaro%26aufirst%3DH.%26aulast%3DLiu%26aufirst%3DS.%26aulast%3DYang%26aufirst%3DC.%26aulast%3DWu%26aufirst%3DH.%26aulast%3DCooper%26aufirst%3DA.%26aulast%3Dde%2BMan%26aufirst%3DJ.%26aulast%3DKaptein%26aufirst%3DA.%26aulast%3DMaloney%26aufirst%3DK.%26aulast%3DHornak%26aufirst%3DV.%26aulast%3DGao%26aufirst%3DY.-D.%26aulast%3DFischmann%26aufirst%3DT.%2BO.%26aulast%3DRaaijmakers%26aufirst%3DH.%26aulast%3DVu-Pham%26aufirst%3DD.%26aulast%3DPresland%26aufirst%3DJ.%26aulast%3DMansueto%26aufirst%3DM.%26aulast%3DXu%26aufirst%3DZ.%26aulast%3DLeccese%26aufirst%3DE.%26aulast%3DZhang-Hoover%26aufirst%3DJ.%26aulast%3DKnemeyer%26aufirst%3DI.%26aulast%3DGarlisi%26aufirst%3DC.%2BG.%26aulast%3DBays%26aufirst%3DN.%26aulast%3DStivers%26aufirst%3DP.%26aulast%3DBrandish%26aufirst%3DP.%2BE.%26aulast%3DHicks%26aufirst%3DA.%26aulast%3DKim%26aufirst%3DR.%26aulast%3DKozlowski%26aufirst%3DJ.%2BA.%26atitle%3DDiscovery%2520of%25208-amino-imidazo%255B1%252C5-a%255Dpyrazines%2520as%2520reversible%2520BTK%2520inhibitors%2520for%2520the%2520treatment%2520of%2520rheumatoid%2520arthritis%26jtitle%3DACS%2520Med.%2520Chem.%2520Lett.%26date%3D2016%26volume%3D7%26spage%3D198%26epage%3D203%26doi%3D10.1021%2Facsmedchemlett.5b00463" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref38"><div class="reference"><strong class="refLabel"><a href="#ref38" class="rightTabRefNumLink">38</a></strong><div class="NLM_citation" id="rightTab-cit38"><span><span class="NLM_contrib-group"><span class="NLM_string-name">De
Lucca, G. V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shi, Q.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, Q.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Batt, D. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Beaudoin Bertrand, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rampulla, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mathur, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Discenza, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">D’Arienzo, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dai, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Obermeier, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vickery, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yang, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Marathe, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tebben, A. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Muckelbauer, J. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chang, C. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gillooly, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Taylor, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pattoli, M. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Skala, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kukral, D. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">McIntyre, K. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Salter-Cid, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fura, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Burke, J. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Barrish, J. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Carter, P. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tino, J. A.</span></span> <span> </span><span class="NLM_article-title">Small Molecule Reversible Inhibitors of Bruton’s Tyrosine Kinase (BTK): Structure-Activity Relationships Leading to the Identification of 7-(2-Hydroxypropan-2-yl)-4-[2-methyl-3-(4-oxo-3,4-dihydroquinazolin-3-yl)phenyl]-9H-carbazole-1-carboxamide (BMS-935177)</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>59</i></span>,  <span class="NLM_fpage">7915</span>– <span class="NLM_lpage">7935</span>, <span class="refDoi"> DOI: 10.1021/acs.jmedchem.6b00722</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.jmedchem.6b00722" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref38/cit38&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00329&amp;key=1%3ACAS%3A528%3ADC%252BC28XhtlCrsL3M" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=59&publication_year=2016&pages=7915-7935&author=G.+V.+De%0ALuccaauthor=Q.+Shiauthor=Q.+Liuauthor=D.+G.+Battauthor=M.+Beaudoin+Bertrandauthor=R.+Rampullaauthor=A.+Mathurauthor=L.+Discenzaauthor=C.+D%E2%80%99Arienzoauthor=J.+Daiauthor=M.+Obermeierauthor=R.+Vickeryauthor=Y.+Zhangauthor=Z.+Yangauthor=P.+Maratheauthor=A.+J.+Tebbenauthor=J.+K.+Muckelbauerauthor=C.+J.+Changauthor=H.+Zhangauthor=K.+Gilloolyauthor=T.+Taylorauthor=M.+A.+Pattoliauthor=S.+Skalaauthor=D.+W.+Kukralauthor=K.+W.+McIntyreauthor=L.+Salter-Cidauthor=A.+Furaauthor=J.+R.+Burkeauthor=J.+C.+Barrishauthor=P.+H.+Carterauthor=J.+A.+Tino&title=Small+Molecule+Reversible+Inhibitors+of+Bruton%E2%80%99s+Tyrosine+Kinase+%28BTK%29%3A+Structure-Activity+Relationships+Leading+to+the+Identification+of+7-%282-Hydroxypropan-2-yl%29-4-%5B2-methyl-3-%284-oxo-3%2C4-dihydroquinazolin-3-yl%29phenyl%5D-9H-carbazole-1-carboxamide+%28BMS-935177%29&doi=10.1021%2Facs.jmedchem.6b00722"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit38R"><div class="casContent"><span class="casTitleNuber">38</span><div class="casTitle"><span class="NLM_cas:atitle">Small Molecule Reversible Inhibitors of Bruton's Tyrosine Kinase (BTK): Structure-Activity Relationships Leading to the Identification of 7-(2-Hydroxypropan-2-yl)-4-[2-methyl-3-(4-oxo-3,4-dihydroquinazolin-3-yl)phenyl]-9H-carbazole-1-carboxamide (BMS-935177)</span></div><div class="casAuthors">De Lucca, George V.; Shi, Qing; Liu, Qingjie; Batt, Douglas G.; Beaudoin Bertrand, Myra; Rampulla, Rick; Mathur, Arvind; Discenza, Lorell; D'Arienzo, Celia; Dai, Jun; Obermeier, Mary; Vickery, Rodney; Zhang, Yingru; Yang, Zheng; Marathe, Punit; Tebben, Andrew J.; Muckelbauer, Jodi K.; Chang, ChiehYing J.; Zhang, Huiping; Gillooly, Kathleen; Taylor, Tracy; Pattoli, Mark A.; Skala, Stacey; Kukral, Daniel W.; McIntyre, Kim W.; Salter-Cid, Luisa; Fura, Aberra; Burke, James R.; Barrish, Joel C.; Carter, Percy H.; Tino, Joseph A.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">59</span>
        (<span class="NLM_cas:issue">17</span>),
    <span class="NLM_cas:pages">7915-7935</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Bruton's tyrosine kinase (BTK) belongs to the TEC family of nonreceptor tyrosine kinases and plays a crit. role in multiple cell types responsible for numerous autoimmune diseases.  This article will detail the structure-activity relationships (SARs) leading to a novel second generation series of potent and selective reversible carbazole inhibitors of BTK.  With an excellent pharmacokinetic profile as well as demonstrated in vivo activity and an acceptable safety profile, 7-(2-hydroxypropan-2-yl)-4-[2-methyl-3-(4-oxo-3,4-dihydroquinazolin-3-yl)phenyl]-9H-carbazole-1-carboxamide 6 (BMS-935177) was selected to advance into clin. development.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGo1HUwZaRn_w7Vg90H21EOLACvtfcHk0liWvvTQKpNRCA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28XhtlCrsL3M&md5=7c7ec1a52121c541753c045c1cbf758b</span></div><a href="/servlet/linkout?suffix=cit38&amp;dbid=16384&amp;doi=10.1021%2Facs.jmedchem.6b00722&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.jmedchem.6b00722%26sid%3Dliteratum%253Aachs%26aulast%3DDe%2BLucca%26aufirst%3DG.%2BV.%26aulast%3DShi%26aufirst%3DQ.%26aulast%3DLiu%26aufirst%3DQ.%26aulast%3DBatt%26aufirst%3DD.%2BG.%26aulast%3DBeaudoin%2BBertrand%26aufirst%3DM.%26aulast%3DRampulla%26aufirst%3DR.%26aulast%3DMathur%26aufirst%3DA.%26aulast%3DDiscenza%26aufirst%3DL.%26aulast%3DD%25E2%2580%2599Arienzo%26aufirst%3DC.%26aulast%3DDai%26aufirst%3DJ.%26aulast%3DObermeier%26aufirst%3DM.%26aulast%3DVickery%26aufirst%3DR.%26aulast%3DZhang%26aufirst%3DY.%26aulast%3DYang%26aufirst%3DZ.%26aulast%3DMarathe%26aufirst%3DP.%26aulast%3DTebben%26aufirst%3DA.%2BJ.%26aulast%3DMuckelbauer%26aufirst%3DJ.%2BK.%26aulast%3DChang%26aufirst%3DC.%2BJ.%26aulast%3DZhang%26aufirst%3DH.%26aulast%3DGillooly%26aufirst%3DK.%26aulast%3DTaylor%26aufirst%3DT.%26aulast%3DPattoli%26aufirst%3DM.%2BA.%26aulast%3DSkala%26aufirst%3DS.%26aulast%3DKukral%26aufirst%3DD.%2BW.%26aulast%3DMcIntyre%26aufirst%3DK.%2BW.%26aulast%3DSalter-Cid%26aufirst%3DL.%26aulast%3DFura%26aufirst%3DA.%26aulast%3DBurke%26aufirst%3DJ.%2BR.%26aulast%3DBarrish%26aufirst%3DJ.%2BC.%26aulast%3DCarter%26aufirst%3DP.%2BH.%26aulast%3DTino%26aufirst%3DJ.%2BA.%26atitle%3DSmall%2520Molecule%2520Reversible%2520Inhibitors%2520of%2520Bruton%25E2%2580%2599s%2520Tyrosine%2520Kinase%2520%2528BTK%2529%253A%2520Structure-Activity%2520Relationships%2520Leading%2520to%2520the%2520Identification%2520of%25207-%25282-Hydroxypropan-2-yl%2529-4-%255B2-methyl-3-%25284-oxo-3%252C4-dihydroquinazolin-3-yl%2529phenyl%255D-9H-carbazole-1-carboxamide%2520%2528BMS-935177%2529%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2016%26volume%3D59%26spage%3D7915%26epage%3D7935%26doi%3D10.1021%2Facs.jmedchem.6b00722" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref39"><div class="reference"><strong class="refLabel"><a href="#ref39" class="rightTabRefNumLink">39</a></strong><div class="NLM_citation" id="rightTab-cit39"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Katewa, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hackney, J. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Huang, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Suto, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ramamoorthi, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Austin, C. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bremer, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, J. Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Crawford, J. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Currie, K. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Blomgren, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">DeVoss, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">DiPaolo, J. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hau, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Johnson, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lesch, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">DeForge, L. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lin, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liimatta, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lubach, J. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">McVay, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Modrusan, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nguyen, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Poon, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lee, W. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wong, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Young, W. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Townsend, M. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Reif, K.</span></span> <span> </span><span class="NLM_article-title">Btk-specific inhibition blocks pathogenic plasma cell signatures and myeloid cell-associated damage in IFNα-driven lupus nephritis</span>. <i>JCI Insight</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>2</i></span>, <span class="NLM_elocation-id">e90111</span> <span class="refDoi"> DOI: 10.1172/jci.insight.90111</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref39/cit39&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00329&amp;key=10.1172%2Fjci.insight.90111" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref39/cit39&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00329&amp;key=28405610" title="">PubMed</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=2&publication_year=2017&author=A.+Katewaauthor=Y.+Wangauthor=J.+A.+Hackneyauthor=T.+Huangauthor=E.+Sutoauthor=N.+Ramamoorthiauthor=C.+D.+Austinauthor=M.+Bremerauthor=J.+Z.+Chenauthor=J.+J.+Crawfordauthor=K.+S.+Currieauthor=P.+Blomgrenauthor=J.+DeVossauthor=J.+A.+DiPaoloauthor=J.+Hauauthor=A.+Johnsonauthor=J.+Leschauthor=L.+E.+DeForgeauthor=Z.+Linauthor=M.+Liimattaauthor=J.+W.+Lubachauthor=S.+McVayauthor=Z.+Modrusanauthor=A.+Nguyenauthor=C.+Poonauthor=J.+Wangauthor=L.+Liuauthor=W.+P.+Leeauthor=H.+Wongauthor=W.+B.+Youngauthor=M.+J.+Townsendauthor=K.+Reif&title=Btk-specific+inhibition+blocks+pathogenic+plasma+cell+signatures+and+myeloid+cell-associated+damage+in+IFN%CE%B1-driven+lupus+nephritis&doi=10.1172%2Fjci.insight.90111"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit39&amp;dbid=16384&amp;doi=10.1172%2Fjci.insight.90111&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1172%252Fjci.insight.90111%26sid%3Dliteratum%253Aachs%26aulast%3DKatewa%26aufirst%3DA.%26aulast%3DWang%26aufirst%3DY.%26aulast%3DHackney%26aufirst%3DJ.%2BA.%26aulast%3DHuang%26aufirst%3DT.%26aulast%3DSuto%26aufirst%3DE.%26aulast%3DRamamoorthi%26aufirst%3DN.%26aulast%3DAustin%26aufirst%3DC.%2BD.%26aulast%3DBremer%26aufirst%3DM.%26aulast%3DChen%26aufirst%3DJ.%2BZ.%26aulast%3DCrawford%26aufirst%3DJ.%2BJ.%26aulast%3DCurrie%26aufirst%3DK.%2BS.%26aulast%3DBlomgren%26aufirst%3DP.%26aulast%3DDeVoss%26aufirst%3DJ.%26aulast%3DDiPaolo%26aufirst%3DJ.%2BA.%26aulast%3DHau%26aufirst%3DJ.%26aulast%3DJohnson%26aufirst%3DA.%26aulast%3DLesch%26aufirst%3DJ.%26aulast%3DDeForge%26aufirst%3DL.%2BE.%26aulast%3DLin%26aufirst%3DZ.%26aulast%3DLiimatta%26aufirst%3DM.%26aulast%3DLubach%26aufirst%3DJ.%2BW.%26aulast%3DMcVay%26aufirst%3DS.%26aulast%3DModrusan%26aufirst%3DZ.%26aulast%3DNguyen%26aufirst%3DA.%26aulast%3DPoon%26aufirst%3DC.%26aulast%3DWang%26aufirst%3DJ.%26aulast%3DLiu%26aufirst%3DL.%26aulast%3DLee%26aufirst%3DW.%2BP.%26aulast%3DWong%26aufirst%3DH.%26aulast%3DYoung%26aufirst%3DW.%2BB.%26aulast%3DTownsend%26aufirst%3DM.%2BJ.%26aulast%3DReif%26aufirst%3DK.%26atitle%3DBtk-specific%2520inhibition%2520blocks%2520pathogenic%2520plasma%2520cell%2520signatures%2520and%2520myeloid%2520cell-associated%2520damage%2520in%2520IFN%25CE%25B1-driven%2520lupus%2520nephritis%26jtitle%3DJCI%2520Insight%26date%3D2017%26volume%3D2%26doi%3D10.1172%2Fjci.insight.90111" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref40"><div class="reference"><strong class="refLabel"><a href="#ref40" class="rightTabRefNumLink">40</a></strong><div class="NLM_citation" id="rightTab-cit40"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Kawahata, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Asami, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Irie, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sawa, M.</span></span> <span> </span><span class="NLM_article-title">Design and synthesis of novel pyrimidine analogs as highly selective, non-covalent BTK inhibitors</span>. <i>Bioorg. Med. Chem. Lett.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>28</i></span>,  <span class="NLM_fpage">145</span>– <span class="NLM_lpage">151</span>, <span class="refDoi"> DOI: 10.1016/j.bmcl.2017.11.037</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref40/cit40&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00329&amp;key=10.1016%2Fj.bmcl.2017.11.037" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref40/cit40&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00329&amp;key=29198867" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref40/cit40&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00329&amp;key=1%3ACAS%3A528%3ADC%252BC2sXhvFWhur7I" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=28&publication_year=2018&pages=145-151&author=W.+Kawahataauthor=T.+Asamiauthor=T.+Irieauthor=M.+Sawa&title=Design+and+synthesis+of+novel+pyrimidine+analogs+as+highly+selective%2C+non-covalent+BTK+inhibitors&doi=10.1016%2Fj.bmcl.2017.11.037"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit40R"><div class="casContent"><span class="casTitleNuber">40</span><div class="casTitle"><span class="NLM_cas:atitle">Design and synthesis of novel pyrimidine analogs as highly selective, non-covalent BTK inhibitors</span></div><div class="casAuthors">Kawahata, Wataru; Asami, Tokiko; Irie, Takayuki; Sawa, Masaaki</div><div class="citationInfo"><span class="NLM_cas:title">Bioorganic & Medicinal Chemistry Letters</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">28</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">145-151</span>CODEN:
                <span class="NLM_cas:coden">BMCLE8</span>;
        ISSN:<span class="NLM_cas:issn">0960-894X</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">BTK is a promising target for the treatment of multiple diseases such as B cell malignances, asthma, and rheumatoid arthritis.  Here, the authors report the discovery of a series of novel pyrimidine analogs as potent, highly selective, non-covalent inhibitors of BTK.  Compd. I demonstrated higher affinity to an unactivated conformation of BTK that resulted in an excellent kinase selectivity.  Compd. I showed a good oral bioavailability in mice, and significantly inhibits the PCA reaction in mice.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqpVaSuT25WJ7Vg90H21EOLACvtfcHk0lgjX5gNIDINVg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXhvFWhur7I&md5=f77ce613ad2c95fe4d34abb41f5c5ea9</span></div><a href="/servlet/linkout?suffix=cit40&amp;dbid=16384&amp;doi=10.1016%2Fj.bmcl.2017.11.037&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bmcl.2017.11.037%26sid%3Dliteratum%253Aachs%26aulast%3DKawahata%26aufirst%3DW.%26aulast%3DAsami%26aufirst%3DT.%26aulast%3DIrie%26aufirst%3DT.%26aulast%3DSawa%26aufirst%3DM.%26atitle%3DDesign%2520and%2520synthesis%2520of%2520novel%2520pyrimidine%2520analogs%2520as%2520highly%2520selective%252C%2520non-covalent%2520BTK%2520inhibitors%26jtitle%3DBioorg.%2520Med.%2520Chem.%2520Lett.%26date%3D2018%26volume%3D28%26spage%3D145%26epage%3D151%26doi%3D10.1016%2Fj.bmcl.2017.11.037" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref41"><div class="reference"><strong class="refLabel"><a href="#ref41" class="rightTabRefNumLink">41</a></strong><div class="NLM_citation" id="rightTab-cit41"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Crawford, J. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Johnson, A. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Misner, D. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Belmont, L. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Castanedo, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Choy, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Coraggio, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dong, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Eigenbrot, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Erickson, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ghilardi, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hau, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Katewa, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kohli, P. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lee, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lubach, J. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">McKenzie, B. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ortwine, D. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schutt, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tay, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wei, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Reif, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wong, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Young, W. B.</span></span> <span> </span><span class="NLM_article-title">Discovery of GDC-0853: A potent, selective, and noncovalent Bruton’s tyrosine kinase inhibitor in early clinical development</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>61</i></span>,  <span class="NLM_fpage">2227</span>– <span class="NLM_lpage">2245</span>, <span class="refDoi"> DOI: 10.1021/acs.jmedchem.7b01712</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.jmedchem.7b01712" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref41/cit41&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00329&amp;key=1%3ACAS%3A528%3ADC%252BC1cXivFCnt7c%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=61&publication_year=2018&pages=2227-2245&author=J.+J.+Crawfordauthor=A.+R.+Johnsonauthor=D.+L.+Misnerauthor=L.+D.+Belmontauthor=G.+Castanedoauthor=R.+Choyauthor=M.+Coraggioauthor=L.+Dongauthor=C.+Eigenbrotauthor=R.+Ericksonauthor=N.+Ghilardiauthor=J.+Hauauthor=A.+Katewaauthor=P.+B.+Kohliauthor=W.+Leeauthor=J.+W.+Lubachauthor=B.+S.+McKenzieauthor=D.+F.+Ortwineauthor=L.+Schuttauthor=S.+Tayauthor=B.+Weiauthor=K.+Reifauthor=L.+Liuauthor=H.+Wongauthor=W.+B.+Young&title=Discovery+of+GDC-0853%3A+A+potent%2C+selective%2C+and+noncovalent+Bruton%E2%80%99s+tyrosine+kinase+inhibitor+in+early+clinical+development&doi=10.1021%2Facs.jmedchem.7b01712"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit41R"><div class="casContent"><span class="casTitleNuber">41</span><div class="casTitle"><span class="NLM_cas:atitle">Discovery of GDC-0853: A Potent, Selective, and Noncovalent Bruton's Tyrosine Kinase Inhibitor in Early Clinical Development</span></div><div class="casAuthors">Crawford, James J.; Johnson, Adam R.; Misner, Dinah L.; Belmont, Lisa D.; Castanedo, Georgette; Choy, Regina; Coraggio, Melis; Dong, Liming; Eigenbrot, Charles; Erickson, Rebecca; Ghilardi, Nico; Hau, Jonathan; Katewa, Arna; Kohli, Pawan Bir; Lee, Wendy; Lubach, Joseph W.; McKenzie, Brent S.; Ortwine, Daniel F.; Schutt, Leah; Tay, Suzanne; Wei, BinQing; Reif, Karin; Liu, Lichuan; Wong, Harvey; Young, Wendy B.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">61</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">2227-2245</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Bruton's tyrosine kinase (Btk) is a nonreceptor cytoplasmic tyrosine kinase involved in B-cell and myeloid cell activation, downstream of B-cell and Fcγ receptors, resp.  Preclin. studies have indicated that inhibition of Btk activity might offer a potential therapy in autoimmune diseases such as rheumatoid arthritis and systemic lupus erythematosus.  Here we disclose the discovery and preclin. characterization of a potent, selective, and noncovalent Btk inhibitor currently in clin. development.  GDC-0853 (29) suppresses B cell- and myeloid cell-mediated components of disease and demonstrates dose-dependent activity in an in vivo rat model of inflammatory arthritis.  It demonstrates highly favorable safety, pharmacokinetic (PK), and pharmacodynamic (PD) profiles in preclin. and Phase 2 studies ongoing in patients with rheumatoid arthritis, lupus, and chronic spontaneous urticaria.  On the basis of its potency, selectivity, long target residence time, and noncovalent mode of inhibition, 29 has the potential to be a best-in-class Btk inhibitor for a wide range of immunol. indications.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqOUJgTOFJ-o7Vg90H21EOLACvtfcHk0lju3-ajbt0xrQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXivFCnt7c%253D&md5=eddbd31f387fe86827a7469e8be45430</span></div><a href="/servlet/linkout?suffix=cit41&amp;dbid=16384&amp;doi=10.1021%2Facs.jmedchem.7b01712&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.jmedchem.7b01712%26sid%3Dliteratum%253Aachs%26aulast%3DCrawford%26aufirst%3DJ.%2BJ.%26aulast%3DJohnson%26aufirst%3DA.%2BR.%26aulast%3DMisner%26aufirst%3DD.%2BL.%26aulast%3DBelmont%26aufirst%3DL.%2BD.%26aulast%3DCastanedo%26aufirst%3DG.%26aulast%3DChoy%26aufirst%3DR.%26aulast%3DCoraggio%26aufirst%3DM.%26aulast%3DDong%26aufirst%3DL.%26aulast%3DEigenbrot%26aufirst%3DC.%26aulast%3DErickson%26aufirst%3DR.%26aulast%3DGhilardi%26aufirst%3DN.%26aulast%3DHau%26aufirst%3DJ.%26aulast%3DKatewa%26aufirst%3DA.%26aulast%3DKohli%26aufirst%3DP.%2BB.%26aulast%3DLee%26aufirst%3DW.%26aulast%3DLubach%26aufirst%3DJ.%2BW.%26aulast%3DMcKenzie%26aufirst%3DB.%2BS.%26aulast%3DOrtwine%26aufirst%3DD.%2BF.%26aulast%3DSchutt%26aufirst%3DL.%26aulast%3DTay%26aufirst%3DS.%26aulast%3DWei%26aufirst%3DB.%26aulast%3DReif%26aufirst%3DK.%26aulast%3DLiu%26aufirst%3DL.%26aulast%3DWong%26aufirst%3DH.%26aulast%3DYoung%26aufirst%3DW.%2BB.%26atitle%3DDiscovery%2520of%2520GDC-0853%253A%2520A%2520potent%252C%2520selective%252C%2520and%2520noncovalent%2520Bruton%25E2%2580%2599s%2520tyrosine%2520kinase%2520inhibitor%2520in%2520early%2520clinical%2520development%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2018%26volume%3D61%26spage%3D2227%26epage%3D2245%26doi%3D10.1021%2Facs.jmedchem.7b01712" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref42"><div class="reference"><strong class="refLabel"><a href="#ref42" class="rightTabRefNumLink">42</a></strong><div class="NLM_citation" id="rightTab-cit42"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Liu, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Halladay, J. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shin, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wong, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Coraggio, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">La, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Baumgardner, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Le, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gopaul, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Boggs, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kuebler, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Davis, J. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liao, X. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lubach, J. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Deese, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sowell, C. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Currie, K. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Young, W. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Khojasteh, S. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hop, C. E. C. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wong, H.</span></span> <span> </span><span class="NLM_article-title">Significant species difference in amide hydrolysis of GDC-0834, a novel potent and selective Bruton’s tyrosine kinase inhibitor</span>. <i>Drug Metab. Dispos.</i> <span class="NLM_year" style="font-weight: bold;">2011</span>,  <span class="NLM_volume"><i>39</i></span>,  <span class="NLM_fpage">1840</span>– <span class="NLM_lpage">1849</span>, <span class="refDoi"> DOI: 10.1124/dmd.111.040840</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref42/cit42&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00329&amp;key=10.1124%2Fdmd.111.040840" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref42/cit42&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00329&amp;key=21742900" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref42/cit42&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00329&amp;key=1%3ACAS%3A528%3ADC%252BC3MXhs1ekurnE" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=39&publication_year=2011&pages=1840-1849&author=L.+Liuauthor=J.+S.+Halladayauthor=Y.+Shinauthor=S.+Wongauthor=M.+Coraggioauthor=H.+Laauthor=M.+Baumgardnerauthor=H.+Leauthor=S.+Gopaulauthor=J.+Boggsauthor=P.+Kueblerauthor=J.+C.+Davisauthor=X.+C.+Liaoauthor=J.+W.+Lubachauthor=A.+Deeseauthor=C.+G.+Sowellauthor=K.+S.+Currieauthor=W.+B.+Youngauthor=S.+C.+Khojastehauthor=C.+E.+C.+A.+Hopauthor=H.+Wong&title=Significant+species+difference+in+amide+hydrolysis+of+GDC-0834%2C+a+novel+potent+and+selective+Bruton%E2%80%99s+tyrosine+kinase+inhibitor&doi=10.1124%2Fdmd.111.040840"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit42R"><div class="casContent"><span class="casTitleNuber">42</span><div class="casTitle"><span class="NLM_cas:atitle">Significant species difference in amide hydrolysis of GDC-0834, a novel potent and selective Bruton's tyrosine kinase inhibitor</span></div><div class="casAuthors">Liu, Lichuan; Halladay, Jason S.; Shin, Young; Wong, Susan; Coraggio, Melis; La, Hank; Baumgardner, Matthew; Le, Hoa; Gopaul, Sashi; Boggs, Jason; Kuebler, Peter; Davis, John C., Jr.; Liao, X. Charlene; Lubach, Joseph W.; Deese, Alan; Sowell, C. Gregory; Currie, Kevin S.; Young, Wendy B.; Khojasteh, S. Cyrus; Hop, Cornelis E. C. A.; Wong, Harvey</div><div class="citationInfo"><span class="NLM_cas:title">Drug Metabolism and Disposition</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">39</span>
        (<span class="NLM_cas:issue">10</span>),
    <span class="NLM_cas:pages">1840-1849</span>CODEN:
                <span class="NLM_cas:coden">DMDSAI</span>;
        ISSN:<span class="NLM_cas:issn">0090-9556</span>.
    
            (<span class="NLM_cas:orgname">American Society for Pharmacology and Experimental Therapeutics</span>)
        </div><div class="casAbstract">(R)-N-(3-(6-(4-(1,4-Dimethyl-3-oxopiperazin-2-yl)phenylamino)-4-methyl-5-oxo-4,5-dihydropyrazin-2-yl)-2-methylphenyl)-4,5,6,7-tetrahydrobenzo[b]thiophene-2-carboxamide (GDC-0834) is a potent and selective inhibitor of Bruton's tyrosine kinase (BTK), investigated as a potential treatment for rheumatoid arthritis.  In vitro metabolite identification studies in hepatocytes revealed predominant formation of an inactive metabolite (M1) via amide hydrolysis in human.  The formation of M1 appeared to be NADPH-independent in human liver microsomes.  M1 was found in only minor to moderate quantities in plasma from preclin. species dosed with GDC-0834.  Human clearance predictions using various methodologies resulted in ests. ranging from low to high.  In addn., GDC-0834 exhibited low clearance in PXB chimeric mice with humanized liver.  Uncertainty in human pharmacokinetic prediction and high interest in a BTK inhibitor for clin. evaluation prompted an investigational new drug strategy, in which GDC-0834 was rapidly advanced to a single-dose human clin. trial.  GDC-0834 plasma concns. in humans were below the limit of quantitation (<1 ng/mL) in most samples from the cohorts dosed orally at 35 and 105 mg.  In contrast, substantial plasma concns. of M1 were obsd.  In human plasma and urine, only M1 and its sequential metabolites were identified.  The formation kinetics of M1 was evaluated in rat, dog, monkey, and human liver microsomes in the absence of NADPH.  The max. rate of M1 formation (Vmax) was substantially higher in human compared with that in other species.  In contrast, the Michaelis-Menten const. (Km) was comparable among species.  Intrinsic clearance (Vmax/Km) of GDC-0834 from M1 formation in human was 23- to 169-fold higher than obsd. in rat, dog, and monkey.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGo_v1aPr50jkLVg90H21EOLACvtfcHk0lju3-ajbt0xrQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXhs1ekurnE&md5=976adc37c4d621924276d174318a1a84</span></div><a href="/servlet/linkout?suffix=cit42&amp;dbid=16384&amp;doi=10.1124%2Fdmd.111.040840&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1124%252Fdmd.111.040840%26sid%3Dliteratum%253Aachs%26aulast%3DLiu%26aufirst%3DL.%26aulast%3DHalladay%26aufirst%3DJ.%2BS.%26aulast%3DShin%26aufirst%3DY.%26aulast%3DWong%26aufirst%3DS.%26aulast%3DCoraggio%26aufirst%3DM.%26aulast%3DLa%26aufirst%3DH.%26aulast%3DBaumgardner%26aufirst%3DM.%26aulast%3DLe%26aufirst%3DH.%26aulast%3DGopaul%26aufirst%3DS.%26aulast%3DBoggs%26aufirst%3DJ.%26aulast%3DKuebler%26aufirst%3DP.%26aulast%3DDavis%26aufirst%3DJ.%2BC.%26aulast%3DLiao%26aufirst%3DX.%2BC.%26aulast%3DLubach%26aufirst%3DJ.%2BW.%26aulast%3DDeese%26aufirst%3DA.%26aulast%3DSowell%26aufirst%3DC.%2BG.%26aulast%3DCurrie%26aufirst%3DK.%2BS.%26aulast%3DYoung%26aufirst%3DW.%2BB.%26aulast%3DKhojasteh%26aufirst%3DS.%2BC.%26aulast%3DHop%26aufirst%3DC.%2BE.%2BC.%2BA.%26aulast%3DWong%26aufirst%3DH.%26atitle%3DSignificant%2520species%2520difference%2520in%2520amide%2520hydrolysis%2520of%2520GDC-0834%252C%2520a%2520novel%2520potent%2520and%2520selective%2520Bruton%25E2%2580%2599s%2520tyrosine%2520kinase%2520inhibitor%26jtitle%3DDrug%2520Metab.%2520Dispos.%26date%3D2011%26volume%3D39%26spage%3D1840%26epage%3D1849%26doi%3D10.1124%2Fdmd.111.040840" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref43"><div class="reference"><strong class="refLabel"><a href="#ref43" class="rightTabRefNumLink">43</a></strong><div class="NLM_citation" id="rightTab-cit43"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Wu, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Huang, Q.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Qi, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liang, Q.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dong, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yu, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hu, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Deng, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gray, N. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wei, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, Q.</span></span> <span> </span><span class="NLM_article-title">Irreversible inhibition of BTK kinase by a novel highly selective inhibitor CHMFL-BTK-11 suppresses inflammatory response in rheumatoid arthritis model</span>. <i>Sci. Rep.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>7</i></span>,  <span class="NLM_fpage">466</span>, <span class="refDoi"> DOI: 10.1038/s41598-017-00482-4</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref43/cit43&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00329&amp;key=10.1038%2Fs41598-017-00482-4" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref43/cit43&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00329&amp;key=28352114" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref43/cit43&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00329&amp;key=1%3ACAS%3A280%3ADC%252BC1cvitFSitQ%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=7&publication_year=2017&pages=466&author=H.+Wuauthor=Q.+Huangauthor=Z.+Qiauthor=Y.+Chenauthor=A.+Wangauthor=C.+Chenauthor=Q.+Liangauthor=J.+Wangauthor=W.+Chenauthor=J.+Dongauthor=K.+Yuauthor=C.+Huauthor=W.+Wangauthor=X.+Liuauthor=Y.+Dengauthor=L.+Wangauthor=B.+Wangauthor=X.+Liauthor=N.+S.+Grayauthor=J.+Liuauthor=W.+Weiauthor=Q.+Liu&title=Irreversible+inhibition+of+BTK+kinase+by+a+novel+highly+selective+inhibitor+CHMFL-BTK-11+suppresses+inflammatory+response+in+rheumatoid+arthritis+model&doi=10.1038%2Fs41598-017-00482-4"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit43R"><div class="casContent"><span class="casTitleNuber">43</span><div class="casTitle"><span class="NLM_cas:atitle">Irreversible inhibition of BTK kinase by a novel highly selective inhibitor CHMFL-BTK-11 suppresses inflammatory response in rheumatoid arthritis model</span></div><div class="casAuthors">Wu Hong; Qi Ziping; Chen Yongfei; Wang Aoli; Chen Cheng; Liang Qianmao; Yu Kailin; Hu Chen; Wang Wenchao; Liu Xiaochuan; Deng Yuanxin; Wang Li; Wang Beilei; Liu Jing; Liu Qingsong; Wu Hong; Wang Aoli; Yu Kailin; Hu Chen; Wang Li; Wang Beilei; Liu Qingsong; Huang Qiong; Chen Wensheng; Dong Jin; Wei Wei; Liang Qianmao; Liu Xiaochuan; Wang Jinghua; Gray Nathanael S; Li Xiaoxiang</div><div class="citationInfo"><span class="NLM_cas:title">Scientific reports</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">7</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">466</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">BTK plays a critical role in the B cell receptor mediated inflammatory signaling in the rheumatoid arthritis (RA).  Through a rational design approach we discovered a highly selective and potent BTK kinase inhibitor (CHMFL-BTK-11) which exerted its inhibitory efficacy through a covalent bond with BTK Cys481.  CHMFL-BTK-11 potently blocked the anti-IgM stimulated BCR signaling in the Ramos cell lines and isolated human primary B cells.  It significantly inhibited the LPS stimulated TNF-α production in the human PBMC cells but only weakly affecting the normal PBMC cell proliferation.  In the adjuvant-induced arthritis rat model, CHMFL-BTK-11 ameliorated the inflammatory response through blockage of proliferation of activated B cells, inhibition of the secretion of the inflammatory factors such as IgG1, IgG2, IgM, IL-6 and PMΦ phagocytosis, stimulation of secretion of IL-10.  The high specificity of CHMFL-BTK-11 makes it a useful pharmacological tool to further detect BTK mediated signaling in the pathology of RA.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcRDP66FiFmnMFQKX3ooHxWjfW6udTcc2eYEkpaCFk-atLntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC1cvitFSitQ%253D%253D&md5=20590a8506a9f4be4b5c0ba739a000b2</span></div><a href="/servlet/linkout?suffix=cit43&amp;dbid=16384&amp;doi=10.1038%2Fs41598-017-00482-4&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fs41598-017-00482-4%26sid%3Dliteratum%253Aachs%26aulast%3DWu%26aufirst%3DH.%26aulast%3DHuang%26aufirst%3DQ.%26aulast%3DQi%26aufirst%3DZ.%26aulast%3DChen%26aufirst%3DY.%26aulast%3DWang%26aufirst%3DA.%26aulast%3DChen%26aufirst%3DC.%26aulast%3DLiang%26aufirst%3DQ.%26aulast%3DWang%26aufirst%3DJ.%26aulast%3DChen%26aufirst%3DW.%26aulast%3DDong%26aufirst%3DJ.%26aulast%3DYu%26aufirst%3DK.%26aulast%3DHu%26aufirst%3DC.%26aulast%3DWang%26aufirst%3DW.%26aulast%3DLiu%26aufirst%3DX.%26aulast%3DDeng%26aufirst%3DY.%26aulast%3DWang%26aufirst%3DL.%26aulast%3DWang%26aufirst%3DB.%26aulast%3DLi%26aufirst%3DX.%26aulast%3DGray%26aufirst%3DN.%2BS.%26aulast%3DLiu%26aufirst%3DJ.%26aulast%3DWei%26aufirst%3DW.%26aulast%3DLiu%26aufirst%3DQ.%26atitle%3DIrreversible%2520inhibition%2520of%2520BTK%2520kinase%2520by%2520a%2520novel%2520highly%2520selective%2520inhibitor%2520CHMFL-BTK-11%2520suppresses%2520inflammatory%2520response%2520in%2520rheumatoid%2520arthritis%2520model%26jtitle%3DSci.%2520Rep.%26date%3D2017%26volume%3D7%26spage%3D466%26doi%3D10.1038%2Fs41598-017-00482-4" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref44"><div class="reference"><strong class="refLabel"><a href="#ref44" class="rightTabRefNumLink">44</a></strong><div class="NLM_citation" id="rightTab-cit44"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Bradshaw, J. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">McFarland, J. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Paavilainen, V. O.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bisconte, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tam, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Phan, V. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Romanov, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Finkle, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shu, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Patel, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ton, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Loughhead, D. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nunn, P. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Karr, D. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gerritsen, M. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Funk, J. O.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Owens, T. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Verner, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Brameld, K. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hill, R. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Goldstein, D. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Taunton, J.</span></span> <span> </span><span class="NLM_article-title">Prolonged and tunable residence time using reversible covalent kinase inhibitors</span>. <i>Nat. Chem. Biol.</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>11</i></span>,  <span class="NLM_fpage">525</span>– <span class="NLM_lpage">531</span>, <span class="refDoi"> DOI: 10.1038/nchembio.1817</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref44/cit44&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00329&amp;key=10.1038%2Fnchembio.1817" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref44/cit44&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00329&amp;key=26006010" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref44/cit44&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00329&amp;key=1%3ACAS%3A528%3ADC%252BC2MXhtFeju7%252FE" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=11&publication_year=2015&pages=525-531&author=J.+M.+Bradshawauthor=J.+M.+McFarlandauthor=V.+O.+Paavilainenauthor=A.+Bisconteauthor=D.+Tamauthor=V.+T.+Phanauthor=S.+Romanovauthor=D.+Finkleauthor=J.+Shuauthor=V.+Patelauthor=T.+Tonauthor=X.+Liauthor=D.+G.+Loughheadauthor=P.+A.+Nunnauthor=D.+E.+Karrauthor=M.+E.+Gerritsenauthor=J.+O.+Funkauthor=T.+D.+Owensauthor=E.+Vernerauthor=K.+A.+Brameldauthor=R.+J.+Hillauthor=D.+M.+Goldsteinauthor=J.+Taunton&title=Prolonged+and+tunable+residence+time+using+reversible+covalent+kinase+inhibitors&doi=10.1038%2Fnchembio.1817"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit44R"><div class="casContent"><span class="casTitleNuber">44</span><div class="casTitle"><span class="NLM_cas:atitle">Prolonged and tunable residence time using reversible covalent kinase inhibitors</span></div><div class="casAuthors">Bradshaw, J. Michael; McFarland, Jesse M.; Paavilainen, Ville O.; Bisconte, Angelina; Tam, Danny; Phan, Vernon T.; Romanov, Sergei; Finkle, David; Shu, Jin; Patel, Vaishali; Ton, Tony; Li, Xiaoyan; Loughhead, David G.; Nunn, Philip A.; Karr, Dane E.; Gerritsen, Mary E.; Funk, Jens Oliver; Owens, Timothy D.; Verner, Erik; Brameld, Ken A.; Hill, Ronald J.; Goldstein, David M.; Taunton, Jack</div><div class="citationInfo"><span class="NLM_cas:title">Nature Chemical Biology</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">11</span>
        (<span class="NLM_cas:issue">7</span>),
    <span class="NLM_cas:pages">525-531</span>CODEN:
                <span class="NLM_cas:coden">NCBABT</span>;
        ISSN:<span class="NLM_cas:issn">1552-4450</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">Drugs with prolonged on-target residence times often show superior efficacy, yet general strategies for optimizing drug-target residence time are lacking.  Here the authors made progress toward this elusive goal by targeting a noncatalytic cysteine in Bruton's tyrosine kinase (BTK) with reversible covalent inhibitors.  Using an inverted orientation of the cysteine-reactive cyanoacrylamide electrophile, the authors identified potent and selective BTK inhibitors that demonstrated biochem. residence times spanning from minutes to 7 d.  An inverted cyanoacrylamide with prolonged residence time in vivo remained bound to BTK for more than 18 h after clearance from the circulation.  The inverted cyanoacrylamide strategy was further used to discover fibroblast growth factor receptor (FGFR) kinase inhibitors with residence times of several days, demonstrating the generalizability of the approach.  Targeting of noncatalytic cysteines with inverted cyanoacrylamides may serve as a broadly applicable platform that facilitates 'residence time by design', the ability to modulate and improve the duration of target engagement in vivo.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrXCpNprhn6kLVg90H21EOLACvtfcHk0lgrfoky1iP0NQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXhtFeju7%252FE&md5=85a73d9ecd62695d03166f7009c68dd8</span></div><a href="/servlet/linkout?suffix=cit44&amp;dbid=16384&amp;doi=10.1038%2Fnchembio.1817&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnchembio.1817%26sid%3Dliteratum%253Aachs%26aulast%3DBradshaw%26aufirst%3DJ.%2BM.%26aulast%3DMcFarland%26aufirst%3DJ.%2BM.%26aulast%3DPaavilainen%26aufirst%3DV.%2BO.%26aulast%3DBisconte%26aufirst%3DA.%26aulast%3DTam%26aufirst%3DD.%26aulast%3DPhan%26aufirst%3DV.%2BT.%26aulast%3DRomanov%26aufirst%3DS.%26aulast%3DFinkle%26aufirst%3DD.%26aulast%3DShu%26aufirst%3DJ.%26aulast%3DPatel%26aufirst%3DV.%26aulast%3DTon%26aufirst%3DT.%26aulast%3DLi%26aufirst%3DX.%26aulast%3DLoughhead%26aufirst%3DD.%2BG.%26aulast%3DNunn%26aufirst%3DP.%2BA.%26aulast%3DKarr%26aufirst%3DD.%2BE.%26aulast%3DGerritsen%26aufirst%3DM.%2BE.%26aulast%3DFunk%26aufirst%3DJ.%2BO.%26aulast%3DOwens%26aufirst%3DT.%2BD.%26aulast%3DVerner%26aufirst%3DE.%26aulast%3DBrameld%26aufirst%3DK.%2BA.%26aulast%3DHill%26aufirst%3DR.%2BJ.%26aulast%3DGoldstein%26aufirst%3DD.%2BM.%26aulast%3DTaunton%26aufirst%3DJ.%26atitle%3DProlonged%2520and%2520tunable%2520residence%2520time%2520using%2520reversible%2520covalent%2520kinase%2520inhibitors%26jtitle%3DNat.%2520Chem.%2520Biol.%26date%3D2015%26volume%3D11%26spage%3D525%26epage%3D531%26doi%3D10.1038%2Fnchembio.1817" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref45"><div class="reference"><strong class="refLabel"><a href="#ref45" class="rightTabRefNumLink">45</a></strong><div class="NLM_citation" id="rightTab-cit45"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Reiff, S. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Muhowski, E. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Guinn, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lehman, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fabian, C. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cheney, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mantel, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Smith, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Johnson, A. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Young, W. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Johnson, A. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Byrd, J. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Woyach, J. A.</span></span> <span> </span><span class="NLM_article-title">Noncovalent inhibition of C481S Bruton tyrosine kinase by GDC-0853: a new treatment strategy for ibrutinib-resistant CLL</span>. <i>Blood</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>132</i></span>,  <span class="NLM_fpage">1039</span>– <span class="NLM_lpage">1049</span>, <span class="refDoi"> DOI: 10.1182/blood-2017-10-809020</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref45/cit45&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00329&amp;key=10.1182%2Fblood-2017-10-809020" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref45/cit45&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00329&amp;key=30018078" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref45/cit45&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00329&amp;key=1%3ACAS%3A528%3ADC%252BC1cXitVegtrnL" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=132&publication_year=2018&pages=1039-1049&author=S.+D.+Reiffauthor=E.+M.+Muhowskiauthor=D.+Guinnauthor=A.+Lehmanauthor=C.+A.+Fabianauthor=C.+Cheneyauthor=R.+Mantelauthor=L.+Smithauthor=A.+J.+Johnsonauthor=W.+B.+Youngauthor=A.+R.+Johnsonauthor=L.+Liuauthor=J.+C.+Byrdauthor=J.+A.+Woyach&title=Noncovalent+inhibition+of+C481S+Bruton+tyrosine+kinase+by+GDC-0853%3A+a+new+treatment+strategy+for+ibrutinib-resistant+CLL&doi=10.1182%2Fblood-2017-10-809020"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit45R"><div class="casContent"><span class="casTitleNuber">45</span><div class="casTitle"><span class="NLM_cas:atitle">Noncovalent inhibition of C481S Bruton tyrosinekinase by GDC-0853: A new treatment strategy foribrutinib-resistant CLL</span></div><div class="casAuthors">Reiff, Sean D.; Muhowski, Elizabeth M.; Guinn, Daphne; Lehman, Amy; Fabian, Catherine A.; Cheney, Carolyn; Mantel, Rose; Smith, Lisa; Johnson, Amy J.; Young, Wendy B.; Johnson, Adam R.; Liu, Lichuan; Byrd, John C.; Woyach, Jennifer A.</div><div class="citationInfo"><span class="NLM_cas:title">Blood</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">132</span>
        (<span class="NLM_cas:issue">10</span>),
    <span class="NLM_cas:pages">1039-1049</span>CODEN:
                <span class="NLM_cas:coden">BLOOAW</span>;
        ISSN:<span class="NLM_cas:issn">1528-0020</span>.
    
            (<span class="NLM_cas:orgname">American Society of Hematology</span>)
        </div><div class="casAbstract">The clin. success of ibrutinib validates Bruton tyrosine kinase (BTK) inhibition as aneffective strategy for treating hematol. malignancies, including chronic lymphocyticleukemia (CLL).  Despite ibrutinib's ability to produce durable remissions in patients, acquiredresistance can develop, mostly commonly by mutation of C481 of BTK in theibrutinib binding site.  Here, we characterize a novel BTK inhibitor, GDC-0853, to evaluateits preclin. efficacy in ibrutinib-naive and ibrutinib-resistant CLL.  GDC-0853 is uniqueamong reported BTK inhibitors in that it does not rely upon covalent reaction with C481 tostabilize its occupancy within BTK's ATP binding site.  As with ibrutinib,GDC-0853 potently reduces B-cell receptor signaling, viability, NF-κB-dependent transcription,activation, and migration in treatment na.ovrddot.ive CLL cells.  We found that GDC-0853also inhibits the most commonly reported ibrutinib-resistant BTK mutant (C481S) both in abiochem. enzyme activity assay and in a stably transfected 293T cell line and maintainscytotoxicity against patient CLL cells harboring C481S BTK mutations.  Addnl., GDC-0853 does not inhibit endothelial growth factor receptor or ITK, 2 alternative targets ofibrutinib that are likely responsible for some adverse events and may reduce the efficacy of ibrutinib-antibodycombinations, resp.  Our results using GDC-0853 indicate that noncovalent, selective BTK inhibition may beeffective in CLL either as monotherapy or in combination with therapeutic antibodies, esp. among the emergingpopulation of patients with acquired resistance to ibrutinib therapy.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpLuDzLD7FMb7Vg90H21EOLACvtfcHk0lgrfoky1iP0NQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXitVegtrnL&md5=f867a4ef8469fb2db96eb45c481a7b76</span></div><a href="/servlet/linkout?suffix=cit45&amp;dbid=16384&amp;doi=10.1182%2Fblood-2017-10-809020&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1182%252Fblood-2017-10-809020%26sid%3Dliteratum%253Aachs%26aulast%3DReiff%26aufirst%3DS.%2BD.%26aulast%3DMuhowski%26aufirst%3DE.%2BM.%26aulast%3DGuinn%26aufirst%3DD.%26aulast%3DLehman%26aufirst%3DA.%26aulast%3DFabian%26aufirst%3DC.%2BA.%26aulast%3DCheney%26aufirst%3DC.%26aulast%3DMantel%26aufirst%3DR.%26aulast%3DSmith%26aufirst%3DL.%26aulast%3DJohnson%26aufirst%3DA.%2BJ.%26aulast%3DYoung%26aufirst%3DW.%2BB.%26aulast%3DJohnson%26aufirst%3DA.%2BR.%26aulast%3DLiu%26aufirst%3DL.%26aulast%3DByrd%26aufirst%3DJ.%2BC.%26aulast%3DWoyach%26aufirst%3DJ.%2BA.%26atitle%3DNoncovalent%2520inhibition%2520of%2520C481S%2520Bruton%2520tyrosine%2520kinase%2520by%2520GDC-0853%253A%2520a%2520new%2520treatment%2520strategy%2520for%2520ibrutinib-resistant%2520CLL%26jtitle%3DBlood%26date%3D2018%26volume%3D132%26spage%3D1039%26epage%3D1049%26doi%3D10.1182%2Fblood-2017-10-809020" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref46"><div class="reference"><strong class="refLabel"><a href="#ref46" class="rightTabRefNumLink">46</a></strong><div class="NLM_citation" id="rightTab-cit46"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Watterson, S. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">De Lucca, G. V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shi, Q.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Langevine, C. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, Q.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Batt, D. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Beaudoin
Bertrand, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gong, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dai, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yip, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sun, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wu, D.-R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Traeger, S. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pattoli, M. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Skala, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cheng, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Obermeier, M. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vickery, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Discenza, L. N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">D’Arienzo, C. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Heimrich, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gillooly, K. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Taylor, T. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pulicicchio, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">McIntyre, K. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Galella, M. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tebben, A. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Muckelbauer, J. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chang, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rampulla, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mathur, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Salter-Cid, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Barrish, J. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Carter, P. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fura, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Burke, J. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tino, J. A.</span></span> <span> </span><span class="NLM_article-title">Discovery of 6-Fluoro-5-(R)-(3-(S)-(8-fluoro-1-methyl-2,4-dioxo-1,2-dihydroquinazolin-3(4H)-yl)-2-methylphenyl)-2-(S)-(2-hydroxypropan-2-yl)-2,3,4,9-tetrahydro-1H-carbazole-8-carboxamide (BMS-986142): A Reversible Inhibitor of Bruton’s Tyrosine Kinase (BTK) Conformationally Constrained by Two Locked Atropisomers</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>59</i></span>,  <span class="NLM_fpage">9173</span>– <span class="NLM_lpage">9200</span>, <span class="refDoi"> DOI: 10.1021/acs.jmedchem.6b01088</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.jmedchem.6b01088" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref46/cit46&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00329&amp;key=1%3ACAS%3A528%3ADC%252BC28XhsVKjsrfF" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=59&publication_year=2016&pages=9173-9200&author=S.+H.+Wattersonauthor=G.+V.+De+Luccaauthor=Q.+Shiauthor=C.+M.+Langevineauthor=Q.+Liuauthor=D.+G.+Battauthor=M.+Beaudoin%0ABertrandauthor=H.+Gongauthor=J.+Daiauthor=S.+Yipauthor=P.+Liauthor=D.+Sunauthor=D.-R.+Wuauthor=C.+Wangauthor=Y.+Zhangauthor=S.+C.+Traegerauthor=M.+A.+Pattoliauthor=S.+Skalaauthor=L.+Chengauthor=M.+T.+Obermeierauthor=R.+Vickeryauthor=L.+N.+Discenzaauthor=C.+J.+D%E2%80%99Arienzoauthor=Y.+Zhangauthor=E.+Heimrichauthor=K.+M.+Gilloolyauthor=T.+L.+Taylorauthor=C.+Pulicicchioauthor=K.+W.+McIntyreauthor=M.+A.+Galellaauthor=A.+J.+Tebbenauthor=J.+K.+Muckelbauerauthor=C.+Changauthor=R.+Rampullaauthor=A.+Mathurauthor=L.+Salter-Cidauthor=J.+C.+Barrishauthor=P.+H.+Carterauthor=A.+Furaauthor=J.+R.+Burkeauthor=J.+A.+Tino&title=Discovery+of+6-Fluoro-5-%28R%29-%283-%28S%29-%288-fluoro-1-methyl-2%2C4-dioxo-1%2C2-dihydroquinazolin-3%284H%29-yl%29-2-methylphenyl%29-2-%28S%29-%282-hydroxypropan-2-yl%29-2%2C3%2C4%2C9-tetrahydro-1H-carbazole-8-carboxamide+%28BMS-986142%29%3A+A+Reversible+Inhibitor+of+Bruton%E2%80%99s+Tyrosine+Kinase+%28BTK%29+Conformationally+Constrained+by+Two+Locked+Atropisomers&doi=10.1021%2Facs.jmedchem.6b01088"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit46R"><div class="casContent"><span class="casTitleNuber">46</span><div class="casTitle"><span class="NLM_cas:atitle">Discovery of 6-Fluoro-5-(R)-(3-(S)-(8-fluoro-1-methyl-2,4-dioxo-1,2-dihydroquinazolin-3(4H)-yl)-2-methylphenyl)-2-(S)-(2-hydroxypropan-2-yl)-2,3,4,9-tetrahydro-1H-carbazole-8-carboxamide (BMS-986142): A Reversible Inhibitor of Bruton's Tyrosine Kinase (BTK) Conformationally Constrained by Two Locked Atropisomers</span></div><div class="casAuthors">Watterson, Scott H.; De Lucca, George V.; Shi, Qing; Langevine, Charles M.; Liu, Qingjie; Batt, Douglas G.; Beaudoin Bertrand, Myra; Gong, Hua; Dai, Jun; Yip, Shiuhang; Li, Peng; Sun, Dawn; Wu, Dauh-Rurng; Wang, Chunlei; Zhang, Yingru; Traeger, Sarah C.; Pattoli, Mark A.; Skala, Stacey; Cheng, Lihong; Obermeier, Mary T.; Vickery, Rodney; Discenza, Lorell N.; D'Arienzo, Celia J.; Zhang, Yifan; Heimrich, Elizabeth; Gillooly, Kathleen M.; Taylor, Tracy L.; Pulicicchio, Claudine; McIntyre, Kim W.; Galella, Michael A.; Tebben, Andy J.; Muckelbauer, Jodi K.; Chang, ChiehYing; Rampulla, Richard; Mathur, Arvind; Salter-Cid, Luisa; Barrish, Joel C.; Carter, Percy H.; Fura, Aberra; Burke, James R.; Tino, Joseph A.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">59</span>
        (<span class="NLM_cas:issue">19</span>),
    <span class="NLM_cas:pages">9173-9200</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Bruton's tyrosine kinase (BTK), a nonreceptor tyrosine kinase, is a member of the Tec family of kinases.  BTK plays an essential role in B cell receptor (BCR)-mediated signaling as well as Fcγ receptor signaling in monocytes and Fcε receptor signaling in mast cells and basophils, all of which have been implicated in the pathophysiol. of autoimmune disease.  As a result, inhibition of BTK is anticipated to provide an effective strategy for the clin. treatment of autoimmune diseases such as lupus and rheumatoid arthritis.  This article details the structure-activity relationships (SAR) leading to a novel series of highly potent and selective carbazole and tetrahydrocarbazole based, reversible inhibitors of BTK.  Of particular interest is that two atropisomeric centers were rotationally locked to provide a single, stable atropisomer, resulting in enhanced potency and selectivity as well as a redn. in safety liabilities.  With significantly enhanced potency and selectivity, excellent in vivo properties and efficacy, and a very desirable tolerability and safety profile, 14f (BMS-986142) was advanced into clin. studies.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpmpBAygRAsYrVg90H21EOLACvtfcHk0liFbEZu7Bi4Sg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28XhsVKjsrfF&md5=91098abc802521b9ad91563d20ac5893</span></div><a href="/servlet/linkout?suffix=cit46&amp;dbid=16384&amp;doi=10.1021%2Facs.jmedchem.6b01088&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.jmedchem.6b01088%26sid%3Dliteratum%253Aachs%26aulast%3DWatterson%26aufirst%3DS.%2BH.%26aulast%3DDe%2BLucca%26aufirst%3DG.%2BV.%26aulast%3DShi%26aufirst%3DQ.%26aulast%3DLangevine%26aufirst%3DC.%2BM.%26aulast%3DLiu%26aufirst%3DQ.%26aulast%3DBatt%26aufirst%3DD.%2BG.%26aulast%3DBeaudoin%2BBertrand%26aufirst%3DM.%26aulast%3DGong%26aufirst%3DH.%26aulast%3DDai%26aufirst%3DJ.%26aulast%3DYip%26aufirst%3DS.%26aulast%3DLi%26aufirst%3DP.%26aulast%3DSun%26aufirst%3DD.%26aulast%3DWu%26aufirst%3DD.-R.%26aulast%3DWang%26aufirst%3DC.%26aulast%3DZhang%26aufirst%3DY.%26aulast%3DTraeger%26aufirst%3DS.%2BC.%26aulast%3DPattoli%26aufirst%3DM.%2BA.%26aulast%3DSkala%26aufirst%3DS.%26aulast%3DCheng%26aufirst%3DL.%26aulast%3DObermeier%26aufirst%3DM.%2BT.%26aulast%3DVickery%26aufirst%3DR.%26aulast%3DDiscenza%26aufirst%3DL.%2BN.%26aulast%3DD%25E2%2580%2599Arienzo%26aufirst%3DC.%2BJ.%26aulast%3DZhang%26aufirst%3DY.%26aulast%3DHeimrich%26aufirst%3DE.%26aulast%3DGillooly%26aufirst%3DK.%2BM.%26aulast%3DTaylor%26aufirst%3DT.%2BL.%26aulast%3DPulicicchio%26aufirst%3DC.%26aulast%3DMcIntyre%26aufirst%3DK.%2BW.%26aulast%3DGalella%26aufirst%3DM.%2BA.%26aulast%3DTebben%26aufirst%3DA.%2BJ.%26aulast%3DMuckelbauer%26aufirst%3DJ.%2BK.%26aulast%3DChang%26aufirst%3DC.%26aulast%3DRampulla%26aufirst%3DR.%26aulast%3DMathur%26aufirst%3DA.%26aulast%3DSalter-Cid%26aufirst%3DL.%26aulast%3DBarrish%26aufirst%3DJ.%2BC.%26aulast%3DCarter%26aufirst%3DP.%2BH.%26aulast%3DFura%26aufirst%3DA.%26aulast%3DBurke%26aufirst%3DJ.%2BR.%26aulast%3DTino%26aufirst%3DJ.%2BA.%26atitle%3DDiscovery%2520of%25206-Fluoro-5-%2528R%2529-%25283-%2528S%2529-%25288-fluoro-1-methyl-2%252C4-dioxo-1%252C2-dihydroquinazolin-3%25284H%2529-yl%2529-2-methylphenyl%2529-2-%2528S%2529-%25282-hydroxypropan-2-yl%2529-2%252C3%252C4%252C9-tetrahydro-1H-carbazole-8-carboxamide%2520%2528BMS-986142%2529%253A%2520A%2520Reversible%2520Inhibitor%2520of%2520Bruton%25E2%2580%2599s%2520Tyrosine%2520Kinase%2520%2528BTK%2529%2520Conformationally%2520Constrained%2520by%2520Two%2520Locked%2520Atropisomers%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2016%26volume%3D59%26spage%3D9173%26epage%3D9200%26doi%3D10.1021%2Facs.jmedchem.6b01088" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref47"><div class="reference"><strong class="refLabel"><a href="#ref47" class="rightTabRefNumLink">47</a></strong><div class="NLM_citation" id="rightTab-cit47"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Neffendorf, J. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gout, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hildebrand, G. D.</span></span> <span> </span><span class="NLM_article-title">Ibrutinib in relapsed chronic lymphocytic leukemia</span>. <i>N. Engl. J. Med.</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>369</i></span>,  <span class="NLM_fpage">1277</span>– <span class="NLM_lpage">1279</span>, <span class="refDoi"> DOI: 10.1056/nejmc1309710</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref47/cit47&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00329&amp;key=10.1056%2Fnejmc1309710" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref47/cit47&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00329&amp;key=24066759" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref47/cit47&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00329&amp;key=1%3ACAS%3A528%3ADC%252BC3sXhsFGktLbM" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=369&publication_year=2013&pages=1277-1279&author=J.+E.+Neffendorfauthor=I.+Goutauthor=G.+D.+Hildebrand&title=Ibrutinib+in+relapsed+chronic+lymphocytic+leukemia&doi=10.1056%2Fnejmc1309710"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit47R"><div class="casContent"><span class="casTitleNuber">47</span><div class="casTitle"><span class="NLM_cas:atitle">Comments on: ibrutinib in relapsed chronic lymphocytic leukemia</span></div><div class="casAuthors">Neffendorf, James E.; Gout, Irina; Hildebrand, G. Darius</div><div class="citationInfo"><span class="NLM_cas:title">New England Journal of Medicine</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">369</span>
        (<span class="NLM_cas:issue">13</span>),
    <span class="NLM_cas:pages">1277-1278</span>CODEN:
                <span class="NLM_cas:coden">NEJMAG</span>;
        ISSN:<span class="NLM_cas:issn">0028-4793</span>.
    
            (<span class="NLM_cas:orgname">Massachusetts Medical Society</span>)
        </div><div class="casAbstract">
                There is no expanded citation for this reference.
            </div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGo-Wf-6sB8Ch7Vg90H21EOLACvtfcHk0liFbEZu7Bi4Sg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXhsFGktLbM&md5=9aecfee27df57c795e046316b3624f33</span></div><a href="/servlet/linkout?suffix=cit47&amp;dbid=16384&amp;doi=10.1056%2Fnejmc1309710&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1056%252Fnejmc1309710%26sid%3Dliteratum%253Aachs%26aulast%3DNeffendorf%26aufirst%3DJ.%2BE.%26aulast%3DGout%26aufirst%3DI.%26aulast%3DHildebrand%26aufirst%3DG.%2BD.%26atitle%3DIbrutinib%2520in%2520relapsed%2520chronic%2520lymphocytic%2520leukemia%26jtitle%3DN.%2520Engl.%2520J.%2520Med.%26date%3D2013%26volume%3D369%26spage%3D1277%26epage%3D1279%26doi%3D10.1056%2Fnejmc1309710" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref48"><div class="reference"><strong class="refLabel"><a href="#ref48" class="rightTabRefNumLink">48</a></strong><div class="NLM_citation" id="rightTab-cit48"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Byrd, J. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Brown, J. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">O’Brien, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Barrientos, J. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kay, N. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Reddy, N. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Coutre, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tam, C. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mulligan, S. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jaeger, U.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Devereux, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Barr, P. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Furman, R. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kipps, T. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cymbalista, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pocock, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Thornton, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Caligaris-Cappio, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Robak, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Delgado, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schuster, S. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Montillo, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schuh, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">de Vos, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gill, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bloor, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dearden, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Moreno, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jones, J. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chu, A. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fardis, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">McGreivy, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Clow, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">James, D. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hillmen, P.</span></span> <span> </span><span class="NLM_article-title">Ibrutinib versus ofatumumab in previously treated chronic lymphoid leukemia</span>. <i>N. Engl. J. Med.</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>371</i></span>,  <span class="NLM_fpage">213</span>– <span class="NLM_lpage">223</span>, <span class="refDoi"> DOI: 10.1056/nejmoa1400376</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref48/cit48&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00329&amp;key=10.1056%2Fnejmoa1400376" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref48/cit48&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00329&amp;key=24881631" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref48/cit48&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00329&amp;key=1%3ACAS%3A528%3ADC%252BC2cXhs1egsbrN" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=371&publication_year=2014&pages=213-223&author=J.+C.+Byrdauthor=J.+R.+Brownauthor=S.+O%E2%80%99Brienauthor=J.+C.+Barrientosauthor=N.+E.+Kayauthor=N.+M.+Reddyauthor=S.+Coutreauthor=C.+S.+Tamauthor=S.+P.+Mulliganauthor=U.+Jaegerauthor=S.+Devereuxauthor=P.+M.+Barrauthor=R.+R.+Furmanauthor=T.+J.+Kippsauthor=F.+Cymbalistaauthor=C.+Pocockauthor=P.+Thorntonauthor=F.+Caligaris-Cappioauthor=T.+Robakauthor=J.+Delgadoauthor=S.+J.+Schusterauthor=M.+Montilloauthor=A.+Schuhauthor=S.+de+Vosauthor=D.+Gillauthor=A.+Bloorauthor=C.+Deardenauthor=C.+Morenoauthor=J.+J.+Jonesauthor=A.+D.+Chuauthor=M.+Fardisauthor=J.+McGreivyauthor=F.+Clowauthor=D.+F.+Jamesauthor=P.+Hillmen&title=Ibrutinib+versus+ofatumumab+in+previously+treated+chronic+lymphoid+leukemia&doi=10.1056%2Fnejmoa1400376"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit48R"><div class="casContent"><span class="casTitleNuber">48</span><div class="casTitle"><span class="NLM_cas:atitle">Ibrutinib versus ofatumumab in previously treated chronic lymphoid leukemia</span></div><div class="casAuthors">Byrd, J. C.; Brown, J. R.; O'Brien, S.; Barrientos, J. C.; Kay, N. E.; Reddy, N. M.; Coutre, S.; Tam, C. S.; Mulligan, S. P.; Jaeger, U.; Devereux, S.; Barr, P. M.; Furman, R. R.; Kipps, T. J.; Cymbalista, F.; Pocock, C.; Thornton, P.; Caligaris-Cappio, F.; Robak, T.; Delgado, J.; Schuster, S. J.; Montillo, M.; Schuh, A.; de Vos, S.; Gill, D.; Bloor, A.; Dearden, C.; Moreno, C.; Jones, J. J.; Chu, A. D.; Fardis, M.; McGreivy, J.; Clow, F.; James, D. F.; Hillmen, P.</div><div class="citationInfo"><span class="NLM_cas:title">New England Journal of Medicine</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">371</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">213-223, 11 pp.</span>CODEN:
                <span class="NLM_cas:coden">NEJMAG</span>;
        ISSN:<span class="NLM_cas:issn">1533-4406</span>.
    
            (<span class="NLM_cas:orgname">Massachusetts Medical Society</span>)
        </div><div class="casAbstract">Background: In patients with chronic lymphoid leukemia (CLL) or small lymphocytic lymphoma (SLL), a short duration of response to therapy or adverse cytogenetic abnormalities are assocd. with a poor outcome.  We evaluated the efficacy of ibrutinib, a covalent inhibitor of Bruton's tyrosine kinase, in patients at risk for a poor outcome.  Methods: In this multicenter, open-label, phase 3 study, we randomly assigned 391 patients with relapsed or refractory CLL or SLL to receive daily ibrutinib or the anti-CD20 antibody ofatumumab.  The primary end point was the duration of progression-free survival, with the duration of overall survival and the overall response rate as secondary end points.  Results: At a median follow-up of 9.4 mo, ibrutinib significantly improved progression-free survival; the median duration was not reached in the ibrutinib group (with a rate of progression-free survival of 88% at 6 mo), as compared with a median of 8.1 mo in the ofatumumab group (hazard ratio for progression or death in the ibrutinib group, 0.22; P < 0.001).  Ibrutinib also significantly improved overall survival (hazard ratio for death, 0.43; P = 0.005).  At 12 mo, the overall survival rate was 90% in the ibrutinib group and 81% in the ofatumumab group.  The overall response rate was significantly higher in the ibrutinib group than in the ofatumumab group (42.6% vs. 4.1%, P < 0.001).  An addnl. 20% of ibrutinib-treated patients had a partial response with lymphocytosis.  Similar effects were obsd. regardless of whether patients had a chromosome 17p13.1 deletion or resistance to purine analogs.  The most frequent nonhematol. adverse events were diarrhea, fatigue, pyrexia, and nausea in the ibrutinib group and fatigue, infusion-related reactions, and cough in the ofatumumab group.  Conclusions: Ibrutinib, as compared with ofatumumab, significantly improved progression-free survival, overall survival, and response rate among patients with previously treated CLL or SLL.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrCuX1vrLZxQLVg90H21EOLACvtfcHk0liORz02rphlpg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXhs1egsbrN&md5=87b692d35faa0fb8666bb945746fb9b0</span></div><a href="/servlet/linkout?suffix=cit48&amp;dbid=16384&amp;doi=10.1056%2Fnejmoa1400376&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1056%252Fnejmoa1400376%26sid%3Dliteratum%253Aachs%26aulast%3DByrd%26aufirst%3DJ.%2BC.%26aulast%3DBrown%26aufirst%3DJ.%2BR.%26aulast%3DO%25E2%2580%2599Brien%26aufirst%3DS.%26aulast%3DBarrientos%26aufirst%3DJ.%2BC.%26aulast%3DKay%26aufirst%3DN.%2BE.%26aulast%3DReddy%26aufirst%3DN.%2BM.%26aulast%3DCoutre%26aufirst%3DS.%26aulast%3DTam%26aufirst%3DC.%2BS.%26aulast%3DMulligan%26aufirst%3DS.%2BP.%26aulast%3DJaeger%26aufirst%3DU.%26aulast%3DDevereux%26aufirst%3DS.%26aulast%3DBarr%26aufirst%3DP.%2BM.%26aulast%3DFurman%26aufirst%3DR.%2BR.%26aulast%3DKipps%26aufirst%3DT.%2BJ.%26aulast%3DCymbalista%26aufirst%3DF.%26aulast%3DPocock%26aufirst%3DC.%26aulast%3DThornton%26aufirst%3DP.%26aulast%3DCaligaris-Cappio%26aufirst%3DF.%26aulast%3DRobak%26aufirst%3DT.%26aulast%3DDelgado%26aufirst%3DJ.%26aulast%3DSchuster%26aufirst%3DS.%2BJ.%26aulast%3DMontillo%26aufirst%3DM.%26aulast%3DSchuh%26aufirst%3DA.%26aulast%3Dde%2BVos%26aufirst%3DS.%26aulast%3DGill%26aufirst%3DD.%26aulast%3DBloor%26aufirst%3DA.%26aulast%3DDearden%26aufirst%3DC.%26aulast%3DMoreno%26aufirst%3DC.%26aulast%3DJones%26aufirst%3DJ.%2BJ.%26aulast%3DChu%26aufirst%3DA.%2BD.%26aulast%3DFardis%26aufirst%3DM.%26aulast%3DMcGreivy%26aufirst%3DJ.%26aulast%3DClow%26aufirst%3DF.%26aulast%3DJames%26aufirst%3DD.%2BF.%26aulast%3DHillmen%26aufirst%3DP.%26atitle%3DIbrutinib%2520versus%2520ofatumumab%2520in%2520previously%2520treated%2520chronic%2520lymphoid%2520leukemia%26jtitle%3DN.%2520Engl.%2520J.%2520Med.%26date%3D2014%26volume%3D371%26spage%3D213%26epage%3D223%26doi%3D10.1056%2Fnejmoa1400376" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref49"><div class="reference"><strong class="refLabel"><a href="#ref49" class="rightTabRefNumLink">49</a></strong><div class="NLM_citation" id="rightTab-cit49"><span><span class="NLM_contrib-group"><span class="NLM_string-name">O’Brien, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Furman, R. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Coutre, S. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sharman, J. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Burger, J. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Blum, K. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Grant, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Richards, D. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Coleman, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wierda, W. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jones, J. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhao, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Heerema, N. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Johnson, A. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Izumi, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hamdy, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chang, B. Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Graef, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Clow, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Buggy, J. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">James, D. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Byrd, J. C.</span></span> <span> </span><span class="NLM_article-title">Ibrutinib as initial therapy for elderly patients with chronic lymphocytic leukaemia or small lymphocytic lymphoma: an open-label, multicentre, phase 1b/2 trial</span>. <i>Lancet Oncol.</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>15</i></span>,  <span class="NLM_fpage">48</span>– <span class="NLM_lpage">58</span>, <span class="refDoi"> DOI: 10.1016/s1470-2045(13)70513-8</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref49/cit49&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00329&amp;key=10.1016%2Fs1470-2045%2813%2970513-8" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref49/cit49&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00329&amp;key=24332241" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref49/cit49&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00329&amp;key=1%3ACAS%3A528%3ADC%252BC3sXitVWjtrzL" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=15&publication_year=2014&pages=48-58&author=S.+O%E2%80%99Brienauthor=R.+R.+Furmanauthor=S.+E.+Coutreauthor=J.+P.+Sharmanauthor=J.+A.+Burgerauthor=K.+A.+Blumauthor=B.+Grantauthor=D.+A.+Richardsauthor=M.+Colemanauthor=W.+G.+Wierdaauthor=J.+A.+Jonesauthor=W.+Zhaoauthor=N.+A.+Heeremaauthor=A.+J.+Johnsonauthor=R.+Izumiauthor=A.+Hamdyauthor=B.+Y.+Changauthor=T.+Graefauthor=F.+Clowauthor=J.+J.+Buggyauthor=D.+F.+Jamesauthor=J.+C.+Byrd&title=Ibrutinib+as+initial+therapy+for+elderly+patients+with+chronic+lymphocytic+leukaemia+or+small+lymphocytic+lymphoma%3A+an+open-label%2C+multicentre%2C+phase+1b%2F2+trial&doi=10.1016%2Fs1470-2045%2813%2970513-8"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit49R"><div class="casContent"><span class="casTitleNuber">49</span><div class="casTitle"><span class="NLM_cas:atitle">Ibrutinib as initial therapy for elderly patients with chronic lymphocytic leukaemia or small lymphocytic lymphoma: an open-label, multicentre, phase 1b/2 trial</span></div><div class="casAuthors">O'Brien, Susan; Furman, Richard R.; Coutre, Steven E.; Sharman, Jeff P.; Burger, Jan A.; Blum, Kristie A.; Grant, Barbara; Richards, Donald A.; Coleman, Morton; Wierda, William G.; Jones, Jeffrey A.; Zhao, Weiqiang; Heerema, Nyla A.; Johnson, Amy J.; Izumi, Raquel; Hamdy, Ahmed; Chang, Betty Y.; Graef, Thorsten; Clow, Fong; Buggy, Joseph J.; James, Danelle F.; Byrd, John C.</div><div class="citationInfo"><span class="NLM_cas:title">Lancet Oncology</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">15</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">48-58</span>CODEN:
                <span class="NLM_cas:coden">LOANBN</span>;
        ISSN:<span class="NLM_cas:issn">1470-2045</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Ltd.</span>)
        </div><div class="casAbstract">Background: Chemoimmunotherapy has led to improved nos. of patients achieving disease response, and longer overall survival in young patients with chronic lymphocytic leukemia; however, its application in elderly patients has been restricted by substantial myelosuppression and infection.  We aimed to assess safety and activity of ibrutinib, an orally administered covalent inhibitor of Bruton tyrosine kinase (BTK), in treatment-naive patients aged 65 years and older with chronic lymphocytic leukemia.  Methods: In our open-label phase 1b/2 trial, we enrolled previously untreated patients at clin. sites in the USA.  Eligible patients were aged at least 65 years, and had symptomatic chronic lymphocytic leukemia or small lymphocytic lymphoma requiring therapy.  Patients received 28 day cycles of once-daily ibrutinib 420 mg or ibrutinib 840 mg.  The 840 mg dose was discontinued after enrollment had begun because comparable activity of the doses has been shown.  The primary endpoint was the safety of the dose-fixed regimen in terms of frequency and severity of adverse events for all patients who received treatment.  This study is registered with ClinicalTrials.gov, no. NCT01105247.  Findings: Between May 20, 2010, and Dec 18, 2012, we enrolled 29 patients with chronic lymphocytic leukemia and two patients with small lymphocytic lymphoma.  Median age was 71 years (range 65-84), and 23 (74%) patients were at least 70 years old.  Toxicity was mainly of mild-to-moderate severity (grade 1-2). 21 (68%) patients had diarrhea (grade 1 in 14 [45%] patients, grade 2 in three [10%] patients, and grade 3 in four [13%] patients). 15 (48%) patients developed nausea (grade 1 in 12 [39%] patients and grade 2 in three [10%] patients).  Ten (32%) patients developed fatigue (grade 1 in five [16%] patients, grade 2 in four [13%] patients, and grade 3 in one [3%] patient).  Three (10%) patients developed grade 3 infections, although no grade 4 or 5 infections occurred.  One patient developed grade 3 neutropenia, and one developed grade 4 thrombocytopenia.  After a median follow-up of 22·1 mo (IQR 18·4-23·2), 22 (71%) of 31 patients achieved an objective response (95% CI 52·0-85·8); four patients (13%) had a complete response, one patient (3%) had a nodular partial response, and 17 (55%) patients had a partial response.  Interpretation: The safety and activity of ibrutinib in elderly, previously untreated patients with symptomatic chronic lymphocytic leukemia, or small lymphocytic lymphoma is encouraging, and merits further investigation in phase 3 trials.  Funding: Pharmacyclics, Leukemia and Lymphoma Society, D Warren Brown Foundation, Mr and Mrs Michael Thomas, Harry Mangurian Foundation, P50 CA140158 to Prof J C Byrd MD.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpaUFztuMSARrVg90H21EOLACvtfcHk0liORz02rphlpg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXitVWjtrzL&md5=1f2e48019c275e2e07e41479c7fc3f21</span></div><a href="/servlet/linkout?suffix=cit49&amp;dbid=16384&amp;doi=10.1016%2Fs1470-2045%2813%2970513-8&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fs1470-2045%252813%252970513-8%26sid%3Dliteratum%253Aachs%26aulast%3DO%25E2%2580%2599Brien%26aufirst%3DS.%26aulast%3DFurman%26aufirst%3DR.%2BR.%26aulast%3DCoutre%26aufirst%3DS.%2BE.%26aulast%3DSharman%26aufirst%3DJ.%2BP.%26aulast%3DBurger%26aufirst%3DJ.%2BA.%26aulast%3DBlum%26aufirst%3DK.%2BA.%26aulast%3DGrant%26aufirst%3DB.%26aulast%3DRichards%26aufirst%3DD.%2BA.%26aulast%3DColeman%26aufirst%3DM.%26aulast%3DWierda%26aufirst%3DW.%2BG.%26aulast%3DJones%26aufirst%3DJ.%2BA.%26aulast%3DZhao%26aufirst%3DW.%26aulast%3DHeerema%26aufirst%3DN.%2BA.%26aulast%3DJohnson%26aufirst%3DA.%2BJ.%26aulast%3DIzumi%26aufirst%3DR.%26aulast%3DHamdy%26aufirst%3DA.%26aulast%3DChang%26aufirst%3DB.%2BY.%26aulast%3DGraef%26aufirst%3DT.%26aulast%3DClow%26aufirst%3DF.%26aulast%3DBuggy%26aufirst%3DJ.%2BJ.%26aulast%3DJames%26aufirst%3DD.%2BF.%26aulast%3DByrd%26aufirst%3DJ.%2BC.%26atitle%3DIbrutinib%2520as%2520initial%2520therapy%2520for%2520elderly%2520patients%2520with%2520chronic%2520lymphocytic%2520leukaemia%2520or%2520small%2520lymphocytic%2520lymphoma%253A%2520an%2520open-label%252C%2520multicentre%252C%2520phase%25201b%252F2%2520trial%26jtitle%3DLancet%2520Oncol.%26date%3D2014%26volume%3D15%26spage%3D48%26epage%3D58%26doi%3D10.1016%2Fs1470-2045%2813%2970513-8" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref50"><div class="reference"><strong class="refLabel"><a href="#ref50" class="rightTabRefNumLink">50</a></strong><div class="NLM_citation" id="rightTab-cit50"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Lu, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chambers, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wipf, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xie, X.-Q.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Englert, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Weber, S.</span></span> <span> </span><span class="NLM_article-title">Lipophilicity screening of novel drug-like compounds and comparison to clogP</span>. <i>J. Chromatogr. A</i> <span class="NLM_year" style="font-weight: bold;">2012</span>,  <span class="NLM_volume"><i>1258</i></span>,  <span class="NLM_fpage">161</span>– <span class="NLM_lpage">167</span>, <span class="refDoi"> DOI: 10.1016/j.chroma.2012.07.078</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref50/cit50&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00329&amp;key=10.1016%2Fj.chroma.2012.07.078" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref50/cit50&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00329&amp;key=22939208" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref50/cit50&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00329&amp;key=1%3ACAS%3A528%3ADC%252BC38XhtlKltL%252FM" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=1258&publication_year=2012&pages=161-167&author=D.+Luauthor=P.+Chambersauthor=P.+Wipfauthor=X.-Q.+Xieauthor=D.+Englertauthor=S.+Weber&title=Lipophilicity+screening+of+novel+drug-like+compounds+and+comparison+to+clogP&doi=10.1016%2Fj.chroma.2012.07.078"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit50R"><div class="casContent"><span class="casTitleNuber">50</span><div class="casTitle"><span class="NLM_cas:atitle">Lipophilicity screening of novel drug-like compounds and comparison to clog P</span></div><div class="casAuthors">Lu, Dujuan; Chambers, Peter; Wipf, Peter; Xie, Xiang-Qun; Englert, Danielle; Weber, Stephen</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Chromatography A</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">1258</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">161-167</span>CODEN:
                <span class="NLM_cas:coden">JCRAEY</span>;
        ISSN:<span class="NLM_cas:issn">0021-9673</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">We detd. the distribution coeffs. of solutes between a polymer film phase (polyvinyl chloride (PVC) with 67% (wt./wt.) dioctyl sebacate (DOS)) and an aq. phase in a 96-well format.  The parallel measurement approach is efficient and uses very little material.  Polymer-water distribution coeffs. (D pw) at different pH values yield the pKa and polymer-water partition coeff. values (P pw) of the solutes. log P pw of a prominent drug-like compd., 2H-1,2,6-thiadiazine, 3-methyl-5-phenyl-,1,1-dioxide, is in good agreement with clog P, while the pK a value is substantially different from calcd. values.  This method has been also successfully applied to a library of novel drug-like compds. log D pw values (at pH 4.0, 7.0, 10.0) of 24 novel drug-like compds. have been detd. with good reproducibility with the 96-well plate approach.  Differences between exptl. values and a variety of available calcd. values are significant.  This emphasizes the need for lab. sepns.-based measurements of log D.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrVeCs5QNEEWrVg90H21EOLACvtfcHk0liORz02rphlpg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38XhtlKltL%252FM&md5=8e49487d24015204688baf5d6efc91f7</span></div><a href="/servlet/linkout?suffix=cit50&amp;dbid=16384&amp;doi=10.1016%2Fj.chroma.2012.07.078&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.chroma.2012.07.078%26sid%3Dliteratum%253Aachs%26aulast%3DLu%26aufirst%3DD.%26aulast%3DChambers%26aufirst%3DP.%26aulast%3DWipf%26aufirst%3DP.%26aulast%3DXie%26aufirst%3DX.-Q.%26aulast%3DEnglert%26aufirst%3DD.%26aulast%3DWeber%26aufirst%3DS.%26atitle%3DLipophilicity%2520screening%2520of%2520novel%2520drug-like%2520compounds%2520and%2520comparison%2520to%2520clogP%26jtitle%3DJ.%2520Chromatogr.%2520A%26date%3D2012%26volume%3D1258%26spage%3D161%26epage%3D167%26doi%3D10.1016%2Fj.chroma.2012.07.078" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref51"><div class="reference"><strong class="refLabel"><a href="#ref51" class="rightTabRefNumLink">51</a></strong><div class="NLM_citation" id="rightTab-cit51"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Böhm, H.-J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Banner, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bendels, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kansy, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kuhn, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Müller, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Obst-Sander, U.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stahl, M.</span></span> <span> </span><span class="NLM_article-title">Fluorine in medicinal chemistry</span>. <i>ChemBioChem</i> <span class="NLM_year" style="font-weight: bold;">2004</span>,  <span class="NLM_volume"><i>5</i></span>,  <span class="NLM_fpage">637</span>– <span class="NLM_lpage">643</span>, <span class="refDoi"> DOI: 10.1002/cbic.200301023</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref51/cit51&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00329&amp;key=10.1002%2Fcbic.200301023" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref51/cit51&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00329&amp;key=15122635" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref51/cit51&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00329&amp;key=1%3ACAS%3A280%3ADC%252BD2c3it1egug%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=5&publication_year=2004&pages=637-643&author=H.-J.+B%C3%B6hmauthor=D.+Bannerauthor=S.+Bendelsauthor=M.+Kansyauthor=B.+Kuhnauthor=K.+M%C3%BCllerauthor=U.+Obst-Sanderauthor=M.+Stahl&title=Fluorine+in+medicinal+chemistry&doi=10.1002%2Fcbic.200301023"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit51R"><div class="casContent"><span class="casTitleNuber">51</span><div class="casTitle"><span class="NLM_cas:atitle">Fluorine in medicinal chemistry</span></div><div class="casAuthors">Bohm Hans-Joachim; Banner David; Bendels Stefanie; Kansy Manfred; Kuhn Bernd; Muller Klaus; Obst-Sander Ulrike; Stahl Martin</div><div class="citationInfo"><span class="NLM_cas:title">Chembiochem : a European journal of chemical biology</span>
        (<span class="NLM_cas:date">2004</span>),
    <span class="NLM_cas:volume">5</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">637-43</span>
        ISSN:<span class="NLM_cas:issn">1439-4227</span>.
    </div><div class="casAbstract">Fluorinated compounds are synthesized in pharmaceutical research on a routine basis and many marketed compounds contain fluorine.  The present review summarizes some of the most frequently employed strategies for using fluorine substituents in medicinal chemistry.  Quite often, fluorine is introduced to improve the metabolic stability by blocking metabolically labile sites.  However, fluorine can also be used to modulate the physicochemical properties, such as lipophilicity or basicity.  It may exert a substantial effect on the conformation of a molecule.  Increasingly, fluorine is used to enhance the binding affinity to the target protein.  Recent 3D-structure determinations of protein complexes with bound fluorinated ligands have led to an improved understanding of the nonbonding protein-ligand interactions that involve fluorine.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcQ4zDG_wo1YGtts4TFFB11gfW6udTcc2ebvLQZw2rmRVbntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BD2c3it1egug%253D%253D&md5=fa5ca2cfc278b83c80d5c96b18dfe312</span></div><a href="/servlet/linkout?suffix=cit51&amp;dbid=16384&amp;doi=10.1002%2Fcbic.200301023&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fcbic.200301023%26sid%3Dliteratum%253Aachs%26aulast%3DB%25C3%25B6hm%26aufirst%3DH.-J.%26aulast%3DBanner%26aufirst%3DD.%26aulast%3DBendels%26aufirst%3DS.%26aulast%3DKansy%26aufirst%3DM.%26aulast%3DKuhn%26aufirst%3DB.%26aulast%3DM%25C3%25BCller%26aufirst%3DK.%26aulast%3DObst-Sander%26aufirst%3DU.%26aulast%3DStahl%26aufirst%3DM.%26atitle%3DFluorine%2520in%2520medicinal%2520chemistry%26jtitle%3DChemBioChem%26date%3D2004%26volume%3D5%26spage%3D637%26epage%3D643%26doi%3D10.1002%2Fcbic.200301023" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref52"><div class="reference"><strong class="refLabel"><a href="#ref52" class="rightTabRefNumLink">52</a></strong><div class="NLM_citation" id="rightTab-cit52"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Boucheron, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ellmeier, W.</span></span> <span> </span><span class="NLM_article-title">The Role of Tec family kinases in the regulation of T-helper-cell differentiation</span>. <i>Int. Rev. Immunol.</i> <span class="NLM_year" style="font-weight: bold;">2012</span>,  <span class="NLM_volume"><i>31</i></span>,  <span class="NLM_fpage">133</span>– <span class="NLM_lpage">154</span>, <span class="refDoi"> DOI: 10.3109/08830185.2012.664798</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref52/cit52&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00329&amp;key=10.3109%2F08830185.2012.664798" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref52/cit52&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00329&amp;key=22449074" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref52/cit52&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00329&amp;key=1%3ACAS%3A528%3ADC%252BC38Xks1Omu7w%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=31&publication_year=2012&pages=133-154&author=N.+Boucheronauthor=W.+Ellmeier&title=The+Role+of+Tec+family+kinases+in+the+regulation+of+T-helper-cell+differentiation&doi=10.3109%2F08830185.2012.664798"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit52R"><div class="casContent"><span class="casTitleNuber">52</span><div class="casTitle"><span class="NLM_cas:atitle">The Role of Tec Family Kinases in the Regulation of T-helper-cell Differentiation</span></div><div class="casAuthors">Boucheron, Nicole; Ellmeier, Wilfried</div><div class="citationInfo"><span class="NLM_cas:title">International Reviews of Immunology</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">31</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">133-154</span>CODEN:
                <span class="NLM_cas:coden">IRIMEH</span>;
        ISSN:<span class="NLM_cas:issn">0883-0185</span>.
    
            (<span class="NLM_cas:orgname">Informa Healthcare</span>)
        </div><div class="casAbstract">A review.  Members of the Tec kinase family (Tec, Btk, Itk, Rlk, and Bmx) play an important role during innate and adaptive immune responses, and mutations in Tec family kinases are linked with immunodeficiencies in humans and mice.  Three members of the Tec kinase family are expressed in T cells (Tec, Itk, and Rlk), and biochem. and genetic studies have revealed important roles for Tec family kinases during T-cell development and in the control of T-cell function.  Here the authors review the role of Tec family kinases in the regulation of T-helper-cell differentiation.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpv3IOWbLRvJ7Vg90H21EOLACvtfcHk0lgGgmWZBRP9Yg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38Xks1Omu7w%253D&md5=c5b80129819a6e6b29de0b30f8875b1e</span></div><a href="/servlet/linkout?suffix=cit52&amp;dbid=16384&amp;doi=10.3109%2F08830185.2012.664798&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.3109%252F08830185.2012.664798%26sid%3Dliteratum%253Aachs%26aulast%3DBoucheron%26aufirst%3DN.%26aulast%3DEllmeier%26aufirst%3DW.%26atitle%3DThe%2520Role%2520of%2520Tec%2520family%2520kinases%2520in%2520the%2520regulation%2520of%2520T-helper-cell%2520differentiation%26jtitle%3DInt.%2520Rev.%2520Immunol.%26date%3D2012%26volume%3D31%26spage%3D133%26epage%3D154%26doi%3D10.3109%2F08830185.2012.664798" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li></ol></li><li id="pane-m3" aria-labelledby="pane-m3" class="tab__pane tab__pane-suppInfo empty"><div class="accessionCode mb-5"><div class="toolbar-section accession-codes"><ul><li><a href="http://www.rcsb.org/pdb/search/structidSearch.do?structureId=4Z3V" onclick="trackOutboundLink('http://www.rcsb.org/pdb/search/structidSearch.do?structureId=4Z3V','PDB','4Z3V'); return false;">PDB: 4Z3V</a></li><li><a href="http://www.rcsb.org/pdb/search/structidSearch.do?structureId=4OTR" onclick="trackOutboundLink('http://www.rcsb.org/pdb/search/structidSearch.do?structureId=4OTR','PDB','4OTR'); return false;">PDB: 4OTR</a></li><li><a href="http://www.rcsb.org/pdb/search/structidSearch.do?structureId=5P9J" onclick="trackOutboundLink('http://www.rcsb.org/pdb/search/structidSearch.do?structureId=5P9J','PDB','5P9J'); return false;">PDB: 5P9J</a></li></ul></div></div><h2 class="supp-info-label">Supporting Information</h2><div class="article_supporting-info" id="rightTab-notes1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="rightTab-rightTab-_i76"><a class="ext-link" href="/doi/suppl/10.1021/acs.jmedchem.9b00329">Supporting Information</a></h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a class="" href="#"><span>Jump To</span><i class="icon-angle-down"></i></a><div class="dropBlock__holder" data-db-target-of="sectionsDB_16427"></div></div></div></div></div><hr /></hr><p class="last">The Supporting Information is available free of charge on the <a class="ext-link" href="/">ACS Publications website</a> at DOI: <a class="ext-link" href="/doi/abs/10.1021/acs.jmedchem.9b00329">10.1021/acs.jmedchem.9b00329</a>.<ul id="rightTab-silist" class="NLM_list-list_type-label"><li><p class="inline">Western blotting data for evaluation EC<sub>50</sub> values of compounds <b>6</b> and <b>25</b>, analytical RP-HPLC trace(s) for compound <b>6</b>, <b>7</b>, <b>17</b>, and <b>25</b>, and NMR spectra of all new compounds (<a class="ext-link" href="/doi/suppl/10.1021/acs.jmedchem.9b00329/suppl_file/jm9b00329_si_001.pdf">PDF</a>)</p></li><li><p class="inline">Docking model of compound <b>7</b> (<a class="ext-link" href="/doi/suppl/10.1021/acs.jmedchem.9b00329/suppl_file/jm9b00329_si_002.pdb">PDB</a>)</p></li><li><p class="inline">Docking model of compound <b>25</b> (<a class="ext-link" href="/doi/suppl/10.1021/acs.jmedchem.9b00329/suppl_file/jm9b00329_si_003.pdb">PDB</a>)</p></li><li><p class="inline">Molecular formula strings (<a class="ext-link" href="/doi/suppl/10.1021/acs.jmedchem.9b00329/suppl_file/jm9b00329_si_004.csv">CSV</a>)</p></li></ul></p><div class="supInfoBoxOnFTP "><div class="sup-info-attachments"><ul><li><a class="suppl-anchor" href="/doi/suppl/10.1021/acs.jmedchem.9b00329/suppl_file/jm9b00329_si_001.pdf">jm9b00329_si_001.pdf (1.1 MB)</a></li><li><a class="suppl-anchor" href="/doi/suppl/10.1021/acs.jmedchem.9b00329/suppl_file/jm9b00329_si_002.pdb">jm9b00329_si_002.pdb (533.2 kb)</a></li><li><a class="suppl-anchor" href="/doi/suppl/10.1021/acs.jmedchem.9b00329/suppl_file/jm9b00329_si_003.pdb">jm9b00329_si_003.pdb (533.3 kb)</a></li><li><a class="suppl-anchor" href="/doi/suppl/10.1021/acs.jmedchem.9b00329/suppl_file/jm9b00329_si_004.csv">jm9b00329_si_004.csv (1.29 kb)</a></li></ul></div></div><div id="rightTab-figshare-widget"></div><br /></br><div class="TermsAndConditionsDropzoneRight" data-pb-dropzone="TermsAndConditionsDropzoneRight"><div data-widget-def="UX3HTMLWidget" data-widget-id="b84e6b6c-b4d0-4427-b286-3cf14d52d013" class="mb-4">
        



        
        <h2 style="font-size: 1rem;margin-bottom: 10px;">Terms & Conditions</h2>
<p>Most electronic Supporting Information files are available without a subscription to ACS Web Editions. Such files may be downloaded by article for research use (if there is a public use license linked to the relevant article, that license may permit other uses). Permission may be obtained from ACS for other uses through requests via the RightsLink permission system:
<a href="/page/copyright/permissions.html" title="RightsLink">http://pubs.acs.org/page/copyright/permissions.html</a>.</p>

        </div></div></div></li></ul><div class="recommendedDropzone7" data-pb-dropzone="recommendedDropzone7"><div data-ajaxurl="/pb/widgets/ux3/ux3-showRecommend?widgetId=b272b1fe-ab4e-454f-940c-a3deaf223d23&amp;doi=10.1021%2Facs.jmedchem.9b00329&amp;pbContext=%3BrequestedJournal%3Ajournal%3Ajmcmar%3Bjournal%3Ajournal%3Ajmcmar%3Bpage%3Astring%3AArticle%2FChapter+View%3Bctype%3Astring%3AJournal+Content%3Bwgroup%3Astring%3AACHS+website+Group%3Bissue%3Aissue%3A10.1021%2Fjmcmar.2019.62.issue-14%3Bwebsite%3Awebsite%3Aacspubs%3BpageGroup%3Astring%3APublication+Pages%3BsubPage%3Astring%3AFull+Text%3Barticle%3Aarticle%3A10.1021%2Facs.jmedchem.9b00329" class="show-recommended-placeholder"></div>




        
        <script>
$(document).ready(function() {
  setTimeout(function() {
    var myLink = $(".show-recommended").find("a").not("[href='http://acsmediakit.org']").not("[href='javascript:void(0);']");
    myLink.attr("href", function(i, href) {
        return href + '?ref=recommended';
    });
  }, 5000);
});
</script></div></div></div></div></div></div></div><div class="col-xs-12.clearfix"><div class="article_qv-xs-container"><div class="article_qv-xs"><ul><li><a href="#" title="In This Article"><span>In This Article</span></a></li><li><a href="#" title="Figures" data-slide-target=".tab__pane-figures" class="w-slide__btn slide-active"><i class="icon-image"></i><span>Figures</span></a></li><li><a href="#" title="References" data-slide-target=".tab__pane-references" class="w-slide__btn slide-active"><i class="icon-link"></i><span>References</span></a></li><li><a href="#" title="Supporting Information" data-slide-target=".tab__pane-suppInfo" class="w-slide__btn slide-active"><i class="icon-supporting-info"></i><span>Supporting Information</span></a></li><li><a href="#" title="Recommended Articles" data-slide-target=".recommendedDropzone7" class="show-recommended-qv w-slide__btn slide-active" target="_self"><i class="icon-newspaper-o"></i><span>Recommended Articles</span></a></li></ul><a title="PDF" href="/doi/pdf/10.1021/acs.jmedchem.9b00329" class="button_primary"><i class="icon-file-pdf-o"></i>PDF  <span class="filesize">[
                3MB]
            </span></a></div></div></div></div></div></div></article></main>




        
        <footer class="footer">



        
        <div class="footer_first-row" id="partners">
	<div class="container">
		<div class="row">
			<div class="col-xs-12">
				<div class="footer_first-row_title">
					<h2>
						Partners
					</h2>
				</div>
				<div class="footer_first-row_logos">
					<div>
						<a href="http://www.atypon.com/">
							<img src="/pb-assets/images/footer_logos/logo-atypon-1525376610217.png" alt="Atypon">
						</a>
					</div>
					<div>
						<a href="http://www.chorusaccess.org/">
							<img src="/pb-assets/images/footer_logos/logo-chorus-1525375622947.png" alt="Chorus">
						</a>
					</div>
					<div>
						<a href="http://publicationethics.org/">
							<img src="/pb-assets/images/footer_logos/logo-cope-1525375622977.png" alt="Cope publication ethics">
						</a>
					</div>
					<div>
						<a href="http://www.projectcounter.org/">
							<img src="/pb-assets/images/footer_logos/logo-counter-1523044519173.jpg" alt="Project Counter">
						</a>
					</div>
					<div>
						<a href="http://www.crossref.org/">
							<img src="/pb-assets/images/footer_logos/logo-crossref-1525377362093.png" alt="Crossref">
						</a>
					</div>
					<div>
						<a href="http://www.crossref.org/crosscheck/index.html">
							<img src="/pb-assets/images/footer_logos/logo-crosscheck-1525375623000.png" alt="Crossref similarity check">
						</a>
					</div>
					<div>
						<a href="http://www.orcid.org/">
							<img src="/pb-assets/images/footer_logos/logo-orcid-1525375623187.png" alt="Orcid Connecting Research and Researchers">
						</a>
					</div>
					<div>
						<a href="http://www.portico.org/">
							<img src="/pb-assets/images/footer_logos/logo-portico-1525375623203.png" alt="Portico digital preservation service">
						</a>
					</div>
				</div>
			</div>
		</div>
	</div>
</div>





        
        <div class="footer_second-row col-xs-12 gutterless ">









        <div data-widget-def="ux3-layout-widget" data-widget-id="f963f9aa-5ade-4a09-8515-e6cd8e6364cf" class="row container">
        



        
        <div class="col-xs-12">



        
        <div class="footer_second-row_left col-md-2 gutterless ">



        
        <a href="/"><img src="/pb-assets/images/pubslogo-small-1444685090580.png" alt="ACS Publications"></a>
<div class="footer_menu">
	<ul>
		<li class="footer_menu_address">
			<span>
				1155 Sixteenth Street N.W.
			</span>
		</li>
		<li class="footer_menu_address">
			<span>
				Washington, DC 20036
			</span>
		</li>

		<li class="footer_menu_copyright">
			<a href="http://www.acs.org/content/acs/en/copyright.html">
				Copyright © 2021<br>
				American Chemical Society
			</a>
		</li>
	</ul>
</div>
</div><div class="footer_second-row_middle col-md-2 gutterless "></div><div class="footer_second-row_right col-md-8 gutterless ">



        
        <div class="footer_second-row_about col-xs-4">



        
        <h2>About</h2>
<ul>
    <li><a href="/page/about-us.html">About ACS Publications</a></li>
    <li><a href="http://acsopenscience.org">ACS & Open Access</a></li>
    <li><a href="https://www.acs.org/content/acs/en/membership/member-benefits/publications-discounts.html">ACS Membership</a></li>
</ul>
</div><div class="footer_second-row_resources col-xs-5">



        
        <h2>Resources and Information</h2>
<ul>
	<li><a href="/action/showPublications?pubType=journal">Journals A-Z</a></li>
	<li><a href="/action/showPublications?pubType=book">Books and Reference</a></li>
    <li><a href="http://acsmediakit.org/digital/acs-pubs/?utm_source=Footer&amp;utm_medium=Pubs&amp;utm_campaign=CEN">Advertising Media Kit</a></li>
    <li><a href="https://solutions.acs.org">Institutional Sales</a></li>
    <li><a href="https://publish.acs.org/publish/">ACS Publishing Center</a></li>
    <li><a href="http://www.acs.org/content/acs/en/privacy.html">Privacy Policy</a></li>
    <li><a href="https://www.acs.org/content/acs/en/terms.html">Terms of Use</a></li>
</ul>
</div><div class="footer_second-row_support col-xs-3">



        
        <h2>Support & Contact</h2>
<ul>
    <li><a href="https://acs.service-now.com/acs">Help</a></li>
    <li><a href="#" onclick="SnapEngage.startLink();return false;" class="help help-chat">Live Chat</a></li>
    <li><a href="https://acs.service-now.com/acs">FAQ</a></li>
</ul>
</div>
</div>




        
        <div class="footer_social_section col-xs-12">



        
        <div class="footer_social_header">
	<h2>Connect with ACS Publications</h2>
</div>
<div class="footer_social">
	<ul>
		<li>
			<a href="https://preferences.acspubs.org/journals" class="icon-envelope-o" aria-label="email">
			</a>
		</li>
		<li>
			<a href="https://www.facebook.com/ACSPublications/" class="icon-facebook" aria-label="facebook" target="_blank" rel="noreferrer">
			</a>
		</li>
		<li>
			<a href="https://twitter.com/ACSPublications" class="icon-twitter" aria-label="twitter" target="_blank" rel="noreferrer">
			</a>
		</li>
		<li>
			<a href="https://www.youtube.com/user/AmerChemSoc" class="icon-youtube-play" aria-label="youtube" target="_blank" rel="noreferrer">
			</a>
		</li>
		<li>
			<a href="/page/follow.html?widget=follow-pane-rss" class="icon-rss" aria-label="rss feed">
			</a>
		</li>
	</ul>
</div>

</div>
</div>

        </div>
    
</div>
</footer>




        
        <script>
(function(){
	
	/*Event Tracking for RIS menu dropdown - Article pages*/

	$('.cit-download-dropdown_button').on('click',function(e)
	{	
		e.preventDefault();
	    ga('send', 'event', 'Citation', 'Export', 'Main');
	});


	$('.cit-download-dropdown_content ul li').on('click',function(e)
	{	
	//	e.preventDefault();
	    var idx = $(this).index();
	    
	    var label = '';
	    if (idx === 0 ) {
	    	label = 'Citation';
	    } else if (idx === 1 ) {
	    	label = 'Abstract';
	    } else if (idx === 2 ) {
	    	label = 'Reference';
	    } else if (idx === 3 ) {
	    	label = 'More Options';
	    }
	   ga('send', 'event', 'Citation', 'Export', label);
	});

	$('.header_contnav-next a').on('click', function(e){
        e.preventDefault();
        ga('send', 'event', 'Article', 'Top', 'Right Arrow');
	}); 

 	$('.header_contnav-pre a').on('click', function(e){
	    e.preventDefault();
	     ga('send', 'event', 'Article', 'Top', 'Left Arrow');
	}); 

	$('.share_button').on('click', function(e){
		e.preventDefault();
		ga('send', 'event', 'Article', 'Top', 'Share');
	});

	$("#pane-m1con").on('click', function(e) {
		e.preventDefault();
		ga('send', 'event', 'Article', 'Sidebar', 'Figures');
	});

	$("#pane-m2con").on('click', function(e) {
		e.preventDefault();
		ga('send', 'event', 'Article', 'Sidebar', 'References');
	});

	$("#pane-m3con").on('click', function(e) {
		e.preventDefault();
		ga('send', 'event', 'Article', 'Sidebar', 'Supporting Info');
	});

	$('.tab__close').on('click', function(){
		ga('send', 'event', 'Article', 'Sidebar', 'Close');
	}); 



})();

</script>






        
        <div aria-live="polite" aria-atomic="true" class="achs-mendeley"><input type="hidden" name="tokenEndpoint" value="https://sso.acs.org/mendeley/token" class="tokenEndpoint"/></input><input type="hidden" name="appID" value="literatum" class="appID"/></input><input type="hidden" name="reopen-mendeley-modal-after-reload" class="reopen-mendeley-modal-after-reload"/></input><input type="hidden" name="statusEndpoint" value="https://sso.acs.org/idp/status" class="statusEndpoint"/></input><input type="hidden" name="clientID" value="atypon-lives" class="clientID"/></input><div class="achs-mendeley_table"><div class="achs-mendeley_row"><div class="achs-mendeley_cell loop-trap"><div class="achs-mendeley_container"><a title="Close" aria-label="close" tabindex="0" class="achs-mendeley_close"><i aria-hidden="true" class="icon-close"></i></a><div class="achs-mendeley_dropzone1"><div class="achs-mendeley_dropzone1_state1">



        
        <p style="font-weight: bold;">Pair your accounts.</p>
<p>Export articles to Mendeley</p>
<p>Get article recommendations from ACS based on references in your Mendeley library.</p>
</div><div class="achs-mendeley_dropzone1_state2">



        
        <p style="font-weight: bold;">Pair your accounts.</p>
<p>Export articles to Mendeley</p>
<p>Get article recommendations from ACS based on references in your Mendeley library.</p>
</div><div class="achs-mendeley_dropzone1_state3">



        
        <p style="font-weight: bold;">You’ve supercharged your research process with ACS and Mendeley!</p>
</div></div><div class="achs-mendeley_continue-header"><button class="achs-mendeley_continue-btn"><span class="achs-mendeley_buttonText">Continue</span></button></div><div class="achs-mendeley_steps"><div class="achs-mendeley_steps_row"><div class="achs-mendeley_steps_cell achs-mendeley_acsLogin"><h6>STEP 1:</h6><button class="button_primary achs-mendeley_acsLogin_button"><span class="achs-mendeley_buttonText">Login with ACS ID</span><span class="achs-mendeley_success_buttonText">Logged in Success</span></button><span class="achs-mendeley_acsLogin_label">Click to create an ACS ID</span><i class="icon-if-arrow-right"></i></div><div class="achs-mendeley_steps_cell achs-mendeley_login"><h6>STEP 2:</h6><button class="button_primary achs-mendeley_login_button"><i class="icon-mendeley"></i><span class="achs-mendeley_buttonText">Login with Mendeley</span><span class="achs-mendeley_success_buttonText">Logged in Success</span></button><a href="https://id.elsevier.com/as/authorization.oauth2?state=c33c27125763433d4d32a15accaacc18&amp;prompt=login&amp;scope=openid%20email%20profile%20els_auth_info&amp;authType=SINGLE_SIGN_IN&amp;response_type=code&amp;platSite=MDY%2Fmendeley&amp;redirect_uri=https%3A%2F%2Fwww.mendeley.com%2Fcallback%2F&amp;client_id=MENDELEY" title="Create a Mendeley account">Create a Mendeley account</a></div></div></div><div class="achs-mendeley_dropzone2"><div class="achs-mendeley_dropzone2_state1">



        
        <p style="font-weight: bold;font-style:italic;">Please note: If you switch to a different device, you may be asked to login again with only your ACS ID.
</p>
</div><div class="achs-mendeley_dropzone2_state2">



        
        <p style="font-weight: bold;font-style:italic;">Please note: If you switch to a different device, you may be asked to login again with only your ACS ID.
</p>
</div><div class="achs-mendeley_dropzone2_state3">



        
        <p style="font-weight: bold;font-style:italic;">Please note: If you switch to a different device, you may be asked to login again with only your ACS ID.
</p>
</div></div></div></div></div></div></div><div class="achs-mendeley_alert"><div class="achs-mendeley_alert_table"><div class="achs-mendeley_alert_row"><div class="achs-mendeley_alert_cell"><div class="achs-mendeley_alert_container"><a title="Close" aria-label="close" class="achs-mendeley_alert_close"><i aria-hidden="true" class="icon-close"></i></a><div role="alert" aria-live="polite" aria-atomic="true" class="achs-mendeley_alert_dropzone">



        
        <p>Please login with your ACS ID before connecting to your Mendeley account.</p><button class="button_tertiary achs-mendeley_acsLogin_button mendeley-acs-custom-login-btn" onclick="loginToAcsSso(event); return false;">Login with ACS ID</button>

<script>
 function loginToAcsSso(event){
 event.preventDefault();
 $('.achs-mendeley_acsLogin .achs-mendeley_acsLogin_button').trigger('click');
 }
</script>
</div><div class="achs-mendeley_alert_error-msg"></div></div></div></div></div><div class="pairing-expired-dialog-container"><div class="pairing-expired-dialog"><div class="pairing-expired-dialog_top-btns"><span class="pairing-expired-dialog_heading">MENDELEY PAIRING EXPIRED</span><button onClick="UX.achsMendeley.reconnectOnClickHandler();" class="pairing-expired-dialog_reconnect">Reconnect</button></div><div class="pairing-expired-dialog_content"><span>Your Mendeley pairing has expired. Please reconnect</span></div></div></div></div>




        
        <style type="text/css">
#gdpr-message-modal {
    display: none;
    /* Hidden by default */
    position: fixed;
    /* Stay in place */
    z-index: 2;
    /* Sit on top */
    /*padding-top: 100px;*/
    /* Location of the box */
    left: 0;
    bottom: 0;
    width: 100%;
    /* Full width */
    /*height: 100%;*/
    /* Full height */
    overflow: auto;
    /* Enable scroll if needed */
    /*background-color: rgb(0,0,0);*/
    /* Fallback color */
    /*background-color: rgba(0,0,0,0.4);*/
    /* Black w/ opacity */
}
#gdpr-message-content {
    font-family: Arial;
    background-color: #005083;
    color: #fff;
    margin: auto;
    padding: 5px 0 10px 0;
    /*border: 1px solid #888;*/
    box-shadow: 0 -1px 3px #666;
    width: 100%;
    display: block;
    bottom: 0;
}
#gdpr-message-container {
    /*width: 1130px;*/
    margin: 0 auto;
}
.gdpr-innerwrap {
    display: block;
    /*width: 1100px;*/
    margin: 0 auto;
    text-align: center;
}
#gdpr-message-content h1 {
    color: #0629b5;
    font-size: 26px;
    margin: 0.5em 0 0 0;
    border-bottom: solid 2px #4c7fb9;
    display: inline;
    padding-bottom: 10px;
}
#gdpr-message-content h4 {
    display: inline-block;
    margin-left: 0;
    margin-right: 14px;
    margin-top: 13px;
    /*width: 980px;*/
    font-size: 14px;
    font-weight: normal;
}
#gdpr-message-content p {
    font-size: 14px;
    margin: 2em 2em 0.5em 0em;
    text-align: left;
    font-weight: bold;
}
#gdpr-message-content a,
#gdpr-message-content a:hover {
    color: #9bcfff;
}
.gdpr-listwrap {
    display: block;
    margin-bottom: 10px;
    min-height: 100px;
    min-width: 200px;
}
#gdpr-message-content ul {
    margin-top: 20px;
    font-size: 13px;
}
#gdpr-ul1 {
    display: inline-block;
    float: left;
}
#gdpr-ul2 {
    display: inline-block;
    margin-left: 10px;
}
#gdpr-message-content ul li {
    margin-top: 4px;
}
a#gdpr-con-btn,
a#gdpr-con-btn:hover {
    width: 110px;
    height: 35px;
    background: #fec82a;
    background-image: none;
    background-image: -webkit-gradient(linear, 50% 0%, 50% 100%, color-stop(0%, #fec82a), color-stop(100%, #daa301));
    background-image: -webkit-linear-gradient(top, #fec82a, #daa301);
    background-image: -moz-linear-gradient(top, #fec82a, #daa301);
    background-image: -o-linear-gradient(top, #fec82a, #daa301);
    background-image: linear-gradient(top, #fec82a, #daa301);
    border-radius: 4px;
    color: #004a7b;
    display: inline-block;
    text-decoration: none;
    line-height: 35px;
    text-align: center;
    margin-top: 5px;
    /*margin-right: 14px;*/
    /*float: right;*/
    font-weight: bold;
}
#gdpr-message-btn {
    width: 60px;
    height: 38px;
    background: #4b8fc2;
    border-radius: 4px;
    color: white;
    display: inline-block;
    margin-top: -4px;
    font-size: 12px;
}
a#closebtn {
    float: right;
    color: #d4e5ef;
}
#gdpr-input {
    width: 200px;
    height: 30px;
    border-radius: 3px;
    border-width: 1px;
    box-shadow: none;
    margin-right: 10px;
    font-size: 14px;
    outline: none;
    padding-left: 2px;
    display: inline-block;
    float: left;
}
#gdpr-message-content p.gdpr_err {
    font-size: 15px;
    margin-top: 10px;
}
#gdpr-message-modal.mobile, #gdpr-message-modal.mobile .gdpr-message-content {
    height: 160px;
}
@media only screen and (min-width: 1026px) and (max-width: 1368px) {
	#gdpr-message-content h4 {
		width: 80%;
		text-align: left;
	}
}
</style>

<div id="gdpr-message-modal">
    <div id="gdpr-message-content">
        
	        <div class="gdpr-innerwrap container">
	            <h4>This website uses cookies to improve your user experience. By continuing to use the site, you are accepting our use of cookies. <a href="http://www.acs.org/content/acs/en/privacy.html">Read the ACS privacy policy</a>.</h4>
	            <a href="#" id="gdpr-con-btn">CONTINUE</a>
	        </div>
        
    </div>
</div>

<script type="text/javascript">
"use strict"
//Script checks gdpr cookie and submits form
	/* 
	Create an in-page pop-up message, only for the InfoCentral homepage, that will gather email registrants for the library marketing list.
	 
	Needs the end point
	*/

var infoCentralCapture = (function() {

    //Detect mobile device
    window.mobilecheck = function() {
        var check = false;
        (function(a){if(/(android|bb\d+|meego).+mobile|avantgo|bada\/|blackberry|blazer|compal|elaine|fennec|hiptop|iemobile|ip(hone|od)|iris|kindle|lge |maemo|midp|mmp|mobile.+firefox|netfront|opera m(ob|in)i|palm( os)?|phone|p(ixi|re)\/|plucker|pocket|psp|series(4|6)0|symbian|treo|up\.(browser|link)|vodafone|wap|windows ce|xda|xiino/i.test(a)||/1207|6310|6590|3gso|4thp|50[1-6]i|770s|802s|a wa|abac|ac(er|oo|s\-)|ai(ko|rn)|al(av|ca|co)|amoi|an(ex|ny|yw)|aptu|ar(ch|go)|as(te|us)|attw|au(di|\-m|r |s )|avan|be(ck|ll|nq)|bi(lb|rd)|bl(ac|az)|br(e|v)w|bumb|bw\-(n|u)|c55\/|capi|ccwa|cdm\-|cell|chtm|cldc|cmd\-|co(mp|nd)|craw|da(it|ll|ng)|dbte|dc\-s|devi|dica|dmob|do(c|p)o|ds(12|\-d)|el(49|ai)|em(l2|ul)|er(ic|k0)|esl8|ez([4-7]0|os|wa|ze)|fetc|fly(\-|_)|g1 u|g560|gene|gf\-5|g\-mo|go(\.w|od)|gr(ad|un)|haie|hcit|hd\-(m|p|t)|hei\-|hi(pt|ta)|hp( i|ip)|hs\-c|ht(c(\-| |_|a|g|p|s|t)|tp)|hu(aw|tc)|i\-(20|go|ma)|i230|iac( |\-|\/)|ibro|idea|ig01|ikom|im1k|inno|ipaq|iris|ja(t|v)a|jbro|jemu|jigs|kddi|keji|kgt( |\/)|klon|kpt |kwc\-|kyo(c|k)|le(no|xi)|lg( g|\/(k|l|u)|50|54|\-[a-w])|libw|lynx|m1\-w|m3ga|m50\/|ma(te|ui|xo)|mc(01|21|ca)|m\-cr|me(rc|ri)|mi(o8|oa|ts)|mmef|mo(01|02|bi|de|do|t(\-| |o|v)|zz)|mt(50|p1|v )|mwbp|mywa|n10[0-2]|n20[2-3]|n30(0|2)|n50(0|2|5)|n7(0(0|1)|10)|ne((c|m)\-|on|tf|wf|wg|wt)|nok(6|i)|nzph|o2im|op(ti|wv)|oran|owg1|p800|pan(a|d|t)|pdxg|pg(13|\-([1-8]|c))|phil|pire|pl(ay|uc)|pn\-2|po(ck|rt|se)|prox|psio|pt\-g|qa\-a|qc(07|12|21|32|60|\-[2-7]|i\-)|qtek|r380|r600|raks|rim9|ro(ve|zo)|s55\/|sa(ge|ma|mm|ms|ny|va)|sc(01|h\-|oo|p\-)|sdk\/|se(c(\-|0|1)|47|mc|nd|ri)|sgh\-|shar|sie(\-|m)|sk\-0|sl(45|id)|sm(al|ar|b3|it|t5)|so(ft|ny)|sp(01|h\-|v\-|v )|sy(01|mb)|t2(18|50)|t6(00|10|18)|ta(gt|lk)|tcl\-|tdg\-|tel(i|m)|tim\-|t\-mo|to(pl|sh)|ts(70|m\-|m3|m5)|tx\-9|up(\.b|g1|si)|utst|v400|v750|veri|vi(rg|te)|vk(40|5[0-3]|\-v)|vm40|voda|vulc|vx(52|53|60|61|70|80|81|83|85|98)|w3c(\-| )|webc|whit|wi(g |nc|nw)|wmlb|wonu|x700|yas\-|your|zeto|zte\-/i.test(a.substr(0,4))) check = true;})(navigator.userAgent||navigator.vendor||window.opera);
              return check;
        };

    var _isMobile = window.mobilecheck();
    if (_isMobile) {
        $('#gdpr-message-modal').addClass('mobile');
    }

    var emailValid = "",
        time = 3000,
        btnStatus = true,
        errorStatus = false,
        errormessage = "<p class='gdpr_err'><b>Please Enter a valid email address<b><p>";

    function init() {
        setTimeout(function() {
            var cookieExist = getCookie("gdpr");
            if (cookieExist) {
                //console.log("gdpr cookie exist");
                return false;
            } else {
                //console.log("gdpr cookie does not exist")
                gdprMessage();
            }
            //Events
            $('#closebtn').on("click", hideForm);

            //Handle submit
            $('#gdpr-message-btn').on("click", function(event) {
                handleClick();
            });

            // //Hide if clicked outside div - TO DO stop handling click after submit
            // $(document).click(function(event) {
            // 	event.stopPropagation();
            //   console.log(event.target);
            //   if (!$(event.target).closest("#gdpr-message-content").length) {
            //     $("body").find("#gdpr-message-modal").hide();
            //     $(this).off();
            //   }
            // });
            $('#gdpr-con-btn').click(function() {
                setCookie("gdpr", "true");
                hideForm();
            });
        }, time);
    }

    //Show the message
    function gdprMessage() {
        //console.log("Show GDPR Message");
        var tMessage, emailInput, messageButton, ewrap;

        $('#gdpr-message-modal').show();
    }

    function handleClick() {
        //console.log($("#gdpr-input").val());
        emailValid = validateEmail($("#gdpr-input").val());
        if (emailValid) {
            //Submit the form
            //Hide form
            if ($('.gdpr_err')) {
                $('.gdpr_err').hide();
            }

            $("#gdpr-message-content")
                //If successful then...
            setCookie("gdpr", "true");
            //console.log("emailValid " + emailValid + " submiting form");
        } else {
            //Show error message
            gdprErrorMessage();
            //console.log("emailValid " + emailValid);
        }
    }

    function gdprErrorMessage() {
        if (errorStatus) {
            return false;
        } else {
            errorStatus = true;
            $("#gdpr-message-content").append(errormessage);
        }
    }

    function validateEmail(email) {
        var re = /^(([^<>()\[\]\\.,;:\s@"]+(\.[^<>()\[\]\\.,;:\s@"]+)*)|(".+"))@((\[[0-9]{1,3}\.[0-9]{1,3}\.[0-9]{1,3}\.[0-9]{1,3}\])|(([a-zA-Z\-0-9]+\.)+[a-zA-Z]{2,}))$/;
        return re.test(String(email).toLowerCase());
    }

    function setCookie(name, value) {
        var expires = "";
        expires = "; expires=Fri, 31 Dec 9999 23:59:59 GMT";
        document.cookie = name + "=" + (value || "") + expires + "; path=/";
    }

    function getCookie(name) {
        var match = document.cookie.match(new RegExp(name + '=([^;]+)'));
        if (match) return match[1];
    }

    function hideForm() { //And set cookie
        $('#gdpr-message-modal').hide();
        setCookie("gdpr", "false");
        ga('send', 'event', 'Pubs GDPR', 'GDPR Modal', 'GDPR Dismissal');
    }

    return {
        init: init
    }
})();

$(document).ready(infoCentralCapture.init);
</script>





        
        <script>
    //Top nav tracking

    (function(){
        $('.header_my-activity a:first').on('click', function(e){
            e.preventDefault();
            //console.log('Button , Activity')
            ga('send', 'event', 'Top Nav', 'Button', 'Activity');
        })


        $('.pubModal_button').on('click', function(e){
            e.preventDefault();
            //console.log('Button , Publications')
            ga('send', 'event', 'Top Nav', 'Button', 'Publications');
        }) 

        $('.header_burger-menu_button').on('click', function(e){
            e.preventDefault();
            //console.log('Button , Hamburger');
            ga('send', 'event', 'Top Nav', 'Button', 'Hamburger');
        }) 

        // $('.header_burger-menu_content ul li').on('click', function(e){
        //     // e.preventDefault();
        //     var idx = $(this).index();
        //     console.log('Menu item' + idx)
        // })
    })();
    
    
</script>




        
        
<script type="text/javascript">
    adroll_adv_id = "3LBZJ4KXKBF2PJ46QCMT3X";
    adroll_pix_id = "6EITYRDI4FFGJPSZQ62UJJ";

    (function () {
        var _onload = function(){
            if (document.readyState && !/loaded|complete/.test(document.readyState)){setTimeout(_onload, 10);return}
            if (!window.__adroll_loaded){__adroll_loaded=true;setTimeout(_onload, 50);return}
            var scr = document.createElement("script");
            var host = (("https:" == document.location.protocol) ? "https://s.adroll.com" : "http://a.adroll.com");
            scr.setAttribute('async', 'true');
            scr.type = "text/javascript";
            scr.src = host + "/j/roundtrip.js";
            ((document.getElementsByTagName('head') || [null])[0] ||
                document.getElementsByTagName('script')[0].parentNode).appendChild(scr);
        };
        if (window.addEventListener) {window.addEventListener('load', _onload, false);}
        else {window.attachEvent('onload', _onload)}
    }());
</script>










        
        <div class="activity-container hidden-lg hidden-md"><div class="recentlyViewed" style="right: -100%;"><div class="activity_title_container"><span class="activity_title">Recently Viewed</span><a href="javascript:void(0)" class="activity_back"><i class="icon-angle-left"></i></a></div></div></div>




        
        <script>
$(document).ready(function(){
    var cookie = "";
    var uri = "/doi/full/10.1021/html_original_uri?id=123";
    console.log("ACSPubs2 start");
    $.getJSON('https://extreme-ip-lookup.com/json/', function(data, status) {
            if ( status == 'success' ) {
                $.each(data, function(i, field){
                    cookie=cookie.concat(i+' = '+field+" - ");
                });
                
            } else {
                    cookie=status;
            }

            cookie1 = cookie;
            cookie = cookie1 + "; path=/; domain=.acs.org";
            //document.cookie = "ACSPubs2= "+ btoa(cookie) ;
            $.cookie("ACSPubs2", btoa(cookie), {path: '/'}); // Session cookie valid across the entire site.
            //TODO send cookie val to the controller for logging
            console.log("ACSPubs2 success");
    })
    .fail(function(xx, status, err){
        cookie="error: 127.0.0.1";
        //document.cookie = "ACSPubs2= "+ btoa(cookie) ;
        $.cookie("ACSPubs2", btoa(cookie), {path: '/'}); // Session cookie valid across the entire site.
        console.log("ACSPubs2 failed");
        //TODO send cookie val to the controller for logging
    });
});    
</script>





        
        



        
    

        </div>
    </div>





	

    <script>if (typeof define !== 'undefined')
    if (define.amd)
        define.amd = false</script><script src="/products/achs/releasedAssets/js/build.lazyload.bundle-191cb5c7d88ed9894acd.js"></script><script src="/products/achs/releasedAssets/js/main.bundle-524acd43b3dccf6df3df.js"></script>

<script type="text/javascript" src="/wro/kfa7~product.js"></script>































    












<script defer src="https://static.cloudflareinsights.com/beacon.min.js" data-cf-beacon='{"rayId":"677a985a7d05198b","token":"d4e766cffbf14806ad37e095398b9c5f","version":"2021.7.0","si":10}'></script>
</body>
</html>
